<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="p">
		<monograph id="1" status="active" ha="yes">
			<mono_name> PACLitaxel (Rx)</mono_name>
			<info>
				<pronunciation>(pa-kli-tax′el)</pronunciation>
			</info>
		</monograph>
<monograph id="2" status="active">
			<mono_name>PACLitaxel nanoparticle albumin-bound (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x260">Abraxane</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Taxane</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x36">
				<para>
					<confusion>
						<tradename id="tnidelem4x360">PACLitaxel</tradename>
						<drug type="generic" refid="idelem4x360">PARoxetine/Paxil</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x40">
				<sec_title>Action:</sec_title>
				<para>Inhibits reorganization of microtubule network needed for interphase and mitotic cellular functions; causes abnormal bundles of microtubules during cell cycle and multiple esters of microtubules during mitosis</para>
			</section>
			<section type="uses" id="sidelem4x45">
				<sec_title>Uses:</sec_title>
				<para>
					<emphasis style="bold">Taxol:</emphasis> metastatic carcinoma of the ovary, breast; AIDS-related Kaposi’s sarcoma (2nd-line), non–small-cell lung cancer (1st-line), adjuvant treatment for node-positive breast cancer</para>
				<section type="none" id="sidelem4x52">
					<section type="none" id="sidelem4x53">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Advanced head, neck, small-cell lung cancer; non-Hodgkin’s lymphoma, adenocarcinoma of the upper GI tract, hormone-refractory prostate cancer, bladder cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x58">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>); hypersensitivity to PACLitaxel or other products with polyoxyethylated castor oil, albumin</para>
				<para>
					<bbw>Neutropenia of &lt;1500/mm3</bbw>
				</para>
				<section type="none" id="sidelem4x75">
					<section type="none" id="sidelem4x76">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, females, geriatric patients, cardiovascular/hepatic/renal disease, CNS disorder, bone marrow suppression, dental disease/work, extravasation, herpes, infection, infertility, jaundice, ocular exposure, radiation therapy, thrombocytopenia, vaccination</para>
						<para>
							<bbw>Taxane hypersensitivity, requires a specialized care setting, requires an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x91">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x94">
					<sec_title>PACLitaxel</sec_title>
					<section type="none" id="sidelem4x97">
						<sec_title>Ovarian carcinoma</sec_title>
						<section type="none" id="sidelem4x105">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x105">
									<item>
										<label>•</label>
										<para> 135 mg/m<emphasis style="sup">2</emphasis> given over 24 hr q3wk, then CISplatin 75 mg/m<emphasis style="sup">2</emphasis>; or (refractory or metastatic) 175 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk; or 175 mg/m<emphasis style="sup">2</emphasis> over 3 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x121">
						<sec_title>Advanced ovarian carcinoma</sec_title>
						<section type="none" id="sidelem4x129">
							<label>•</label>
							<sec_title>Adult<route> IV/INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x129">
									<item>
										<label>•</label>
										<para> 175 mg/m<emphasis style="sup">2</emphasis> with CISplatin 75 mg/m<emphasis style="sup">2</emphasis> using a 3-hr regimen q3wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x139">
						<sec_title>Breast carcinoma</sec_title>
						<section type="none" id="sidelem4x147">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x147">
									<item>
										<label>•</label>
										<para> 175 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk × 4 courses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x154">
						<sec_title>AIDS-related Kaposi’s sarcoma</sec_title>
						<section type="none" id="sidelem4x162">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x162">
									<item>
										<label>•</label>
										<para> 135 mg/m<emphasis style="sup">2</emphasis> over 3 hr q3wk or 100 mg/m<emphasis style="sup">2</emphasis> over 3 hr q2wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x172">
						<sec_title>1st-line non–small-cell lung cancer</sec_title>
						<section type="none" id="sidelem4x180">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x180">
									<item>
										<label>•</label>
										<para> 135 mg/m<emphasis style="sup">2</emphasis>/24 hr infusion with CISplatin 75 mg/m<emphasis style="sup">2</emphasis> × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x190">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x198">
							<label>•</label>
							<sec_title>Adult<route> for 135 mg/m</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x225">
						<sec_title>Bladder cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x233">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x233">
									<item>
										<label>•</label>
										<para> 225 mg/m<emphasis style="sup">2</emphasis> over 3 hr with CARBOplatin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x240">
						<sec_title>Head/neck cancer (unlabeled)</sec_title>
						<section type="none" id="sidelem4x248">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x248">
									<item>
										<label>•</label>
										<para> 40-45 mg/m<emphasis style="sup">2</emphasis> with CARBOplatin over 24 hr or 175-300 mg/m<emphasis style="sup">2</emphasis> over 3 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x258">
						<sec_title>Stem cell transplant/bone marrow ablation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x266">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x266">
									<item>
										<label>•</label>
										<para> 250-775 mg/m<emphasis style="sup">2</emphasis> over 24 hr in combination with other chemotherapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x273">
					<sec_title>PACLitaxel protein-bound particles</sec_title>
					<section type="none" id="sidelem4x281">
						<label>•</label>
						<sec_title>Adult<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x281">
								<item>
									<label>•</label>
									<para> 260 mg/m<emphasis style="sup">2</emphasis> q3wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x289">
						<sec_title>Available forms:</sec_title>
						<para> Inj 6 mg/ml, 30 mg/5-ml vial, 100 mg/16.7-ml vial, 150 mg/25-ml vial, 300 mg/50-ml vial; powder for inj, lyophilized 100 mg in single-use vials (Abraxane)</para>
					</section>
					<section type="none" id="sidelem4x294">
						<sec_title>Administer:</sec_title>
						<para>
							<bbw>CBC, differential, platelet count before treatment and weekly; withhold product if WBC is &lt;1500/mm3 or platelet count is &lt;100,000/mm3; notify prescriber</bbw>
						</para>
						<para>
							<list id="lidelem4x313">
								<item>
									<label>•</label>
									<para>If CISplatin is given, use after taxane</para>
								</item>
								<item>
									<label>•</label>
									<para>Confirmation that dexamethasone was given 12 hr and 6 hr before infusion begins</para>
								</item>
								<item>
									<label>•</label>
									<para>Store prepared sol up to 27 hr in refrigerator</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x329">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x333">
									<item>
										<label>•</label>
										<para>After premedicating with dexamethasone 20 mg PO 12 hr and 6 hr before PACLitaxel, diphenhydrAMINE 50 mg IV <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before PACLitaxel and cimetidine 300 mg or ranitidine 50 mg IV <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before PACLitaxel</para>
									</item>
									<item>
										<label>•</label>
										<para>For extravasation if given by regular IV, not port</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x356">
					<sec_title>PACLitaxel</sec_title>
					<para>
						<list id="lidelem4x360">
							<item>
								<label>•</label>
								<para>After diluting in 0.9% NaCl, D<emphasis style="inf">5</emphasis>, D<emphasis style="inf">5</emphasis> and 0.9% NaCl, D<emphasis style="inf">5</emphasis>LR (0.3-1.2 mg/ml), chemo dispensing pin or similiar devices with spikes should not be used in vials of Taxol; use in-line filter ≤0.22 micron; give as 3-hr or 24-hr infusion</para>
							</item>
							<item>
								<label>•</label>
								<para>Using only glass bottles, polypropylene, polyolefin bags, and administration sets; do not use PVC infusion bags or sets</para>
							</item>
						</list>
					</para>
					<para>
						<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amikacin, aminophylline, ampicillin/sulbactam, bleomycin, butorphanol, calcium chloride, CARBOplatin, cefepime, cefoTEtan, cefTAZidime, cefTRIAXone, cimetidine, CISplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, dexamethasone, diphenhydrAMINE, DOXOrubicin, droperidol, etoposide, famotidine, floxuridine, fluconazole, fluorouracil, furosemide, ganciclovir, gentamicin, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, ifosfamide, LORazepam, magnesium sulfate, mannitol, meperidine, mesna, methotrexate, metoclopramide, morphine, nalbuphine, ondansetron, pentostatin, potassium chloride, prochlorperazine, propofol, ranitidine, sodium bicarbonate, thiotepa, vancomycin, vinBLAStine, vinCRIStine, zidovudine</para>
				</section>
				<section type="none" id="sidelem4x385">
					<sec_title>Abraxane</sec_title>
					<para/>
					<section type="none" id="sidelem4x389">
						<sec_title>Intermittent IV INFUSION route</sec_title>
						<para>
							<list id="lidelem4x393">
								<item>
									<label>•</label>
									<para>Reconstitute vial by injecting 20 ml of 0.9% NaCl; slowly inject 20 ml of 0.9% NaCl over at least 1 min to direct sol flow on wall of vial; do not inject 0.9% NaCl directly onto lyophilized cake (foaming will occur); allow vial to sit for at least 5 min to ensure proper wetting of lyophilized cake; gently swirl or invert vial slowly for ≥2 min until completely dissolved</para>
								</item>
								<item>
									<label>•</label>
									<para>Calculate dose by dosing vol/ml = total dose (mg) ÷ 5 (mg/ml)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x404">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x407">
					<section type="none" id="sidelem4x408">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Peripheral neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x415">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, <emphasis style="italic">hypotension,</emphasis> abnormal ECG, <emphasis style="bold">supraventricular tachycardia (SVT)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x425">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea, mucositis, stomatitis, increased bilirubin, alk phos, AST</emphasis></para>
					</section>
					<section type="none" id="sidelem4x432">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, thrombocytopenia, anemia,</emphasis> bleeding, infections</para>
					</section>
					<section type="none" id="sidelem4x440">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia,</emphasis><emphasis style="bold">tissue necrosis,</emphasis> generalized urticaria, <emphasis style="italic">flushing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x452">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Arthralgia, myalgia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x459">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pulmonary embolism,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x467">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Hypersensitivity reactions,</emphasis><emphasis style="bold">anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x476">
				<sec_title>Pharmacokinetics</sec_title>
				<para>89%-98% of product serum protein bound, metabolized in liver, excreted in bile and urine; terminal half-life 5.3-17.4 hr</para>
			</section>
			<section type="interactions" id="sidelem4x481">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—other antineoplastics, radiation</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> DOXOrubicin levels—DOXOrubicin</para>
				<para>
					<emphasis alert="nurse">Increase: toxicity, decrease metabolism—ketoconazole; avoid concurrent use</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> PACLitaxel metabolism—verapamil, diazepam, cycloSPORINE, teniposide, etoposide, quiNIDine, dexamethasone, vinCRIStine, testosterone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> PACLitaxel levels—CYP2C8, CYP2C9 inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> immune response—live virus vaccines</para>
				<section type="none" id="sidelem4x513">
					<section type="none" id="sidelem4x514">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> AST/ALT, alk phos, triglycerides</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> neutrophils, platelets, WBC, Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x525">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x528">
					<section type="none" id="sidelem4x529">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Requires a specialized care setting such as a hospital or facility with management of complications; should be used by a clinician experienced in cytotoxic agents</bbw>
						</para>
						<section type="none" id="sidelem4x546">
							<label>•</label>
							<sec_title>Cardiovascular status</sec_title>
							<para>
								<list id="lidelem4x546">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cardiovascular status:</emphasis> ECG continuously in CV conditions; monitor for hypotension, sinus bradycardia/tachycardia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x553">
							<label>•</label>
							<sec_title>Peripheral neuropathy</sec_title>
							<para>
								<list id="lidelem4x553">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Peripheral neuropathy:</emphasis> paresthesias, numbness; during infusion, use ice packs on extremities to lessen continued neuropathy; may use acupuncture for some relief; use of ice on extremities when infusing</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x560">
							<label>•</label>
							<sec_title>Arthralgia, myalgia</sec_title>
							<para>
								<list id="lidelem4x560">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Arthralgia, myalgia:</emphasis> may begin 2-3 days after infusion and continue for 4-5 days; may use analgesics</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x567">
							<label>•</label>
							<sec_title>Nausea, vomiting</sec_title>
							<para>
								<list id="lidelem4x567">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Nausea, vomiting:</emphasis> premedicate with antiemetics; nausea and vomiting occur often</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x571">
								<item>
									<label>•</label>
									<para>Hepatic studies before, during therapy (bilirubin, AST, ALT, LDH) prn or monthly, check for jaundiced skin and sclera, dark urine, clay-colored stool, itchy skin, abdominal pain, fever, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x576">
								<item>
									<label>•</label>
									<para>VS during 1st hr of infusion, check IV site for signs of infiltration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x582">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity reactions, anaphylaxis: hypotension, dyspnea, angioedema, generalized urticaria; discontinue infusion immediately; keep emergency equipment available, monitor continuously during first 30-60 min, then periodically</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x590">
							<label>•</label>
							<sec_title>Flush</sec_title>
							<para>
								<list id="lidelem4x590">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Flush:</emphasis> for mild to moderate flush, may continue diphenhydrAMINE for ≤48 hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x594">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x599">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x603">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased tumor size, spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x609">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x614">
								<item>
									<label>•</label>
									<para>To report signs of infection: fever, sore throat, flulike symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x619">
								<item>
									<label>•</label>
									<para>To report signs of anemia: fatigue, headache, faintness, SOB, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x624">
								<item>
									<label>•</label>
									<para>To report bleeding; to avoid use of razors, commercial mouthwash; to use soft-bristle toothbrush; to use viscous xylocaine or compounded formula for stomatitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x629">
								<item>
									<label>•</label>
									<para>To avoid use of aspirin, ibuprofen</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x634">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with known infections</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x639">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment; that a wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x644">
								<item>
									<label>•</label>
									<para>That pain in muscles and joints 2-5 days after infusion is common</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x652">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D); do not breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x655">
								<item>
									<label>•</label>
									<para>To avoid receiving vaccinations while taking product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name> palbociclib</mono_name>
			<info>
				<pronunciation>(pal-boe-sye′klib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x6670">Ibrance</tradename>
				</tradenames>
				<class type="func"> Antineoplastic</class>
				<class type="chem"> Signal transduction inhibitor</class>
			</info>
			<section type="actions" id="sidelem4x677">
				<sec_title>Action:</sec_title>
				<para> Inhibits progression of the cell cycle from G<emphasis style="inf">1</emphasis> into S phase, decreased proliferation of ER-positive breast cancer cell lines. When combined with antiestrogen therapy (letrozole), decreases retinoblastoma protein (Rb) phosphorylation, reducing E2F expression and signaling, and increasing growth arrest</para>
			</section>
			<section type="uses" id="sidelem4x687">
				<sec_title>Uses:</sec_title>
				<para> Treatment of estrogen receptor (ER)–positive, HER2-negative advanced breast cancer in postmenopausal women, in combination with letrozole as initial endocrine-based therapy</para>
			</section>
			<section type="contra" id="sidelem4x692">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x697">
					<section type="none" id="sidelem4x698">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, fungal/viral infection, infants, infertility, neutropenia, pregnancy, testicular failure, thromboembolic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x703">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x711">
					<label>•</label>
					<sec_title>Adult females<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x711">
							<item>
								<label>•</label>
								<para> 125 mg daily with food × 21 days, followed by 7 days off, repeat q28 days with letrozole 2.5 mg daily, given continuously through each 28-day cycle until progressive disease or unacceptable toxicity occurs</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x715">
					<section type="none" id="sidelem4x716">
						<sec_title>Available forms:</sec_title>
						<para> Caps 75, 100, 125 mg</para>
					</section>
					<section type="none" id="sidelem4x721">
						<sec_title>Administer:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x725">
						<sec_title>Treatment-related hepatotoxicity:</sec_title>
						<section type="none" id="sidelem4x733">
							<label>•</label>
							<sec_title>Grade 1 or 2 hepatotoxicity<route> No dosage change</route></sec_title>
						</section>
						<section type="none" id="sidelem4x739">
							<label>•</label>
							<sec_title>Grade ≥3 hepatotoxicity (AST or ALT &gt;5 × ULN or total bilirubin &gt;3 × ULN) that persists despite medical treatment<route> Hold until toxicity resolves to grade ≤2 (AST or ALT ≤5 × ULN or total bilirubin ≤3 × ULN), resume treatment at the next lower dose level if not considered a safety risk for the patient; discontinue if grade ≥3 toxicity occurs at a dose of 75 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x742">
						<sec_title>Treatment-related nephrotoxicity:</sec_title>
						<section type="none" id="sidelem4x750">
							<label>•</label>
							<sec_title>Grade 1 or 2 nephrotoxicity<route> No change</route></sec_title>
						</section>
						<section type="none" id="sidelem4x756">
							<label>•</label>
							<sec_title>Grade ≥3 nephrotoxicity (CCr &gt;3 × baseline or &gt;4 mg/dl, or requiring hospitalization or dialysis) that persists despite medical treatment<route> Hold therapy. When toxicity resolves to grade ≤2 (CCr &lt;3 × baseline or &lt;4 mg/dl), resume at the next lower dose level if not considered a safety risk for the patient, discontinue if grade ≥3 toxicity occurs at a dose of 75 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x759">
						<sec_title>Other dosage adjustments</sec_title>
						<section type="none" id="sidelem4x767">
							<label>•</label>
							<sec_title>Strong CYP3A4 inhibitors<route> Avoid concomitant use. If a strong CYP3A4 inhibitor is needed, consider reducing the dose to 75 mg daily, if the strong CYP3A4 inhibitor is discontinued, increase the dose upward to the previously tolerated/recommended dose after a washout period of 3-5 half-lives of the inhibitor</route></sec_title>
						</section>
						<section type="none" id="sidelem4x773">
							<label>•</label>
							<sec_title>Strong CYP3A4 inducers<route> Avoid use</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x776">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x779">
					<section type="none" id="sidelem4x780">
						<sec_title>CNS:</sec_title>
						<para> Weakness, fever, fatigue</para>
					</section>
					<section type="none" id="sidelem4x785">
						<sec_title>EENT:</sec_title>
						<para> Stomatitis, oral ulceration, glossitis, pharyngitis, sinusitis, epistaxis</para>
					</section>
					<section type="none" id="sidelem4x790">
						<sec_title>GI:</sec_title>
						<para> Vomiting, nausea, anorexia, diarrhea,</para>
					</section>
					<section type="none" id="sidelem4x795">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, neutropenia, leukopenia, lymphopenia, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x802">
						<sec_title>MISC:</sec_title>
						<para> Peripheral neuropathy, alopecia, <emphasis style="bold">infection, pulmonary embolism, thromboembolism</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x809">
				<sec_title>Pharmacokinetics</sec_title>
				<para>85% protein bound, elimination half-life was 24-34 hr, metabolized by CYP3A, peak 6-12 hr</para>
			</section>
			<section type="interactions" id="sidelem4x814">
				<sec_title>Interactions</sec_title>
				<para>Avoid use with CYp3A inhibitors and inducers</para>
				<section type="none" id="sidelem4x819">
					<section type="none" id="sidelem4x820">
						<sec_title>Drug/Herb:</sec_title>
						<para> Avoid use with St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x825">
						<sec_title>Drug/Food:</sec_title>
						<para> Avoid use with grapefruit juice</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x830">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x833">
					<section type="none" id="sidelem4x834">
						<sec_title>Assess:</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x838">
						<sec_title>Pregnancy:</sec_title>
						<para> <emphasis style="bold">Product can cause fetal harm, identify if the patient is pregnant or if pregnancy is planned</emphasis></para>
					</section>
					<section type="none" id="sidelem4x845">
						<sec_title>Pulmonary embolism/thromboembolic events:</sec_title>
						<para> <emphasis style="bold">Dyspnea/shortness of breath, chest pain, arm or leg swelling, sudden numbness or weakness, severe headache or confusion, or problems with vision, speech, or balance</emphasis></para>
					</section>
					<section type="none" id="sidelem4x852">
						<sec_title>Blood dyscrasias:</sec_title>
						<para> <emphasis style="bold">CBC/differential</emphasis></para>
					</section>
					<section type="none" id="sidelem4x859">
						<sec_title>Evaluate:</sec_title>
						<para> Therapeutic response: Decreased progression of disease</para>
					</section>
					<section type="none" id="sidelem4x865">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x873">
							<label>•</label>
							<sec_title>
								<route>Identify if pregnancy is planned or suspected. Discuss the need for contraception due to possible fetal harm, avoid breastfeeding</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x876">
								<item>
									<label>•</label>
									<para>Laboratory testing will be needed during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x884">
							<label>•</label>
							<sec_title>Pulmonary/thromboembolic events<route> Instruct to seek medical attention if dyspnea/shortness of breath, chest pain, arm or leg swelling, sudden numbness or weakness, severe headache or confusion, or problems with vision, speech, or balance develop</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>paliperidone (Rx)</mono_name>
			<info>
				<pronunciation>(pal-ee-per′i-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x8921">Invega</tradename>
					<tradename id="tnidelem4x8920">Invega Sustenna</tradename>
				</tradenames>
				<class type="func"> Antipsychotic</class>
				<class type="chem"> Benzisoxazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x902">
				<para>
					<confusion>
						<tradename id="tnidelem4x9020">Invega</tradename>
						<drug type="generic" refid="idelem4x9020">Iveegam</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x909">
				<sec_title>Action:</sec_title>
				<para>Mediated through both DOPamine type 2 (D<emphasis style="inf">2</emphasis>) and serotonin type 2 (5-HT<emphasis style="inf">2</emphasis>) antagonism</para>
			</section>
			<section type="uses" id="sidelem4x920">
				<sec_title>Uses:</sec_title>
				<para>Schizophrenia, schizoaffective disorder</para>
				<section type="none" id="sidelem4x925">
					<section type="none" id="sidelem4x926">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x931">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, geriatric patients, seizure disorders, AV block, QT prolongation, torsades de pointes; hypersensitivity to this product, risperidone</para>
				<section type="none" id="sidelem4x936">
					<section type="none" id="sidelem4x937">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children, renal/hepatic disease, obesity, Parkinson’s disease, suicidal ideation, diabetes mellitus, hematological disease</para>
						<para>
							<bbw>Dementia-related psychosis (mortality)</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x952">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x960">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x960">
							<item>
								<label>•</label>
								<para> 6 mg/day, max 12 mg/day;  234 mg on day 1, then 156 mg 1 wk later; after 2nd dose, give 117 mg each mo; range 39-234 mg, dosage change may be needed when used with CYP3A4 inducers</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x970">
					<label>•</label>
					<sec_title>Child/adolescent ≥12 yr and ≥51 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x970">
							<item>
								<label>•</label>
								<para> 3 mg daily, may increase if needed by 3 mg/day in intervals of &gt;5 days, up to max 12 mg/day; &lt;51 kg max 6 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x974">
					<section type="none" id="sidelem4x975">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x983">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 50-79 ml/min, 3 mg/day, max 6 mg/day; EXT REL/IM 156 mg on day 1, 117 mg 1 wk later, then 78 mg each mo; CCr 10-49 ml/min, 1.5 mg/day, max 3 mg/day; IM not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x986">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel tabs 1.5, 3, 6, 9 mg; ext rel susp for inj 39 mg/0.25 ml, 78 mg/0.5 ml, 117 mg/0.75 ml, 156 mg/ml, 234 mg/1.5 ml</para>
					</section>
					<section type="none" id="sidelem4x991">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x995">
								<item>
									<label>•</label>
									<para>Avoid use with CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1001">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1005">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel tabs; use plenty of water</para>
									</item>
									<item>
										<label>•</label>
										<para>Without regard for food</para>
									</item>
									<item>
										<label>•</label>
										<para>Reduced dose for geriatric patients</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1021">
							<sec_title>IM route</sec_title>
							<section type="none" id="sidelem4x1029">
								<label>•</label>
								<sec_title>deltoid inj</sec_title>
								<para>
									<list id="lidelem4x1029">
										<item>
											<label>•</label>
											<para>Use for IM only; do not use IV or subcut; inj kits contain prefilled syringe and 2 safety needles; for single use only; shake for 10 sec; <emphasis style="bold">deltoid inj:</emphasis> ≥90 kg, use 1.5-inch, 22-G needle; &lt;90 kg, use 1-inch, 23-G needle; alternate injections between deltoid muscles; <emphasis style="bold">gluteal inj:</emphasis> use 1.5-inch, 22-G needle; attach needle to Luer connection in clockwise motion; pull needle sheath away using straight pull; bring syringe with attached needle upright to de-aerate, de-aerate, inject; after inj, use finger, thumb, or flat surface to activate needle protection system until click heard; use deltoid × 2 doses</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1037">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1040">
					<section type="none" id="sidelem4x1041">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; drowsiness, insomnia, agitation, anxiety, headache,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome,</emphasis> dizziness</para>
					</section>
					<section type="none" id="sidelem4x1051">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">tachycardia; heart failure, QT prolongation, heart block, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1058">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, cough</para>
					</section>
					<section type="none" id="sidelem4x1063">
						<sec_title>ENDO:</sec_title>
						<para> Hyperinsulinemia, weight gain, hyperglycemia, dyslipidemia, diabetes mellitus</para>
					</section>
					<section type="none" id="sidelem4x1069">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, <emphasis style="italic">anorexia, constipation,</emphasis> weight gain in adolescents, xerostomia</para>
					</section>
					<section type="none" id="sidelem4x1080">
						<sec_title>GU:</sec_title>
						<para> Priapism, menstrual irregularities</para>
					</section>
					<section type="none" id="sidelem4x1085">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1092">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 24 hr; elimination half-life 23 hr; excreted 80% urine, 11% feces, protein binding &gt;74%</para>
			</section>
			<section type="interactions" id="sidelem4x1097">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—other CNS depressants, alcohol, sedative/hypnotics, opiates</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> EPS—other antipsychotics</para>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA, III antidysrhythmics, azole antifungals, tricyclics (high doses), some phenothiazines, β-blockers, chloroquine, pimozide, droperidol, some antipsychotics, abarelix, alfuzosin, amoxapine, apomorphine, dasatinib, dolasetron, flecainide, halogenated anesthetics</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: neurotoxicity—lithium</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of paliperidone—carBAMazepine, other CYP3A4 inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> levodopa effect—levodopa</para>
				<section type="none" id="sidelem4x1127">
					<section type="none" id="sidelem4x1128">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> prolactin levels</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1135">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1138">
					<section type="none" id="sidelem4x1139">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Mental status: mood, behavior, confusion, orientation, suicidal thoughts/behaviors; dementia, especially in geriatric patients before initial administration and periodically</bbw>
						</para>
						<para>
							<list id="lidelem4x1155">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1160">
								<item>
									<label>•</label>
									<para>AIMS assessment, blood glucose, CBC, glycosylated hemoglobulin A1c (HbA1c), LFTs, neurologic function, pregnancy testing, serum creatinine/electrolytes/lipid profile/prolactin, thyroid function tests, weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1165">
								<item>
									<label>•</label>
									<para>Swallowing of PO medication; check for hoarding, giving of medication to others</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1170">
								<item>
									<label>•</label>
									<para>Affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1175">
								<item>
									<label>•</label>
									<para>B/P (standing, lying), pulse, respirations; q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1183">
							<label>•</label>
							<sec_title>Hyperprolactinemia</sec_title>
							<para>
								<list id="lidelem4x1183">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperprolactinemia:</emphasis> sexual dysfunction, decreased menstruation, breast pain</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1187">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1195">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x1195">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> akathisia, tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1200">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin syndrome, neuroleptic malignant syndrome: hyperthermia, increased CPK, altered mental status, muscle rigidity, fever, seizures, discontinue</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1205">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk and water in diet; monitor for weight gain, especially among adolescents</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1210">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient is stabilized on medication; do not involve patient in strenuous exercise program because fainting is possible; patient should not stand still for a long time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1215">
								<item>
									<label>•</label>
									<para>Increased fluids to prevent constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1220">
								<item>
									<label>•</label>
									<para>Sips of water, candy, gum for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1225">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1229">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1235">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1240">
								<item>
									<label>•</label>
									<para>That orthostatic hypotension may occur; to rise gradually from sitting or lying position</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1245">
								<item>
									<label>•</label>
									<para>To avoid hot tubs, hot showers, tub baths because hypotension may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1250">
								<item>
									<label>•</label>
									<para>To avoid abrupt withdrawal of this product because EPS may result; that product should be withdrawn slowly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1255">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (cough, hay fever, cold) unless approved by prescriber because serious product interactions may occur; to avoid alcohol because increased drowsiness may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1262">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if drowsy or dizzy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1267">
								<item>
									<label>•</label>
									<para>About compliance with product regimen; that nonabsorbable tab shell is expelled in stool</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1272">
								<item>
									<label>•</label>
									<para>To report impaired vision, tremors, muscle twitching</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1280">
							<label>•</label>
							<sec_title>
								<route>That heat stroke may occur in hot weather; to take extra precautions to stay cool</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1286">
							<label>•</label>
							<sec_title>
								<route>To use contraception; to inform prescriber if pregnancy is planned or suspected; do not breastfeed</route>
							</sec_title>
						</section>
						<para>
							<bbw>To notify prescriber of suicidal thoughts/behaviors, other changes in behavior; identify dementia in the elderly</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>palonosetron (Rx)</mono_name>
			<info>
				<pronunciation>(pa-lone-o′se-tron)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x13110">Aloxi</tradename>
				</tradenames>
				<class type="func"> Antiemetic</class>
				<class type="chem"> 5-HT receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1324">
				<sec_title>Action:</sec_title>
				<para>Prevents nausea, vomiting by blocking serotonin peripherally, centrally, and in the small intestine at the 5-HT<emphasis style="inf">3</emphasis> receptor</para>
			</section>
			<section type="uses" id="sidelem4x1332">
				<sec_title>Uses:</sec_title>
				<para>Prevention of nausea, vomiting associated with cancer chemotherapy, postoperative nausea/vomiting</para>
			</section>
			<section type="contra" id="sidelem4x1337">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x1342">
					<section type="none" id="sidelem4x1343">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hypokalemia, hypomagnesium, patients taking diuretics</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1348">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1356">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x1356">
							<item>
								<label>•</label>
								<para> 0.25 mg as single dose over 30 sec <emphasis style="sup">1</emphasis>⁄<emphasis style="inf">2</emphasis> hr before chemotherapy, max 25 mg  over q7days</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x1369">
					<section type="none" id="sidelem4x1370">
						<sec_title>Postoperative nausea/vomiting prophylaxis for ≤24 hr after surgery</sec_title>
						<section type="none" id="sidelem4x1378">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1378">
									<item>
										<label>•</label>
										<para> 0.075 mg given over 10 sec immediately before induction</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1382">
						<section type="none" id="sidelem4x1383">
							<sec_title>Available forms:</sec_title>
							<para> Inj 0.25 mg/5 ml</para>
						</section>
						<section type="none" id="sidelem4x1388">
							<sec_title>Administer:</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x1392">
							<sec_title>Direct IV route</sec_title>
							<section type="none" id="sidelem4x1400">
								<label>•</label>
								<sec_title>Chemotherapy nausea/vomiting</sec_title>
								<para>
									<list id="lidelem4x1400">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Chemotherapy nausea/vomiting:</emphasis> give as single dose over 30 sec</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x1407">
								<label>•</label>
								<sec_title>Postoperative nausea/vomiting</sec_title>
								<para>
									<list id="lidelem4x1407">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Postoperative nausea/vomiting:</emphasis> give over 10 sec immediately before anesthesia induction</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Dexamethasone</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alemtuzumab, alfentanil, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B liposome, ampicillin, ampicillin/sulbactam, atracurium, atropine, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, caspofungin, ceFAZolin, cefepime, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DACTINomycin, dantrolene, DAPTOmycin, DAUNOrubicin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin hydrochloride, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, eptifibatide, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gemcitabine, gentamicin, glycopyrrolate, haloperidol, heparin, hydrALAZINE, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, inamrinone, insulin, irinotecan, isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, mitoMYcin, mitoXANtrone, mivacurium, morphine, nalbuphine, naloxone, neostigmine, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, oxaliplatin, oxytocin, PACLitaxel, pamidronate, pancuronium, pentazocine, PHENobarbital, phentolamine, phenylephrine, piperacillin/tazobactam, potassium acetate/chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, streptozocin, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, tobramycin, topotecan, trimethobenzamide, trimethoprim/sulfamethoxazole, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1421">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1424">
					<section type="none" id="sidelem4x1425">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, drowsiness, fatigue, insomnia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1432">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, constipation,</emphasis> abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x1440">
						<sec_title>MISC:</sec_title>
						<para> Weakness, hyperkalemia, anxiety, rash, <emphasis style="bold">bronchospasm</emphasis> (rare), arthralgia<emphasis style="italic">, fever, urinary retention</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1450">
				<sec_title>Pharmacokinetics</sec_title>
				<para>62% protein bound; metabolized by liver; unchanged product and metabolites excreted by kidney; terminal elimination half-life 40 hr</para>
			</section>
			<section type="interactions" id="sidelem4x1455">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x1463">
					<label>•</label>
					<sec_title>Possible QT prolongation<route> class 1A antidysrhythmics (disopyramide, procainamide, quiNIDine), class III antidysrhythmics (amiodarone, dofetilide, ibutilide, sotalol), chloroquine, clarithromycin, droperidol, erythromycin, haloperidol, levomethadyl, methadone, pentamidine, some phenothiazines, diuretics (except potassium sparing)</route></sec_title>
				</section>
				<para>
					<emphasis alert="lifethreat">Increase: hypotension, severe—apomorphine</emphasis>
				</para>
				<section type="none" id="sidelem4x1469">
					<section type="none" id="sidelem4x1470">
						<sec_title>Drug/Lab</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> potassium</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1477">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1480">
					<section type="none" id="sidelem4x1481">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1489">
							<label>•</label>
							<sec_title>
								<route>For agents that cause QT prolongation, even if manufacturer has removed QT prolongation from warnings</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1492">
								<item>
									<label>•</label>
									<para>Absence of nausea, vomiting during chemotherapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1500">
							<label>•</label>
							<sec_title>Hypersensitivity reaction<route> rash, bronchospasm (rare)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1503">
								<item>
									<label>•</label>
									<para>Cardiac disease: check ECG before use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1508">
								<item>
									<label>•</label>
									<para>Hyperkalemia: monitor potassium baseline and periodically</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1513">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1517">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting during cancer chemotherapy, postoperatively</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1523">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x1531">
							<label>•</label>
							<sec_title>
								<route>To report diarrhea, constipation, rash, changes in respirations, or discomfort at insertion site</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1534">
								<item>
									<label>•</label>
									<para>To avoid alcohol, barbiturates</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1539">
								<item>
									<label>•</label>
									<para>Use other antiemetics if nausea occurs</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active">
			<mono_name>pamidronate (Rx)</mono_name>
			<info>
				<pronunciation>(pam-i-drone′ate)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x15490">Aredia</tradename>
				</tradenames>
				<class type="func"> Bone-resorption inhibitor, electrolyte modifier</class>
				<class type="chem"> Bisphosphonate</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x1559">
				<para>
					<confusion>
						<tradename id="tnidelem4x15590">Aredia</tradename>
						<drug type="generic" refid="idelem4x15590">Adriamycin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x1563">
				<sec_title>Action:</sec_title>
				<para>Inhibits bone resorption, apparently without inhibiting bone formation and mineralization; adsorbs calcium phosphate crystals in bone and may directly block the dissolution of hydroxyapatite crystals of bone</para>
			</section>
			<section type="uses" id="sidelem4x1569">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe Paget’s disease, hypercalcemia, osteolytic bone metastases in breast cancer, patients with multiple myeloma</para>
				<section type="none" id="sidelem4x1574">
					<section type="none" id="sidelem4x1575">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Postmenopausal osteoporosis and prevention, osteoporosis prophylaxis, ankylosing spondylitis, osteogenesis imperfecta, hyperparathyroidism</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x1580">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity to bisphosphonates</para>
				<section type="none" id="sidelem4x1585">
					<section type="none" id="sidelem4x1586">
						<sec_title>Precautions:</sec_title>
						<para> Children, nursing mothers, renal dysfunction, poor dentition</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x1591">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x1594">
					<section type="none" id="sidelem4x1595">
						<sec_title>Hypercalcemia of malignancy</sec_title>
						<section type="none" id="sidelem4x1603">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1603">
									<item>
										<label>•</label>
										<para> 60-90 mg as single dose for moderate hypercalcemia; 90 mg for severe hypercalcemia over 2-24 hr; dose should be diluted in 1000 ml 0.45% NaCl, 0.9% NaCl, or D<emphasis style="inf">5</emphasis>W; wait 7 days before 2nd course</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1610">
						<sec_title>Osteolytic lesions</sec_title>
						<section type="none" id="sidelem4x1618">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1618">
									<item>
										<label>•</label>
										<para> 90 mg/500 ml of D<emphasis style="inf">5</emphasis>W, 0.45% NaCl, or 0.9% NaCl given over 4 hr each mo (multiple myeloma) or over 2 hr q3-4wk (breast carcinoma)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1625">
						<sec_title>Paget’s disease</sec_title>
						<section type="none" id="sidelem4x1633">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1633">
									<item>
										<label>•</label>
										<para> 30 mg/day given over 4 hr × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1637">
						<sec_title>Severe osteogenesis imperfecta (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1645">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1645">
									<item>
										<label>•</label>
										<para> 1.5-3 mg/kg/cycle, cycle dose is divided in 3, administered via slow IV over 4 hr/day × 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1649">
						<sec_title>Hypercalcemia (hyperparathyroidism) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1657">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1657">
									<item>
										<label>•</label>
										<para> 15-60 mg as a single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1661">
						<sec_title>Corticosteroid-induced osteoporosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1669">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1669">
									<item>
										<label>•</label>
										<para> 30 mg q3mo × 1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1673">
						<sec_title>Ankylosing spondylitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1681">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1681">
									<item>
										<label>•</label>
										<para> 60 mg over 4 hr; 6-hr infusion for 1st dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1685">
						<sec_title>Osteoporosis prophylaxis in Crohn’s disease (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1693">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x1693">
									<item>
										<label>•</label>
										<para> 30 mg over 1 hr q3mo × 1 yr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1697">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 30, 90 mg/vial; inj 3, 6, 9 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x1702">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x1705">
							<sec_title>IV route</sec_title>
							<section type="none" id="sidelem4x1713">
								<label>•</label>
								<sec_title>
									<route>(hypercalcemia);</route>
								</sec_title>
								<para>
									<list id="lidelem4x1713">
										<item>
											<label>•</label>
											<para>After reconstituting by adding 10 ml sterile water for inj to each vial (30 mg/10 ml or 90 mg/10 ml, depending on vial used); add to 1000 ml of sterile 0.45%, 0.9% NaCl, D<emphasis style="inf">5</emphasis>W, run over 2-24 hr  dilute reconstituted sol in 500 ml of 0.9% NaCl, 0.45% NaCl, or D<emphasis style="inf">5</emphasis>W, give over 4 hr  dilute reconstituted sol in 250 ml of 0.9% NaCl, 0.45% NaCl, or D<emphasis style="inf">5</emphasis>W; give over 2 hr </para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x1732">
									<item>
										<label>•</label>
										<para>Do not mix with calcium-containing infusion sol such as Ringer’s sol</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1737">
									<item>
										<label>•</label>
										<para>Store infusion sol up to 24 hr at room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1742">
									<item>
										<label>•</label>
										<para>Reconstituted sol with sterile water may be refrigerated for ≤24 hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, amphotericin B liposome, ampicillin, anidulafungin, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, CARBOplatin, carmustine, ceFAZolin, cefepime, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dacarbazine, DAPTOmycin, dexamethasone, dexmedetomidine, dexrazoxane, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, dolasetron, DOPamine, doxacurium, DOXOrubicin, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, ertapenem, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium, ganciclovir, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, haloperidol, heparin, hetastarch 6%, hydrALAZINE, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, inamrinone, insulin (regular), isoproterenol, ketorolac, labetalol, levofloxacin, levorphanol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, meropenem, mesna, metaraminol, methotrexate, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, milrinone, minocycline, mitoXANtrone, mivacurium, morphine, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, niCARdipine, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxytocin, PACLitaxel, palonosetron, pancuronium, PEMEtrexed, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, piperacillin, polymyxin B, potassium chloride/phosphates, procainamide, prochlorperazine, promethazine, propranolol, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, teniposide, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, topotecan, trimethobenzamide, vancomycin, vasopressin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, voriconazole, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1753">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1756">
					<section type="none" id="sidelem4x1757">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fever,</emphasis> fatigue</para>
					</section>
					<section type="none" id="sidelem4x1765">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">atrial fibrillation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1772">
						<sec_title>EENT:</sec_title>
						<para> Ocular pain, inflammation, vision impairment</para>
					</section>
					<section type="none" id="sidelem4x1777">
						<sec_title>GI:</sec_title>
						<para> Abdominal pain, anorexia, constipation, nausea, vomiting, dyspepsia</para>
					</section>
					<section type="none" id="sidelem4x1782">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1789">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, anemia, leukopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1796">
						<sec_title>INTEG:</sec_title>
						<para> Redness, swelling, induration, pain on palpation at site of catheter insertion</para>
					</section>
					<section type="none" id="sidelem4x1801">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hypokalemia, hypomagnesemia, hypophosphatemia, hypocalcemia,</emphasis> hypothyroidism</para>
					</section>
					<section type="none" id="sidelem4x1809">
						<sec_title>MS:</sec_title>
						<para> Severe bone pain, myalgia, osteonecrosis of the jaw</para>
					</section>
					<section type="none" id="sidelem4x1814">
						<sec_title>RESP:</sec_title>
						<para> Coughing, dyspnea, upper respiratory tract infection</para>
					</section>
					<section type="none" id="sidelem4x1819">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1826">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly cleared from circulation and taken up mainly by bones, primarily in areas of high bone turnover; eliminated primarily by kidneys; half-life 21-35 hr, terminal half-life in bone is 300 days</para>
			</section>
			<section type="interactions" id="sidelem4x1831">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypokalemia—loop diuretics</para>
				<para>
					<emphasis alert="lifethreat">Increase: nephrotoxicity—aminoglycosides, NSAIDs, vancomycin, radiopaque contrast agents, cycloSPORINE, tacrolimus</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of entecavir</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pamidronate effect—calcium, vit D</para>
				<section type="none" id="sidelem4x1849">
					<section type="none" id="sidelem4x1850">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatinine</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> potassium, magnesium, phosphate, calcium, WBC, platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1861">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1864">
					<section type="none" id="sidelem4x1865">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x1873">
							<label>•</label>
							<sec_title>Hypocalcemia</sec_title>
							<para>
								<list id="lidelem4x1873">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypocalcemia:</emphasis> nausea, vomiting, constipation, thirst, dysrhythmias, hypocalcemia, paresthesia, twitching, laryngospasm, Chvostek’s sign, Trousseau’s sign; <emphasis style="bold">hypercalcemia:</emphasis> thirst, nausea, vomiting, dysrhythmias</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1880">
								<item>
									<label>•</label>
									<para>Dehydration/hypovolemia: should be corrected during treatment of hypercalcemia, before therapy, maintain adequate urine output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1885">
								<item>
									<label>•</label>
									<para>Monitor WBCs, platelets, electrolytes, creatinine, BUN, Hgb/Hct before beginning treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1893">
							<label>•</label>
							<sec_title>Dental health</sec_title>
							<para>
								<list id="lidelem4x1893">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Dental health:</emphasis> cover with antiinfectives for dental extractions</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x1897">
								<item>
									<label>•</label>
									<para>Temperature may be elevated during the first 3 days after a dose; risk of fever increases as dose increases</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1905">
							<label>•</label>
							<sec_title>Renal disease<route> max 90-mg single dose, longer infusions &gt;2 hr may increase risk for renal toxicity</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1908">
								<item>
									<label>•</label>
									<para>Bone pain; use analgesics</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1914">
								<item>
									<label>•</label>
									<para>I&amp;O, check for fluid overload edema, crackles, increased B/P; BUN, creatinine</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1919">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1923">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased calcium levels</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1929">
						<sec_title>Teach patient/family</sec_title>
						<section type="none" id="sidelem4x1937">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected, pregnancy (D)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x1940">
								<item>
									<label>•</label>
									<para>To report hypercalcemic relapse: nausea, vomiting, bone pain, thirst; unusual muscle twitching, muscle spasms; severe diarrhea, constipation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1945">
								<item>
									<label>•</label>
									<para>To continue with dietary recommendations, including calcium and vit D</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1950">
								<item>
									<label>•</label>
									<para>To obtain analgesic from provider for bone pain</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1955">
								<item>
									<label>•</label>
									<para>That, if nausea, vomiting occur, small, frequent meals may help</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1960">
								<item>
									<label>•</label>
									<para>To report ocular symptoms to prescriber: blurred vision, edema, inflammation</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>pancrelipase (Rx)</mono_name>
			<info>
				<pronunciation>(pan-kre-li′pase)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x19709">Creon</tradename>
					<tradename id="tnidelem4x19708">
						<country code="CAN">DMH </country>
					</tradename>
					<tradename id="tnidelem4x19707">
						<country code="CAN">Pancrease </country>
					</tradename>
					<tradename id="tnidelem4x19706">Pancreaze</tradename>
					<tradename id="tnidelem4x19705">Pancrecarb MS</tradename>
					<tradename id="tnidelem4x19704">Pertzye</tradename>
					<tradename id="tnidelem4x19703">Ultrase MT</tradename>
					<tradename id="tnidelem4x19702">Ultresa</tradename>
					<tradename id="tnidelem4x19701">Viokase</tradename>
					<tradename id="tnidelem4x19700">Zenpep</tradename>
				</tradenames>
				<class type="func"> Digestant</class>
				<class type="chem"> Pancreatic enzyme—bovine/porcine</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x1986">
				<sec_title>Action:</sec_title>
				<para>Pancreatic enzyme needed for the breakdown of substances released from the pancreas</para>
			</section>
			<section type="uses" id="sidelem4x1991">
				<sec_title>Uses:</sec_title>
				<para>Exocrine pancreatic secretion insufficiency, cystic fibrosis (digestive aid), steatorrhea, pancreatic enzyme deficiency</para>
			</section>
			<section type="contra" id="sidelem4x1996">
				<sec_title>Contraindications:</sec_title>
				<para>Allergy to pork</para>
				<section type="none" id="sidelem4x2001">
					<section type="none" id="sidelem4x2002">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), ileus, pancreatitis, Crohn’s disease, diabetes mellitus</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2007">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2016">
					<label>•</label>
					<sec_title>Adult/adolescent/child ≥4 yr (del rel caps<route> Creon Caps, Zenpap Caps, Pancreaze Caps)</route></sec_title>
					<para>
						<list id="lidelem4x2016">
							<item>
								<label>•</label>
								<para> 500 lipase units/kg/meal, titrate based on patient response, max 2500 lipase units/kg/meal</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2023">
					<label>•</label>
					<sec_title>Child 1-4 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x2023">
							<item>
								<label>•</label>
								<para> 1000 lipase units/kg/meal, titrate based on patient response, max 2500 lipase units/kg/meal</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2027">
					<section type="none" id="sidelem4x2028">
						<sec_title>Available forms:</sec_title>
						<para> Tabs (Viokase) 10, 20; cap, del rel 4, 8, 16 (Pancrecarb MS), 12, 18, 20 (Ultrase MT), Ultrase; cap 3000, 4200, 5000, 6000, 8000, 10,500, 12,000, 15,000, 16,000, 16,800, 24,000, 25,000 units</para>
					</section>
					<section type="none" id="sidelem4x2033">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x2038">
								<item>
									<label>•</label>
									<para>After antacid or cimetidine; decreased pH inactivates product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2043">
								<item>
									<label>•</label>
									<para>Low-fat diet for GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2048">
								<item>
									<label>•</label>
									<para>Have patient sit up during administration; give with meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2053">
								<item>
									<label>•</label>
									<para>Do not crush, chew del rel products, caps</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2061">
							<label>•</label>
							<sec_title>
								<route>Viokase is not interchangeable with other products</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2064">
								<item>
									<label>•</label>
									<para>Store in tight container at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2069">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2072">
					<section type="none" id="sidelem4x2073">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x2078">
						<sec_title>GI:</sec_title>
						<para> Anorexia, nausea, vomiting, diarrhea, cramping, bloating</para>
					</section>
					<section type="none" id="sidelem4x2083">
						<sec_title>GU:</sec_title>
						<para> Hyperuricuria, hyperuricemia</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2088">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption—cimetidine, antacids, oral iron</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of acarbose, miglitol</para>
			</section>
			<section type="considerations" id="sidelem4x2099">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2102">
					<section type="none" id="sidelem4x2103">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x2108">
								<item>
									<label>•</label>
									<para>Appropriate height, weight development before and periodically; may be delayed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2113">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; watch for increasing urinary output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2118">
								<item>
									<label>•</label>
									<para>Fecal fat, nitrogen, PT during treatment</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2126">
							<label>•</label>
							<sec_title>Diabetes mellitus</sec_title>
							<para>
								<list id="lidelem4x2126">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Diabetes mellitus:</emphasis> for polyuria, polydipsia, polyphagia; monitor glucose level more frequently</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2130">
								<item>
									<label>•</label>
									<para>Pork sensitivity; cross-sensitivity may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2135">
								<item>
									<label>•</label>
									<para>Adequate hydration</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2141">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2145">
								<item>
									<label>•</label>
									<para>Therapeutic response: improved digestion of carbohydrates, protein, fat; absence of steatorrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2151">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x2159">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of allergic reactions, abdominal pain, cramping, or blood in urine</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2162">
								<item>
									<label>•</label>
									<para>To always take with food; not to crush, chew del rel product, caps</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2167">
								<item>
									<label>•</label>
									<para>To store at room temperature, away from moisture</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="8" status="active" ha="yes">
			<mono_name> pancuronium (Rx)</mono_name>
			<info>
				<pronunciation>(pan-kyoo-roe′nee-um)</pronunciation>
				<class type="func"> Neuromuscular blocker (nondepolarizing)</class>
				<class type="chem"> Synthetic curariform</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2187">
				<sec_title>Action:</sec_title>
				<para>Inhibits transmission of nerve impulses by binding with cholinergic receptor sites, antagonizing action of acetylcholine</para>
			</section>
			<section type="uses" id="sidelem4x2192">
				<sec_title>Uses:</sec_title>
				<para>Facilitation of endotracheal intubation, skeletal muscle relaxation during mechanical ventilation, surgery, or general anesthesia</para>
			</section>
			<section type="contra" id="sidelem4x2197">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to bromide ion</para>
				<section type="none" id="sidelem4x2202">
					<section type="none" id="sidelem4x2203">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;2 yr, neuromuscular/ cardiac/renal/hepatic disease, electrolyte imbalances, dehydration, previous anaphylactic reactions (other neuromuscular blockers)</para>
						<para>
							<bbw>Respiratory insufficiency</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2218">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2226">
					<label>•</label>
					<sec_title>Adult/child/infant &gt;1 mo<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x2226">
							<item>
								<label>•</label>
								<para> 0.04-0.1 mg/kg initially or 0.05 mg/kg after initial dose of succinylcholine; maintenance 0.01 mg/kg 60-100 min after initial dose, then 0.01 mg/kg q25-60min as needed; for obese patients, use ideal body weight</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2233">
					<label>•</label>
					<sec_title>Neonate &lt;1 mo<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x2233">
							<item>
								<label>•</label>
								<para> test dose 0.02 mg/kg, then 0.03 mg/kg/dose initially, repeat 2× as needed at 5-10 min intervals; maintenance 0.03-0.09 mg/kg/dose q30min-4 hr as needed</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2237">
					<section type="none" id="sidelem4x2238">
						<sec_title>Available forms:</sec_title>
						<para> Inj 1, 2 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x2243">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2246">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x2250">
									<item>
										<label>•</label>
										<para>May be given undiluted over 1-2 min (1 mg/ml [10-ml vial], 2 mg/ml [2-, 5-ml vial])</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2256">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2260">
									<item>
										<label>•</label>
										<para>Add 100 mg of product to 250 ml D<emphasis style="inf">5</emphasis>W, NS, LR (0.4 mg/ml)</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator; do not store in plastic; use only fresh sol</para>
									</item>
									<item>
										<label>•</label>
										<para>Reassurance if communication is difficult during recovery from neuromuscular blockade</para>
									</item>
									<item>
										<label>•</label>
										<para>Frequent (q2hr) instillation of artificial tears, covering of eyes to prevent drying of cornea</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Verapamil, ciprofloxacin</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Aminophylline, ceFAZolin, cefuroxime, cimetidine, DOBUTamine, DOPamine, EPINEPHrine, esmolol, fenoldopam, fentaNYL, fluconazole, gentamicin, heparin, hydrocortisone, isoproterenol, levofloxacin, LORazepam, midazolam, morphine, nitroglycerin, ranitidine, trimethoprim-sulfamethoxazole, vancomycin</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2292">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2295">
					<section type="none" id="sidelem4x2296">
						<sec_title>CV:</sec_title>
						<para> Bradycardia; tachycardia; increased, decreased B/P; ventricular extrasystoles, edema, hypertension</para>
					</section>
					<section type="none" id="sidelem4x2301">
						<sec_title>EENT:</sec_title>
						<para> Increased secretions</para>
					</section>
					<section type="none" id="sidelem4x2306">
						<sec_title>INTEG:</sec_title>
						<para> Rash, flushing, pruritus, urticaria, sweating, salivation</para>
					</section>
					<section type="none" id="sidelem4x2311">
						<sec_title>MS:</sec_title>
						<para> Weakness to prolonged skeletal muscle relaxation</para>
					</section>
					<section type="none" id="sidelem4x2316">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Prolonged apnea, bronchospasm, cyanosis, respiratory depression,</emphasis> dyspnea</para>
					</section>
					<section type="none" id="sidelem4x2325">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2332">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x2335">
					<section type="none" id="sidelem4x2336">
						<sec_title>IV:</sec_title>
						<para> Onset 3-5 min, dose dependent, peak 3-5 min; metabolized (small amounts), excreted in urine (unchanged), crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x2341">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x2345">
						<item>
							<label>•</label>
							<para>Dysrhythmias: theophylline</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neuromuscular blockade—aminoglycosides, clindamycin, enflurane, isoflurane, lincomycin, lithium, local anesthetics, opioid analgesics, polymyxin antiinfectives, quiNIDine, thiazides</para>
				<section type="none" id="sidelem4x2355">
					<section type="none" id="sidelem4x2356">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> cholinesterase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2363">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2366">
					<section type="none" id="sidelem4x2367">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x2375">
							<label>•</label>
							<sec_title>Respiratory recovery</sec_title>
							<para>
								<list id="lidelem4x2375">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory recovery:</emphasis> decreased paralysis of face, diaphragm, leg, arm, rest of body; allow to recover fully before neurologic assessment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x2379">
								<item>
									<label>•</label>
									<para>Electrolyte imbalances (K, Mg); may lead to increased action of product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2384">
								<item>
									<label>•</label>
									<para>VS (B/P, pulse, respirations, airway) until fully recovered; rate, depth, pattern of respirations, strength of hand grip</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2389">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for urinary retention, frequency, hesitancy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2395">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, fever, respiratory distress, pruritus; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2400">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2404">
								<item>
									<label>•</label>
									<para>Therapeutic response: paralysis of jaw, eyelid, head, neck, rest of body</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="9" status="active" ha="yes">
			<mono_name> panitumumab (Rx)</mono_name>
			<info>
				<pronunciation>(pan-i-tue′moo-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x24220">Vectibix</tradename>
				</tradenames>
				<class type="func"> Antineoplastic—miscellaneous</class>
				<class type="chem"> Multikinase inhibitor, signal transduction inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2432">
				<sec_title>Action:</sec_title>
				<para>Decreases growth and survival of cancer cells by competitive inhibition of EGF receptor</para>
			</section>
			<section type="uses" id="sidelem4x2437">
				<sec_title>Uses:</sec_title>
				<para>EGFR expressing metastatic colorectal cancer; not beneficial with KRAS mutations in codon 12 or 13</para>
			</section>
			<section type="contra" id="sidelem4x2442">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x2447">
					<section type="none" id="sidelem4x2448">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, hepatic disease, acute bronchospasm, diarrhea, hamster protein allergy, hypomagnesemia, hypotension, pulmonary fibrosis, sepsis, KRAS mutations, soft tissue toxicities</para>
						<para>
							<bbw>Exfoliative dermatitis, infusion-related reactions</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2463">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2471">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x2471">
							<item>
								<label>•</label>
								<para> 6 mg/kg over 60 min every 2 wk; doses &gt;1000 mg over 90 min</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x2475">
					<section type="none" id="sidelem4x2476">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 20 mg/ml (100 mg/5 ml, 400 mg/20 ml)</para>
					</section>
					<section type="none" id="sidelem4x2481">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2484">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x2489">
									<item>
										<label>•</label>
										<para>Give in hospital or clinic setting with full resuscitation equipment</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2494">
									<item>
										<label>•</label>
										<para>Only as IV infusion using controlled IV infusion pump; do not give IV push or bolus; use low-protein binding 0.2- or 0.22-micron in-line filter; flush line with 0.9% NaCl before and after administration</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2500">
									<item>
										<label>•</label>
										<para>Give over 60 min through a peripheral line or indwelling catheter; infuse doses of &gt;1000 mg over 90 min</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2505">
									<item>
										<label>•</label>
										<para>Dilute in 100 ml of 0.9% NaCl; dilute doses &gt;1000 mg in 150 ml of 0.9% NaCl; mix by inverting; do not exceed 10 mg/ml; use within 6 hr if stored at room temperature; can be stored between 2° C and 8° C for up to 24 hr</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2513">
								<label>•</label>
								<sec_title>Dosage adjustment for infusion/dermatologic reaction; Grade 1 or 2<route> reduce infusion by 50%; Grade 3 or 4</route></sec_title>
							</section>
							<para>
								<list id="lidelem4x2516">
									<item>
										<label>•</label>
										<para>Store unopened vials in refrigerator; do not shake; protect from direct sunlight; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2521">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2524">
					<section type="none" id="sidelem4x2525">
						<sec_title>CNS:</sec_title>
						<para> Fatigue</para>
					</section>
					<section type="none" id="sidelem4x2530">
						<sec_title>CV:</sec_title>
						<para> Peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x2535">
						<sec_title>EENT:</sec_title>
						<para> Ocular irritation, <emphasis style="bold">ocular toxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2542">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting,</emphasis> anorexia, mouth ulceration, abdominal pain, constipation</para>
					</section>
					<section type="none" id="sidelem4x2550">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombophlebitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2557">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, <emphasis style="bold">exfoliative dermatitis,</emphasis> skin fissure, <emphasis style="bold">angioedema, severe/fatal INFUSION reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2570">
						<sec_title>META:</sec_title>
						<para> Hypocalcemia, hypomagnesemia, antibody formation</para>
					</section>
					<section type="none" id="sidelem4x2575">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm, cough,</emphasis> dyspnea, <emphasis style="bold">hypoxia, pulmonary fibrosis/embolism,</emphasis> pneumonitis, wheezing, <emphasis style="bold">interstitial lung disease</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2588">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 38%-49%; elimination half-life 7.5 days; peak 3 hr; high-fat meal decreases bioavailability; plasma protein binding 99.5%; metabolized in liver; oxidative metabolism by CYP3A4, glucuronidation by UGT1A9; 77% excreted in feces</para>
			</section>
			<section type="interactions" id="sidelem4x2593">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x2601">
					<label>•</label>
					<sec_title>
						<route>Do not use in combination with other antineoplastics</route>
					</sec_title>
				</section>
			</section>
			<section type="considerations" id="sidelem4x2604">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x2607">
					<section type="none" id="sidelem4x2608">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Serious skin disorders:</emphasis> fever, sore throat, fatigue, then lesions in mouth, lips; withhold product, notify prescriber</bbw>
						</para>
						<para>
							<list id="lidelem4x2624">
								<item>
									<label>•</label>
									<para>Serum electrolytes periodically (calcium, magnesium)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2632">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x2632">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Infusion reactions:</emphasis> bronchospasm, fever, chills, hypotension; may require discontinuation, have emergency equipment available</bbw>
						</para>
						<section type="none" id="sidelem4x2652">
							<label>•</label>
							<sec_title>Ocular toxicity</sec_title>
							<para>
								<list id="lidelem4x2652">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ocular toxicity:</emphasis> ocular irritation, hyperemia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x2659">
							<label>•</label>
							<sec_title>Pulmonary fibrosis<route> dyspnea, cough, wheezing; may require discontinuation</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x2662">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x2666">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in colon carcinoma progression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x2672">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x2678">
								<item>
									<para>
										<emphasis alert="nurse">To report adverse reactions immediately: difficulty breathing, mouth sores, skin rash, ocular toxicity</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x2683">
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results, adverse reactions</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x2691">
							<label>•</label>
							<sec_title>
								<route>To use contraception while taking product, for 6 mo after treatment; not to breastfeed for ≥2 mo after stopping treatment, enroll in Amgen Pregnancy Surveillance Program (1-800-772-6436)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x2694">
								<item>
									<label>•</label>
									<para>To avoid the sun, use sunscreen while taking product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>pantoprazole (Rx)</mono_name>
			<info>
				<pronunciation>(pan-toe-pray′zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x27044">
						<country code="CAN">Panto </country>
					</tradename>
					<tradename id="tnidelem4x27043">
						<country code="CAN">Pantoloc </country>
					</tradename>
					<tradename id="tnidelem4x27042">Protonix</tradename>
					<tradename id="tnidelem4x27041">Prontonix IV</tradename>
					<tradename id="tnidelem4x27040">Tecta</tradename>
				</tradenames>
				<class type="func"> Proton pump inhibitor</class>
				<class type="chem"> Benzimidazole</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x2720">
				<sec_title>Action:</sec_title>
				<para>Suppresses gastric secretion by inhibiting hydrogen/potassium ATPase enzyme system in gastric parietal cell; characterized as gastric acid pump inhibitor because it blocks the final step of acid production</para>
			</section>
			<section type="uses" id="sidelem4x2727">
				<sec_title>Uses:</sec_title>
				<para>Gastroesophageal reflux disease (GERD), severe erosive esophagitis; maintenance of long-term pathologic hypersecretory conditions, including Zollinger-Ellison syndrome</para>
				<section type="none" id="sidelem4x2732">
					<section type="none" id="sidelem4x2733">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Duodenal/gastric ulcer, NSAID ulcer prophylaxis, <emphasis style="italic">Helicobacter pylori-</emphasis>associated ulcer, dyspepsia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x2741">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or benzimidazole</para>
				<section type="none" id="sidelem4x2746">
					<section type="none" id="sidelem4x2747">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, proton pump hypersensitivity</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x2752">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x2755">
					<section type="none" id="sidelem4x2756">
						<sec_title>GERD</sec_title>
						<section type="none" id="sidelem4x2764">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2764">
									<item>
										<label>•</label>
										<para> 40 mg/day × 8 wk, may repeat course</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2768">
						<sec_title>Erosive esophagitis</sec_title>
						<section type="none" id="sidelem4x2776">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x2776">
									<item>
										<label>•</label>
										<para> 40 mg/day × 7-10 day;  40 mg/day × 8 wk; may repeat  course</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2786">
						<sec_title>Pathologic hypersecretory conditions</sec_title>
						<section type="none" id="sidelem4x2794">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2794">
									<item>
										<label>•</label>
										<para> 40 mg bid;  80 mg q12hr, max 240 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2801">
						<sec_title>Duodenal ulcer/gastric ulcer/ NSAID ulcer prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2809">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2809">
									<item>
										<label>•</label>
										<para> 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2813">
						<sec_title>
							<emphasis style="bold">
								<emphasis style="italic">H. pylori–</emphasis>
							</emphasis>associated ulcers (unlabeled)</sec_title>
						<section type="none" id="sidelem4x2824">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x2824">
									<item>
										<label>•</label>
										<para> 40 mg bid; may be used with other products</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x2828">
						<sec_title>Available forms:</sec_title>
						<para> Del rel tabs 20, 40 mg; powder for inj 40 mg/vial; del rel granules for susp 40 mg</para>
					</section>
					<section type="none" id="sidelem4x2833">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x2836">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x2841">
									<item>
										<label>•</label>
										<para>Swallow del rel tabs whole; do not break, crush, or chew; take del rel tabs at same time of day</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2846">
									<item>
										<label>•</label>
										<para>May take with/without food</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2854">
								<label>•</label>
								<sec_title>Suspension</sec_title>
								<para>
									<list id="lidelem4x2854">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Suspension:</emphasis> give in apple juice 30 min before a meal or sprinkled on 1 tbsp of applesauce</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2861">
								<label>•</label>
								<sec_title>NG tube</sec_title>
								<para>
									<list id="lidelem4x2861">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">NG tube:</emphasis> empty contents of packet of granules into barrel of a 60-ml catheter tip syringe (plunger removed) connected to ≥16F NG tube; add 10 ml apple juice and tap or shake barrel of syringe to empty into the tube; add another 10 ml of apple juice; rinse with additional apple juice until syringe is clear</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x2865">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x2870">
									<item>
										<label>•</label>
										<para>Use of Protonix IV vials with spiked IV system adaptors is not recommended</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2875">
									<item>
										<label>•</label>
										<para>Visually inspect for particulate matter and discoloration before use</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2880">
									<item>
										<label>•</label>
										<para>Give as an IV infusion over 15 min either through a dedicated line or a <emphasis style="sans-serif">Y</emphasis>-site; a 2-min slow-injection regimen is also approved; do not give fast IV push</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x2888">
									<item>
										<label>•</label>
										<para>When using a <emphasis style="sans-serif">Y</emphasis>-site, immediately stop use if a precipitation or discoloration occurs</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x2899">
								<label>•</label>
								<sec_title>
									<route>Reconstitution of vial</route>
								</sec_title>
								<para>
									<list id="lidelem4x2899">
										<item>
											<label>•</label>
											<para>: use 40-mg vial/10 ml NS; do not freeze</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2906">
								<label>•</label>
								<sec_title>Two-minute slow IV infusion injection</sec_title>
								<para>
									<list id="lidelem4x2906">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Two-minute slow IV infusion injection:</emphasis> dilute one or two 40-mg vials with 10 ml NS per vial to 4 mg/ml; store ≤24 hr at room temperature before use; infuse slowly over ≥2 min; do not give with other IV fluids or medications; flush line with D<emphasis style="inf">5</emphasis>W, NS, or LR before and after each dose</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x2916">
								<label>•</label>
								<sec_title>Fifteen-minute IV infusion</sec_title>
								<para>
									<list id="lidelem4x2916">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Fifteen-minute IV infusion:</emphasis> dilute each 40-mg dose with 10 ml NS; the reconstituted vial should be further admixed with 100 ml (for one vial) or 80 ml (for 2 vials) of D<emphasis style="inf">5</emphasis>W, NS, or LR (to 0.4 mg/ml or 0.8 mg/ml, respectively); store ≤6 at room temperature before further dilution; the admixed solution (0.4 mg/ml or 0.8 mg/ml) may be stored at room temperature and must be used within 24 hr from the time of initial reconstitution; infuse over 15 min at 7 ml/min; do not administer with other IV fluids or medications; flush IV line with D<emphasis style="inf">5</emphasis>W, NS, or LR before and after each dose</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amoxicillin-clavulanate, amphotericin B liposome, ampicillin, ampicillin-sulbactam, anidulafungin, azithromycin, bleomycin, bumetanide, calcium gluconate, CARBOplatin, carmustine, ceFAZolin, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dextrose 3.3% in sodium chloride 0.3%, digoxin, dimenhyDRINATE, DOCEtaxel, DOPamine, doripenem, doxycycline, enalaprilat, EPINEPHrine, ertapenem, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gentamicin, granisetron, heparin, hydrocortisone HYDROmorphone, imipenem-cilastatin, inamrinone, insulin (regular), irinotecan, isoproterenol, magnesium, mannitol, mesna, methohexital, methyldopate, metoclopramide, nafcillin, nitroglycerin, nitroprusside, ofloxacin, oxytocin, PACLitaxel, pentazocine, PENTobarbital, phenylephrine, piperacillin-tazobactam, potassium chloride, procainamide, rifampin, sodium bicarbonate, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, teniposide, theophylline, thiopental, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, traMADol, vasopressin, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x2932">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x2935">
					<section type="none" id="sidelem4x2936">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> insomnia, asthenia, fatigue, malaise, insomnia, somnolence</para>
					</section>
					<section type="none" id="sidelem4x2944">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, abdominal pain,</emphasis> flatulence, <emphasis style="bold">pancreatitis,</emphasis> weight changes</para>
					</section>
					<section type="none" id="sidelem4x2955">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2962">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, weight gain/loss, hyponatremia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x2967">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis, myalgia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2974">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Pneumonia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x2981">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x2988">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2.4 hr, duration &gt;24 hr, half-life 1.5 hr, protein binding 97%, eliminated in urine as metabolites and in feces; in geriatric patients, elimination rate decreased; some Asian patients (15%-20%) may be poor metabolizers</para>
			</section>
			<section type="interactions" id="sidelem4x2993">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> pantoprazole serum levels—diazepam, phenytoin, flurazepam, triazolam, clarithromycin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—warfarin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of these products—sucralfate, calcium carbonate, vit B<emphasis style="inf">12</emphasis>, ketoconazole, itraconazole, atazanavir, ampicillin, iron salts</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clopidogrel effect</para>
				<section type="none" id="sidelem4x3015">
					<section type="none" id="sidelem4x3016">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect of pantoprazole—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3023">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3026">
					<section type="none" id="sidelem4x3027">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3035">
							<label>•</label>
							<sec_title>GI system</sec_title>
							<para>
								<list id="lidelem4x3035">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">GI system:</emphasis> bowel sounds q8hr; abdomen for pain, swelling; anorexia</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3042">
							<label>•</label>
							<sec_title>Hepatic studies</sec_title>
							<para>
								<list id="lidelem4x3042">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic studies:</emphasis> AST, ALT, alk phos during treatment</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3046">
								<item>
									<label>•</label>
									<para>For vit B<emphasis style="inf">12</emphasis> deficiency in patients receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3055">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin reactions: toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis: fever, sore throat, fatigue, thin ulcers; lesions in the mouth, lips</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3063">
							<label>•</label>
							<sec_title>Electrolyte imbalances</sec_title>
							<para>
								<list id="lidelem4x3063">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Electrolyte imbalances:</emphasis> hyponatremia; hypomagnesemia in patients using product 3 mo to 1 year; if hypomagnesemia occurs, use of magnesium supplements may be sufficient; if severe, discontinuation of product may be required</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3068">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis, myalgia: muscle pain, increased CPK; weakness, swelling of affected muscles</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3073">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3077">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of epigastric pain, swelling, fullness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3083">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3088">
								<item>
									<label>•</label>
									<para>To report severe diarrhea; black, tarry stools; abdominal pain; product may have to be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3093">
								<item>
									<label>•</label>
									<para>That hyperglycemia may occur in diabetic patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3098">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, NSAIDs; may cause GI irritation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3106">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnant or planning to become pregnant; not to breastfeed</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3109">
								<item>
									<label>•</label>
									<para>To continue taking even if feeling better</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>paricalcitol (Rx)</mono_name>
			<info>
				<pronunciation>(par-ih-cal′sih-tol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x31200">Zemplar</tradename>
				</tradenames>
				<class type="func"> Vit D analog</class>
				<class type="chem"> Fat-soluble vitamin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x3130">
				<sec_title>Action:</sec_title>
				<para>Reduces parathyroid hormone (PTH) levels; suppresses PTH levels in patients with chronic renal failure with absence of hypercalcemia/hyperphosphatemia; serum PO<emphasis style="inf">4</emphasis>, calcium, CaXP may increase</para>
			</section>
			<section type="uses" id="sidelem4x3138">
				<sec_title>Uses:</sec_title>
				<para>Hyperparathyroidism in chronic renal failure</para>
				<section type="none" id="sidelem4x3143">
					<section type="none" id="sidelem4x3144">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Renal osteodystrophy</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3149">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, hypercalcemia</para>
				<section type="none" id="sidelem4x3154">
					<section type="none" id="sidelem4x3155">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CV disease, renal calculi</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3160">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3168">
					<label>•</label>
					<sec_title>Adult<route> IV BOL</route></sec_title>
					<para>
						<list id="lidelem4x3168">
							<item>
								<label>•</label>
								<para> 0.04-0.1 mcg/kg (2.8-7 mcg) no more than every other day during dialysis; may increase by 2-4 mcg q2-4wk until target serum intact PTH (1.5-3× nonuremic upper limit of normal) achieved;  1 mcg/day or 2 mcg 3×/wk (IPTH ≤500 pg/ml); 2 mcg/day or 4 mcg 3×/wk (IPTH &gt;500 pg/ml)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3175">
					<section type="none" id="sidelem4x3176">
						<sec_title>Available forms:</sec_title>
						<para> Inj 2, 5 mcg/ml; caps 1, 2, 4 mcg</para>
					</section>
					<section type="none" id="sidelem4x3181">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3184">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x3188">
									<item>
										<label>•</label>
										<para>Daily or 3×/wk; may give without regard to food</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3194">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x3198">
									<item>
										<label>•</label>
										<para>By IV bolus only</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3204">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3207">
					<section type="none" id="sidelem4x3208">
						<sec_title>CNS:</sec_title>
						<para> Lightheadedness</para>
					</section>
					<section type="none" id="sidelem4x3213">
						<sec_title>CV:</sec_title>
						<para> Palpitations</para>
					</section>
					<section type="none" id="sidelem4x3218">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x3223">
						<sec_title>OTHER:</sec_title>
						<para> Pneumonia, edema, chills, fever, flu, <emphasis style="bold">sepsis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3230">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Crosses placenta, enters breast milk</para>
			</section>
			<section type="interactions" id="sidelem4x3235">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> paricalcitol effect—cholestyramine, colestipol, mineral oil, orlistat, corticosteroids, barbiturates, hydantoins, CYP3A4 enzymes (nevirapine, rifampin, bosentan)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> calcium levels—thiazide diuretics, calcium products, vit D supplements</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of cardiac glycosides</para>
				<para>
					<emphasis style="bold">Altered:</emphasis> paricalcitol effect—CYP3A4 inhibitors (amiodarone, protease inhibitors, systemic azole antifungals, chloramphenicol, clarithromycin, delavirdine, erythromycin)</para>
			</section>
			<section type="considerations" id="sidelem4x3254">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3257">
					<section type="none" id="sidelem4x3258">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x3266">
							<label>•</label>
							<sec_title>Hypocalcemia</sec_title>
							<para>
								<list id="lidelem4x3266">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypocalcemia:</emphasis> twitching, dysrhythmias, Chvostek’s/Trousseau signs, paresthesia, laryngospasm, prolonged QTc/ST interval</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3270">
								<item>
									<label>•</label>
									<para>Serum calcium, serum intact parathyroid hormone concentrations (iPTH), phosphate 2×/wk during initial therapy; after dose is established, take calcium and phosphorus monthly</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3275">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3279">
								<item>
									<label>•</label>
									<para>Decreased hypoparathyroidism with chronic renal disease, normal serum calcium, phosphate, iPTH</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3285">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3290">
								<item>
									<label>•</label>
									<para>To report weakness, lethargy, headache, anorexia, loss of weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3295">
								<item>
									<label>•</label>
									<para>To report nausea, vomiting, palpitations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3300">
								<item>
									<label>•</label>
									<para>To adhere to dietary regimen of calcium supplementation/phosphorus restriction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3305">
								<item>
									<label>•</label>
									<para>To avoid excessive use of aluminum compounds, antacids</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3314">
							<label>•</label>
							<sec_title>
								<route>Not to breastfeed</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x3320">
							<label>•</label>
							<sec_title>
								<route>Not to take mineral oil, antacids (magnesium) while taking vit D</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>PARoxetine (Rx)</mono_name>
			<info>
				<pronunciation>(par-ox′e-teen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x33282">Paxil</tradename>
					<tradename id="tnidelem4x33281">Paxil CR</tradename>
					<tradename id="tnidelem4x33280">Pexeva</tradename>
				</tradenames>
				<class type="func"> Antidepressant, SSRI</class>
				<class type="chem"> Phenylpiperidine derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x3338">
				<para>
					<confusion>
						<tradename id="tnidelem4x33380">PARoxetine</tradename>
						<drug type="generic" refid="idelem4x33380">PACLitaxel</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x3345">
				<sec_title>Action:</sec_title>
				<para>Inhibits CNS neuron uptake of serotonin but not of norepinephrine or DOPamine</para>
			</section>
			<section type="uses" id="sidelem4x3350">
				<sec_title>Uses:</sec_title>
				<para>Major depressive disorder, obsessive-compulsive disorder, panic disorder, generalized anxiety disorder, posttraumatic stress disorder, premenstrual disorders, social anxiety disorder</para>
				<section type="none" id="sidelem4x3355">
					<section type="none" id="sidelem4x3356">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Premature ejaculation, hot flashes, menopause</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3361">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, MAOI use, alcohol use</para>
				<section type="none" id="sidelem4x3366">
					<section type="none" id="sidelem4x3367">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients, seizure history; patients with history of mania, renal/hepatic disease</para>
						<para>
							<bbw>Children, suicidal ideation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3382">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3385">
					<section type="none" id="sidelem4x3386">
						<sec_title>Generalized anxiety disorder</sec_title>
						<section type="none" id="sidelem4x3394">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3394">
									<item>
										<label>•</label>
										<para> 20 mg/day in <emphasis style="smallcaps">am</emphasis>, range 20-50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3401">
						<sec_title>Posttraumatic stress disorder</sec_title>
						<section type="none" id="sidelem4x3409">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3409">
									<item>
										<label>•</label>
										<para> 20 mg/day, range 20-60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3413">
						<sec_title>Depression</sec_title>
						<section type="none" id="sidelem4x3421">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3421">
									<item>
										<label>•</label>
										<para> 20 mg/day in <emphasis style="smallcaps">am</emphasis>; after 4 wk, if no clinical improvement is noted, dose may be increased by 10 mg/day each wk to desired response, max 50 mg/day or  25 mg/day, may increase by 12.5 mg/day/wk up to 62.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3434">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3434">
									<item>
										<label>•</label>
										<para> 10 mg/day, increase by 10 mg to desired dose, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3438">
						<sec_title>Obsessive-compulsive disorder</sec_title>
						<section type="none" id="sidelem4x3446">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3446">
									<item>
										<label>•</label>
										<para> 40 mg/day in <emphasis style="smallcaps">am</emphasis>, start with 20 mg/day, increase in 10-mg/day increments, max 60 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3453">
						<sec_title>Panic disorder</sec_title>
						<section type="none" id="sidelem4x3461">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3461">
									<item>
										<label>•</label>
										<para> start with 10 mg/day, increase in 10-mg/day increments to 40 mg/day, max 60 mg/day or  12.5 mg/day, max 75 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3468">
						<sec_title>Premenstrual disorders</sec_title>
						<section type="none" id="sidelem4x3476">
							<label>•</label>
							<sec_title>Adult<route> CONT REL</route></sec_title>
							<para>
								<list id="lidelem4x3476">
									<item>
										<label>•</label>
										<para> 12.5 mg/day in <emphasis style="smallcaps">am</emphasis></para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3482">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x3490">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-60 ml/min, lower doses may be needed; CCr &lt;30 ml/min, 10 mg/day initially, regular rel, max 40 mg/day; CONT REL 12.5 mg/day initially, max 50 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x3493">
						<sec_title>Hepatic dose</sec_title>
						<section type="none" id="sidelem4x3501">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3501">
									<item>
										<label>•</label>
										<para> 10 mg/day initially, max 40 mg  12.5 mg/day initially, max 50 mg/day </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3510">
						<sec_title>Menopause symptoms/hot flashes (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3518">
							<label>•</label>
							<sec_title>Adult<route> PO (CONT REL)</route></sec_title>
							<para>
								<list id="lidelem4x3518">
									<item>
										<label>•</label>
										<para> 12.5 mg/day, may increase to 25 mg/day after 1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3522">
						<sec_title>Premature ejaculation (unlabeled)</sec_title>
						<section type="none" id="sidelem4x3530">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x3530">
									<item>
										<label>•</label>
										<para> 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x3534">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 30, 40 mg; oral susp 10 mg/5 ml; cont rel tab 12.5, 25, 37.5 mg</para>
					</section>
					<section type="none" id="sidelem4x3539">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x3547">
							<label>•</label>
							<sec_title>
								<route>Do not substitute Pexeva with Paxil, Paxil CR, or generic PARoxetine</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3550">
								<item>
									<label>•</label>
									<para>Store at room temperature; do not freeze</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3555">
								<item>
									<label>•</label>
									<para>Increased fluids, bulk in diet for constipation, urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3560">
								<item>
									<label>•</label>
									<para>With food, milk for GI symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3565">
								<item>
									<label>•</label>
									<para>Crushed if patient is unable to swallow medication whole (regular rel only)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3570">
								<item>
									<label>•</label>
									<para>Gum, hard candy, frequent sips of water for dry mouth</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3575">
								<item>
									<label>•</label>
									<para>Avoid use with other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3583">
							<label>•</label>
							<sec_title>Oral susp</sec_title>
							<para>
								<list id="lidelem4x3583">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral susp:</emphasis> shake, measure with oral syringe or calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3590">
							<label>•</label>
							<sec_title>Cont rel tab</sec_title>
							<para>
								<list id="lidelem4x3590">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Cont rel tab:</emphasis> do not cut, chew, crush; do not give concurrently with antacids</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3595">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3598">
					<section type="none" id="sidelem4x3599">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> nervousness, insomnia, <emphasis style="italic">drowsiness, anxiety, tremors, dizziness,</emphasis> fatigue, <emphasis style="italic">sedation,</emphasis> abnormal dreams, agitation, apathy, euphoria, hallucinations, delusions, psychosis, <emphasis style="bold">seizures, neuroleptic-malignant-syndrome–like reactions,</emphasis> restless leg syndrome</para>
					</section>
					<section type="none" id="sidelem4x3616">
						<sec_title>CV:</sec_title>
						<para> Vasodilation, postural hypotension, palpitations, bleeding</para>
					</section>
					<section type="none" id="sidelem4x3621">
						<sec_title>EENT:</sec_title>
						<para> Visual changes</para>
					</section>
					<section type="none" id="sidelem4x3626">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, dry mouth,</emphasis> anorexia, dyspepsia, <emphasis style="italic">constipation,</emphasis> cramps, vomiting, taste changes, flatulence, decreased appetite</para>
					</section>
					<section type="none" id="sidelem4x3637">
						<sec_title>GU:</sec_title>
						<para> Dysmenorrhea, decreased libido, urinary frequency, UTI, amenorrhea, cystitis, impotence; decreased sperm quality, decreased fertility, <emphasis style="italic">abnormal ejaculation (male)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x3644">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Sweating,</emphasis> rash</para>
					</section>
					<section type="none" id="sidelem4x3652">
						<sec_title>MS:</sec_title>
						<para> Pain, arthritis, myalgia, myopathy, myosthenia</para>
					</section>
					<section type="none" id="sidelem4x3657">
						<sec_title>RESP:</sec_title>
						<para> Infection, pharyngitis, nasal congestion, sinus headache, sinusitis, cough, dyspnea, yawning</para>
					</section>
					<section type="none" id="sidelem4x3662">
						<sec_title>SYST:</sec_title>
						<para> Asthenia, fever, abrupt withdrawal syndrome</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x3667">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x3670">
					<section type="none" id="sidelem4x3671">
						<sec_title>PO:</sec_title>
						<para> Peak 5.2 hr, ext rel peak 6-10 hr; metabolized in liver by CYP2D6 enzyme system, unchanged products and metabolites excreted in feces and urine; half-life 21 hr (reg rel); 15-20 hr (cont rel); protein binding 95%</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x3676">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: serotonin syndrome—SSRIs, SNRIs, atypical psychotics, serotonin-receptor agonists, tricyclics, amphetamines, methylphenidate, traMADol</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> level of digoxin</para>
				<para>
					<emphasis alert="nurse">Do not use with MAOIs, pimozide, thioridazine; potentially fatal reactions can occur</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding—NSAIDs, thrombolytics, salicylates, platelet inhibitors, anticoagulants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> PARoxetine plasma levels—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> agitation—<emphasis style="smallcaps">l</emphasis>-tryptophan</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—highly protein-bound products</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> theophylline levels—theophylline</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity—CYP2D6 inhibitors (aprepitant, delavirdine, imatinib, nefazodone)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> PARoxetine levels—PHENobarbital and phenytoin</para>
				<section type="none" id="sidelem4x3724">
					<section type="none" id="sidelem4x3725">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x3730">
								<item>
									<label>•</label>
									<para>Avoid use with St. John’s wort, kava</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3735">
								<item>
									<label>•</label>
									<para>Possible serotonin syndrome: St. John’s wort</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3743">
							<label>•</label>
							<sec_title>Hypertensive crisis<route> ephedra</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x3746">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x3749">
					<section type="none" id="sidelem4x3750">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Depression/OCD/anxiety/panic attacks:</emphasis> mental status: mood, sensorium, affect, suicidal tendencies (especially in child/young adult), increase in psychiatric symptoms, decreasing obsessive thoughts, compulsive behaviors, restrict amount available</bbw>
						</para>
						<section type="none" id="sidelem4x3769">
							<label>•</label>
							<sec_title>Postural hypotension</sec_title>
							<para>
								<list id="lidelem4x3769">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Postural hypotension:</emphasis> B/P (lying/standing), pulse q4hr; if systolic B/P drops 20 mm Hg, hold product, notify prescriber; take vital signs q4hr for patients with CV disease</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3773">
								<item>
									<label>•</label>
									<para>Hepatic/renal studies: AST, ALT, bilirubin, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3778">
								<item>
									<label>•</label>
									<para>Weight weekly; appetite may decrease with product, constipation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3786">
							<label>•</label>
							<sec_title>
								<route>ECG for flattening of T wave, bundle branch or AV block, dysrhythmias in cardiac patients</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x3789">
								<item>
									<label>•</label>
									<para>EPS, primarily in geriatric patients: rigidity, dystonia, akathisia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x3797">
							<label>•</label>
							<sec_title>Renal status</sec_title>
							<para>
								<list id="lidelem4x3797">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Renal status:</emphasis> BUN, creatinine, urinary retention</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x3804">
							<label>•</label>
							<sec_title>Withdrawal symptoms</sec_title>
							<para>
								<list id="lidelem4x3804">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Withdrawal symptoms:</emphasis> headache, nausea, vomiting, muscle pain, weakness; not usual unless product discontinued abruptly, taper over 1-2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x3808">
								<item>
									<label>•</label>
									<para>Alcohol intake; if alcohol is consumed, hold dose until morning</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x3815">
								<item>
									<para>
										<emphasis alert="nurse">Serotonin, neuroleptic malignant syndrome: hallucinations, coma, headache, agitation, shivering, sweating, tachycardia, diarrhea, tremors, hypertension, hyperthermia, rigidity, delirium, coma, myoclonus, agitation, nausea, vomiting</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3820">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x3824">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased depression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x3830">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x3834">
								<item>
									<label>•</label>
									<para>That therapeutic effect may take 1-4 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To use caution when driving, performing other activities requiring alertness because of drowsiness, dizziness, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue medication quickly after long-term use; may cause nausea, headache, malaise (abrupt withdrawal syndrome)</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>That depression may worsen, suicidal thoughts/behaviors; children/adolescents, young adults, to notify prescriber</bbw>
						</para>
						<para>
							<list id="lidelem4x3860">
								<item>
									<label>•</label>
									<para>To avoid alcohol ingestion, OTC products unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To report bleeding, headache, nausea, anxiety, or if depression continues</para>
								</item>
								<item>
									<label>•</label>
									<para>To discuss sexual side effects: impotence, possible male infertility while taking product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active" ha="yes">
			<mono_name> pazopanib</mono_name>
			<info>
				<pronunciation>(paz-oh′pa-nib)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x38880">Votrient</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic response modifiers/multikinase angiogenesis inhibitor</class>
				<class type="chem"> Kinase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x3898">
				<sec_title>Action:</sec_title>
				<para>Targets vascular endothelial growth factor receptors; a multikinase angiogenesis inhibitor</para>
			</section>
			<section type="uses" id="sidelem4x3903">
				<sec_title>Uses:</sec_title>
				<para>Advanced renal cell carcinoma; soft-tissue sarcoma patients who have received prior chemotherapy</para>
				<section type="none" id="sidelem4x3908">
					<section type="none" id="sidelem4x3909">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Breast, ovarian cancer</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x3914">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypothyroidism, QT prolongation, MI, wound dehiscence, hypertension</para>
				<section type="none" id="sidelem4x3919">
					<section type="none" id="sidelem4x3920">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, cardiac/renal/hepatic/dental disease, GI bleeding</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x3935">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x3943">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x3943">
							<item>
								<label>•</label>
								<para> 800 mg/day without food (1 hr before, 2 hr after a meal), may decrease to 400 mg/day if not tolerated (renal cell cancer); or adjust in 200-mg increments based on toxicity (soft-tissue sarcoma)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x3947">
					<section type="none" id="sidelem4x3948">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 200 mg</para>
					</section>
					<section type="none" id="sidelem4x3953">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x3957">
								<item>
									<label>•</label>
									<para>Give on an empty stomach (1 hr before or 2 hr after a meal); separate doses by ∼24 hr</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush tablets owing to the potential for an increased rate of absorption, which can affect systemic exposure; only intact, whole tablets should be used</para>
								</item>
								<item>
									<label>•</label>
									<para>If a dose is missed, it should not be taken if it is &lt;12 hr until the next dose</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at 77°F (25°C)</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x3978">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x3981">
					<section type="none" id="sidelem4x3982">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Intracranial bleeding,</emphasis> headache</para>
					</section>
					<section type="none" id="sidelem4x3990">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure,</emphasis> hypertension, <emphasis style="bold">hypertensive crisis,</emphasis> chest pain, <emphasis style="bold">MI, QT prolongation, torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4003">
						<sec_title>GI:</sec_title>
						<para> Nausea, <emphasis style="bold">hepatotoxicity,</emphasis> vomiting, dyspepsia, <emphasis style="bold">GI hemorrhage,</emphasis> anorexia, abdominal pain, <emphasis style="bold">GI perforation, pancreatitis,</emphasis> diarrhea; <emphasis style="bold">hepatotoxicity (geriatric)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4019">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, thrombocytopenia, bleeding</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4026">
						<sec_title>INTEG:</sec_title>
						<para> Rash, alopecia</para>
					</section>
					<section type="none" id="sidelem4x4031">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, epistaxis, pyrexia, hot sweats, increased weight, flulike symptoms, hypothyroidism, <emphasis style="bold">hand–foot syndrome,</emphasis> retinal tear/detachment</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4040">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding 99%, peak 2-4 hr, duration 24 hr, half-life 31 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4045">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pazopanib concentrations—CYP3A4 inhibitors (ketoconazole, itraconazole, erythromycin, clarithromycin)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentrations of simvastatin, calcium-channel blockers, ergots</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> plasma concentration of warfarin; avoid use with warfarin; use low-molecular-weight anticoagulants instead</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pazopanib concentrations—CYP3A4 inducers (dexamethasone, phenytoin, carBAMazepine, rifampin, PHENobarbital)</para>
				<section type="none" id="sidelem4x4067">
					<section type="none" id="sidelem4x4068">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> pazopanib effect—grapefruit juice; avoid use while taking product</para>
					</section>
					<section type="none" id="sidelem4x4075">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> pazopanib concentration—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4082">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4085">
					<section type="none" id="sidelem4x4086">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Hepatic disease: fatal hepatotoxicity can occur; obtain LFTs baseline and at least every 2 wk × 2 mo, then monthly</bbw>
						</para>
						<para>
							<emphasis alert="nurse">Fatal bleeding: from GI, respiratory, GU tracts, permanently discontinue in those with severe bleeding</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Palmar-plantar erythrodysesthesia (hand-foot syndrome): more common in those previously treated; reddening swelling, numbness, desquamation on palms and soles</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">GI perforation/fistula: discontinue if this occurs, assess for pain in epigastric area, dyspepsia, flatulence, fever, chills</emphasis>
						</para>
						<para>
							<emphasis alert="nurse">Hypertension/hypertensive crisis: hypertension usually occurs in the first cycle; in those with preexisting hypertension, do not start treatment until B/P is controlled; monitor B/P every wk × 6 wk, then at start of each cycle or more often if needed, temporarily or permanently discontinue for severe uncontrolled hypertension</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4119">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4123">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased in size, spread of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4129">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4133">
								<item>
									<label>•</label>
									<para>To report adverse reactions immediately: bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>About reason for treatment, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>That effect on male fertility is unknown</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="14" status="active" ha="yes">
			<mono_name> pegfilgrastim (Rx)</mono_name>
			<info>
				<pronunciation>(peg-fill-grass′stim)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x41560">Neulasta</tradename>
				</tradenames>
				<class type="func"> Hematopoietic agent</class>
				<class type="chem"> Granulocyte colony-stimulating factor</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4166">
				<sec_title>Action:</sec_title>
				<para>Stimulates proliferation and differentiation of neutrophils</para>
			</section>
			<section type="uses" id="sidelem4x4171">
				<sec_title>Uses:</sec_title>
				<para>To decrease infection in patients receiving antineoplastics that are myelosuppressive; to increase WBC count in patients with product-induced neutropenia</para>
			</section>
			<section type="contra" id="sidelem4x4176">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to proteins of <emphasis style="italic">Escherichia coli,</emphasis> filgrastim</para>
				<section type="none" id="sidelem4x4184">
					<section type="none" id="sidelem4x4185">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;45 kg, adolescents, myeloid malignancies, sickle cell disease, leukocytosis, splenic rupture, ARDS, allergic-type reactions, peripheral blood stem cell (PBSC) mobilization</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4191">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4199">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x4199">
							<item>
								<label>•</label>
								<para> 6 mg per chemotherapy cycle</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4203">
					<section type="none" id="sidelem4x4204">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 6 mg/0.6 ml</para>
					</section>
					<section type="none" id="sidelem4x4209">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4212">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x4216">
									<item>
										<label>•</label>
										<para>Using single-use vials; after dose is withdrawn, do not reenter vial</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use 6-mg fixed dose in infants, children, or others &lt;45 kg</para>
									</item>
									<item>
										<label>•</label>
										<para>Inspect sol for discoloration, particulates; if present, do not use</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer during the period 14 days before and 24 hr after cytotoxic chemotherapy</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in refrigerator; do not freeze; may store at room temperature up to 6 hr; avoid shaking, protect from light</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4242">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4245">
					<section type="none" id="sidelem4x4246">
						<sec_title>CNS:</sec_title>
						<para> Fever, fatigue, headache, dizziness, insomnia, peripheral edema</para>
					</section>
					<section type="none" id="sidelem4x4251">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, mucositis, anorexia, constipation, dyspepsia, abdominal pain, stomatitis, <emphasis style="bold">splenic rupture</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4261">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukocytosis, granulocytopenia, sickle cell crisis, hemoglobin S disease with crisis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4268">
						<sec_title>INTEG:</sec_title>
						<para> Alopecia</para>
					</section>
					<section type="none" id="sidelem4x4273">
						<sec_title>MISC:</sec_title>
						<para> Chest pain, hyperuricemia, <emphasis style="bold">anaphylaxis, influenza-like illness, angioedema, antibody formation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4280">
						<sec_title>MS:</sec_title>
						<para> Skeletal pain</para>
					</section>
					<section type="none" id="sidelem4x4285">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory distress syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4292">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life: 15-80 hr; 20-38 hr (children)</para>
			</section>
			<section type="interactions" id="sidelem4x4297">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x4305">
					<label>•</label>
					<sec_title>
						<route>Do not use product concomitantly, 2 wk before, or 24 hr after administration of cytotoxic chemotherapy</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> release of neutrophils—lithium</para>
				<section type="none" id="sidelem4x4312">
					<section type="none" id="sidelem4x4313">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> uric acid, LDH, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4320">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4323">
					<section type="none" id="sidelem4x4324">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x4330">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions, anaphylaxis: rash, urticaria; discontinue product, have emergency equipment nearby</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4336">
								<item>
									<para>
										<emphasis alert="nurse">ARDS: dyspnea, fever, tachypnea, occasionally confusion; obtain ABGs, chest x-ray; product may need to be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4344">
							<label>•</label>
							<sec_title>
								<route>Bone pain;</route>
							</sec_title>
							<para>
								<list id="lidelem4x4344">
									<item>
										<label>•</label>
										<para> give mild analgesics</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4348">
								<item>
									<label>•</label>
									<para>Blood studies: CBC with differential, platelet count before treatment, 2× weekly; neutrophil counts may be increased for 2 days after therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4353">
								<item>
									<label>•</label>
									<para>B/P, respirations, pulse before and during therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4358">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4362">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4368">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4373">
								<item>
									<label>•</label>
									<para>How to perform the technique for self-administration if product to be given at home: dose, side effects, disposal of containers and needles; provide instruction sheet</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4381">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber immediately of allergic reaction, trouble breathing, abdominal pain</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name> peginterferon alfa-2a (Rx)</mono_name>
			<info>
				<pronunciation>(peg-in-ter-feer′on)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x43910">Pegasys</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="16" status="active">
			<mono_name>peginterferon alfa-2b (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x43961">PegIntron</tradename>
					<tradename id="tnidelem4x43960">SYLATRON</tradename>
				</tradenames>
				<class type="func"> Immunomodulator</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4402">
				<sec_title>Action:</sec_title>
				<para>Stimulates genes to modulate many biologic effects, including the inhibition of viral replication; inhibits ion cell proliferation, immunomodulation; stimulates effector proteins; decreases leukocyte, platelet counts</para>
			</section>
			<section type="uses" id="sidelem4x4407">
				<sec_title>Uses:</sec_title>
				<para>Chronic hepatitis C infections in adults with compensated liver disease; chronic hepatitis B in adults who are HBe AG positive, HBe AG negative; HCV patients coinfected with HIV; nonresponders or relapsers with chronic hepatitis C, malignant melanoma</para>
				<section type="none" id="sidelem4x4414">
					<section type="none" id="sidelem4x4415">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adenovirus, coronavirus, encephalomyocarditis virus, herpes simplex types 1 and 2, hepatitis D, acute hepatitis C, HIV, HPV, polio virus, rhinovirus, varicella-zoster, variola, vesicular stomatitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x4420">
				<sec_title>Contraindications:</sec_title>
				<para>Neonates, infants, sepsis; hypersensitivity to interferons, benzyl alcohol, <emphasis style="italic">Escherichia coli</emphasis> protein</para>
				<section type="none" id="sidelem4x4428">
					<section type="none" id="sidelem4x4429">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, geriatric patients, thyroid disorders, myelosuppression, renal/hepatic disease, suicidal/homicidal ideation, preexisting ophthalmologic disorders, pancreatitis, hemodialysis</para>
						<para>
							<bbw>Cardiac disease, depression, autoimmune disease, infection, use with ribavirin</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4444">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4447">
					<section type="none" id="sidelem4x4448">
						<sec_title>Pegasys</sec_title>
						<section type="none" id="sidelem4x4456">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4456">
									<item>
										<label>•</label>
										<para> 180 mcg weekly × 48 wk; if poorly tolerated, reduce dose to 135 mcg weekly; in some cases, reduction to 90 mcg may be needed</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4460">
						<sec_title>Peg-Intron</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x4464">
						<sec_title>(chronic hepatitis C with compensated liver disease)</sec_title>
						<section type="none" id="sidelem4x4472">
							<label>•</label>
							<sec_title>Adult &gt;105 kg<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4472">
									<item>
										<label>•</label>
										<para> 1.5 mcg/kg/wk plus ribavirin 600 mg in <emphasis style="smallcaps">am</emphasis> and 800 mg in <emphasis style="smallcaps">pm</emphasis> plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">86-105 kg:</emphasis> 150 mcg/0.5 ml (0.5 ml of 150 mcg vial or Redipen) per wk plus ribavirin 1200 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">81-85 kg:</emphasis> 120 mcg/0.5 ml (0.5 ml of 120 mcg vial or Redipen) per wk plus ribavirin 1200 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">76-80 kg:</emphasis> 120 mcg/0.5 ml (0.5 ml of 120 mcg vial or Redipen) per wk plus ribavirin 400 mg in <emphasis style="smallcaps">am</emphasis> and 600 mg in <emphasis style="smallcaps">pm</emphasis> plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">66-75 kg:</emphasis> 96 mcg/0.4 ml (0.4 ml of 120 mcg vial or Redipen) per wk plus ribavirin 400 mg in <emphasis style="smallcaps">am</emphasis> and 600 mg in <emphasis style="smallcaps">pm</emphasis> plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">61-65 kg:</emphasis> 96 mcg/0.4 ml (0.4 ml of 120 mcg vial or Redipen) per wk plus ribavirin 800 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">51-60 kg:</emphasis> 80 mcg/0.5 ml (0.5 ml of 80 mcg vial or Redipen) per wk plus ribavirin 800 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">40-50 kg:</emphasis> 64 mcg/0.4 ml (0.4 ml of 80 mcg vial or Redipen) per wk plus ribavirin 800 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor; <emphasis style="bold">&lt;40 kg:</emphasis> 50 mcg/0.5 ml (0.5 ml of 50 mcg vial or Redipen) per wk plus ribavirin 800 mg/day in 2 divided doses plus a HCV NS3/4A protease inhibitor</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4518">
						<sec_title>Malignant melanoma (SYLATRON only)</sec_title>
						<section type="none" id="sidelem4x4526">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x4526">
									<item>
										<label>•</label>
										<para> 6 mcg/kg/wk × 8 wk then 3 mcg/kg/wk × ≤5 yr, premedicate with acetaminophen 500-1000 mg 30 min before first dose, prn for subsequent doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x4530">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="bold">Pegasys:</emphasis> inj 180 mcg/0.5 ml; <emphasis style="bold">Pegintron:</emphasis> 50, 80, 120, 150 mcg/0.5 ml; <emphasis style="bold">SYLATRON</emphasis> 296, 444, 888 mcg powder for inj</para>
					</section>
					<section type="none" id="sidelem4x4544">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x4548">
								<item>
									<label>•</label>
									<para>In evening to reduce discomfort, to allow patient to sleep through some side effects</para>
								</item>
								<item>
									<label>•</label>
									<para>Continue pediatric dose in those who turn 18 yr</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4559">
							<sec_title>Interferon alfa-2a</sec_title>
							<para>
								<list id="lidelem4x4563">
									<item>
										<label>•</label>
										<para>Use prefilled syringes; store in refrigerator</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4569">
							<sec_title>Interferon alfa-2b</sec_title>
							<para/>
						</section>
						<section type="none" id="sidelem4x4573">
							<sec_title>SUBCUT/IM route</sec_title>
							<para>
								<list id="lidelem4x4577">
									<item>
										<label>•</label>
										<para>Reconstitute with 1 ml of provided diluent/10-, 18-, or 50-million unit vials, swirl; sol for inj vials do not need reconstitution</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4583">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4586">
					<section type="none" id="sidelem4x4587">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, insomnia, dizziness,</emphasis> anxiety, hostility, lability, nervousness, depression, fatigue, poor concentration, pyrexia, <emphasis style="bold">suicidal ideation, homicidal ideation,</emphasis> relapse of drug addiction, emotional lability, mania, psychosis</para>
					</section>
					<section type="none" id="sidelem4x4600">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Ischemic CV events</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4607">
						<sec_title>ENDO:</sec_title>
						<para> Hypothyroidism, diabetes</para>
					</section>
					<section type="none" id="sidelem4x4612">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Abdominal pain, nausea, diarrhea, anorexia, vomiting,</emphasis> dry mouth, <emphasis style="bold">fatal colitis, fatal pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4622">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia,</emphasis> neutropenia, anemia, lymphopenia</para>
					</section>
					<section type="none" id="sidelem4x4630">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Alopecia, pruritus, rash,</emphasis> dermatitis</para>
					</section>
					<section type="none" id="sidelem4x4638">
						<sec_title>MISC:</sec_title>
						<para> Blurred vision, inj-site reaction, rigors</para>
					</section>
					<section type="none" id="sidelem4x4643">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="italic">Back pain,</emphasis> myalgia, arthralgia</para>
					</section>
					<section type="none" id="sidelem4x4651">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4656">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 15-80 hr, large variability in other pharmacokinetics</para>
			</section>
			<section type="interactions" id="sidelem4x4661">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x4665">
						<item>
							<label>•</label>
							<para>Use caution when giving with theophylline, myelosuppressive agents</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hepatic damage-NNRTIs, NRTIs, protein inhibitors</para>
				<section type="none" id="sidelem4x4675">
					<section type="none" id="sidelem4x4676">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> triglycerides, ALT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb, platelets, WBCs, neutrophils</para>
						<para>
							<emphasis style="bold">Abnormal:</emphasis> thyroid function test</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x4691">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4694">
					<section type="none" id="sidelem4x4695">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4703">
							<label>•</label>
							<sec_title>Neuropsychiatric symptoms</sec_title>
							<para>
								<list id="lidelem4x4703">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Neuropsychiatric symptoms:</emphasis> severe depression with suicidal ideation; monitor q3wk then 8 wk, then q6mo</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4707">
								<item>
									<label>•</label>
									<para>B/P, blood glucose, ophthalmic exam, pulmonary function</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4712">
								<item>
									<label>•</label>
									<para>ALT, HCV viral load; patients who show no reduction in ALT, HCV unlikely to show benefit of treatment after 6 mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4717">
								<item>
									<label>•</label>
									<para>Platelet counts, heme concentration, ANC, serum creatinine concentration, albumin, bilirubin, TSH, T<emphasis style="inf">4</emphasis>, AFP</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4726">
								<item>
									<para>
										<emphasis alert="nurse">Myelosuppression: hold dose if neutrophil count is &lt;500 × 10<emphasis style="sup">6</emphasis>/L or if platelets are &lt;50 × 10<emphasis style="sup">9</emphasis>/L</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x4740">
							<label>•</label>
							<sec_title>Hypersensitivity</sec_title>
							<para>
								<list id="lidelem4x4740">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypersensitivity:</emphasis> discontinue immediately if hypersensitivity occurs</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x4747">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x4747">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> vital signs, increased WBCs, fever; product may need to be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<emphasis alert="nurse">Colitis/pancreatitis: may be fatal; diarrhea, fever, nausea, vomiting, severe abdominal pain; if these occur, product should be discontinued</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x4756">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x4760">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased chronic hepatitis C signs, symptoms; undetectable viral load</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x4766">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x4771">
								<item>
									<label>•</label>
									<para>Provide patient or family member with written, detailed information about product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4776">
								<item>
									<label>•</label>
									<para>Use 2 forms of effective contraception throughout treatment and for 6 mo after treatment (men and women) (combination therapy with ribavirin)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4781">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if dizziness, confusion, fatigue, somnolence occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4786">
								<item>
									<label>•</label>
									<para>To use puncture-resistant container for disposal of needles/syringes if using at home</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x4792">
								<item>
									<para>
										<emphasis alert="nurse">To report suicidal/homicidal ideation, visual changes, bleeding/bruising, pulmonary symptoms</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>pegloticase (Rx)</mono_name>
			<info>
				<pronunciation>(peg-loe′ti-kase)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x48020">Krystexxa</tradename>
				</tradenames>
				<class type="func"> Antigout agent</class>
				<class type="chem"> Pegylated, recombinant, mammalian urate oxidase enzyme</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x4812">
				<sec_title>Action:</sec_title>
				<para>Lowers plasma uric acid concentration by converting uric acid to allantoin, which is readily excreted by the kidneys</para>
			</section>
			<section type="uses" id="sidelem4x4817">
				<sec_title>Uses:</sec_title>
				<para>Chronic gout in patients experiencing treatment failure</para>
			</section>
			<section type="contra" id="sidelem4x4822">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, G6PD deficiency</para>
				<section type="none" id="sidelem4x4827">
					<section type="none" id="sidelem4x4828">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children/infants/neonates, African-American patients, heart failure</para>
						<para>
							<bbw>Requires specialized setting, experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x4844">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x4852">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x4852">
							<item>
								<label>•</label>
								<para> 8 mg over 2 hr q2wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x4856">
					<section type="none" id="sidelem4x4857">
						<sec_title>Available forms:</sec_title>
						<para> Sol for inj 8 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x4862">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x4865">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x4873">
								<label>•</label>
								<sec_title>Reconstitute</sec_title>
								<para>
									<list id="lidelem4x4873">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Reconstitute:</emphasis>
												</emphasis> visually inspect for particulate matter, discoloration whenever sol/container permits; use aseptic technique; withdraw 8 mg (1 ml) of product/250 ml 0.9% NaCl or 0.45% NaCl; invert several times to mix, do not shake; discard remaining product in vial</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4881">
								<label>•</label>
								<sec_title>Premedicate</sec_title>
								<para>
									<list id="lidelem4x4881">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Premedicate:</emphasis>
												</emphasis> with antihistamines and corticosteroids in all patients and acetaminophen if deemed necessary to prevent anaphylaxis, infusion site reactions</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x4889">
								<label>•</label>
								<sec_title>Infusion</sec_title>
								<para>
									<list id="lidelem4x4889">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Infusion:</emphasis>
												</emphasis> if refrigerated, allow to come to room temperature; do not warm artificially; give over 120 min; do not give IV push or bolus; use infusion by gravity feed, syringe-type pump, or infusion pump; given in a specialized setting by those who can manage anaphylaxis or inj-site reactions; monitor during and for 1 hr after infusion; if reaction occurs, slow or stop infusion, may be restarted at a slower rate; do not admix</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x4894">
									<item>
										<label>•</label>
										<para>Store diluted product in refrigerator or at room temperature for up to 4 hr; refrigerator is preferred; protect from light; do not freeze; use within 4 hr of preparation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x4899">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x4902">
					<section type="none" id="sidelem4x4903">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x4908">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Chest pain,</emphasis><emphasis style="bold">heart failure,</emphasis> hypotension</para>
					</section>
					<section type="none" id="sidelem4x4918">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, constipation</para>
					</section>
					<section type="none" id="sidelem4x4926">
						<sec_title>GU:</sec_title>
						<para> Nephrolithiasis</para>
					</section>
					<section type="none" id="sidelem4x4931">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4938">
						<sec_title>INTEG:</sec_title>
						<para> Ecchymosis, <emphasis style="italic">erythema, pruritus, urticaria</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4945">
						<sec_title>MS:</sec_title>
						<para> Back pain, arthralgia, muscle spasm</para>
					</section>
					<section type="none" id="sidelem4x4950">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Antibody formation, infection, anaphylaxis, infusion-related reactions</emphasis></para>
					</section>
					<section type="none" id="sidelem4x4957">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea,</emphasis> upper respiratory infection</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x4965">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Remains primarily in intravascular space after administration, elimination half-life 2 wk, mean nadir uric acid concentration 24-72 hr</para>
			</section>
			<section type="interactions" id="sidelem4x4970">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Do not use with urate-lowering agents (allopurinol, probenecid, febuxostat, sulfinpyrazone)</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x4976">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x4979">
					<section type="none" id="sidelem4x4980">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x4988">
							<label>•</label>
							<sec_title>Gout</sec_title>
							<para>
								<list id="lidelem4x4988">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Gout:</emphasis> pain in big toe, feet, knees, redness, swelling, tenderness lasting a few days to weeks; intake of alcohol, purines, if patient is overweight or taking diuretics</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x4992">
								<item>
									<label>•</label>
									<para>Obtain uric acid levels at baseline, before administration; 2 consecutive uric acid levels of &gt;6 mg/dl may indicate therapy failure; greater chance of anaphylaxis; infection-related reactions</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Specialized care setting: use only in facility where emergency equipment is available, anaphylaxis may occur</bbw>
						</para>
						<para>
							<bbw>Infusion reactions: monitor for reactions for ≥1 hr after use</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x5017">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5021">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease uric acid levels; relief of pain, swelling, redness in toes, feet, knees</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5027">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5031">
								<item>
									<label>•</label>
									<para>About reason for infusion, expected results</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber during infusion of allergic reactions or redness, swelling, pain at infusion site</para>
								</item>
								<item>
									<label>•</label>
									<para>That continuing follow-up exams and uric acid levels will be needed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ha="yes">
			<mono_name> PEMEtrexed (Rx)</mono_name>
			<info>
				<pronunciation>(pem-ah-trex′ed)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x50550">Alimta</tradename>
				</tradenames>
				<class type="func"> Antineoplastic-antimetabolite</class>
				<class type="chem"> Folic acid antagonist</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x5065">
				<sec_title>Action:</sec_title>
				<para>Inhibits multiple enzymes that reduce folic acid, which is needed for cell replication</para>
			</section>
			<section type="uses" id="sidelem4x5070">
				<sec_title>Uses:</sec_title>
				<para>Malignant pleural mesothelioma in combination with CISplatin; non–small-cell lung cancer as single agent; nonsquamous, non–small-cell lung cancer (1st-line treatment)</para>
				<section type="none" id="sidelem4x5075">
					<section type="none" id="sidelem4x5076">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Bladder, breast, colorectal, gastric, head/neck, pancreatic, renal cancers</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x5081">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, ANC &lt;1500 cells/mm<emphasis style="sup">3</emphasis>, CCr &lt;45 ml/min, thrombocytopenia (&lt;100,000/mm<emphasis style="sup">3</emphasis>), anemia</para>
				<section type="none" id="sidelem4x5092">
					<section type="none" id="sidelem4x5093">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5098">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5106">
					<label>•</label>
					<sec_title>Adult<route> IV INFUSION</route></sec_title>
					<para>
						<list id="lidelem4x5106">
							<item>
								<label>•</label>
								<para> 500-600 mg/m<emphasis style="sup">2</emphasis> given over 10 min on day 1 of 21-day cycle with CISplatin 75 mg/m<emphasis style="sup">2</emphasis> infused over 2 hr beginning <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr after end of PEMEtrexed infusion</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5122">
					<section type="none" id="sidelem4x5123">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x5131">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION CCr &lt;45 ml/min, not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5134">
						<sec_title>Available forms:</sec_title>
						<para> Inj, single-use vials, 100, 500 mg</para>
					</section>
					<section type="none" id="sidelem4x5139">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x5143">
								<item>
									<label>•</label>
									<para>Store at 77° F, excursions permitted at 59° F to 86° F, not light sensitive, discard unused portions</para>
								</item>
								<item>
									<label>•</label>
									<para>Vit B<emphasis style="inf">12</emphasis> and low-dose folic acid as prophylactic measure to treat related hematologic, GI toxicity; 400-1000 mcg/day × 7 days before 1st dose and × 21 days after last dose, vit B<emphasis style="inf">12</emphasis> 1 mg IM 1 wk before 1st dose and q 3 cycles (9 wk) thereafter</para>
								</item>
								<item>
									<label>•</label>
									<para>Premedicate with corticosteroid (dexamethasone) given PO bid day before, day of, and day after administration of PEMEtrexed</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5165">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<section type="none" id="sidelem4x5173">
								<label>•</label>
								<sec_title>
									<route>Use cytotoxic handling procedures</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x5176">
									<item>
										<label>•</label>
										<para>Reconstitute 500-mg vial/20 ml 0.9% NaCl inj (preservative free) = 25 mg/ml, swirl until dissolved, further dilute with 100 ml 0.9% NaCl inj (preservative free), give as IV infusion over 10 mg</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5181">
									<item>
										<label>•</label>
										<para>Use only 0.9% NaCl inj (preservative free) for reconstitution, dilution</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5190">
								<label>•</label>
								<sec_title>
									<route>Do not begin a new cycle unless neutrophils (ANC) are ≥1500 cells/mm3, platelets are ≥100,000 cells/mm3, CCr is ≥45 ml/min</route>
								</sec_title>
							</section>
							<section type="none" id="sidelem4x5202">
								<label>•</label>
								<sec_title>Platelet nadir &lt;50,000/mm3 regardless of the ANC<route> if necessary, delay until platelet count recovery, reduce PEMEtrexed and CISplatin by 50%; if grade 3/4 toxicity occurs after 2 reductions, discontinue both products</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5211">
								<label>•</label>
								<sec_title>ANC nadir &lt;500/mm3 when platelet nadir is ≥50,000/mm3<route> if necessary, delay until ANC recovery, reduce PEMEtrexed and CISplatin by 75%; if grade 3/4 toxicity occurs after 2 reductions, discontinue both products</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5223">
								<label>•</label>
								<sec_title>CTC Grade 3/4 nonhematologic toxicity including diarrhea requiring hospitalization and excluding neurotoxicity, mucositis, and grade 3 transaminase elevations<route> withhold therapy until pretherapy value or condition, reduce by 75% both products; if grade 3 or 4 toxicity occurs after 2 reductions, discontinue both products</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5229">
								<label>•</label>
								<sec_title>CTC grade 3/4 mucositis<route> withhold therapy until pretherapy condition, reduce 50% of PEMEtrexed; if grade 3 or 4 mucositis occurs after 2 dosage reductions, discontinue both products</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5235">
								<label>•</label>
								<sec_title>CTC grade 2 neurotoxicity<route> withhold therapy until pretherapy value or condition, reduce dose of CISplatin by 50%</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5241">
								<label>•</label>
								<sec_title>CTC grade 3/4 neurotoxicity<route> discontinue both products</route></sec_title>
							</section>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir sodium, alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, ampicillin, ampicillin-sulbactam, atenolol, atracurium, azithromycin, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, CARBOplatin, carmustine, ceftizoxime, cefTRIAXone, cefuroxime, cimetidine, cisatracurium, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOCEtaxel, dolasetron, DOPamine, doxacurium, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, ertapenem, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, ganciclovir, gatifloxacin, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem-cilastatin, insulin (regular), isoproterenol, ketorolac, labetalol, leucovorin, levofloxacin, lidocaine, linezolid, LORazepam, magnesium, mannitol, meperidine, meropenem, mesna, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, midazolam, milrinone, mitoMYcin, mivacurium, morphine, moxifloxacin, nafcillin, naloxone, nesiritide, nitroglycerin, norepinephrine, octreotide, oxaliplatin, PACLitaxel, pamidronate, pancuronium, PENTobarbital, PHENobarbital, piperacillin-tazobactam, polymyxin B, potassium chloride/phosphates, procainamide, promethazine, propranolol, ranitidine, remifentanil, rocuronium, sodium acetate/bicarbonate/phosphates, succinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, theophylline, thiopental, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, trimethobenzamide, vancomycin, vecuronium, verapamil, vinBLAStine, vinCRIStine, vinorelbine, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5248">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5251">
					<section type="none" id="sidelem4x5252">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Fatigue</emphasis>, <emphasis style="italic">fever</emphasis>, <emphasis style="italic">mood alteration, neuropathy</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5265">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Thrombosis/embolism,</emphasis><emphasis style="italic">chest pain,</emphasis> arrhythmia exacerbation</para>
					</section>
					<section type="none" id="sidelem4x5275">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea, ulcerative stomatitis, constipation, dysphagia, dehydration</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5282">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure,</emphasis> creatinine elevation</para>
					</section>
					<section type="none" id="sidelem4x5290">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Neutropenia, leukopenia, thrombocytopenia, myelosuppression, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5297">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, desquamation</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5304">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Dyspnea</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5311">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Infection with/without neutropenia, radiation recall reaction, toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x5318">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Not metabolized; excreted in urine (unchanged 70%-90%); not known if excreted in breast milk; half-life 3.5 hr, 81% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x5323">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, platelet inhibitors, salicylates, thrombolytics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> clearance of PEMEtrexed—nephrotoxic products</para>
			</section>
			<section type="considerations" id="sidelem4x5334">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5337">
					<section type="none" id="sidelem4x5338">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5344">
								<item>
									<para>
										<emphasis alert="nurse">Previous radiation treatments; radiation recall reactions have occurred (erythema, exfoliative dermatitis, pain, burning)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5350">
								<item>
									<para>
										<emphasis alert="nurse">Bone marrow depression: CBC, differential, platelet count; monitor for nadir, recovery; new cycle should not begin if ANC &lt;1500 cells/mm<emphasis style="sup">3</emphasis>, platelets &lt;100,000 cells/mm<emphasis style="sup">3</emphasis>, CCr &lt;45 ml/min</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5361">
								<item>
									<label>•</label>
									<para>Renal studies: BUN, serum uric acid, urine CCr, electrolytes before, during therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5366">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report fall in urine output to &lt;30 ml/hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5371">
								<item>
									<label>•</label>
									<para>Monitor temperature q4hr; fever may indicate beginning infection; no rectal temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5378">
								<item>
									<para>
										<emphasis alert="nurse">Neurotoxicity: CTC grade 2: withhold until resolution to at least pretherapy value/condition, reduce CISplatin by 50%; CTC grade 3-4: immediately discontinue product and CISplatin if given in combination</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5386">
							<label>•</label>
							<sec_title>Mucositis</sec_title>
							<para>
								<list id="lidelem4x5386">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Mucositis:</emphasis> CTC 3/4: withhold until resolution to at least pretherapy value/condition, reduce dose by 50%; if grade 3/4 occurs after 2 dosage reductions, discontinue product and CISplatin</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5393">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x5393">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> bleeding time, coagulation time during treatment; bleeding: hematuria, guaiac, bruising or petechiae, mucosa or orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x5397">
								<item>
									<label>•</label>
									<para>Buccal cavity q8hr for dryness, sores, ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5403">
								<item>
									<para>
										<emphasis alert="nurse">Severe allergic reaction/toxic epidermal necrolysis: rash, urticaria, itching, flushing</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5408">
								<item>
									<label>•</label>
									<para>Rinsing of mouth tid-qid with water, club soda; brushing of teeth bid-tid with soft brush or cotton-tipped applicators for stomatitis; use unwaxed dental floss</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5413">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5417">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased spread of malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5423">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x5428">
								<item>
									<label>•</label>
									<para>To report any complaints, side effects to nurse or prescriber: black, tarry stools, chills, fever, sore throat, bleeding, bruising, cough, SOB, dark or bloody urine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5433">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture if stomatitis is present</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5438">
								<item>
									<label>•</label>
									<para>To report stomatitis: any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily; to report symptoms to nurse; to use good oral hygiene</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5446">
							<label>•</label>
							<sec_title>
								<route>That contraceptive measures recommended during therapy, for ≤8 wk after cessation of therapy; to discontinue breastfeeding because toxicity to infant may occur</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x5449">
								<item>
									<label>•</label>
									<para>To avoid alcohol, salicylates, live vaccines</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5454">
								<item>
									<label>•</label>
									<para>To avoid use of razors, commercial mouthwash</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5459">
								<item>
									<label>•</label>
									<para>To eat foods high in folic acid; to take supplements as prescribed</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active" ha="yes">
			<mono_name> pembrolizumab</mono_name>
			<info>
				<pronunciation>(pem′broe-liz′ue-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x54710">Keytruda</tradename>
				</tradenames>
				<class type="func"> Antineoplastics, biologic response modifiers</class>
				<class type="chem"> Monoclonal antibodies</class>
			</info>
			<section type="actions" id="sidelem4x5481">
				<sec_title>Action:</sec_title>
				<para> A human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) found on T-cells and blocks the interaction of PD-1 with its ligands, PD-L1 and PD-L2, on the tumor cell</para>
			</section>
			<section type="uses" id="sidelem4x5486">
				<sec_title>Uses:</sec_title>
				<para> Treatment of unresectable or metastatic malignant melanoma in those who have disease progression after ipilimumab or in BRAF V600 mutation–positive patients who have disease progression after ipilimumab and a BRAF inhibitor</para>
			</section>
			<section type="contra" id="sidelem4x5491">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, pregnancy (D), breastfeeding</para>
				<section type="none" id="sidelem4x5496">
					<section type="none" id="sidelem4x5497">
						<sec_title>Precautions:</sec_title>
						<para> Immune-mediated colitis, immune-mediated hepatitis, immune-mediated hyperthyroidism/hypothyroidism; immune-mediated nephritis, acute interstitial nephritis, and renal failure; immune-mediated pneumonitis, adrenocortical insufficiency, arthritis, exfoliative dermatitis, hemolytic anemia, hypophysitis, myasthenia syndrome, myositis, optic neuritis, pancreatitis, partial seizures after inflammatory foci identified in brain parenchyma, rhabdomyolysis, uveitis, incidence of abortion/stillbirths</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5502">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5510">
					<label>•</label>
					<sec_title>Adults<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x5510">
							<item>
								<label>•</label>
								<para> INFUSION: 2 mg/kg over 30 min q3wk until disease progression</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x5514">
					<section type="none" id="sidelem4x5515">
						<sec_title>Available forms:</sec_title>
						<para> Powder for injection 50 mg</para>
					</section>
					<section type="none" id="sidelem4x5520">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x5523">
							<sec_title>IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x5528">
									<item>
										<label>•</label>
										<para>Add 2.3 ml of sterile water for injection, 50-mg vial (25 mg/ml); inject sterile water along the walls of the vial and not directly on the powder</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5535">
									<item>
										<label>•</label>
										<para>Gently swirl and allow up to 5 min for bubbles to clear, do not shake, solution will be a clear to slightly opalescent, colorless to slightly yellow</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5540">
									<item>
										<label>•</label>
										<para>Add the required amount of product to a bag of normal saline (0.9% sodium chloride injection) to a final diluted concentration between 1 and 10 mg/ml; mix by gentle inversion</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5545">
									<item>
										<label>•</label>
										<para>Discard any unused solution left in the vial</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5553">
								<label>•</label>
								<sec_title>Storage after reconstitution and dilution</sec_title>
								<para>
									<list id="lidelem4x5553">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Storage after reconstitution and dilution:</emphasis> Store at room temperature up to 4 hr or refrigerate up to 24 hr (includes reconstitution, dilution, and administration time). If refrigerated, allow the diluted solution to warm to room temperature before use, give over 30 min</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x5557">
									<item>
										<label>•</label>
										<para>Use a sterile, nonpyrogenic, low-protein binding 0.2- to 5-micron in-line or add-on filter</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x5562">
									<item>
										<label>•</label>
										<para>Do not use with other drugs through the same infusion line</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x5570">
								<label>•</label>
								<sec_title>Grade 2 or 3 toxicity<route> Withhold and give corticosteroids; resume when the adverse event recovers to grade ≤1. Permanently discontinue if there is no recovery within 12 wk, if the corticosteroid dose cannot be reduced to ≤10 mg/day of prednisone (or equivalent) within 12 wk, or for recurrent severe or grade 3 colitis</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5576">
								<label>•</label>
								<sec_title>Grade 4 toxicity<route> Permanently discontinue, give corticosteroids</route></sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x5579">
							<sec_title>Hepatitis:</sec_title>
							<section type="none" id="sidelem4x5587">
								<label>•</label>
								<sec_title>Grade 2 toxicity (AST or ALT &gt;3-5 × upper limit of normal [ULN] or total bilirubin &gt;1.5-3 × ULN)<route> Withhold and give corticosteroids; resume when adverse event recovers to grade 1 or less. Permanently discontinue if there is no recovery within 12 wks or if the corticosteroid dose cannot be reduced to ≤10 mg/day of prednisone (or equivalent) within 12 wks</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5593">
								<label>•</label>
								<sec_title>Grade 3 or 4 toxicity (AST or ALT &gt;5 × ULN or total bilirubin &gt;3 × ULN)<route> Permanently discontinue, give corticosteroids</route></sec_title>
							</section>
							<section type="none" id="sidelem4x5599">
								<label>•</label>
								<sec_title>Liver metastases and grade 2 elevated transaminase levels at baseline<route> Permanently discontinue if AST/ALT levels increase by ≥50% over baseline and transaminase level elevations persist for at least 1 wk</route></sec_title>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x5602">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x5605">
					<section type="none" id="sidelem4x5606">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Seizures,</emphasis> myasthenia, headache, fever, insomnia, chills, dizziness, fatigue</para>
					</section>
					<section type="none" id="sidelem4x5614">
						<sec_title>ENDO:</sec_title>
						<para> Hyponatremia, hypothyroidism/hyperthyroidism, hyperglycemia, hypocalcemia</para>
					</section>
					<section type="none" id="sidelem4x5619">
						<sec_title>EENT:</sec_title>
						<para> Optic neuritis</para>
					</section>
					<section type="none" id="sidelem4x5624">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, abdominal pain, <emphasis style="bold">pancreatitis,</emphasis> colitis, diarrhea, <emphasis style="bold">hepatitis,</emphasis> constipation</para>
					</section>
					<section type="none" id="sidelem4x5635">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Interstitial nephritis, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5642">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, pneumonitis</para>
					</section>
					<section type="none" id="sidelem4x5647">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, skin discoloration</para>
					</section>
					<section type="none" id="sidelem4x5652">
						<sec_title>MS:</sec_title>
						<para> Myalgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x5659">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Exfoliative dermatitis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x5666">
				<sec_title>Interactions</sec_title>
				<para>None known</para>
				<section type="none" id="sidelem4x5671">
					<section type="none" id="sidelem4x5672">
						<sec_title>Drug/lab test</sec_title>
						<para/>
					</section>
					<section type="none" id="sidelem4x5676">
						<sec_title>Increase:</sec_title>
						<para> LFTs, renal function studies</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x5681">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x5684">
					<section type="none" id="sidelem4x5685">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x5690">
								<item>
									<label>•</label>
									<para>For hyperthyroidism/hypothyroidism, renal function studies baseline, periodically during therapy, temporarily withheld or permanently discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x5695">
								<item>
									<label>•</label>
									<para>For pneumonitis (new or worsening cough, chest pain, shortness of breath), confirm with radiographic imaging</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x5703">
							<label>•</label>
							<sec_title>
								<route>Liver function tests and hepatitis (e.g., jaundice, severe nausea/vomiting, easy bleeding or bruising, withhold and give corticosteroids if grade 2 hepatitis (AST or ALT &gt;3-5 × ULN or total bilirubin &gt;1.5-3 × ULN)</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5706">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x5710">
								<item>
									<label>•</label>
									<para>Therapeutic response: Decreased progression of multiple myeloma</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x5717">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x5725">
							<label>•</label>
							<sec_title>
								<route>To use highly effective contraceptive methods during and for 4 months after treatment, to contact their health care provider if pregnancy is suspected or confirmed (pregnancy D)</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>penciclovir topical</mono_name>
			<section type="none" id="sidelem4x5731">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>PENICILLINS</mono_name>
			<info>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x5773">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-wall replication of susceptible organisms; lysis is mediated by cell-wall autolytic enzymes, results in cell death</para>
			</section>
			<section type="uses" id="sidelem4x5778">
				<sec_title>Uses:</sec_title>
				<para>Respiratory infections, scarlet fever, erysipelas, otitis media, pneumonia, skin and soft-tissue infections, gonorrhea; effective for gram-positive cocci <emphasis style="italic">(Staphylococcus, Streptococcus pyogenes, S. viridans, S. faecalis, S. bovis, S. pneumoniae),</emphasis> gram-negative cocci <emphasis style="italic">(Neisseria gonorrhoeae),</emphasis> gram-positive bacilli <emphasis style="italic">(Actinomyces, Bacillus anthracis, Clostridium perfringens, C. tetani, Corynebacterium diphtheriae, Listeria monocytogenes),</emphasis> gram-negative bacilli <emphasis style="italic">(Escherichia coli, Proteus mirabilis, Salmonella, Shigella, Enterobacter, Streptobacillus moniliformis),</emphasis> spirochetes <emphasis style="italic">(Treponema pallidum)</emphasis></para>
			</section>
			<section type="contra" id="sidelem4x5797">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins, corn</para>
				<section type="none" id="sidelem4x5802">
					<section type="none" id="sidelem4x5803">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding; hypersensitivity to cephalosporins, carbapenem, sulfites; severe renal disease, GI disease, asthma</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x5808">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x5811">
					<sec_title>
						<emphasis style="italic">Penicillin G benzathine</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x5815">
						<sec_title>Early syphilis</sec_title>
						<section type="none" id="sidelem4x5823">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5823">
									<item>
										<label>•</label>
										<para> 2.4 million units in single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5827">
						<sec_title>Congenital syphilis</sec_title>
						<section type="none" id="sidelem4x5835">
							<label>•</label>
							<sec_title>Child &lt;2 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5835">
									<item>
										<label>•</label>
										<para> 50,000 units/kg in single dose, max 2.4 million units as single inj</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5839">
						<sec_title>Prophylaxis of rheumatic fever, glomerulonephritis</sec_title>
						<section type="none" id="sidelem4x5847">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5847">
									<item>
										<label>•</label>
										<para> 1.2 million units in single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5854">
							<label>•</label>
							<sec_title>Child &gt;27 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5854">
									<item>
										<label>•</label>
										<para> 900,000-1.2 million units as single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5861">
							<label>•</label>
							<sec_title>Child ≤27 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5861">
									<item>
										<label>•</label>
										<para> 300,000-600,000 units as single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5865">
						<sec_title>Upper respiratory infections (group A streptococcal)</sec_title>
						<section type="none" id="sidelem4x5873">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5873">
									<item>
										<label>•</label>
										<para> 1.2 million units as single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5880">
							<label>•</label>
							<sec_title>Child &gt;27 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5880">
									<item>
										<label>•</label>
										<para> 900,000-1.2 million units as single dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5887">
							<label>•</label>
							<sec_title>Child &lt;27 kg<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5887">
									<item>
										<label>•</label>
										<para> 300,000-600,000 units as single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5891">
						<sec_title>Available forms:</sec_title>
						<para> Inj 600,000 units/ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5896">
					<sec_title>
						<emphasis style="italic">Penicillin G</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x5900">
						<sec_title>Pneumococcal/streptococcal infections (serious)</sec_title>
						<section type="none" id="sidelem4x5908">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x5908">
									<item>
										<label>•</label>
										<para> 5-24 million units in divided doses q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5915">
							<label>•</label>
							<sec_title>Child &lt;12 yr<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x5915">
									<item>
										<label>•</label>
										<para> 150,000-300,000 units/kg/day in 4-6 divided doses; max 24 million units/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5919">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x5927">
							<label>•</label>
							<sec_title>
								<route>CCr &lt;10 ml/min, give full loading dose then 1/2 of loading dose q8-10hr</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x5936">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 1, 5, 20 million units/vial; inj 1, 2, 3 million units/50 ml</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5941">
					<sec_title>
						<emphasis style="italic">Penicillin G procaine</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x5945">
						<sec_title>Moderate to severe pneumococcal infections</sec_title>
						<section type="none" id="sidelem4x5953">
							<label>•</label>
							<sec_title>Adult/child<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5953">
									<item>
										<label>•</label>
										<para> 600,000-1 million units as single dose or divided bid doses/day for 10 days to 2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5958">
						<sec_title>Pneumococcal pneumonia</sec_title>
						<section type="none" id="sidelem4x5966">
							<label>•</label>
							<sec_title>Adult/child &gt;12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5966">
									<item>
										<label>•</label>
										<para> 600,000-1 million units/day × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5970">
						<sec_title>Moderately severe group A streptococcal/staphylococcal pneumonia</sec_title>
						<section type="none" id="sidelem4x5978">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥60 lbs<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5978">
									<item>
										<label>•</label>
										<para> 600,000-1 million units/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x5985">
							<label>•</label>
							<sec_title>Adolescent/child &lt;60 lbs<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x5985">
									<item>
										<label>•</label>
										<para> 300,000 units/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x5989">
						<sec_title>Available forms:</sec_title>
						<para> Inj 600,000, 1,200,000 units/unit dose</para>
					</section>
				</section>
				<section type="none" id="sidelem4x5994">
					<sec_title>
						<emphasis style="italic">Penicillin V</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x5998">
						<sec_title>Pneumococcal/staphylococcal infections</sec_title>
						<section type="none" id="sidelem4x6006">
							<label>•</label>
							<sec_title>Adult/adolescents/child &gt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6006">
									<item>
										<label>•</label>
										<para> 250-500 mg q6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6013">
							<label>•</label>
							<sec_title>Child &lt;12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6013">
									<item>
										<label>•</label>
										<para> 25-50 mg/kg/day in divided doses q6-8hr; max 2 g/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6017">
						<sec_title>Streptococcal infections</sec_title>
						<section type="none" id="sidelem4x6025">
							<label>•</label>
							<sec_title>Adult/adolescent/child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6025">
									<item>
										<label>•</label>
										<para> 125-250 mg q6-8hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6032">
							<label>•</label>
							<sec_title>Child &lt;12 yr and &gt;27 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6032">
									<item>
										<label>•</label>
										<para> 500 mg q8 or 12 hr × 10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6039">
							<label>•</label>
							<sec_title>Child &lt;12 yr and ≤27 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6039">
									<item>
										<label>•</label>
										<para> 250 mg q8hr or q12hr or 40 mg/kg/day in 3 divided doses × 10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6043">
						<sec_title>Prevention of recurrence of rheumatic fever/chorea</sec_title>
						<section type="none" id="sidelem4x6051">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6051">
									<item>
										<label>•</label>
										<para> 125-250 mg bid continuously</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6055">
						<sec_title>Vincent’s gingivitis/pharyngitis</sec_title>
						<section type="none" id="sidelem4x6063">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x6063">
									<item>
										<label>•</label>
										<para> 250-500 mg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6067">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6075">
							<label>•</label>
							<sec_title>
								<route>Dosage reduction indicated with renal impairment (CCr &lt;50 ml/min) based on clinical response, degree of impairment</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x6078">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 250, 500 mg; powder for oral sol 125, 250 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x6083">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6087">
								<item>
									<label>•</label>
									<para>Store in dry, tight container; oral susp refrigerated 2 wk</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6093">
							<sec_title>Penicillin G benzathine</sec_title>
							<para>
								<list id="lidelem4x6097">
									<item>
										<label>•</label>
										<para>No dilution needed, shake well, deep IM inj in large muscle mass; avoid intravascular inj; aspirate; do not give IV</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6103">
							<sec_title>Penicillin G</sec_title>
							<para>
								<list id="lidelem4x6107">
									<item>
										<label>•</label>
										<para>Penicillin G sodium or potassium can be given IM or IV, vials containing 10 or 20 million units not for IM use</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6113">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6117">
									<item>
										<label>•</label>
										<para>Vials/bulk packages: dilute according to manufacturer’s directions</para>
									</item>
									<item>
										<label>•</label>
										<para>Frozen bags: thaw at room temperature, do not force thaw, no reconstitution needed</para>
									</item>
									<item>
										<label>•</label>
										<para>Final concentration (100,000-500,000 units/ml—adults; 50,000 units/ml—neonate/infant)</para>
									</item>
									<item>
										<label>•</label>
										<para>Total daily dose divided q4-6hr and given over 1-2 hr (adult), 15 min (infant/neonate)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6138">
							<sec_title>Penicillin G potassium</sec_title>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, amiodarone, cyclophosphamide, diltiazem, enalaprilat, esmolol, fluconazole, foscarnet, heparin, HYDROmorphone, labetalol, magnesium sulfate, meperidine, morphine, perphenazine, potassium chloride, tacrolimus, theophylline, verapamil, vit B/C</para>
						</section>
						<section type="none" id="sidelem4x6145">
							<sec_title>Penicillin G procaine</sec_title>
							<para>
								<list id="lidelem4x6149">
									<item>
										<label>•</label>
										<para>No dilution needed; give deep IM inj; avoid intravascular inj; aspirate; do not give IV</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6155">
							<sec_title>Penicillin V</sec_title>
							<para>
								<list id="lidelem4x6159">
									<item>
										<label>•</label>
										<para>Orally on empty stomach for best absorption</para>
									</item>
									<item>
										<label>•</label>
										<para>Oral susp: tap bottle to loosen, add <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> total amount of water, shake, add remaining water, shake; final concentration (125 or 250 mg/ml) store in refrigerator after reconstitution, discard after 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6176">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6179">
					<section type="none" id="sidelem4x6180">
						<sec_title>CNS:</sec_title>
						<para> Lethargy, hallucinations, anxiety, depression, twitching, <emphasis style="bold">coma, seizures,</emphasis> hyperreflexia</para>
					</section>
					<section type="none" id="sidelem4x6188">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea,</emphasis> increased AST, ALT, abdominal pain, glossitis, colitis, <emphasis style="bold">pseudomembranous colitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6198">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, proteinuria, hematuria,</emphasis><emphasis style="italic">vaginitis, moniliasis,</emphasis><emphasis style="bold">glomerulonephritis, renal tubular damage</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6209">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, granulocytopenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6216">
						<sec_title>META:</sec_title>
						<para> Hypo/hyperkalemia, alkalosis, hypernatremia</para>
					</section>
					<section type="none" id="sidelem4x6221">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, serum sickness, Stevens-Johnson syndrome,</emphasis><emphasis style="italic">local pain,</emphasis> tenderness and fever with IM inj</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6232">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6235">
					<section type="none" id="sidelem4x6236">
						<sec_title>Penicillin G benzathine:</sec_title>
						<para>
							<emphasis style="bold">IM:</emphasis> Very slow absorption; time to peak 12-24 hr; duration 21-28 days; excreted in urine, feces, breast milk; crosses placenta</para>
					</section>
					<section type="none" id="sidelem4x6243">
						<sec_title>Penicillin G:</sec_title>
						<para>
							<emphasis style="bold">IV:</emphasis> Peak immediate</para>
						<para>
							<emphasis style="bold">IM:</emphasis> Peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">4</emphasis>-<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
						<para>
							<emphasis style="bold">PO:</emphasis> Peak 1 hr, duration 6 hr</para>
						<para>Excreted in urine unchanged, excreted in breast milk, crosses placenta, half-life 30-60 min</para>
					</section>
					<section type="none" id="sidelem4x6272">
						<sec_title>Penicillin G procaine:</sec_title>
						<para>
							<emphasis style="bold">IM:</emphasis> Peak 1-4 hr, duration 15 hr, excreted in urine</para>
					</section>
					<section type="none" id="sidelem4x6279">
						<sec_title>Penicillin V:</sec_title>
						<para>
							<emphasis style="bold">PO:</emphasis> Peak 30-60 min, half-life 30 min, excreted in urine, breast milk</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6286">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> penicillin effect—aspirin, probenecid</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of heparin, methotrexate</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of oral contraceptives, typhoid vaccine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antimicrobial effect of penicillin—tetracyclines</para>
				<section type="none" id="sidelem4x6305">
					<section type="none" id="sidelem4x6306">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine glucose, urine protein</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6313">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6316">
					<section type="none" id="sidelem4x6317">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x6325">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x6325">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> temperature; characteristics of sputum; wounds; urine; stools before, during, after treatment; C&amp;S before therapy; product may be given as soon as culture is taken</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x6329">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria because penicillin in high doses is nephrotoxic; renal tests: urinalysis, protein, blood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6335">
								<item>
									<para>
										<emphasis alert="nurse">Any patient with compromised renal system because product is excreted slowly with poor renal system function; toxicity may occur rapidly</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6340">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6345">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hct, Hgb, bleeding time</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6351">
								<item>
									<para>
										<emphasis alert="nurse">Pseudomembranous colitis: diarrhea, mucus, pus; bowel pattern before, during treatment</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6356">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6362">
								<item>
									<para>
										<emphasis alert="nurse">Allergies before initiation of treatment, reaction of each medication; because of prolonged action, allergic reaction may be prolonged and severe; watch for anaphylaxis: rash, dyspnea, pruritus, laryngeal edema; skin eruptions after administration of penicillin to 1 wk after discontinuing product</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6367">
								<item>
									<label>•</label>
									<para>EPINEPHrine, suction, tracheostomy set, endotracheal intubation equipment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6372">
								<item>
									<label>•</label>
									<para>Adequate fluid intake (2 L) during diarrhea episodes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6377">
								<item>
									<label>•</label>
									<para>Scratch test to assess allergy after securing order from prescriber; usually done when penicillin is only product of choice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6382">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6386">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of infection</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6392">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6396">
								<item>
									<label>•</label>
									<para>To report sore throat, fever, fatigue; may indicate superinfection; CNS effects: depression, hallucinations, seizures</para>
								</item>
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
								<item>
									<label>•</label>
									<para>To report diarrhea, with blood, pus, mucus to prevent dehydration</para>
								</item>
								<item>
									<label>•</label>
									<para>To shake susp well before each dose; to store in refrigerator for up to 2 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To use all medication prescribed</para>
								</item>
								<item>
									<label>•</label>
									<para>To use additional contraception if using any of these products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="1" status="active">
			<mono_name>pentamidine (Rx)</mono_name>
			<info>
				<pronunciation>(pen-tam′i-deen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x64421">NebuPent</tradename>
					<tradename id="tnidelem4x64420">Pentam 300</tradename>
				</tradenames>
				<class type="func"> Antiprotozoal</class>
				<class type="chem"> Aromatic diamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x6452">
				<sec_title>Action:</sec_title>
				<para>Interferes with DNA/RNA synthesis in protozoa</para>
			</section>
			<section type="uses" id="sidelem4x6458">
				<sec_title>Uses:</sec_title>
				<para>Treatment/prevention of <emphasis style="italic">Pneumocystis jiroveci</emphasis> infections</para>
				<section type="none" id="sidelem4x6466">
					<section type="none" id="sidelem4x6467">
						<sec_title>Unlabeled uses:</sec_title>
						<para> <emphasis style="italic">Leishmania/Trypanosoma</emphasis> infections</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x6475">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x6480">
					<section type="none" id="sidelem4x6481">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, blood dyscrasias, cardiac/renal/hepatic disease, diabetes mellitus, hypocalcemia, hypo/hypertension, anemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6486">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6494">
					<label>•</label>
					<sec_title>Adult and child ≥4 mo<route> IV/IM</route></sec_title>
					<para>
						<list id="lidelem4x6494">
							<item>
								<label>•</label>
								<para> 4 mg/kg/day × 2-3 wk;  300 mg via specific nebulizer given q4wk for prevention</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6501">
					<section type="none" id="sidelem4x6502">
						<sec_title>Available forms:</sec_title>
						<para> Inj, aerosol 300 mg/vial; sol for aerosol 60 mg/vial <country code="CAN">FIX_STRUCTURE Inj, aerosol 300 mg/vial; sol for aerosol 60 mg/vial </country></para>
					</section>
					<section type="none" id="sidelem4x6509">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6513">
								<item>
									<label>•</label>
									<para>Store in refrigerator protected from light</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6519">
							<sec_title>Inhalation route</sec_title>
							<para>
								<list id="lidelem4x6523">
									<item>
										<label>•</label>
										<para>Through nebulizer, using Raspirgard II jet nebulizer; mix contents in 6 ml of sterile water; do not use low pressure (&lt;20 psi); flow rate should be 5-7 L/min (40-50 psi) air or O<emphasis style="inf">2</emphasis> source over 30-45 min until chamber is empty</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6532">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x6536">
									<item>
										<label>•</label>
										<para>300 mg diluted in 3 ml sterile water; give deep IM by <emphasis style="sans-serif">Z</emphasis>-track; if painful by this route, rotate inj site</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6545">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x6549">
									<item>
										<label>•</label>
										<para>Reconstitute 300 mg/3-5 ml of sterile water for inj, D<emphasis style="inf">5</emphasis>W, withdraw dose and further dilute in 50-250 ml D<emphasis style="inf">5</emphasis>W, give over 1-2 hr with patient lying down; check B/P often</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, atracurium, atropine, benztropine, buprenorphine, calcium gluconate, CARBOplatin, caspofungin, chlorproMAZINE, cimetidine, CISplatin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, diltiazem, gatifloxacin, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6565">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6568">
					<section type="none" id="sidelem4x6569">
						<sec_title>CNS:</sec_title>
						<para> Disorientation, hallucinations, <emphasis style="italic">dizziness,</emphasis> confusion, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x6577">
						<sec_title>CV:</sec_title>
						<para> Hypotension, ventricular tachycardia, <emphasis style="bold">QT prolongation, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6584">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia;</emphasis> increased AST, ALT; <emphasis style="bold">acute pancreatitis,</emphasis> metallic taste</para>
					</section>
					<section type="none" id="sidelem4x6595">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Acute renal failure, increased serum creatinine, renal toxicity,</emphasis> decreased urination</para>
					</section>
					<section type="none" id="sidelem4x6603">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">leukopenia, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6610">
						<sec_title>INTEG:</sec_title>
						<para> Sterile abscess, pain at inj site, pruritus, urticaria, <emphasis style="italic">rash</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6617">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hyperkalemia,</emphasis> hypocalcemia, hypoglycemia, hypomagnesemia</para>
					</section>
					<section type="none" id="sidelem4x6625">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, fever, chills, night sweats, <emphasis style="bold">anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6632">
						<sec_title>RESP:</sec_title>
						<para> Cough, SOB, <emphasis style="bold">bronchospasm</emphasis> (with aerosol), sore throat</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6640">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x6643">
					<section type="none" id="sidelem4x6644">
						<sec_title>IV:</sec_title>
						<para> Peak 1 hr</para>
					</section>
					<section type="none" id="sidelem4x6649">
						<sec_title>IM:</sec_title>
						<para> Peak 30 min</para>
						<para>Excreted unchanged in urine (66%); half-life 9-12 hr (IM), 6 hr (IV)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x6656">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x6661">
						<item>
							<label>•</label>
							<para>Nephrotoxicity: aminoglycosides, amphotericin B, CISplatin, NSAIDs, vancomycin</para>
						</item>
					</list>
				</para>
				<para>
					<list id="lidelem4x6667">
						<item>
							<para>
								<emphasis alert="nurse">Fatal dysrhythmias: erythromycin IV</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin, arsenic trioxide, levomethadyl); CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> myelosuppression—antineoplastics, radiation</para>
				<section type="none" id="sidelem4x6679">
					<section type="none" id="sidelem4x6680">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, platelets, Hbg, Hct</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> BUN, creatinine</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x6691">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x6694">
					<section type="none" id="sidelem4x6695">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x6700">
								<item>
									<label>•</label>
									<para>Blood tests, blood glucose, CBC, platelets, calcium, magnesium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6705">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6711">
								<item>
									<label>•</label>
									<para>ECG for cardiac dysrhythmias; patient should be lying down when receiving product; severe hypotension may develop; monitor B/P during administration and until B/P stable</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6716">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6721">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, creatinine; nephrotoxicity may occur; any patient with compromised renal system; product is excreted slowly with poor renal system function; toxicity may occur rapidly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6726">
								<item>
									<label>•</label>
									<para>Signs of infection, anemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6731">
								<item>
									<label>•</label>
									<para>Bowel pattern before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6736">
								<item>
									<label>•</label>
									<para>Sterile abscess, pain at inj site</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6741">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, dyspnea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x6746">
								<item>
									<label>•</label>
									<para>Dizziness, confusion, hallucination</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6754">
							<label>•</label>
							<sec_title>
								<route>Allergies before treatment, reaction of each medication; place allergies on chart in bright red letters; notify all people giving products</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x6757">
								<item>
									<label>•</label>
									<para>Diabetic patients, hypoglycemia may occur, then hyperglycemia with prolonged therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6762">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x6766">
								<item>
									<label>•</label>
									<para>Therapeutic response: resolution of AIDS-related PCP</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x6772">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x6776">
								<item>
									<label>•</label>
									<para>To report sore throat, fever, fatigue (may indicate superinfection)</para>
								</item>
								<item>
									<label>•</label>
									<para>To maintain adequate fluid intake</para>
								</item>
								<item>
									<label>•</label>
									<para>IM injection is painful</para>
								</item>
								<item>
									<label>•</label>
									<para>Complete entire course of medication</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active" ha="yes">
			<mono_name> pentazocine (Rx)</mono_name>
			<info>
				<pronunciation>(pen-taz′oh-seen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x68041">Talwin</tradename>
					<tradename id="tnidelem4x68040">Talwin NX</tradename>
				</tradenames>
				<class type="func"> Opiate analgesic, antagonist</class>
				<class type="chem"> Synthetic benzomorphan</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="4">IV</schedule></class>
			</info>
			<section type="actions" id="sidelem4x6816">
				<sec_title>Action:</sec_title>
				<para>Inhibits ascending pain pathways in CNS, increases pain threshold, alters pain perception</para>
			</section>
			<section type="uses" id="sidelem4x6821">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe pain</para>
			</section>
			<section type="contra" id="sidelem4x6826">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or sulfites; addiction (opiate)</para>
				<section type="none" id="sidelem4x6831">
					<section type="none" id="sidelem4x6832">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;18 yr, addictive personality, increased intracranial pressure, MI (acute), severe heart disease, respiratory depression, renal/hepatic disease, seizure disorder, head trauma, bowel impaction, geriatric patients</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x6837">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x6845">
					<label>•</label>
					<sec_title>Adult<route> IV/IM/SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x6845">
							<item>
								<label>•</label>
								<para> 30 mg q3-4hr prn, max 360 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x6849">
					<section type="none" id="sidelem4x6850">
						<sec_title>Labor</sec_title>
						<section type="none" id="sidelem4x6858">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x6858">
									<item>
										<label>•</label>
										<para> 30 mg as a single dose;  20 mg q2-3hr when contractions are regular, max 2-3 times</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6865">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x6873">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x6873">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> CCr 10-50 ml/min, reduce dose by 25%; CCr &lt;10 ml/min, reduce dose by 50%</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x6877">
						<sec_title>Available forms:</sec_title>
						<para> Inj 30 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x6882">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x6886">
								<item>
									<label>•</label>
									<para>Store in light-resistant area at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>With antiemetic if nausea, vomiting occur</para>
								</item>
								<item>
									<label>•</label>
									<para>When pain is beginning to return; determine dosage interval by patient response</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x6903">
							<sec_title>IM/SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x6907">
									<item>
										<label>•</label>
										<para>Give IM deeply into large muscle mass, rotate sites; SUBCUT may cause necrosis with repeated inj</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x6913">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x6917">
									<item>
										<label>•</label>
										<para>Undiluted or diluted in 5 mg/ml of sterile water for inj; give ≤5 mg over 1 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Atropine, benzquinamide, butorphanol, chlorproMAZINE, cimetidine, dimenhyDRINATE, diphenhydrAMINE, droperidol, fentaNYL, HYDROmorphone, hydrOXYzine, meperidine, metoclopramide, morphine, perphenazine, prochlorperazine, promazine, promethazine, ranitidine, scopolamine</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Heparin, hydrocortisone, potassium chloride, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x6931">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x6934">
					<section type="none" id="sidelem4x6935">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, dizziness, confusion, headache, sedation, euphoria,</emphasis> hallucinations, dreaming, insomnia, lightheadedness</para>
					</section>
					<section type="none" id="sidelem4x6943">
						<sec_title>CV:</sec_title>
						<para> Palpitations, bradycardia, change in B/P, tachycardia, increased B/P (high doses), hypotension, syncope, flushing</para>
					</section>
					<section type="none" id="sidelem4x6948">
						<sec_title>EENT:</sec_title>
						<para> Tinnitus, blurred vision, miosis, diplopia</para>
					</section>
					<section type="none" id="sidelem4x6953">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, constipation, <emphasis style="italic">cramps,</emphasis> dry mouth</para>
					</section>
					<section type="none" id="sidelem4x6964">
						<sec_title>GU:</sec_title>
						<para> Increased urinary output, dysuria, urinary retention</para>
					</section>
					<section type="none" id="sidelem4x6969">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Eosinophilia, decreased WBC</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6976">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> urticaria, bruising, flushing, diaphoresis, pruritus, severe irritation at inj sites, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x6986">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x6993">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys, crosses placenta, half-life 2-3 hr, extensive first-pass metabolism with &lt;20% entering circulation</para>
				<section type="none" id="sidelem4x6998">
					<section type="none" id="sidelem4x6999">
						<sec_title>IM/SUBCUT:</sec_title>
						<para> Onset 15-30 min, peak 1-2 hr, duration 2-4 hr</para>
					</section>
					<section type="none" id="sidelem4x7004">
						<sec_title>IV:</sec_title>
						<para> Onset 2-3 min, duration 4-6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x7009">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Unpredictable reactions: MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—CNS depressants; alcohol, sedative/hypnotics, antipsychotics, skeletal muscle relaxants</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects—opiates</para>
				<section type="none" id="sidelem4x7025">
					<section type="none" id="sidelem4x7026">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> amylase</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7033">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7036">
					<section type="none" id="sidelem4x7037">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7045">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x7045">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> intensity, duration, location before and 1 hr after SUBCUT/IM dose or 30 min after IV dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7049">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for decreasing output; may indicate urinary retention</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7054">
								<item>
									<label>•</label>
									<para>Bowel status: constipation; may need stimulant laxatives/stool softeners</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7062">
							<label>•</label>
							<sec_title>
								<route>Withdrawal symptoms</route>
							</sec_title>
							<para>
								<list id="lidelem4x7062">
									<item>
										<label>•</label>
										<para> in opiate-dependent patients</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7066">
								<item>
									<label>•</label>
									<para>Abscesses, ulcerations, WBC count</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7071">
								<item>
									<label>•</label>
									<para>CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7076">
								<item>
									<label>•</label>
									<para>Allergic reactions: rash, urticaria</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7084">
							<label>•</label>
							<sec_title>Respiratory depression</sec_title>
							<para>
								<list id="lidelem4x7084">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Respiratory depression:</emphasis> character, rate, rhythm; notify prescriber if respirations are &lt;10/min</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7088">
								<item>
									<label>•</label>
									<para>Need for pain medication, physical dependence</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7093">
								<item>
									<label>•</label>
									<para>Assistance with ambulation</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7098">
								<item>
									<label>•</label>
									<para>Safety measures: night-light, call bell within easy reach</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7103">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7107">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7113">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7117">
								<item>
									<label>•</label>
									<para>To report any symptoms of CNS changes, allergic reactions</para>
								</item>
								<item>
									<label>•</label>
									<para>That physical dependency may result from extended use</para>
								</item>
								<item>
									<label>•</label>
									<para>That withdrawal symptoms may occur: nausea, vomiting, cramps, fever, faintness, anorexia</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid CNS depressants, alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, operating machinery if drowsiness occurs</para>
								</item>
								<item>
									<label>•</label>
									<para>To use good oral hygiene, frequent rinsing of mouth to decrease dry mouth; to avoid gum, candy if drowsy</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active">
			<mono_name>peramivir</mono_name>
			<info>
				<pronunciation>(per-am′i-vir)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x71620">Rapivab</tradename>
				</tradenames>
				<class type="func"> Antiviral</class>
			</info>
			<section type="actions" id="sidelem4x7168">
				<sec_title>Action:</sec_title>
				<para> Competitively binds to the active site of the influenza virus, inhibits the activity of strains of influenza A and B viruses</para>
			</section>
			<section type="uses" id="sidelem4x7173">
				<sec_title>Uses:</sec_title>
				<para> Treatment of uncomplicated acute influenza (seasonal influenza A virus infection or seasonal influenza B virus infection)</para>
				<para>
					<emphasis style="bold">Unlabeled uses:</emphasis> Treatment of H1N1 influenza A virus (swine influenza) infection in pediatric patients requiring hospitalization</para>
			</section>
			<section type="contra" id="sidelem4x7182">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
				<para>
					<emphasis style="bold">Precautions:</emphasis> Breastfeeding, children, dialysis, infants, infection, pregnancy, psychosis, renal impairment</para>
			</section>
			<section type="doses" id="sidelem4x7191">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7194">
					<sec_title>
						<emphasis style="italic">Influenzae</emphasis>
					</sec_title>
					<section type="none" id="sidelem4x7203">
						<label>•</label>
						<sec_title>Adults<route> IV</route></sec_title>
						<para>
							<list id="lidelem4x7203">
								<item>
									<label>•</label>
									<para> 600 mg as a single dose infused over 15-30 min, give within 48 hr of onset of influenza symptoms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7207">
						<sec_title>Available forms:</sec_title>
						<para> Solution for injection 200 mg/20 ml</para>
					</section>
					<section type="none" id="sidelem4x7212">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7217">
								<item>
									<label>•</label>
									<para>For IV use only, do not give IM, visually inspect parenteral products for particulate matter and discoloration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7225">
							<label>•</label>
							<sec_title>
								<route>Dilute</route>
							</sec_title>
							<para>
								<list id="lidelem4x7225">
									<item>
										<label>•</label>
										<para> the 10 mg/ml to a max volume of 100 ml, use only 0.9% or 0.45% NaCl, 5% dextrose, or LR</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7232">
							<label>•</label>
							<sec_title>Storage of diluted solution</sec_title>
							<para>
								<list id="lidelem4x7232">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Storage of diluted solution:</emphasis> Use immediately or refrigerate up to 24 hr. Refrigerated solution should be allowed to reach room temperature before administration. Discard any unused diluted solution after 24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7236">
								<item>
									<label>•</label>
									<para>Give over 15-30 min, do not mix or coadminister with other IV products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7241">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7244">
					<section type="none" id="sidelem4x7245">
						<sec_title>CNS:</sec_title>
						<para> delirium, psychosis, hallucinations, insomnia</para>
					</section>
					<section type="none" id="sidelem4x7250">
						<sec_title>GI:</sec_title>
						<para> Constipation, diarrhea, vomiting</para>
					</section>
					<section type="none" id="sidelem4x7255">
						<sec_title>MISC:</sec_title>
						<para> Rash, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7262">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Protein binding &lt;30%</para>
			</section>
			<section type="interactions" id="sidelem4x7267">
				<sec_title>Interactions</sec_title>
				<para>Avoid use with intranasal influenza vaccines, H1N1 vaccines</para>
			</section>
			<section type="considerations" id="sidelem4x7272">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7275">
					<section type="none" id="sidelem4x7276">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x7280">
								<item>
									<label>•</label>
									<para>Hypersensitivity reactions/Stevens-Johnson syndrome</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7286">
						<sec_title>Neuropsychiatric reactions:</sec_title>
						<para> Delirium, psychosis, hallucinations</para>
					</section>
					<section type="none" id="sidelem4x7291">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7295">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of developing influenza A or B</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7301">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7305">
								<item>
									<label>•</label>
									<para>That product is only for use within 48 hr of infection</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="4" status="active">
			<mono_name>perindopril (Rx)</mono_name>
			<info>
				<pronunciation>(per-in′doe-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x73161">Aceon</tradename>
					<tradename id="tnidelem4x73160">
						<country code="CAN">Coversyl </country>
					</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x7328">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses the renin-angiotensin-aldosterone system; inhibits ACE; prevents the conversion of angiotensin I to angiotensin II and the dilation of arterial and venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x7333">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, MI prophylaxis</para>
				<section type="none" id="sidelem4x7338">
					<section type="none" id="sidelem4x7339">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Heart failure, MI</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x7344">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, history of angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x7360">
					<section type="none" id="sidelem4x7361">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, renal disease, hyperkalemia, hepatic failure, dehydration, bilateral renal artery stenosis, cough, severe CHF, aortic stenosis, African descent</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7366">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7369">
					<section type="none" id="sidelem4x7370">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x7378">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7378">
									<item>
										<label>•</label>
										<para> 4 mg/day, may increase or decrease to desired response, range 4-8 mg/day; may give in 2 divided doses or as single dose, max 16 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7382">
						<sec_title>Patients on diuretics</sec_title>
						<section type="none" id="sidelem4x7390">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7390">
									<item>
										<label>•</label>
										<para> 2-4 mg/day in 1-2 divided doses, range 4-8 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7394">
						<sec_title>Stable CAD</sec_title>
						<section type="none" id="sidelem4x7402">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x7402">
									<item>
										<label>•</label>
										<para> 4 mg/day × 2 wk, then increase as tolerated to 8 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7406">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x7414">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 16-29 ml/min, 2 mg every other day; CCr 30-59 ml/min, 2 mg/day; CCr ≤15 ml/min 2 mg on dialysis days only</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7417">
						<sec_title>Available forms:</sec_title>
						<para> Tabs scored 2, 4, 8 mg</para>
					</section>
					<section type="none" id="sidelem4x7422">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7426">
								<item>
									<label>•</label>
									<para>As single dose or in 2 divided doses, without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7432">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7435">
					<section type="none" id="sidelem4x7436">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Insomnia, dizziness,</emphasis> paresthesias, <emphasis style="italic">headache,</emphasis> fatigue, anxiety, depression</para>
					</section>
					<section type="none" id="sidelem4x7447">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> chest pain, tachycardia, dysrhythmias, syncope, <emphasis style="bold">cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7457">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Tinnitus;</emphasis> visual changes; sore throat; double vision; dry, burning eyes</para>
					</section>
					<section type="none" id="sidelem4x7465">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, colitis, cramps, diarrhea, constipation, flatulence, dry mouth, loss of taste, <emphasis style="bold">liver failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7472">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Proteinuria, renal failure,</emphasis> increased frequency of polyuria or oliguria</para>
					</section>
					<section type="none" id="sidelem4x7480">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, neutropenia, bone marrow suppression</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7487">
						<sec_title>INTEG:</sec_title>
						<para> Rash, purpura, alopecia, hyperhidrosis</para>
					</section>
					<section type="none" id="sidelem4x7492">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Hyperkalemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7499">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="italic">dry cough,</emphasis> crackles</para>
					</section>
					<section type="none" id="sidelem4x7507">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7514">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 75%; peak 1 hr parent product, 3-7 hr prodrug; protein binding 68%; metabolized by liver (active metabolite perindoprilat); half-life 0.8-10 hr; excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x7519">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of neuromuscular blocking agents, antihypertensives, lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—diuretics, NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypersensitivity—allopurinol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypotension—diuretics, other antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—salt substitutes, potassium-sparing diuretics, potassium supplements, angiotensin II receptor antagonists</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of NSAIDs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs, salicylates</para>
				<section type="none" id="sidelem4x7550">
					<section type="none" id="sidelem4x7551">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ephedra</para>
					</section>
					<section type="none" id="sidelem4x7562">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, alk phos, cholesterol, uric acid</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> Hgb/Hct</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> glucose/insulin tolerance tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x7577">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7580">
					<section type="none" id="sidelem4x7581">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x7589">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x7589">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, pulse q4hr; note rate, rhythm, quality</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x7593">
								<item>
									<label>•</label>
									<para>Electrolytes: K, Na, Cl during 1st 2 wk of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7598">
								<item>
									<label>•</label>
									<para>Baselines of renal, hepatic studies before therapy begins, 1 wk into therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7603">
								<item>
									<label>•</label>
									<para>Skin turgor, dryness of mucous membranes for hydration status, dry mouth</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7611">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x7611">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema, dyspnea, wet crackles</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7619">
							<label>•</label>
							<sec_title>Angioedema<route> facial swelling, urticaria; product should be discontinued, may be more common in African Americans</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x7622">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7626">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7633">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x7638">
								<item>
									<label>•</label>
									<para>Not to use OTC (cough, cold, allergy) products unless directed by prescriber; to avoid salt substitutes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7643">
								<item>
									<label>•</label>
									<para>To avoid sunlight or to wear sunscreen for photosensitivity</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7648">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7656">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of mouth sores, sore throat, fever, swelling of hands or feet, irregular heartbeat, chest pains, signs of angioedema</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7659">
								<item>
									<label>•</label>
									<para>That excessive perspiration, dehydration, vomiting, diarrhea may lead to fall in B/P; to consult prescriber if these occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7664">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting; that lightheadedness may occur during 1st few days of therapy; to avoid hazardous activities</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7672">
							<label>•</label>
							<sec_title>
								<route>That product may cause skin rash or impaired perspiration; that angioedema may occur and to discontinue product if it occurs</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x7675">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7680">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7685">
								<item>
									<label>•</label>
									<para>To report persistent, sustained cough</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x7690">
								<item>
									<label>•</label>
									<para>To avoid potassium supplements, salt substitutes</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>To notify prescriber if pregnancy is planned or suspected; pregnancy (D)</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="5" status="active">
			<mono_name>pertuzumab</mono_name>
			<info>
				<pronunciation>(per-too′zoo-mab)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x77180">Perjeta</tradename>
				</tradenames>
				<class type="func"> Antineoplastic biologic-response modifier</class>
				<class type="chem"> Monoclonal antibody, antineoplastic</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x7728">
				<sec_title>Action:</sec_title>
				<para>Blocks liquid-dependent action of human epidermal growth factor-2 (HER2), inhibiting signal pathways</para>
			</section>
			<section type="uses" id="sidelem4x7733">
				<sec_title>Uses:</sec_title>
				<para>First-line treatment of (HER2) positive metastatic breast cancer with trastuzumab and DOCEtaxel</para>
			</section>
			<section type="contra" id="sidelem4x7738">
				<sec_title>Contraindications:</sec_title>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x7751">
					<section type="none" id="sidelem4x7752">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children, infants, neonates, cardiac arrhythmias, MI, cardiac disease, heart failure, hypertension, infusion-related reactions</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x7757">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x7765">
					<label>•</label>
					<sec_title>Adult<route> IV</route></sec_title>
					<para>
						<list id="lidelem4x7765">
							<item>
								<label>•</label>
								<para> 840 mg over 60 min, then after 3 wk 420 mg over 30-60 min every 3 wk; give with trastuzumab 8 mg/kg IV over 90 min, then after 3 wk 6 mg/kg over 30-90 min every 3 wk and DOCEtaxel 75 mg/m<emphasis style="sup">2</emphasis> IV every 3 wk; dosage may be escalated to 100 mg/m<emphasis style="sup">2</emphasis></para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x7774">
					<section type="none" id="sidelem4x7775">
						<sec_title>Available forms:</sec_title>
						<para> Solution for inj 420 mg/14 ml (single-use vials)</para>
					</section>
					<section type="none" id="sidelem4x7780">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x7784">
								<item>
									<label>•</label>
									<para>Visually inspect for particulate matter and discoloration</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x7790">
							<sec_title>Dilution and preparation</sec_title>
							<para>
								<list id="lidelem4x7794">
									<item>
										<label>•</label>
										<para>Withdraw the calculated dose from the vial and add to 250 ml 0.9% sodium chloride to PVC or non-PVC polyolefin infusion bag; do not dilute with dextrose 5% solution</para>
									</item>
									<item>
										<label>•</label>
										<para>Dilute in normal saline only; do not mix or dilute with other drugs or dextrose solutions</para>
									</item>
									<item>
										<label>•</label>
										<para>Mix the diluted solution by gentle inversion; do not shake</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7810">
							<sec_title>IV infusion</sec_title>
							<para>
								<list id="lidelem4x7814">
									<item>
										<label>•</label>
										<para>Administer the diluted solution immediately</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not administer as an IV push or bolus</para>
									</item>
									<item>
										<label>•</label>
										<para>Give the first dose of 840 mg over 60 min and subsequent 420 mg doses over 30–60 min</para>
									</item>
									<item>
										<label>•</label>
										<para>If the diluted solution is not used immediately, store at 2°-8° C for up to 24 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x7836">
							<sec_title>Delayed or missed doses</sec_title>
							<para>
								<list id="lidelem4x7840">
									<item>
										<label>•</label>
										<para>If time since previous dose is &lt;6 wk, give 420 mg IV (do not wait for next scheduled dose)</para>
									</item>
									<item>
										<label>•</label>
										<para>If time since previous dose is ≥6 wk, give 840 mg IV over 60 min, followed 3 wk later by 420 mg IV over 30–60 min repeated every 3 wk</para>
									</item>
									<item>
										<label>•</label>
										<para>If DOCEtaxel is discontinued, this product and trastuzumab may continue</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x7856">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x7859">
					<section type="none" id="sidelem4x7860">
						<sec_title>CNS:</sec_title>
						<para> Headache, fever, <emphasis style="italic">peripheral neuropathy,</emphasis> chills, <emphasis style="italic">fatigue</emphasis>, asthenia</para>
					</section>
					<section type="none" id="sidelem4x7871">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7878">
						<sec_title>EENT:</sec_title>
						<para> Lacrimation, stomatitis</para>
					</section>
					<section type="none" id="sidelem4x7883">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea</emphasis>, vomiting, diarrhea, dysgeusia</para>
					</section>
					<section type="none" id="sidelem4x7891">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, <emphasis style="bold">neutropenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x7898">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x7903">
						<sec_title>RESP:</sec_title>
						<para> Upper respiratory infection</para>
					</section>
					<section type="none" id="sidelem4x7908">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis,</emphasis> infection, antibody formation</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x7916">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Median half-life 18 days</para>
			</section>
			<section type="considerations" id="sidelem4x7921">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x7924">
					<section type="none" id="sidelem4x7925">
						<sec_title>Assess:</sec_title>
						<para>
							<emphasis style="bold">HER2 overexpression:</emphasis> Testing should be done to identify HER2 overexpression before using this product</para>
						<para>
							<emphasis alert="lifethreat">Decreased left ventricular ejection fraction (LVEF):</emphasis>
							<emphasis alert="nurse">Can occur and is increased in those with a history of prior anthracycline use or radiotherapy to the chest; evaluate LVEF at baseline and every 3 mo; withhold therapy ×3 wk if LVEF is &lt;40% or LVEF is 40%-45% with a 10% or greater absolute decrease from baseline; resume therapy if the LVEF is recovered to &gt;45% or to 40%-45% with &lt;10% absolute decrease at reassessment; if the LVEF has not improved or has declined further, consider permanently discontinuing pertuzumab and trastuzumab after a risk/benefit assessment</emphasis>
						</para>
						<para>
							<emphasis alert="lifethreat">Infusion-related reactions/hypersensitivity:</emphasis>
							<emphasis alert="nurse">Assess anaphylactoid reaction, acute infusion reaction, cytokine-release syndrome 60 min after the first infusion, 30 min after other infusions; monitor for pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting; if a significant reaction occurs, slow or interrupt the infusion; permanent discontinuation may be needed in severe reactions</emphasis>
						</para>
						<para>
							<bbw>Pregnancy: Determine if pregnancy is planned or suspected; patients who become pregnant during therapy should report exposure to the Genentech Adverse Event line at 1-888-835-2555 and enroll in the MOTHER pregnancy registry at 1-800-690-6720</bbw>
						</para>
						<para>
							<emphasis alert="lifethreat">Neutropenia:</emphasis>
							<emphasis alert="nurse">Can occur, but occurs more commonly when trastuzumab is also used</emphasis>
						</para>
						<section type="none" id="sidelem4x7963">
							<sec_title>Upper respiratory infection:</sec_title>
							<para>
								<list id="lidelem4x7967">
									<item>
										<label>•</label>
										<para>Monitor for dyspnea, shortness of breath, fever</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x7973">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x7977">
								<item>
									<label>•</label>
									<para>Decreased size, spread of tumor</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x7983">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<bbw>Counsel women of childbearing age on the need for contraception during and for 6 mo after therapy; advise patients who suspect pregnancy to contact their health care provider immediately; discontinue breastfeeding</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="6" status="active" ru="yes">
			<mono_name> phentolamine (Rx)</mono_name>
			<info>
				<pronunciation>(fen-tole′a-meen)</pronunciation>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> α-Adrenergic blocker</class>
			</info>
			<section type="uses" id="sidelem4x8011">
				<sec_title>Uses:</sec_title>
				<para>Hypertension; pheochromocytoma; prevention/treatment of dermal necrosis following extravasation of norepinephrine, DOPamine, EPINEPHrine</para>
			</section>
			<section type="contra" id="sidelem4x8016">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, MI, coronary insufficiency, angina, hypotension</para>
			</section>
			<section type="doses" id="sidelem4x8023">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8026">
					<section type="none" id="sidelem4x8027">
						<sec_title>Treatment of hypertensive episodes in pheochromocytoma</sec_title>
						<section type="none" id="sidelem4x8035">
							<label>•</label>
							<sec_title>Adult<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x8035">
									<item>
										<label>•</label>
										<para>5 mg, repeat if necessary</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8042">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8042">
									<item>
										<label>•</label>
										<para> 0.05-0.1 mg/kg/dose, repeat if necessary; max 5 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8046">
						<sec_title>Diagnosis of pheochromocytoma</sec_title>
						<section type="none" id="sidelem4x8054">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8054">
									<item>
										<label>•</label>
										<para> 5 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8061">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8061">
									<item>
										<label>•</label>
										<para> 0.05 mg/kg; if negative, repeat with 0.1 mg/kg IV</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8065">
						<sec_title>Treatment of necrosis</sec_title>
						<section type="none" id="sidelem4x8073">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x8073">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 5-10 mg/10 ml  injected into area of norepinephrine extravasation within 12 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8083">
							<label>•</label>
							<sec_title>Child</sec_title>
							<para>
								<list id="lidelem4x8083">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Child:</emphasis> 0.1-0.2 mg/kg, max 5 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8087">
						<sec_title>Prevention of necrosis</sec_title>
						<section type="none" id="sidelem4x8095">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x8095">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 10 mg/L of norepinephrine-containing sol</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8102">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8102">
									<item>
										<label>•</label>
										<para> 0.1-0.2 mg/kg, max 5 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="7" status="active">
			<mono_name>phenylephrine nasal agent</mono_name>
			<section type="none" id="sidelem4x8109">
				<para>See<see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="8" status="active">
			<mono_name>phenylephrine ophthalmic</mono_name>
			<section type="none" id="sidelem4x8116">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="9" status="active">
			<mono_name>phenytoin (Rx)</mono_name>
			<info>
				<pronunciation>(fen′i-toh-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x81252">Dilantin</tradename>
					<tradename id="tnidelem4x81251">Dilantin Infatabs</tradename>
					<tradename id="tnidelem4x81250">Phenytek</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant; antidysrhythmic (IB)</class>
				<class type="chem"> Hydantoin</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x8135">
				<sec_title>Action:</sec_title>
				<para>Inhibits spread of seizure activity in motor cortex by altering ion transport; increases AV conduction</para>
			</section>
			<section type="uses" id="sidelem4x8140">
				<sec_title>Uses:</sec_title>
				<para>Generalized tonic-clonic seizures; status epilepticus; nonepileptic seizures associated with Reye’s syndrome or after head trauma; complex partial seizures</para>
				<section type="none" id="sidelem4x8145">
					<section type="none" id="sidelem4x8146">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraines, diabetic neuropathy, neuropathic pain, paroxysmal atrial tachycardia, ventricular tachycardia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x8151">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), hypersensitivity, psychiatric condition, bradycardia, SA and AV block, Stokes-Adams syndrome</para>
				<section type="none" id="sidelem4x8156">
					<section type="none" id="sidelem4x8157">
						<sec_title>Precautions:</sec_title>
						<para> Geriatric patients, allergies, renal/hepatic disease, petit mal seizures, hypotension, myocardial insufficiency, Asian patients positive for HLA-B1502, hepatic failure, acute intermittent porphyria</para>
						<para>
							<bbw>IV use</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8172">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8175">
					<section type="none" id="sidelem4x8176">
						<sec_title>Seizures</sec_title>
						<section type="none" id="sidelem4x8184">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8184">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg (ext rel) in 3-4 divided doses given q2hr or 400 mg, then 300 mg q2hr × 2 doses; maintenance 4-7 mg/kg/day;  15-20 mg/kg, max 25-50 mg/min, then 100 mg q6-8hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8194">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8194">
									<item>
										<label>•</label>
										<para> 5 mg/kg/day in 2-3 divided doses, maintenance 4-8 mg/kg/day in 2-3 divided doses, max 300 mg/day;  15-20 mg/kg at 1-3 mg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8201">
						<sec_title>Status epilepticus</sec_title>
						<section type="none" id="sidelem4x8209">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8209">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg, max 25-50 mg/min, may give 100 mg q6-8hr thereafter</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8216">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x8216">
									<item>
										<label>•</label>
										<para> 15-20 mg/kg, max in divided doses 1-3 mg/kg/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8220">
						<sec_title>Ventricular dysrhythmias</sec_title>
						<section type="none" id="sidelem4x8228">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8228">
									<item>
										<label>•</label>
										<para> loading dose 1 g divided over 24 hr, then 500 mg/day × 2 days;  250 mg over 5 min until dysrhythmias subside or until 1 g is given or 100 mg q15min until dysrhythmias subside or until 1 g is given</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8238">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8238">
									<item>
										<label>•</label>
										<para> 3-8 mg/kg or 250 mg/m<emphasis style="sup">2</emphasis>/day as single dose or 2 divided doses;  3-8 mg/kg over several min or 250 mg/m<emphasis style="sup">2</emphasis>/day as single dose or 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8252">
						<sec_title>Renal/hepatic dose</sec_title>
						<section type="none" id="sidelem4x8260">
							<label>•</label>
							<sec_title>
								<route>Do not use loading dose if CCr &lt;10 ml/min or hepatic failure</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8263">
						<sec_title>Neuropathic pain/diabetic neuropathy (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8271">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8271">
									<item>
										<label>•</label>
										<para> 300 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8275">
						<sec_title>Migraine prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x8283">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8283">
									<item>
										<label>•</label>
										<para> 200-400 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8287">
						<sec_title>Available forms:</sec_title>
						<para> Susp 25 mg/5 ml; chewable tabs 50 mg; inj 50 mg/ml; ext rel caps 100, 200, 300 mg; prompt rel caps 100 mg</para>
					</section>
					<section type="none" id="sidelem4x8292">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x8295">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x8300">
									<item>
										<label>•</label>
										<para>Do not interchange chewable product with caps, not equivalent; only ext rel caps to be used for once-a-day dosing</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x8308">
								<label>•</label>
								<sec_title>Oral susp</sec_title>
								<para>
									<list id="lidelem4x8308">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral susp:</emphasis> shake well before each dose given via G tube/NG tube; dilute susp before administration; flush tube with 20 ml water after dose; hold tube feedings 1 hr before and 1 hr after dose</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x8312">
									<item>
										<label>•</label>
										<para>Allow 7-10 days between dosage changes</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8317">
									<item>
										<label>•</label>
										<para>Divided PO doses with or after meals to decrease adverse effects</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8322">
									<item>
										<label>•</label>
										<para>2 hr before or after antacid, enteral feeding</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8327">
							<sec_title>Direct IV route</sec_title>
							<para>
								<bbw>Give undiluted at ≤50 mg/min (adult) 1-3 mg/kg/min; 0.5-1 mg/kg/min (neonates), monitor for CV reactions</bbw>
							</para>
						</section>
						<section type="none" id="sidelem4x8340">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<bbw>Dilute dose in NS to ≤6.7 mg/ml; complete infusion within 1 hr of preparation; use 0.22- or 0.55-micron in-line particulate final filter between IV catheter and tubing; flush IV line or catheter with NS before and after use; give at ≤50 mg/min (adult), 0.5-1 mg/kg/min (child, infant, neonate)</bbw>
							</para>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Do not admix</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8357">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8360">
					<section type="none" id="sidelem4x8361">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, insomnia, paresthesias, depression, <emphasis style="bold">suicidal tendencies,</emphasis> aggression, headache, confusion, slurred speech, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x8369">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">ventricular fibrillation, bradycardia, cardiac arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8376">
						<sec_title>EENT:</sec_title>
						<para> Nystagmus, diplopia, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x8381">
						<sec_title>ENDO:</sec_title>
						<para> Diabetes insipidus</para>
					</section>
					<section type="none" id="sidelem4x8386">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, constipation, anorexia, weight loss, <emphasis style="bold">hepatitis,</emphasis> jaundice, gingival hyperplasia, abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x8394">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephritis,</emphasis> urine discoloration, sexual dysfunction</para>
					</section>
					<section type="none" id="sidelem4x8402">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, leukopenia, aplastic anemia, thrombocytopenia, megaloblastic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8409">
						<sec_title>INTEG:</sec_title>
						<para> Rash, <emphasis style="bold">lupus erythematosus, Stevens-Johnson syndrome,</emphasis> hirsutism, <emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8419">
						<sec_title>SYST:</sec_title>
						<para> Hypocalcemia, <emphasis style="bold">purple glove syndrome (IV), DRESS, anaphylaxis,</emphasis> exacerbates myasthenia gravis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8427">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver, excreted by kidneys, protein binding 90%-95%, half-life 7-42 hr, dose dependent</para>
				<section type="none" id="sidelem4x8432">
					<section type="none" id="sidelem4x8433">
						<sec_title>PO:</sec_title>
						<para> Onset 2-24 hr, peak 1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 6-12 hr</para>
					</section>
					<section type="none" id="sidelem4x8450">
						<sec_title>PO-ER:</sec_title>
						<para> Onset 2-24 hr, peak 4-12 hr, duration 12-36 hr</para>
					</section>
					<section type="none" id="sidelem4x8455">
						<sec_title>IV:</sec_title>
						<para> Onset 1-2 hr, duration 12-24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x8460">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x8468">
					<label>•</label>
					<sec_title>
						<route>Do not use with delavirdine, decreased response, resistance</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> phenytoin effect—benzodiazepines, cimetidine, tricyclics, salicylates, valproate, cycloSERINE, diazepam, chloramphenicol, disulfiram, alcohol, amiodarone, sulfonamides, FLUoxetine, gabapentin, H<emphasis style="inf">2</emphasis> antagonists, azole antifungals, estrogens, succinamides, phenothiazines, methylphenidate, felbamate, traZODone</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> phenytoin effects—alcohol (chronic use), antacids, barbiturates, carBAMazepine, rifampin, calcium (high dose), folic acid</para>
				<section type="none" id="sidelem4x8482">
					<section type="none" id="sidelem4x8483">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Enteral tube feeding:</emphasis> may decrease absorption of oral product; do not use enteral feedings 2 hr before or 2 hr after dose</para>
					</section>
					<section type="none" id="sidelem4x8491">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> glucose, alk phos, GGT</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> dexamethasone, metyrapone test serum, PBI, urinary steroids</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x8502">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8505">
					<section type="none" id="sidelem4x8506">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x8512">
								<item>
									<para>
										<emphasis alert="nurse">Phenytoin hypersensitivity syndrome 3-12 wk after start of treatment: rash, temperature, lymphadenopathy; may cause hepatotoxicity, renal failure, rhabdomyolysis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8518">
								<item>
									<para>
										<emphasis alert="nurse">Serious skin disorders: for beginning rash that may lead to Stevens-Johnson syndrome or toxic epidermal necrolysis; phenytoin should not be used again; may occur more often among Asian patients with HLA-B 1502</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8524">
								<item>
									<para>
										<emphasis alert="nurse">Purple glove syndrome with IV use</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8532">
							<label>•</label>
							<sec_title>Phenytoin level<route> toxic level 30-50 mcg/ml, therapeutic level</route></sec_title>
						</section>
						<section type="none" id="sidelem4x8538">
							<label>•</label>
							<sec_title>Seizures<route> duration, type, intensity, precipitating factors; obtain EEG periodically; monitor therapeutic level</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x8541">
								<item>
									<label>•</label>
									<para>Blood studies: CBC, platelets q2wk until stabilized, then monthly × 12, then q3mo; discontinue product if neutrophils &lt;1600/mm<emphasis style="sup">3</emphasis>; renal function: albumin concentration; folic acid levels, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8550">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, memory (long, short), suicidal thoughts/behaviors</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8555">
								<item>
									<label>•</label>
									<para>Monitor EKG, B/P, respiratory function during IV loading dose; verify potency of IV access port before IV infusion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8560">
								<item>
									<label>•</label>
									<para>Monitor EEG function and serum levels periodically</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8568">
							<label>•</label>
							<sec_title>Blood dyscrasias<route> fever, sore throat, bruising, rash, jaundice</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x8571">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8575">
								<item>
									<label>•</label>
									<para>Therapeutic response; decrease in severity of seizures, ventricular dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8581">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8586">
								<item>
									<label>•</label>
									<para>That, if diabetic, blood glucose should be monitored</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8591">
								<item>
									<label>•</label>
									<para>That urine may turn pink</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8599">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue product abruptly because seizures may occur</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8605">
							<label>•</label>
							<sec_title>Oral hygiene</sec_title>
							<para>
								<list id="lidelem4x8605">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral hygiene:</emphasis> about the proper brushing of teeth using a soft toothbrush, flossing to prevent gingival hyperplasia; about the need to see dentist frequently</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8609">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until stabilized on product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8614">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating product use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8619">
								<item>
									<label>•</label>
									<para>That heavy use of alcohol may diminish effect of product; to avoid OTC medications</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8624">
								<item>
									<label>•</label>
									<para>Not to change brands or forms once stabilized on therapy because brands may vary</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x8629">
								<item>
									<label>•</label>
									<para>Not to use antacids within 2 hr of product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8637">
							<label>•</label>
							<sec_title>
								<route>To use nonhormonal contraception; to notify prescriber if pregnancy is planned or suspected, pregnancy (D)</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8643">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of unusual bleeding, bruising, petechiae (bleeding), clay-colored stools, abdominal pain, dark urine, yellowing of skin or eyes (hepatotoxicity); slurred speech, headache, drowsiness</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x8649">
							<label>•</label>
							<sec_title>
								<route>To report suicidal thoughts/behaviors immediately</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="10" status="active">
			<mono_name>phosphate/biphosphate (<emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x86581">Fleet Enema</tradename>
					<tradename id="tnidelem4x86580">Phospho-Soda</tradename>
				</tradenames>
				<class type="func"> Laxative, saline</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8664">
				<sec_title>Action:</sec_title>
				<para>Increases water absorption in the small intestine by osmotic action; laxative effect occurs by increased peristalsis and water retention</para>
			</section>
			<section type="uses" id="sidelem4x8669">
				<sec_title>Uses:</sec_title>
				<para>Constipation, bowel or rectal preparation for surgery, exam</para>
			</section>
			<section type="contra" id="sidelem4x8674">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, rectal fissures, abdominal pain, nausea, vomiting, appendicitis, acute surgical abdomen, ulcerated hemorrhoids, sodium-restricted diet, renal failure, hyperphosphatemia, hypocalcemia, hypokalemia, hypernatremia, Addison’s disease, CHF, ascites, bowel perforation, megacolon, imperforate anus</para>
				<para>
					<bbw>GI obstruction, renal failure</bbw>
				</para>
				<section type="none" id="sidelem4x8690">
					<section type="none" id="sidelem4x8691">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
						<para>
							<bbw>Colitis, geriatric hypovolemia, renal disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8706">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8714">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8714">
							<item>
								<label>•</label>
								<para> 20-30 ml (Phospho-Soda)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8721">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x8721">
							<item>
								<label>•</label>
								<para> 5-15 ml (Phospho-Soda)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8728">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> RECT</route></sec_title>
					<para>
						<list id="lidelem4x8728">
							<item>
								<label>•</label>
								<para> 1 enema (118 ml)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8735">
					<label>•</label>
					<sec_title>Child 2-12 yr<route> RECT</route></sec_title>
					<para>
						<list id="lidelem4x8735">
							<item>
								<label>•</label>
								<para>
									<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> enema (59 ml)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x8744">
					<section type="none" id="sidelem4x8745">
						<sec_title>Available forms:</sec_title>
						<para> Enema 7 g phosphate/19 g biphosphate/118 ml; oral sol 18 g phosphate/48 g biphosphate/100 ml</para>
					</section>
					<section type="none" id="sidelem4x8750">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8754">
								<item>
									<label>•</label>
									<para>Alone for better absorption; do not take within 1-2 hr of other products</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x8760">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x8763">
					<section type="none" id="sidelem4x8764">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias, cardiac arrest,</emphasis> hypotension, <emphasis style="bold">widening QRS complex</emphasis></para>
					</section>
					<section type="none" id="sidelem4x8774">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, cramps,</emphasis> diarrhea</para>
					</section>
					<section type="none" id="sidelem4x8782">
						<sec_title>META:</sec_title>
						<para> Electrolyte, fluid imbalances</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x8787">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 30 min-3 hr, excreted in feces</para>
			</section>
			<section type="considerations" id="sidelem4x8792">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x8795">
					<section type="none" id="sidelem4x8796">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x8804">
							<label>•</label>
							<sec_title>Stools</sec_title>
							<para>
								<list id="lidelem4x8804">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Stools:</emphasis> color, amount, consistency; bowel pattern, bowel sounds, flatulence, distention, fever, dietary patterns, exercise; cramping, rectal bleeding, nausea, vomiting; if these occur, product should be discontinued</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x8808">
								<item>
									<label>•</label>
									<para>Blood, urine electrolytes if product used often</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8813">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x8817">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in constipation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x8823">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x8827">
								<item>
									<label>•</label>
									<para>Not to use laxatives for long-term therapy because bowel tone will be lost</para>
								</item>
								<item>
									<label>•</label>
									<para>That normal bowel movements do not always occur daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use in presence of abdominal pain, nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if constipation unrelieved or if symptoms of electrolyte imbalance occur: muscle cramps, pain, weakness, dizziness, excessive thirst</para>
								</item>
								<item>
									<label>•</label>
									<para>To maintain fluid consumption</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="11" status="active">
			<mono_name>physostigmine ophthalmic</mono_name>
			<section type="none" id="sidelem4x8856">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="12" status="active">
			<mono_name>phytonadione (Rx)</mono_name>
			<info>
				<pronunciation>(fye-toe-na-dye′one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x88651">Mephyton</tradename>
					<tradename id="tnidelem4x88650">Vit K</tradename>
				</tradenames>
				<class type="func"> Vit K, fat-soluble vitamin</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x8874">
				<sec_title>Action:</sec_title>
				<para>Needed for adequate blood clotting (factors II, VII, IX, X)</para>
			</section>
			<section type="uses" id="sidelem4x8879">
				<sec_title>Uses:</sec_title>
				<para>Vit K malabsorption, hypoprothrombinemia, prevention of hypoprothrombinemia caused by oral anticoagulants, prevention of hemorrhagic disease of the newborn</para>
			</section>
			<section type="contra" id="sidelem4x8884">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe hepatic disease, last few weeks of pregnancy</para>
				<section type="none" id="sidelem4x8889">
					<section type="none" id="sidelem4x8890">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), neonates, hepatic disease</para>
						<para>
							<bbw>IV use</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x8905">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x8908">
					<section type="none" id="sidelem4x8909">
						<sec_title>Hypoprothrombinemia caused by vit K malabsorption</sec_title>
						<section type="none" id="sidelem4x8917">
							<label>•</label>
							<sec_title>Adult<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x8917">
									<item>
										<label>•</label>
										<para> 2.5-25 mg, may repeat or increase to 50 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8924">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x8924">
									<item>
										<label>•</label>
										<para> 2.5-5 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x8931">
							<label>•</label>
							<sec_title>Infant<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x8931">
									<item>
										<label>•</label>
										<para> 2 mg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8935">
						<sec_title>Prevention of hemorrhagic disease of the newborn</sec_title>
						<section type="none" id="sidelem4x8943">
							<label>•</label>
							<sec_title>Neonate<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x8943">
									<item>
										<label>•</label>
										<para> 0.5-1 mg within 1 hr after birth, repeat after 2-3 wk if required</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8947">
						<sec_title>Hypoprothrombinemia caused by oral anticoagulants</sec_title>
						<section type="none" id="sidelem4x8955">
							<label>•</label>
							<sec_title>Adult and child<route> PO/SUBCUT/IM</route></sec_title>
							<para>
								<list id="lidelem4x8955">
									<item>
										<label>•</label>
										<para> 1-10 mg, may repeat 12-48 hr after  dose or 6-8 hr after  dose based on INR</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x8967">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg; inj 10 mg/ml, 1 mg/0.5 ml</para>
					</section>
					<section type="none" id="sidelem4x8972">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x8976">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container (PO)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x8982">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x8987">
									<item>
										<label>•</label>
										<para>After diluting with ≥10 ml D<emphasis style="inf">5</emphasis>NS; give max 1 mg/min</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x8996">
									<item>
										<para>
											<emphasis alert="nurse">IV only when other routes not possible (deaths have occurred)</emphasis>
										</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, aminophylline, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, ceFAZolin, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, chloramphenicol, chlorproMAZINE, cimetidine, clindamycin, cyanocobalamin, cycloSPORINE, dexamethasone, digoxin, diphenhydrAMINE, DOPamine, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, erythromycin, esmolol, famotidine, fentaNYL, fluconazole, folic acid, furosemide, ganciclovir, gentamicin, glycopyrrolate, heparin, hydrocortisone, imipenem/cilastatin, indomethacin, insulin, isoproterenol, ketorolac, labetalol, lidocaine, mannitol, meperidine, metaraminol, methoxamine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, midazolam, morphine, multivitamins, nafcillin, nalbuphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxytocin, papaverine, penicillin G potassium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, potassium chloride, procainamide, prochlorperazine, propranolol, pyridoxime, ranitidine, sodium bicarbonate, succinylcholine, SUFentanil, theophylline, thiamine, ticarcillin/clavulanate, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, verapamil, vit B with C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9005">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9008">
					<section type="none" id="sidelem4x9009">
						<sec_title>CNS:</sec_title>
						<para> Headache, <emphasis style="bold">brain damage</emphasis> (large doses)</para>
					</section>
					<section type="none" id="sidelem4x9017">
						<sec_title>GI:</sec_title>
						<para> Nausea, decreased LFTs</para>
					</section>
					<section type="none" id="sidelem4x9022">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, hemoglobinuria, hyperbilirubinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9029">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria</para>
					</section>
					<section type="none" id="sidelem4x9034">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Bronchospasm,</emphasis> dyspnea, feeling of chest constriction, <emphasis style="bold">respiratory arrest</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9044">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x9047">
					<section type="none" id="sidelem4x9048">
						<sec_title>PO/INJ:</sec_title>
						<para> Metabolized, crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9053">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of phytonadione—bile acid sequestrants, sucralfate, antiinfectives, salicylates, mineral oil</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of warfarin—large dose of product</para>
			</section>
			<section type="considerations" id="sidelem4x9064">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9067">
					<section type="none" id="sidelem4x9068">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9076">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x9076">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> emesis, stools, urine; pressure on all venipuncture sites; avoid all inj if possible</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9080">
								<item>
									<label>•</label>
									<para>PT during treatment (2-sec deviation from control time, bleeding time, clotting time); monitor for bleeding, pulse, and B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9085">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9089">
								<item>
									<label>•</label>
									<para>Therapeutic response: prevention of hemorrhagic disease of the newborn, resolution of hypoprothrombinemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9095">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9099">
								<item>
									<label>•</label>
									<para>Not to take other supplements, OTC products, prescription products unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>About the necessary foods for associated diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid IM inj; to use soft toothbrush; not to floss; to use electric razor until coagulation defect corrected</para>
								</item>
								<item>
									<label>•</label>
									<para>To report symptoms of bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of frequent lab tests to monitor coagulation factors</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify all health care providers of use of this product</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID describing condition and products used</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="13" status="active">
			<mono_name>pilocarpine ophthalmic</mono_name>
			<section type="none" id="sidelem4x9139">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="14" status="active">
			<mono_name>pimecrolimus topical</mono_name>
			<section type="none" id="sidelem4x9146">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="15" status="active" ha="yes">
			<mono_name> pioglitazone (Rx)</mono_name>
			<info>
				<pronunciation>(pie-oh-glye′ta-zone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x91570">Actos</tradename>
				</tradenames>
				<class type="func"> Antidiabetic, oral</class>
				<class type="chem"> Thiazolidinedione</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9167">
				<sec_title>Action:</sec_title>
				<para>Specifically targets insulin resistance; an insulin sensitizer; regulates the transcription of a number of insulin-responsive genes</para>
			</section>
			<section type="uses" id="sidelem4x9172">
				<sec_title>Uses:</sec_title>
				<para>Type 2 diabetes mellitus</para>
			</section>
			<section type="contra" id="sidelem4x9177">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, children, hypersensitivity to thiazolidinedione, diabetic ketoacidosis</para>
				<para>
					<bbw>NYHA Class III/IV heart failure</bbw>
				</para>
				<section type="none" id="sidelem4x9192">
					<section type="none" id="sidelem4x9193">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, geriatric patients with CV disease, renal/hepatic/thyroid disease, edema, polycystic ovary syndrome, bladder cancer, osteoporosis, pulmonary disease, secondary malignancy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9198">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9201">
					<section type="none" id="sidelem4x9202">
						<sec_title>Monotherapy</sec_title>
						<section type="none" id="sidelem4x9210">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9210">
									<item>
										<label>•</label>
										<para> 15 or 30 mg/day, may increase to 45 mg/day; with strong CYP2C8, max 15 mg/day; with NYHA class I/II heart failure, max 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9214">
						<sec_title>Combination therapy</sec_title>
						<section type="none" id="sidelem4x9222">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x9222">
									<item>
										<label>•</label>
										<para> 15 or 30 mg/day with a sulfonylurea, metFORMIN, or insulin; decrease sulfonylurea dose if hypoglycemia occurs; decrease insulin dose by 10%-25% if hypoglycemia occurs or if plasma glucose is &lt;100 mg/dl, max 45 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9226">
						<sec_title>Hepatic dose</sec_title>
						<para>
							<list id="lidelem4x9230">
								<item>
									<label>•</label>
									<para>Do not use in active hepatic disease or if ALT &gt;2.5 times ULN</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9236">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 15, 30, 45 mg</para>
					</section>
					<section type="none" id="sidelem4x9241">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9245">
								<item>
									<label>•</label>
									<para>Once a day; without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Tabs crushed and mixed with food or fluids for patients with difficulty swallowing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9256">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9259">
					<section type="none" id="sidelem4x9260">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9267">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">MI, heart failure, death (geriatric patients)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9274">
						<sec_title>ENDO:</sec_title>
						<para> Hypo/hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x9279">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Sinusitis, upper respiratory tract infection, pharyngitis,</emphasis><emphasis style="bold">hepatotoxicity,</emphasis> edema, weight gain, anemia, macular edema; <emphasis style="bold">risk of bladder cancer (use &gt;1 yr), peripheral/pulmonary edema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9291">
						<sec_title>MS:</sec_title>
						<para> <emphasis style="bold">Rhabdomyolysis,</emphasis> fractures (females), myalgia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9299">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Maximal reduction in FBS after 12 wk; half-life 3-7 hr, terminal 16-24 hr; protein binding &gt;99%</para>
			</section>
			<section type="interactions" id="sidelem4x9304">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of atorvastatin</para>
				<para>
					<emphasis alert="lifethreat">Decrease: effect of oral contraceptives; use alternative contraceptive method</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pioglitazone effect—CYP2C8 inducers (ketoconazole, fluconazole, itraconazole, miconazole, voriconazole)</para>
				<section type="none" id="sidelem4x9318">
					<section type="none" id="sidelem4x9319">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> hypoglycemia—garlic, green tea, horse chestnut</para>
					</section>
					<section type="none" id="sidelem4x9326">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK, LFTs, HDL, cholesterol</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> glucose, Hct/Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x9337">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9340">
					<section type="none" id="sidelem4x9341">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Heart failure: do not use in NYHA Class III/IV; excessive/rapid weight gain &gt;5 lb, dyspnea, edema; may need to be reduced or discontinued</bbw>
						</para>
						<section type="none" id="sidelem4x9359">
							<label>•</label>
							<sec_title>Bladder cancer<route> avoid use in a history of bladder cancer; use of pioglitazone &gt;1 yr has shown an increase in bladder cancer</route></sec_title>
						</section>
						<section type="none" id="sidelem4x9365">
							<label>•</label>
							<sec_title>Hypoglycemic reactions</sec_title>
							<para>
								<list id="lidelem4x9365">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemic reactions:</emphasis> sweating, weakness, dizziness, anxiety, tremors, hunger; hyperglycemic reactions soon after meals (rare); may occur more often with insulin or other antidiabetics</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9372">
							<label>•</label>
							<sec_title>Hepatic disease<route> check LFTs periodically</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9375">
								<item>
									<label>•</label>
									<para>FBS, glycosylated HbA1c, plasma lipids/lipoproteins, B/P, body weight during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9380">
								<item>
									<label>•</label>
									<para>CBC with differential before and during therapy; more necessary in those with anemia, Hct/Hgb (may be decreased in first few months of treatment)</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9385">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9389">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; blood glucose A1c improvement</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9395">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9400">
								<item>
									<label>•</label>
									<para>To self-monitor using a blood glucose meter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9405">
								<item>
									<label>•</label>
									<para>About the symptoms of hypo/hyperglycemia; what to do about each</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9410">
								<item>
									<label>•</label>
									<para>That product must be continued on daily basis; about the consequences of discontinuing product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9415">
								<item>
									<label>•</label>
									<para>To avoid OTC medications or herbal preparations unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9420">
								<item>
									<label>•</label>
									<para>That diabetes is a lifelong illness; that product is not a cure, it only controls symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9428">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if oral contraceptives are used, effect may be decreased; not to use product if breastfeeding</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x9434">
							<label>•</label>
							<sec_title>To report symptoms of hepatic dysfunction<route> nausea, vomiting, abdominal pain, fatigue, anorexia, dark urine, jaundice</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9437">
								<item>
									<label>•</label>
									<para>To report weight gain, edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9442">
								<item>
									<label>•</label>
									<para>That lab work, eye exams will be needed periodically</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="16" status="active">
			<mono_name>piperacillin/tazobactam (Rx)</mono_name>
			<info>
				<pronunciation>(pip′er-ah-sill′in/ta-zoe-bak′tam)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x94521">
						<country code="CAN">Tazocin</country>
					</tradename>
					<tradename id="tnidelem4x94520">Zosyn</tradename>
				</tradenames>
				<class type="func"> Antiinfective, broad spectrum</class>
				<class type="chem"> Extended-spectrum penicillin, β-lactamase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x9465">
				<sec_title>Action:</sec_title>
				<para>Interferes with cell-wall replication of susceptible organisms; tazobactam is a β-lactamase inhibitor that protects piperacillin from enzymatic degradation</para>
			</section>
			<section type="uses" id="sidelem4x9470">
				<sec_title>Uses:</sec_title>
				<para>Moderate to severe infections: piperacillin-resistant, β-lactamase–producing strains causing infections in respiratory, skin, urinary tract, bone, gonorrhea, pneumonia; effective for resistant <emphasis style="italic">Staphylococcus aureus,</emphasis> resistant <emphasis style="italic">Escherichia coli, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides vulgatus, Haemophilus influenzae</emphasis></para>
				<section type="none" id="sidelem4x9480">
					<section type="none" id="sidelem4x9481">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Endocarditis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x9486">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to penicillins; neonates; carbapenem allergy</para>
				<section type="none" id="sidelem4x9491">
					<section type="none" id="sidelem4x9492">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, renal insufficiency in neonates, hypersensitivity to cephalosporins, seizures, GI disease, electrolyte imbalances, biliary obstruction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9497">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9500">
					<section type="none" id="sidelem4x9501">
						<sec_title>Nosocomial pneumonia</sec_title>
						<section type="none" id="sidelem4x9509">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9509">
									<item>
										<label>•</label>
										<para> 4.5 g q6hr or 3.375 g q4hr with an aminoglycoside or antipseudomonal fluoroquinolone × 1-2 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9513">
						<sec_title>Appendicitis/peritonitis</sec_title>
						<section type="none" id="sidelem4x9521">
							<label>•</label>
							<sec_title>Adults/adolescents/child ≥40 kg (88 lb)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9521">
									<item>
										<label>•</label>
										<para>3.375 g q6hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9528">
							<label>•</label>
							<sec_title>Child ≥9 mo and &lt;40 kg<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9528">
									<item>
										<label>•</label>
										<para> 100 mg/kg (piperacillin)/kg q8hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9536">
							<label>•</label>
							<sec_title>Infant 2 mo to &lt;9 mo<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x9536">
									<item>
										<label>•</label>
										<para> 80 mg/kg (piperacillin) q8hr × 7-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x9540">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x9548">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 20-40 ml/min, give 3.375 g q6hr (nosocomial pneumonia); give 2.25 g q6hr (all other indications); CCr &lt;20 ml/min, give 2.25 g q6hr (nosocomial pneumonia); give 2.25 g q8hr (all other indications)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x9551">
						<sec_title>Available forms:</sec_title>
						<para> Powder for inj 2 g piperacillin/0.25 g tazobactam, 3 g piperacillin/0.375 g tazobactam, 4 g piperacillin/0.5 g tazobactam, 36 g piperacillin/4.5 g tazobactam</para>
					</section>
					<section type="none" id="sidelem4x9556">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x9564">
							<label>•</label>
							<sec_title>
								<route>Separate aminoglycoside from piperacillin to avoid inactivation</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x9567">
								<item>
									<label>•</label>
									<para>Product after C&amp;S is complete</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9572">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x9576">
									<item>
										<label>•</label>
										<para>Reconstitute each 1 g of product/5 ml 0.9% NaCl for inj or sterile water for inj, dextrose 5%; shake well; further dilute in ≥50 ml compatible IV sol, run as int infusion over ≥30 min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9582">
							<sec_title>ADD-Vantage IV solution: Reconstitution:</sec_title>
							<para>
								<list id="lidelem4x9586">
									<item>
										<label>•</label>
										<para>Reconstitute with 0.9% sodium chloride or D<emphasis style="inf">5</emphasis>W in the appropriate flexible diluent container provided; for 500-mg vials, use at least a 100 ml diluent container and for 750 mg and 1-g vials, use only the 250-ml diluent container</para>
									</item>
									<item>
										<label>•</label>
										<para>Remove the protective covers from the top of the vial and vial port; remove vial cap (do not access with a syringe) and vial port cover; screw the vial into the vial port until it will go no further to assure a seal; once vial is sealed to the port, do not remove; to activate the contents of the vial, squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial; with the other hand, push the drug vial down into the container telescoping walls of the container and grasp the inner cap of the vial through the walls of the container; pull the inner cap from the drug vial; verify the rubber stopper has been pulled out, allowing the drug and diluent to mix; mix the container contents thoroughly</para>
									</item>
									<item>
										<label>•</label>
										<para>
											<emphasis style="italic">Storage after reconstitution:</emphasis> the admixture solution may be stored for up to 24 hr at room temperature; do not refrigerate or freeze after reconstitution</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use in series connections with flexible containers</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x9612">
							<sec_title>Premixed Galaxy IV solution:</sec_title>
							<para>
								<list id="lidelem4x9617">
									<item>
										<label>•</label>
										<para>Thaw frozen containers at room temperature (20-25°C or 68-77°F) or under refrigeration (2-8°C or 36-46°F); do not force thaw by immersion in water baths or by microwaving; check for leaks by squeezing bag firmly</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9622">
									<item>
										<label>•</label>
										<para>Do not admix</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x9627">
									<item>
										<label>•</label>
										<para>Contents of the solution may precipitate in the frozen state and should dissolve with little or no agitation once the solution has reached room temperature</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x9635">
								<label>•</label>
								<sec_title>Storage</sec_title>
								<para>
									<list id="lidelem4x9635">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">
													<emphasis style="italic">Storage:</emphasis>
												</emphasis> the thawed solution is stable for 24 hr at room temperature or for 14 days under refrigeration; do not refreeze thawed product</para>
										</item>
									</list>
								</para>
							</section>
							<section type="none" id="sidelem4x9643">
								<label>•</label>
								<sec_title>
									<route>Do not use plastic containers in series connections as this could result in an embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is complete</route>
								</sec_title>
							</section>
						</section>
						<section type="none" id="sidelem4x9646">
							<sec_title>IV INFUSION:</sec_title>
							<para>
								<list id="lidelem4x9650">
									<item>
										<label>•</label>
										<para>Infuse IV over at least 30 min; ambulatory intravenous infusion pumps can be used; the solution is stable for up to 12 hr at room temperature</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, allopurinol, amifostine, amikacin, aminocaproic acid, aminophylline, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, argatroban, atenolol, aztreonam, bivalirudin, bleomycin, bumetanide, buprenorphine, busulfan, butorphanol, calcium acetate/chloride/gluconate, CARBOplatin, carmustine, cefepime, chloramphenicol, cimetidine, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, dexrazoxane, diazepam, digoxin, diphenhydrAMINE, DOCEtaxel, DOPamine, doxacurium, enalaprilat, ePHEDrine, EPINEPHrine, eptifibatide, erythromycin, esmolol, etoposide, fenoldopam, fentaNYL, floxuridine, fluconazole, fludarabine, fluorouracil, foscarnet, fosphenytoin, furosemide, gallium, granisetron, heparin, hydrocortisone, HYDROmorphone, ifosfamide, isoproterenol, ketorolac, lansoprazole, lepirudin, leucovorin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, mesna, metaraminol, methotrexate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, milrinone, morphine, naloxone, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, PENTobarbital, PHENobarbital, phentolamine, phenylephrine, plicamycin, potassium chloride/phosphates, procainamide, ranitidine, remifentanil, riTUXimab, sargramostim, sodium acetate/bicarbonate/phosphates, uccinylcholine, SUFentanil, sulfamethoxazole-trimethoprim, tacrolimus, telavancin, teniposide, theophylline, thiotepa, tigecycline, tirofiban, trimethobenzamide, vasopressin, vinBLAStine, vinCRIStine, voriconazole, zidovudine, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9662">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9665">
					<section type="none" id="sidelem4x9666">
						<sec_title>CNS:</sec_title>
						<para> Lethargy, hallucinations, anxiety, depression, twitching, insomnia, headache, fever, dizziness, <emphasis style="bold">seizures,</emphasis> vertigo</para>
					</section>
					<section type="none" id="sidelem4x9674">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Cardiac toxicity,</emphasis> edema</para>
					</section>
					<section type="none" id="sidelem4x9682">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, diarrhea;</emphasis> increased AST, ALT; abdominal pain, glossitis, <emphasis style="bold">pseudomembranous colitis,</emphasis> constipation, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9695">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Oliguria, proteinuria, hematuria,</emphasis><emphasis style="italic">vaginitis, moniliasis,</emphasis><emphasis style="bold">glomerulonephritis, renal failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9706">
						<sec_title>HEMA:</sec_title>
						<para> Anemia, increased bleeding time, <emphasis style="bold">bone marrow depression, agranulocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9713">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, <emphasis style="bold">exfoliative dermatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x9720">
						<sec_title>META:</sec_title>
						<para> Hypokalemia, hypernatremia</para>
					</section>
					<section type="none" id="sidelem4x9725">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Serum sickness, anaphylaxis, Stevens-Johnson syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9732">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 0.7-1.2 hr; excreted in urine, bile, breast milk; crosses placenta; 33% bound to plasma proteins</para>
				<section type="none" id="sidelem4x9737">
					<section type="none" id="sidelem4x9738">
						<sec_title>IV:</sec_title>
						<para> Peak completion of IV</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x9743">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of neuromuscular blockers, oral anticoagulants, methotrexate</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> piperacillin concentrations—aspirin, probenecid</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antimicrobial effect of piperacillin—tetracyclines, aminoglycosides IV</para>
				<para>
					<emphasis alert="lifethreat">Drug/Lab Test</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> eosinophilia, neutropenia, leukopenia, serum creatinine, PTT, AST, ALT, alk phos, bilirubin, BUN, electrolytes</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> Hct, Hgb, electrolytes</para>
				<para>
					<emphasis style="bold">False positive:</emphasis> urine glucose, urine protein, Coombs’ test</para>
			</section>
			<section type="considerations" id="sidelem4x9773">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x9776">
					<section type="none" id="sidelem4x9777">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x9785">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x9785">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> temperature, stools, urine, sputum, wounds</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x9789">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; report hematuria, oliguria because penicillin in high doses is nephrotoxic; maintain hydration unless contraindicated</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9794">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT before treatment and periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9799">
								<item>
									<label>•</label>
									<para>Blood studies: WBC, RBC, Hct, Hgb, bleeding time before treatment and periodically thereafter; serum potassium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9804">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, protein, blood, BUN, creatinine before treatment and periodically thereafter</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9809">
								<item>
									<label>•</label>
									<para>C&amp;S before product therapy; product may be given as soon as culture is taken</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9817">
							<label>•</label>
							<sec_title>Pseudomembranous colitis<route> diarrhea, bloody stools, fever, abdominal cramps; may occur ≤2 mo after treatment; bowel pattern before and during treatment</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9820">
								<item>
									<label>•</label>
									<para>Skin eruptions after administration of penicillin to 1 wk after discontinuing product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9825">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, character, wheezing, tightness in chest</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9833">
							<label>•</label>
							<sec_title>Anaphylaxis<route> wheezing, laryngeal edema, rash, itching; discontinue product, have emergency equipment nearby</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9836">
								<item>
									<label>•</label>
									<para>Adequate intake of fluids (2 L) during diarrhea episodes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9842">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x9846">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fever, purulent drainage, redness, inflammation; culture shows decreased organisms</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x9852">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x9857">
								<item>
									<label>•</label>
									<para>That culture may be taken after completed course of medication</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x9865">
							<label>•</label>
							<sec_title>To report sore throat, fever, fatigue (superinfection); CNS effects (anxiety, depression, hallucinations, seizures); pseudomembranous colitis<route> fever, diarrhea with blood, pus, mucus</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x9868">
								<item>
									<label>•</label>
									<para>To wear or carry emergency ID if allergic to penicillins</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x9873">
								<item>
									<label>•</label>
									<para>To notify nurse of diarrhea</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="17" status="active">
			<mono_name>pirbuterol (Rx)</mono_name>
			<info>
				<pronunciation>(peer-byoo′ter-ole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x98910">Maxair</tradename>
				</tradenames>
				<class type="func"> Bronchodilator</class>
				<class type="chem"> β-Adrenergic agonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x9901">
				<sec_title>Action:</sec_title>
				<para>Causes bronchodilation with little effect on heart rate by action on β-receptors, causing increased cAMP and relaxation of smooth muscle</para>
			</section>
			<section type="uses" id="sidelem4x9906">
				<sec_title>Uses:</sec_title>
				<para>Reversible bronchospasm (prevention, treatment) including asthma; may be given with theophylline or steroids</para>
			</section>
			<section type="contra" id="sidelem4x9911">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, tachycardia</para>
				<section type="none" id="sidelem4x9916">
					<section type="none" id="sidelem4x9917">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breast-feeding, cardiac disorders, hyperthyroidism, hypertension, diabetes mellitus, prostatic hypertrophy</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x9922">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x9930">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr</sec_title>
					<para>
						<list id="lidelem4x9930">
							<item>
								<label>•</label>
								<para>
									<emphasis style="bold">Adult and child &gt;12 yr:</emphasis> INH 1-2 inhalations (0.4 mg) q4-6hr; max 12 INH/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x9934">
					<section type="none" id="sidelem4x9935">
						<sec_title>Available forms:</sec_title>
						<para> Aerosol delivery 0.2 mg pirbuterol/actuation</para>
					</section>
					<section type="none" id="sidelem4x9940">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x9944">
								<item>
									<label>•</label>
									<para>Store in light-resistant container; do not expose to temperatures over 86º F (30º C)</para>
								</item>
								<item>
									<label>•</label>
									<para>After shaking; exhale; place mouthpiece in mouth; inhale slowly; hold breath; remove; exhale slowly</para>
								</item>
								<item>
									<label>•</label>
									<para>Gum, sips of water for dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x9960">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x9963">
					<section type="none" id="sidelem4x9964">
						<sec_title>CNS:</sec_title>
						<para> Tremors, anxiety, insomnia, headache, dizziness, stimulation, restlessness, hallucinations, drowsiness, irritability</para>
					</section>
					<section type="none" id="sidelem4x9969">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypertension, angina, hypotension, dysrhythmias</para>
					</section>
					<section type="none" id="sidelem4x9974">
						<sec_title>EENT:</sec_title>
						<para> Dry nose and mouth, irritation of nose, throat</para>
					</section>
					<section type="none" id="sidelem4x9979">
						<sec_title>GI:</sec_title>
						<para> Gastritis, nausea, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x9984">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps</para>
					</section>
					<section type="none" id="sidelem4x9989">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Paradoxical bronchospasm,</emphasis> dyspnea, coughing</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x9997">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x10000">
					<section type="none" id="sidelem4x10001">
						<sec_title>INH:</sec_title>
						<para> Onset 3 min, peak <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr, duration 5 hr, terminal half-life 2 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x10012">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Hypertensive crisis: MAOIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> action of other aerosol bronchodilators</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pirbuterol action—tricyclics, antihistamines, levothyroxine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pirbuterol action—β-blockers</para>
				<section type="none" id="sidelem4x10032">
					<section type="none" id="sidelem4x10033">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> action of both—cola nut, guarana, yerba maté</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> effect—green tea (large amounts), guarana</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10044">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10047">
					<section type="none" id="sidelem4x10048">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10053">
								<item>
									<label>•</label>
									<para>Respiratory function: vital capacity, forced expiratory volume, ABGs, B/P, lung sounds, pulse, characteristics of sputum</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10059">
								<item>
									<para>
										<emphasis alert="nurse">Paradoxical bronchospasm, that can occur rapidly, hold product, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10064">
								<item>
									<label>•</label>
									<para>Fluid intake &gt;2 L/day to liquefy thick secretions</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10069">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10073">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of dyspnea, wheezing over 1 hr</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10080">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10084">
								<item>
									<label>•</label>
									<para>Not to use OTC medications; extra stimulation may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Use of inhaler; review package insert with patient</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid getting aerosol in eyes</para>
								</item>
								<item>
									<label>•</label>
									<para>Actuator is for Maxair autoinhaler; do not use with other inhaler canister</para>
								</item>
								<item>
									<label>•</label>
									<para>About all aspects of product; avoid smoking, smoke-filled rooms, persons with respiratory infections</para>
								</item>
								<item>
									<label>•</label>
									<para>To keep ﬂuid intake &gt;2 L/day to liquefy thick secretions</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="18" status="active" ru="yes">
			<mono_name> pirfenidone</mono_name>
			<info>
				<pronunciation>(pir-fen′i-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x101270">Esbriet</tradename>
				</tradenames>
				<class type="func"> Respiratory agent</class>
			</info>
			<section type="uses" id="sidelem4x10133">
				<sec_title>Uses:</sec_title>
				<para> Pulmonary fibrosis</para>
			</section>
			<section type="contra" id="sidelem4x10138">
				<sec_title>Contraindications:</sec_title>
				<para> Hypersensitivity</para>
			</section>
			<section type="doses" id="sidelem4x10143">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10151">
					<label>•</label>
					<sec_title>Adults<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10151">
							<item>
								<label>•</label>
								<para> Titrate over 2 wk to a maintenance dose of 801 mg tid. Give 267 mg tid on days 1-7, 534 mg tid on days 8-14, and 801 mg tid from day 15 onward</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10155">
					<section type="none" id="sidelem4x10156">
						<sec_title>Available forms:</sec_title>
						<para> Cap 267 mg</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="19" status="active">
			<mono_name>pitavastatin (Rx)</mono_name>
			<info>
				<pronunciation>(pit′a-va-stat′-in)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x101660">Livalo</tradename>
				</tradenames>
				<class type="func"> Antilipidemic</class>
				<class type="chem"> HMG-CoA reductase inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x10176">
				<para>
					<confusion>
						<tradename id="tnidelem4x101760">pitavastatin</tradename>
						<drug type="generic" refid="idelem4x101760">pravastatin</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x10180">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis; high doses lead to plaque regression</para>
			</section>
			<section type="uses" id="sidelem4x10185">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types Ia, Ib), dysbetalipoproteinemia, elevated triglyceride levels, prevention of CV disease by reduction of heart risk in those with mildly elevated cholesterol</para>
				<section type="none" id="sidelem4x10190">
					<section type="none" id="sidelem4x10191">
						<sec_title>Unlabeled Uses:</sec_title>
						<para> Atherosclerosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10196">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease, cholestasis</para>
				<section type="none" id="sidelem4x10201">
					<section type="none" id="sidelem4x10202">
						<sec_title>Precautions:</sec_title>
						<para> Past hepatic disease, alcoholism, severe acute infections, trauma, severe metabolic disorders, electrolyte imbalance, seizures, surgery, organ transplant, endocrine disease, females, hypotension, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10207">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10215">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10215">
							<item>
								<label>•</label>
								<para> 2 mg/day, usual range 1-4, max 4 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10219">
					<section type="none" id="sidelem4x10220">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x10228">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-&lt;60 ml/min, 1 mg daily, max 2 mg daily; CCr &lt;30 ml/min on hemodialysis, 1 mg daily, max 2 mg daily; CCr &lt;30 ml/min, not recommended</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10231">
						<sec_title>Atherosclerosis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x10239">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10239">
									<item>
										<label>•</label>
										<para> 4 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10243">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 4 mg</para>
					</section>
					<section type="none" id="sidelem4x10248">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10252">
								<item>
									<label>•</label>
									<para>Total daily dose any time of day without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in tight container protected from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10263">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10266">
					<section type="none" id="sidelem4x10267">
						<sec_title>CNS:</sec_title>
						<para> Headache</para>
					</section>
					<section type="none" id="sidelem4x10272">
						<sec_title>GI:</sec_title>
						<para> Constipation, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x10277">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, alopecia</para>
					</section>
					<section type="none" id="sidelem4x10282">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, myalgia, <emphasis style="bold">rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10289">
						<sec_title>RESP:</sec_title>
						<para> Pharyngitis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10294">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1 hr; metabolized in liver, excreted in urine, feces; half-life 12 hr; protein binding 99%; concentrations lower in healthy African Americans</para>
			</section>
			<section type="interactions" id="sidelem4x10300">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: risk for possible rhabdomyolysis—azole antifungals, cycloSPORINE, erythromycin, niacin, gemfibrozil, clofibrate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> levels of pitavastatin—erythromycin</para>
				<para>
					<emphasis alert="lifethreat">Drug/Herb</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pitavastatin—red yeast rice</para>
				<para>
					<emphasis alert="lifethreat">Drug/Lab Test</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bilirubin, alk phos, ALT, AST</para>
				<para>
					<emphasis style="bold">Interference:</emphasis> thyroid function tests</para>
			</section>
			<section type="considerations" id="sidelem4x10328">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10331">
					<section type="none" id="sidelem4x10332">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x10340">
							<label>•</label>
							<sec_title>
								<route>Diet;</route>
							</sec_title>
							<para>
								<list id="lidelem4x10340">
									<item>
										<label>•</label>
										<para> obtain diet history including fat, cholesterol in diet</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x10344">
								<item>
									<label>•</label>
									<para>Cholesterol, triglyceride levels periodically during treatment; check lipid panel 6 wk after changing dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10349">
								<item>
									<label>•</label>
									<para>Hepatic studies at 12 wk after starting treatment, then q6mo; if AST &gt;3× normal, reduce or discontinue; AST, ALT, LFTs may be increased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10354">
								<item>
									<label>•</label>
									<para>Renal studies in patients with compromised renal system: BUN, I&amp;O ratio, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10360">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle pain, tenderness; obtain CPK baseline; if markedly increased, product may need to be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10365">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10369">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in cholesterol to desired level after 6 wk</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10375">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x10380">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10385">
								<item>
									<label>•</label>
									<para>To report blurred vision, severe GI symptoms, headache, muscle pain, weakness, tenderness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10390">
								<item>
									<label>•</label>
									<para>That previously prescribed regimen will continue: low-cholesterol diet, exercise program, smoking cessation</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x10398">
							<label>•</label>
							<sec_title>
								<route>Not to take product if pregnant (X) or if pregnancy is planned or suspected (notify prescriber); to avoid breastfeeding</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="20" status="active">
			<mono_name>plasma protein fraction (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x104040">Plasmanate</tradename>
				</tradenames>
				<class type="func"> Hematological agent</class>
				<class type="chem"> Plasma volume expander</class>
			</info>
			<section type="uses" id="sidelem4x10414">
				<sec_title>Uses:</sec_title>
				<para>Hypovolemic shock, hypoproteinemia, ARDS, preoperative cardiopulmonary bypass, acute hepatic failure, nephrotic syndrome, cardiogenic shock</para>
			</section>
			<section type="contra" id="sidelem4x10419">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or albumin; CHF, severe anemia, renal insufficiency, hyponatremia, cardiopulmonary bypass</para>
			</section>
			<section type="doses" id="sidelem4x10424">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10427">
					<section type="none" id="sidelem4x10428">
						<sec_title>Hypovolemia</sec_title>
						<section type="none" id="sidelem4x10436">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x10436">
									<item>
										<label>•</label>
										<para> 250-500 ml (12.5-25 g protein), max 10 ml/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x10443">
							<label>•</label>
							<sec_title>Child<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x10443">
									<item>
										<label>•</label>
										<para> 10-30 ml/kg at max 5-10 ml/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10447">
						<sec_title>Hypoproteinemia</sec_title>
						<section type="none" id="sidelem4x10455">
							<label>•</label>
							<sec_title>Adult<route> IV INFUSION</route></sec_title>
							<para>
								<list id="lidelem4x10455">
									<item>
										<label>•</label>
										<para> 1000-1500 ml/day, max 8 ml/min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="21" status="active">
			<mono_name>plerixafor (Rx)</mono_name>
			<info>
				<pronunciation>(pler-ix′a-fore)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x104640">Mozobil</tradename>
				</tradenames>
				<class type="func"> Biologic modifier</class>
				<class type="chem"> Colony-stimulating factor</class>
			</info>
			<section type="uses" id="sidelem4x10474">
				<sec_title>Uses:</sec_title>
				<para>For peripheral blood stem cell (PBSC) mobilization for collection and autologous transplant in patients with non-Hodgkin’s lymphoma, multiple myeloma; used with a granulocyte colony-stimulating factor (G-CSF)</para>
			</section>
			<section type="contra" id="sidelem4x10479">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding, pregnancy (D)</para>
			</section>
			<section type="doses" id="sidelem4x10484">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10492">
					<label>•</label>
					<sec_title>Adult<route> SUBCUT</route></sec_title>
					<para>
						<list id="lidelem4x10492">
							<item>
								<label>•</label>
								<para> 0.24 mg/kg daily about 11 hr before initiation of apheresis, give for up to 4 consecutive days; give filgrastim 10 mcg/kg;  daily each <emphasis style="smallcaps">am</emphasis> beginning 4 days before the 1st evening dose of plerixafor and on each day of apheresis; give filgrastim before procedure</para>
							</item>
						</list>
					</para>
				</section>
			</section>
		</monograph>
<monograph id="22" status="active">
			<mono_name>pomalidomide</mono_name>
			<info>
				<pronunciation>(pom–a-lid′oh-mide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x105080">Pomalyst</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, biologic response modifier, hormone</class>
				<class type="chem"> TNF modifier</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="actions" id="sidelem4x10518">
				<sec_title>Action:</sec_title>
				<para>Inhibits growth of tumor cells and induces apoptosis, can be used in those resistant to lenalidomide</para>
			</section>
			<section type="uses" id="sidelem4x10523">
				<sec_title>Uses:</sec_title>
				<para>Multiple myeloma in those who have received ≥2 treatments including lenalidomide and bortezomib and disease has progressed within 60 days of completion of the treatment or in BRAF V600 mutation-positive patients who have disease progression following ipilimumab and a BRAF inhibitor</para>
			</section>
			<section type="contra" id="sidelem4x10528">
				<sec_title>Contraindications:</sec_title>
				<para>Breastfeeding, hypersensitivity</para>
				<para>
					<bbw>Pregnancy (X)</bbw>
				</para>
				<section type="none" id="sidelem4x10543">
					<section type="none" id="sidelem4x10544">
						<sec_title>Precautions:</sec_title>
						<para> Children, geriatric patients, accidental exposure, bone marrow suppression, uterine bleeding, dental disease, fungal/viral infections, smoking</para>
						<para>
							<bbw>Thrombocytopenia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10559">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10567">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10567">
							<item>
								<label>•</label>
								<para> 4 mg on days 1-21</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10571">
					<section type="none" id="sidelem4x10572">
						<sec_title>Hepatic/renal dose:</sec_title>
						<section type="none" id="sidelem4x10580">
							<label>•</label>
							<sec_title>Adult<route> PO bilirubin &gt;2 mg/dl and AST/ALT &gt;3× ULN or CCr &gt;3 mg/dl, do not use</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x10583">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2, 3, 4 mg</para>
					</section>
					<section type="none" id="sidelem4x10588">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x10592">
								<item>
									<label>•</label>
									<para>With or without dexamethasone, may use dexamethasone 40 mg on days 1, 8, 15, 22 of each cycle, if &gt;75 yr, decrease dexamethasone to 20 mg/dose</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10598">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10601">
					<section type="none" id="sidelem4x10602">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue, fever, headache, peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x10607">
						<sec_title>CV:</sec_title>
						<para> Chest pain</para>
					</section>
					<section type="none" id="sidelem4x10612">
						<sec_title>GI:</sec_title>
						<para> Constipation, diarrhea, nausea/vomiting, <emphasis style="bold">hepatic failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10619">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, neutropenia, thrombocytopenia, pancytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10626">
						<sec_title>META:</sec_title>
						<para> Hypokalemia</para>
					</section>
					<section type="none" id="sidelem4x10631">
						<sec_title>MS:</sec_title>
						<para> Arthralgia, back pain</para>
					</section>
					<section type="none" id="sidelem4x10636">
						<sec_title>RESP:</sec_title>
						<para> Cough, dyspnea, <emphasis style="bold">pulmonary embolism,</emphasis> epistaxis</para>
					</section>
					<section type="none" id="sidelem4x10644">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10651">
				<sec_title>Pharmacokinetics</sec_title>
				<para>12%-44% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x10656">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> pomalidomide effect—CYP3A4 inhibitors (amprenavir, boceprevir, delavirdine, ketoconazole, indinavir, itraconazole, dalfopristin/quinupristin, ritonavir, tipranavir, fluconazole, isoniazid, miconazole); P-gb inhibitors; avoid using together</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pomalidomide effect—CYP3A4 inducers (rifampin, rifapentine, rifabutin, primidone, phenytoin, PHENobarbital, nevirapine, nafcillin, modafinil, griseofulvin, etravirine, efavirenz, barbiturates, bexarotene, bosentan, carBAMazepine, enzalutamide, dexamethasone); avoid using together</para>
				<section type="none" id="sidelem4x10667">
					<section type="none" id="sidelem4x10668">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x10672">
								<item>
									<label>•</label>
									<para>Decreased pomalidomide effect—St. John’s wort, avoid using together</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10678">
						<sec_title>Drug/Smoking</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> pomalidomide effect—cigarettes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10685">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10688">
					<section type="none" id="sidelem4x10689">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Blood studies: Hct, Hgb, thrombolytic disease may occur</bbw>
						</para>
						<para>
							<bbw>For pregnancy before treatment, pregnancy (X)</bbw>
						</para>
					</section>
					<section type="none" id="sidelem4x10713">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x10717">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased growth of tumor cells</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x10723">
						<sec_title>Team patient/family:</sec_title>
						<para>
							<list id="lidelem4x10727">
								<item>
									<label>•</label>
									<para>To avoid driving or hazardous activity during beginning of treatment</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>Advise patient to use adequate contraception, pregnancy (X)</bbw>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="23" status="active">
			<mono_name>posaconazole (Rx)</mono_name>
			<info>
				<pronunciation>(poe′sa-kon′a-zole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x107481">Noxafil</tradename>
					<tradename id="tnidelem4x107480">
						<country code="CAN">Posanol </country>
					</tradename>
				</tradenames>
				<class type="func"> Antifungal—systemic</class>
				<class type="chem"> Triazole derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x10760">
				<sec_title>Action:</sec_title>
				<para>Inhibits a portion of cell-wall synthesis; alters cell membranes and inhibits several fungal enzymes</para>
			</section>
			<section type="uses" id="sidelem4x10765">
				<sec_title>Uses:</sec_title>
				<para>Prevention of aspergillus, candida infection, oropharyngeal candidiasis in immunocompromised patients, chemotherapy-induced neutropenia, mucocutaneous candidiasis</para>
				<section type="none" id="sidelem4x10770">
					<section type="none" id="sidelem4x10771">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Aspergillosis, cellulitis, coccidioidomycosis, endocarditis, endophthalmitis, esophageal candidiasis, febrile neutropenia, fungal keratitis, fusariosis, histoplasmosis, infectious arthritis, myocarditis, osteomyelitis, pericarditis, sinusitis, tracheobronchitis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x10776">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or other systemic antifungals or azoles; fungal meningitis, onchomycosis or dermatomycosis in cardiac dysfunction; use with ergots, sirolimus, CYP3A4 substrates</para>
				<section type="none" id="sidelem4x10781">
					<section type="none" id="sidelem4x10782">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, cardiac/hepatic/renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x10787">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x10795">
					<label>•</label>
					<sec_title>Adult, adolescent<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x10795">
							<item>
								<label>•</label>
								<para> 600 mg/day in 2-4 divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x10799">
					<section type="none" id="sidelem4x10800">
						<sec_title>Oropharyngeal Candidiasis</sec_title>
						<section type="none" id="sidelem4x10808">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10808">
									<item>
										<label>•</label>
										<para> 100 mg bid × 1 day, then 100 mg/day × 13 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10812">
						<sec_title>Oropharyngeal candidiasis resistant to fluconazole or itraconazole</sec_title>
						<section type="none" id="sidelem4x10818">
							<sec_title>Adult/Child ≥13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x10818">
									<item>
										<para> 400 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x10822">
						<sec_title>Available forms:</sec_title>
						<para> Oral susp 200 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x10827">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x10830">
							<sec_title>PO route</sec_title>
							<section type="none" id="sidelem4x10838">
								<label>•</label>
								<sec_title>Oral susp</sec_title>
								<para>
									<list id="lidelem4x10838">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Oral susp:</emphasis> shake well; use calibrated measuring device; take only with full meal or liquid nutritional supplements such as Ensure; rinse measuring device after each use</para>
										</item>
									</list>
								</para>
							</section>
							<para>
								<list id="lidelem4x10842">
									<item>
										<label>•</label>
										<para>Store in tight container in refrigerator; do not freeze</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x10847">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x10850">
					<section type="none" id="sidelem4x10851">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> insomnia, fever, rigors, weakness, anxiety</para>
					</section>
					<section type="none" id="sidelem4x10859">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, tachycardia, anemia, <emphasis style="bold">QT prolongation, torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10866">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> cramps, abdominal pain, flatulence, <emphasis style="bold">GI bleeding, hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10876">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia, impotence, decreased libido</para>
					</section>
					<section type="none" id="sidelem4x10881">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Pruritus,</emphasis> fever, <emphasis style="italic">rash,</emphasis><emphasis style="bold">toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x10893">
						<sec_title>MISC:</sec_title>
						<para> <emphasis style="italic">Edema, fatigue,</emphasis> malaise, hypokalemia, tinnitus, <emphasis style="bold">rhabdomyolysis,</emphasis> hypokalemia</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x10904">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, enhanced by food, protein binding 98%-99%, peak 3-5 hr, half-life 35 hr, metabolized in liver, excreted in feces (77% unchanged)</para>
			</section>
			<section type="interactions" id="sidelem4x10909">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x10917">
					<label>•</label>
					<sec_title>
						<route>Do not use with lovastatin, atorvastatin</route>
					</sec_title>
				</section>
				<para>
					<list id="lidelem4x10921">
						<item>
							<para>
								<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β agonists, local anesthetics, tricyclics, haloperidol, chloroquine, droperidol, pentamidine; CYP3A4 inhibitors (amiodarone, clarithromycin, erythromycin, telithromycin, troleandomycin), arsenic trioxide, levomethadyl; CYP3A4 substrates (methadone, pimozide, QUEtiapine, quiNIDine, risperiDONE, ziprasidone)</emphasis>
							</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> tinnitus, hearing loss—quiNIDine</para>
				<para>
					<emphasis alert="lifethreat">Increase: hepatotoxicity—other hepatotoxic products</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> severe hypoglycemia—oral hypoglycemics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> sedation—triazolam, oral midazolam</para>
				<para>
					<emphasis alert="lifethreat">Increase: levels, toxicity—busPIRone, busulfan, calcium-channel blockers, clarithromycin, cycloSPORINE, diazepam, digoxin, felodipine, HMG-CoA reductase inhibitors, indinavir, isradipine, midazolam, niCARdipine, NIFEdipine, niMODipine, phenytoin, quiNIDine, ritonavir, saquinavir, sirolimus, tacrolimus, vinca alkaloids, warfarin</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> posaconazole level—cimetidine, phenytoin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> posaconazole action—antacids, H<emphasis style="inf">2</emphasis>-receptor antagonists, rifamycin, didanosine</para>
				<section type="none" id="sidelem4x10956">
					<section type="none" id="sidelem4x10957">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x10961">
								<item>
									<label>•</label>
									<para>Food increases absorption</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x10967">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x10970">
					<section type="none" id="sidelem4x10971">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x10977">
								<item>
									<para>
										<emphasis alert="nurse">Infection: type of, may begin treatment before obtaining results; temperature, WBC, sputum at baseline and periodically, break-through infections may occur when used with fosamprenavir</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10982">
								<item>
									<label>•</label>
									<para>I&amp;O ratio, electrolytes; correct electrolyte imbalances before starting treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10987">
								<item>
									<label>•</label>
									<para>For allergic reaction: rash, photosensitivity, urticaria, dermatitis</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10993">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle pain, increased CPK; weakness, swelling of affected muscles; if these occur and if confirmed by CPK, product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x10999">
								<item>
									<para>
										<emphasis alert="nurse">Hepatotoxicity: nausea, vomiting, jaundice, clay-colored stools, fatigue; hepatic studies (ALT, AST, bilirubin) if patient receiving long-term therapy</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11005">
								<item>
									<para>
										<emphasis alert="nurse">QT prolongation: ECG for QT prolongation, ejection fraction; assess for chest pain, palpitations, dyspnea</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11010">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11014">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of fungal infection, negative C&amp;S for infecting organism</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11020">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11025">
								<item>
									<label>•</label>
									<para>That long-term therapy may be needed to clear infection (1 wk-6 mo, depending on infection)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11031">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizziness occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11036">
								<item>
									<label>•</label>
									<para>To take 2 hr before administration of other products that increase gastric pH (antacids, H<emphasis style="inf">2</emphasis>-blockers, omeprazole, sucralfate, anticholinergics); to notify health care provider of all medications taken (many interactions)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11044">
								<item>
									<label>•</label>
									<para>About the importance of compliance with product regimen; to use alternative method of contraception</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11052">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber of GI symptoms, signs of hepatic dysfunction (fatigue, nausea, anorexia, vomiting, dark urine, pale stools)</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11055">
								<item>
									<label>•</label>
									<para>To take during or within 20 min of eating</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="24" status="active">
			<mono_name>potassium acetate</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110630"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="25" status="active">
			<mono_name>potassium bicarbonate (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110702">K Effervescent</tradename>
					<tradename id="tnidelem4x110701">Klor-Con EF</tradename>
					<tradename id="tnidelem4x110700">K-Vescent</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="26" status="active">
			<mono_name>potassium bicarbonate and potassium chloride (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110780">
						<country code="CAN">Neo-K </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="27" status="active">
			<mono_name>potassium bicarbonate and potassium citrate (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110880"/>
				</tradenames>
			</info>
		</monograph>
<monograph id="28" status="active" ha="yes">
			<mono_name> potassium chloride (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x110974">Epiklor</tradename>
					<tradename id="tnidelem4x110973">Klor-Con</tradename>
					<tradename id="tnidelem4x110972">K-Tab</tradename>
					<tradename id="tnidelem4x110971">Micro-K</tradename>
					<tradename id="tnidelem4x110970">
						<country code="CAN">Odan K-20 </country>
					</tradename>
				</tradenames>
			</info>
		</monograph>
<monograph id="29" status="active">
			<mono_name>potassium gluconate (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<class type="func"> Electrolyte, mineral replacement</class>
				<class type="chem"> Potassium</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11115">
				<sec_title>Action:</sec_title>
				<para>Needed for the adequate transmission of nerve impulses and cardiac contraction, renal function, intracellular ion maintenance</para>
			</section>
			<section type="uses" id="sidelem4x11120">
				<sec_title>Uses:</sec_title>
				<para>Prevention and treatment of hypokalemia</para>
			</section>
			<section type="contra" id="sidelem4x11125">
				<sec_title>Contraindications:</sec_title>
				<para>Renal disease (severe), severe hemolytic disease, Addison’s disease, hyperkalemia, acute dehydration, extensive tissue breakdown</para>
				<section type="none" id="sidelem4x11130">
					<section type="none" id="sidelem4x11131">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), cardiac disease, potassium-sparing diuretic therapy, systemic acidosis</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11136">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11139">
					<section type="none" id="sidelem4x11140">
						<sec_title>Hypokalemia (prevention) (bicarbonate, chloride, gluconate)</sec_title>
						<section type="none" id="sidelem4x11148">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11148">
									<item>
										<label>•</label>
										<para> 20 mEq/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11155">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11155">
									<item>
										<label>•</label>
										<para> 1-2 mEq/kg/day in 1-2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11159">
						<sec_title>Hypokalemia, digoxin toxicity (acetate, chloride)</sec_title>
						<section type="none" id="sidelem4x11167">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x11167">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> serum potassium concentration &gt;2.5 mEq/L:  max 10 mEq/1 hr with 24-hr max dose 200 mEq, initial dose of 20-40 mEq has been recommended;  40-100 mEq/day in 2-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11180">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x11180">
									<item>
										<label>•</label>
										<para> 0.25-0.5 mEq/kg/dose at 0.25-0.5 mEq/kg/hr;  2-5 mEq/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11187">
						<sec_title>Available forms:</sec_title>
						<para> Tabs for sol 6.5, 25 mEq; ext rel caps 8, 10 mEq; powder for sol 3.3, 5, 6.7, 10, 13.3 mEq/5 ml; tabs 2, 4, 5, 13.4 mEq; ext rel tabs 6.7, 8, 10 mEq; elix 6.7 mEq/5 ml; oral sol 2.375 mEq/5 ml; inj for prep of IV 1.5, 2, 2.4, 3, 3.2, 4.4, 4.7 mEq/ml</para>
					</section>
					<section type="none" id="sidelem4x11192">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x11195">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x11199">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel tabs, caps, or enteric products</para>
									</item>
									<item>
										<label>•</label>
										<para>With or after meals; dissolve effervescent tabs, powder in 8 oz cold water or juice; do not give IM, SUBCUT</para>
									</item>
									<item>
										<label>•</label>
										<para>Caps with full glass of liquid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11215">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x11219">
									<item>
										<label>•</label>
										<para>Through large-bore needle to decrease vein inflammation; check for extravasation; in large vein, avoid scalp vein in child (IV)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11225">
							<sec_title>Potassium acetate</sec_title>
							<para>
								<emphasis style="bold">Additive compatibilities:</emphasis> Metoclopramide</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Ciprofloxacin</para>
						</section>
						<section type="none" id="sidelem4x11236">
							<sec_title>Potassium chloride</sec_title>
							<section type="none" id="sidelem4x11244">
								<label>•</label>
								<sec_title>
									<route>Potassium chloride</route>
								</sec_title>
								<para>
									<list id="lidelem4x11244">
										<item>
											<label>•</label>
											<para> must be diluted; concentrated potassium injections fatal</para>
										</item>
									</list>
								</para>
							</section>
						</section>
						<section type="none" id="sidelem4x11248">
							<sec_title>Continuous IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x11252">
									<item>
										<label>•</label>
										<para>Concentration max 80 mcg/L for peripheral line; 120 mEq/L for central line</para>
									</item>
									<item>
										<label>•</label>
										<para>Dehydrated patients should receive 1 L of potassium-free hydrating solution, then infuse 10 mEq/hr; in severe hypokalemia, rate may be 40 mEq/hr</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, aldesleukin, allopurinol, amifostine, aminophylline, amiodarone, ampicillin, amrinone, atropine, aztreonam, betamethasone, calcium gluconate, cephalothin, cephapirin, chlordiazePOXIDE, chlorproMAZINE, ciprofloxacin, cladribine, cyanocobalamin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOPamine, droperidol, edrophonium, enalaprilat, EPINEPHrine, esmolol, estrogens, ethacrynate, famotidine, fentaNYL, filgrastim, fludarabine, fluorouracil, furosemide, gallium, granisetron, heparin, hydrALAZINE, IDArubicin, indomethacin, insulin (regular), isoproterenol, kanamycin, labetalol, lidocaine, LORazepam, magnesium sulfate, melphalan, meperidine, methicillin, methoxamine, methylergonovine, midazolam, minocycline, morphine, neostigmine, norepinephrine, ondansetron, oxacillin, oxytocin, PACLitaxel, penicillin G potassium, pentazocine, phytonadione, piperacillin/tazobactam, prednisoLONE, procainamide, prochlorperazine, propofol, propranolol, pyridostigmine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, teniposide, theophylline, thiotepa, trimethaphan, trimethoenzamide, vinorelbine, warfarin, zidovudine</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11267">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11270">
					<section type="none" id="sidelem4x11271">
						<sec_title>CNS:</sec_title>
						<para> Confusion</para>
					</section>
					<section type="none" id="sidelem4x11276">
						<sec_title>CV:</sec_title>
						<para> Bradycardia, <emphasis style="bold">cardiac depression, dysrhythmias, arrest; peaking T waves, lowered R, depressed RST, prolonged P-R interval, widened QRS complex</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11284">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, cramps,</emphasis> pain, <emphasis style="italic">diarrhea,</emphasis> ulceration of small bowel</para>
					</section>
					<section type="none" id="sidelem4x11295">
						<sec_title>GU:</sec_title>
						<para> Oliguria</para>
					</section>
					<section type="none" id="sidelem4x11300">
						<sec_title>INTEG:</sec_title>
						<para> Cold extremities, rash</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11305">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11308">
					<section type="none" id="sidelem4x11309">
						<sec_title>PO:</sec_title>
						<para> Excreted by kidneys and in feces; onset of action ≈30 min</para>
					</section>
					<section type="none" id="sidelem4x11314">
						<sec_title>IV:</sec_title>
						<para> Immediate onset of action</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11319">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—potassium phosphate IV; products containing calcium or magnesium; potassium-sparing diuretic or other potassium products; ACE inhibitors</para>
			</section>
			<section type="considerations" id="sidelem4x11326">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11329">
					<section type="none" id="sidelem4x11330">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11338">
							<label>•</label>
							<sec_title>Hyperkalemia<route> indicates toxicity; fatigue, muscle weakness, confusion, dyspnea, palpitation; ECG for peaking T waves, lowered R, depressed RST, prolonged P-R interval, widening QRS complex, hyperkalemia; product should be reduced or discontinued, administer sodium bicarbonate (metabolic acidosis)</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x11341">
								<item>
									<label>•</label>
									<para>Potassium level during treatment (3.5-5 mg/dl is normal level)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11346">
								<item>
									<label>•</label>
									<para>Determine hydration status, I&amp;O ratio; watch for decreased urinary output; notify prescriber immediately</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11351">
								<item>
									<label>•</label>
									<para>Cardiac status: rate, rhythm, CVP, PWP, PAWP if being monitored directly</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11356">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11360">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of fatigue, muscle weakness; decreased thirst, urinary output; cardiac changes</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11366">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11370">
								<item>
									<label>•</label>
									<para>To add potassium-rich foods to diet: bananas, orange juice, avocados, whole grains, broccoli, carrots, prunes, cocoa after product is discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products: antacids, salt substitutes, analgesics, vitamin preparations unless specifically directed by prescriber; to avoid licorice in large amounts because it may cause hypokalemia, sodium retention</para>
								</item>
								<item>
									<label>•</label>
									<para>To report hyperkalemia symptoms (lethargy, confusion, diarrhea, nausea, vomiting, fainting, decreased output) or continued hypokalemia symptoms (fatigue, weakness, polyuria, polydipsia, cardiac changes)</para>
								</item>
								<item>
									<label>•</label>
									<para>To dissolve powder or tablet completely in ≥120 ml water or juice</para>
								</item>
								<item>
									<label>•</label>
									<para>About the importance of regular follow-up visits</para>
								</item>
								<item>
									<label>•</label>
									<para>That potassium levels will need to be monitored periodically</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="30" status="active">
			<mono_name>potassium iodide (Rx)</mono_name>
			<info>
				<tradenames>
					<tradename id="tnidelem4x114044">Lugol’s</tradename>
					<tradename id="tnidelem4x114043">SSKI</tradename>
					<tradename id="tnidelem4x114042">Pima</tradename>
					<tradename id="tnidelem4x114041">ThyroSafe</tradename>
					<tradename id="tnidelem4x114040">ThyroShield</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone antagonist</class>
				<class type="chem"> Iodine product</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x11414">
				<sec_title>Action:</sec_title>
				<para>Inhibits secretion of thyroid hormone, fosters colloid accumulation in thyroid follicles, decreases vascularity of gland</para>
			</section>
			<section type="uses" id="sidelem4x11419">
				<sec_title>Uses:</sec_title>
				<para>Preparation for thyroidectomy, thyrotoxic crisis, neonatal thyrotoxicosis, radiation protectant, thyroid storm</para>
				<section type="none" id="sidelem4x11424">
					<section type="none" id="sidelem4x11425">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Erythema multiforme, erythema nodosum leprosum (ENL), sporotrichosis, thyroid involution induction</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x11430">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), pulmonary edema, pulmonary TB, bronchitis, hypersensitivity to iodine</para>
				<section type="none" id="sidelem4x11435">
					<section type="none" id="sidelem4x11436">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, children</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11441">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11444">
					<section type="none" id="sidelem4x11445">
						<sec_title>Hyperthyroidism/thyrotoxicosis</sec_title>
						<section type="none" id="sidelem4x11453">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11453">
									<item>
										<label>•</label>
										<para> (SSKI) 250 mg tid × 10-14 days preoperatively</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11457">
						<sec_title>Preparation for thyroidectomy</sec_title>
						<section type="none" id="sidelem4x11465">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11465">
									<item>
										<label>•</label>
										<para> 3-5 gtt strong iodine sol tid or 1-5 drops SSKI in water tid after meals for 10 days before surgery</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11470">
						<sec_title>Radiation exposure (radioactive iodine)</sec_title>
						<section type="none" id="sidelem4x11478">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11478">
									<item>
										<label>•</label>
										<para> 130 mg/day (distribution by government/public health officials or OTC purchase)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11485">
							<label>•</label>
							<sec_title>Child ≥3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11485">
									<item>
										<label>•</label>
										<para> 65 mg daily</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11492">
							<label>•</label>
							<sec_title>Child/infant &gt;1 mo-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11492">
									<item>
										<label>•</label>
										<para> 32 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x11499">
							<label>•</label>
							<sec_title>Neonate<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11499">
									<item>
										<label>•</label>
										<para> 16 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11503">
						<sec_title>Available forms:</sec_title>
						<para> Oral sol (Lugol’s solution) iodine 5%/potassium iodide 10%; oral sol (SSKI) 1 g/ml (ThyroShield) 65 mg/ml; syrup (PIMA) 325 mg/5 ml; tabs 65, 130 mg</para>
					</section>
					<section type="none" id="sidelem4x11508">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11512">
								<item>
									<label>•</label>
									<para>Products are not interchangeable</para>
								</item>
								<item>
									<label>•</label>
									<para>Strong iodine solution after diluting with water or juice to improve taste</para>
								</item>
								<item>
									<label>•</label>
									<para>Through straw to prevent tooth discoloration</para>
								</item>
								<item>
									<label>•</label>
									<para>With meals to decrease GI upset</para>
								</item>
								<item>
									<label>•</label>
									<para>At same time each day to maintain product level</para>
								</item>
								<item>
									<label>•</label>
									<para>At lowest dose that relieves symptoms; discontinue before RAIU</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11543">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11546">
					<section type="none" id="sidelem4x11547">
						<sec_title>CNS:</sec_title>
						<para> Headache, confusion, paresthesias</para>
					</section>
					<section type="none" id="sidelem4x11552">
						<sec_title>EENT:</sec_title>
						<para> Metallic taste, stomatitis, salivation, periorbital edema, sore teeth and gums, cold symptoms</para>
					</section>
					<section type="none" id="sidelem4x11557">
						<sec_title>ENDO:</sec_title>
						<para> Hypothyroidism, hyperthyroid adenoma</para>
					</section>
					<section type="none" id="sidelem4x11562">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting,</emphasis> small-bowel lesions, upper gastric pain, metallic taste</para>
					</section>
					<section type="none" id="sidelem4x11570">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">angioneurotic edema,</emphasis> acne, mucosal hemorrhage, fever</para>
					</section>
					<section type="none" id="sidelem4x11578">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11583">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x11586">
					<section type="none" id="sidelem4x11587">
						<sec_title>PO:</sec_title>
						<para> Onset 24-48 hr, peak 10-15 days after continuous therapy, uptake by thyroid gland or excreted in urine, crosses placenta</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x11592">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypothyroidism—lithium, other antithyroid agents</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—angiotensin II receptor antagonist, ACE inhibitors, potassium salts, potassium-sparing diuretics</para>
			</section>
			<section type="considerations" id="sidelem4x11603">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11606">
					<section type="none" id="sidelem4x11607">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x11612">
								<item>
									<label>•</label>
									<para>Pulse, B/P, temperature; serum potassium</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11617">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for edema: puffy hands, feet, periorbit; indicate hypothyroidism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11622">
								<item>
									<label>•</label>
									<para>Weight daily; same clothing, scale, time of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11627">
								<item>
									<label>•</label>
									<para>T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, which is increased; serum TSH, which is decreased; free thyroxine index, which is increased if dosage is too low; discontinue product 3-4 wk before RAIU</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11639">
								<item>
									<para>
										<emphasis alert="nurse">Overdose: peripheral edema, heat intolerance, diaphoresis, palpitations, dysrhythmias, severe tachycardia, fever, delirium, CNS irritability</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11647">
							<label>•</label>
							<sec_title>Hypersensitivity<route> rash; enlarged cervical lymph nodes may indicate product should be discontinued</route></sec_title>
						</section>
						<section type="none" id="sidelem4x11653">
							<label>•</label>
							<sec_title>Hypoprothrombinemia</sec_title>
							<para>
								<list id="lidelem4x11653">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoprothrombinemia:</emphasis> bleeding, petechiae, ecchymosis</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11657">
								<item>
									<label>•</label>
									<para>Clinical response: after 3 wk should include increased weight, pulse; decreased T<emphasis style="inf">4</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11664">
								<item>
									<label>•</label>
									<para>Fluids to 3-4 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11669">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11673">
								<item>
									<label>•</label>
									<para>Therapeutic response: weight gain; decreased pulse, T<emphasis style="inf">4</emphasis>, size of thyroid gland</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11682">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11686">
								<item>
									<label>•</label>
									<para>To abstain from breastfeeding after delivery</para>
								</item>
								<item>
									<label>•</label>
									<para>To keep graph of weight, pulse, mood</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products that contain iodine</para>
								</item>
								<item>
									<label>•</label>
									<para>That seafood, other iodine products may be restricted</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly; that thyroid crisis may occur as part of stress response</para>
								</item>
								<item>
									<label>•</label>
									<para>That response may take several mo if thyroid is large</para>
								</item>
								<item>
									<label>•</label>
									<para>To discontinue product, notify prescriber of fever, rash, metallic taste, swelling of throat; burning of mouth, throat; sore gums, teeth; severe GI distress, enlargement of thyroid, cold symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="31" status="active">
			<mono_name>pramipexole (Rx)</mono_name>
			<info>
				<pronunciation>(pra-mi-pex′ol)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x117281">Mirapex</tradename>
					<tradename id="tnidelem4x117280">Mirapex ER</tradename>
				</tradenames>
				<class type="func"> Antiparkinson agent</class>
				<class type="chem"> DOPamine-receptor agonist, non-ergot</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x11738">
				<sec_title>Action:</sec_title>
				<para>Selective agonist for D<emphasis style="inf">2</emphasis> receptors (presynaptic/postsynaptic sites); binding at D<emphasis style="inf">3</emphasis> receptor contributes to antiparkinson effects</para>
			</section>
			<section type="uses" id="sidelem4x11749">
				<sec_title>Uses:</sec_title>
				<para>Idiopathic Parkinson’s disease, restless leg syndrome</para>
			</section>
			<section type="contra" id="sidelem4x11754">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x11759">
					<section type="none" id="sidelem4x11760">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), cardiac/renal disease, MI with dysrhythmias, affective disorders, psychosis, preexisting dyskinesias, history of falling asleep during daily activities, rapid dose reduction</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x11765">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x11768">
					<section type="none" id="sidelem4x11769">
						<sec_title>Parkinson’s disease</sec_title>
						<section type="none" id="sidelem4x11777">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11777">
									<item>
										<label>•</label>
										<para> 0.125 mg tid; increase gradually by 0.125 mg/dose at 5- to 7-day intervals until total daily dose of 4.5 mg/day reached; ER 0.375 mg daily initially, then up to 0.75 mg/day; may increase by 0.75 mg/day no more than q5-7days as needed, max 4.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11781">
						<sec_title>Restless leg syndrome</sec_title>
						<section type="none" id="sidelem4x11789">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x11789">
									<item>
										<label>•</label>
										<para> 0.125 mg 2-3 hr before bedtime, increase gradually, max 0.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x11793">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x11801">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 35-59 ml/min, 0.125 mg bid, may increase q5-7days to 1.5 mg bid if required; CCr 15-34 ml/min, 0.125 mg/day, increase q5-7days to 1.5 mg/day</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x11804">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 0.125, 0.25, 0.5, 1, 1.5 mg; ER tab 0.375, 0.75, 1.5, 3.0, 4.5 mg</para>
					</section>
					<section type="none" id="sidelem4x11809">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x11813">
								<item>
									<label>•</label>
									<para>Adjust dosage to patient response, titrate slowly, taper when discontinuing</para>
								</item>
								<item>
									<label>•</label>
									<para>With meals to minimize GI symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not crush, chew, or break ext rel product</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x11829">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x11832">
					<section type="none" id="sidelem4x11833">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Agitation, insomnia,</emphasis> psychosis, hallucinations, depression, dizziness, headache, confusion, amnesia, dream disorder, asthenia, dyskinesia, hypersomnolence, <emphasis style="bold">sudden sleep onset,</emphasis> impulse control disorders</para>
					</section>
					<section type="none" id="sidelem4x11844">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Orthostatic hypotension,</emphasis> edema, syncope, tachycardia, increased B/P, heart rate, <emphasis style="bold">heart failure</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11854">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, retinal/vision deterioration</para>
					</section>
					<section type="none" id="sidelem4x11859">
						<sec_title>ENDO:</sec_title>
						<para> Antidiuretic hormone secretion (SIADH)</para>
					</section>
					<section type="none" id="sidelem4x11864">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia,</emphasis> constipation, dysphagia, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x11872">
						<sec_title>GU:</sec_title>
						<para> Impotence, urinary frequency</para>
					</section>
					<section type="none" id="sidelem4x11877">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Hemolytic anemia, leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x11884">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x11889">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Minimally metabolized, peak 2 hr, half-life 8 hr, 8.5-12 hr in geriatric patients</para>
			</section>
			<section type="interactions" id="sidelem4x11894">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> pramipexole levels—levodopa, cimetidine, ranitidine, diltiazem, triamterene, verapamil, quiNIDine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pramipexole levels—DOPamine antagonists, phenothiazines, metoclopramide, butyrophenones</para>
			</section>
			<section type="considerations" id="sidelem4x11905">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x11908">
					<section type="none" id="sidelem4x11909">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x11917">
							<label>•</label>
							<sec_title>Parkinson’s disease</sec_title>
							<para>
								<list id="lidelem4x11917">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Parkinson’s disease:</emphasis> involuntary movements: bradykinesia, tremors, staggering gait, muscle rigidity, drooling</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x11921">
								<item>
									<label>•</label>
									<para>B/P, ECG, respiration during initial treatment; hypo/hypertension should be reported</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11926">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression; complete suicide assessment, worsening of symptoms of restless leg syndrome, impulse control disorders</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11933">
								<item>
									<para>
										<emphasis alert="nurse">Sleep attacks: may fall asleep during activities without warning; may need to discontinue medication</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11938">
								<item>
									<label>•</label>
									<para>Assistance with ambulation during beginning therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11943">
								<item>
									<label>•</label>
									<para>Testing for diabetes mellitus, acromegaly if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11948">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x11952">
								<item>
									<label>•</label>
									<para>Therapeutic response: movement disorder improves</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x11958">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x11963">
								<item>
									<label>•</label>
									<para>That therapeutic effects may take several weeks to a few months</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11968">
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x11976">
							<label>•</label>
							<sec_title>
								<route>To use product exactly as prescribed; if product is discontinued abruptly, parkinsonian crisis may occur; to avoid alcohol, OTC sleeping products</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x11979">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy is planned or suspected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x11984">
								<item>
									<label>•</label>
									<para>To notify prescriber of impulse control disorders: shopping</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="32" status="active" ha="yes">
			<mono_name> pramlintide (Rx)</mono_name>
			<info>
				<pronunciation>(pram′lin-tide)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x119960">Symlin</tradename>
				</tradenames>
				<class type="func"> Antidiabetic</class>
				<class type="chem"> Synthetic human amylin analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x12006">
				<sec_title>Action:</sec_title>
				<para>Modulates and slows stomach emptying, prevents postprandial rise in plasma glucagon, decreases appetite, leads to decreased caloric intake and weight loss</para>
			</section>
			<section type="uses" id="sidelem4x12011">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct prandial to insulin therapy for uncontrolled type 1 or type 2 diabetes</para>
			</section>
			<section type="contra" id="sidelem4x12016">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or cresol; gastroparesis</para>
				<para>
					<bbw>Hypoglycemia</bbw>
				</para>
				<section type="none" id="sidelem4x12031">
					<section type="none" id="sidelem4x12032">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12037">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12040">
					<section type="none" id="sidelem4x12041">
						<sec_title>Type 1 diabetes</sec_title>
						<section type="none" id="sidelem4x12049">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x12049">
									<item>
										<label>•</label>
										<para> 15 mcg before each meal (≥30 g carbohydrate), titrate up in 15-mcg increments to target dose of 60 mcg/dose; each dose titration should occur after no nausea for 3 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12053">
						<sec_title>Type 2 diabetes</sec_title>
						<section type="none" id="sidelem4x12061">
							<label>•</label>
							<sec_title>Adult<route> SUBCUT</route></sec_title>
							<para>
								<list id="lidelem4x12061">
									<item>
										<label>•</label>
										<para> 60 mcg before each meal (≥30 g CHO), titrate up to 120 mcg  with each meal after no nausea for 3-7 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12068">
						<sec_title>Available forms:</sec_title>
						<para> PEN 60, 120 (1000 mcg/ml solution for j-injection)</para>
					</section>
					<section type="none" id="sidelem4x12073">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12077">
								<item>
									<label>•</label>
									<para>Store at room temperature for ≤30 days; keep away from heat and sunlight; refrigerate all other supply</para>
								</item>
								<item>
									<label>•</label>
									<para>Premeal insulin should be decreased by 50% when starting and adjusted to therapeutic dose to prevent hypoglycemia</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12088">
							<sec_title>SUBCUT route</sec_title>
							<para>
								<list id="lidelem4x12092">
									<item>
										<label>•</label>
										<para>Rotate injection sites, allow solution to warm to room temperature before use</para>
									</item>
									<item>
										<label>•</label>
										<para>Take immediately before mealtime or if 30 g of carbohydrates will be consumed</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if a meal is skipped</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use if discolored; do not give in arm; absorption is variable</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12113">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12116">
					<section type="none" id="sidelem4x12117">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache,</emphasis> fatigue, dizziness, confusion</para>
					</section>
					<section type="none" id="sidelem4x12125">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x12130">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x12138">
						<sec_title>INTEG:</sec_title>
						<para> Inj-site reactions, diaphoresis</para>
					</section>
					<section type="none" id="sidelem4x12143">
						<sec_title>META:</sec_title>
						<para> Hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x12148">
						<sec_title>MS:</sec_title>
						<para> Arthralgia</para>
					</section>
					<section type="none" id="sidelem4x12153">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough,</emphasis> pharyngitis</para>
					</section>
					<section type="none" id="sidelem4x12161">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="italic">Systemic allergy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12168">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability 30%-40%, not extensively bound to blood cells or albumin, 40% bound in plasma, half-life 48 min, metabolized by kidneys, peak 20 min, duration 3 hr</para>
			</section>
			<section type="interactions" id="sidelem4x12174">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x12182">
					<label>•</label>
					<sec_title>
						<route>Do not use with erythromycin, metoclopramide</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of acetaminophen</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> pramlintide action—antimuscarinics, α-glucosidase inhibitors, diphenoxylate, loperamide, octreotide, opiate agonist, tricyclics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypoglycemia—ACE inhibitors, disopyramide, anabolic steroids, androgens, fibric acid derivatives, alcohol, corticosteroids, insulin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperglycemia—phenothiazines</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypoglycemia—niacin, dextrothyroxine, thiazide diuretics, triamterene, estrogens, progestins, oral contraceptives, MAOIs</para>
			</section>
			<section type="considerations" id="sidelem4x12205">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12208">
					<section type="none" id="sidelem4x12209">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12214">
								<item>
									<label>•</label>
									<para>Fasting blood glucose, 2 hr post-prandiol (80-150 mg/dl, normal fasting level; 70-130 mg/dl, normal 2 hr level); A1c may also be drawn to identify treatment effectiveness; also monitor weight, appetite</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12222">
							<label>•</label>
							<sec_title>Hypoglycemic reaction</sec_title>
							<para>
								<list id="lidelem4x12222">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoglycemic reaction:</emphasis> sweating; weakness; dizziness; chills; confusion; headache; nausea; rapid, weak pulse; fatigue; tachycardia; memory lapses; slurred speech; staggering gait; anxiety; tremors; hunger</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12229">
							<label>•</label>
							<sec_title>Hyperglycemia</sec_title>
							<para>
								<list id="lidelem4x12229">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperglycemia:</emphasis> acetone breath; polyuria; fatigue; polydipsia; flushed, dry skin; lethargy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12233">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12237">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in polyuria, polydipsia, polyphagia; clear sensorium; absence of dizziness; stable gait; improving blood glucose, A1c</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12243">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12247">
								<item>
									<label>•</label>
									<para>That product does not cure diabetes but rather controls symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry emergency ID as diabetic</para>
								</item>
								<item>
									<label>•</label>
									<para>To recognize hypoglycemia reaction: headache, fatigue, weakness, fast pulse</para>
								</item>
								<item>
									<label>•</label>
									<para>About the dosage, route, mixing instructions, diet restrictions, disease process</para>
								</item>
								<item>
									<label>•</label>
									<para>To carry a glucose source (candy or lump sugar, glucose tabs) to treat hypoglycemia</para>
								</item>
								<item>
									<label>•</label>
									<para>About the symptoms of ketoacidosis: nausea; thirst; polyuria; dry mouth; decreased B/P; dry, flushed skin; acetone breath; drowsiness; Kussmaul respirations</para>
								</item>
								<item>
									<label>•</label>
									<para>That a plan is necessary for diet, exercise; that all food on diet should be eaten; that exercise routine should not vary</para>
								</item>
								<item>
									<label>•</label>
									<para>About blood glucose testing; how to determine glucose level</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC products, alcohol unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to operate machinery or drive until effect is known</para>
								</item>
								<item>
									<label>•</label>
									<para>About how to use pen</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="33" status="active">
			<mono_name>pramoxine topical</mono_name>
			<section type="none" id="sidelem4x12311">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="34" status="active" ha="yes">
			<mono_name> prasugrel (Rx)</mono_name>
			<info>
				<pronunciation>(pra′soo-grel)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x123220">Effient</tradename>
				</tradenames>
				<class type="func"> Platelet aggregation inhibitor</class>
				<class type="chem"> ADP receptor antagonist</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x12332">
				<sec_title>Action:</sec_title>
				<para>Inhibits ADP-induced platelet aggregation</para>
			</section>
			<section type="uses" id="sidelem4x12337">
				<sec_title>Uses:</sec_title>
				<para>Reducing the risk of stroke, MI, vascular death, peripheral arterial disease in high-risk patients</para>
			</section>
			<section type="contra" id="sidelem4x12342">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, stroke, TIA</para>
				<para>
					<bbw>Active bleeding</bbw>
				</para>
				<section type="none" id="sidelem4x12357">
					<section type="none" id="sidelem4x12358">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, hepatic disease, increased bleeding risk, neutropenia, agranulocytosis, renal disease, surgery, trauma, thrombotic thrombocytopenic purpura, Asian patients, weight &lt;60 kg, CABG, abrupt discontinuation</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12365">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12373">
					<label>•</label>
					<sec_title>Adult/geriatric &lt;75 yr and ≥60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12373">
							<item>
								<label>•</label>
								<para> 60-mg loading dose, then 10 mg daily with aspirin (75-325 mg/day)</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12380">
					<label>•</label>
					<sec_title>Adult/geriatric &lt;75 yr and &lt;60 kg<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12380">
							<item>
								<label>•</label>
								<para> 60 mg loading dose, then 5 mg daily</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12387">
					<label>•</label>
					<sec_title>&gt;75 yr</sec_title>
					<para>
						<list id="lidelem4x12387">
							<item>
								<label>•</label>
								<para>Geriatric <emphasis style="bold">&gt;75 yr:</emphasis> not recommended</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12392">
					<section type="none" id="sidelem4x12393">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10 mg</para>
					</section>
					<section type="none" id="sidelem4x12398">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12402">
								<item>
									<label>•</label>
									<para>With food to decrease gastric symptoms</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not break tablets</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not discontinue therapy abruptly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12418">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12421">
					<section type="none" id="sidelem4x12422">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x12427">
						<sec_title>CV:</sec_title>
						<para> Edema, atrial fibrillation, bradycardia, chest pain, hypo/hypertension</para>
					</section>
					<section type="none" id="sidelem4x12432">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x12437">
						<sec_title>HEMA:</sec_title>
						<para> Epistaxis, <emphasis style="bold">leukopenia, thrombocytopenia, neutropenia, anaphylaxis, angioedema, anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12444">
						<sec_title>INTEG:</sec_title>
						<para> Rash, hypercholesterolemia</para>
					</section>
					<section type="none" id="sidelem4x12449">
						<sec_title>MISC:</sec_title>
						<para> Fatigue, <emphasis style="bold">intracranial hemorrhage, secondary malignancy, angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12456">
						<sec_title>MS:</sec_title>
						<para> Back pain</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12461">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Rapidly absorbed; peak 30 min; metabolized by liver (CYP3A4; CYP2B6); excreted in urine, feces; half-life 7 hr</para>
			</section>
			<section type="interactions" id="sidelem4x12466">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—anticoagulants, aspirin, NSAIDs, abciximab, eptifibatide, tirofiban, thrombolytics, ticlopidine, SSRIs, treprostinil, rifampin</para>
			</section>
			<section type="considerations" id="sidelem4x12473">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12476">
					<section type="none" id="sidelem4x12477">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12483">
								<item>
									<para>
										<emphasis alert="nurse">Thrombotic/thrombocytic purpura: fever, thrombocytopenia, neurolytic anemia</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12488">
								<item>
									<label>•</label>
									<para>Hepatic studies: AST, ALT, bilirubin, creatinine with long-term therapy</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12496">
							<para>
								<list id="lidelem4x12496">
									<item>
										<label>•</label>
										<para>Blood studies: CBC, differential, Hct, Hgb, PT, cholesterol with long-term therapy
<bbw>
												<emphasis alert="lifethreat">Bleeding:</emphasis> may be fatal, decreased B/P in those who have had CABG may be the first indication; bleeding should be controlled while continuing product; may use transfusion; do not use within 1 wk of CABG; may use lower doses in those &lt;60 kg</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12509">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12513">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of stroke, MI</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12519">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12523">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>To report any unusual bruising, bleeding to prescriber; that it may take longer to stop bleeding</para>
								</item>
								<item>
									<label>•</label>
									<para>To take with food or just after eating to minimize GI discomfort</para>
								</item>
								<item>
									<label>•</label>
									<para>To report diarrhea, skin rashes, subcutaneous bleeding, chills, fever, sore throat</para>
								</item>
								<item>
									<label>•</label>
									<para>To tell all health care providers that prasugrel is being used; that product may be held before surgery</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="35" status="active">
			<mono_name>pravastatin (Rx)</mono_name>
			<info>
				<pronunciation>(pra′va-sta-tin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x125540">Pravachol</tradename>
				</tradenames>
				<class type="func"> Antilipemic</class>
				<class type="chem"> HMG-CoA reductase enzyme</class>
				<class type="preg">Pregnancy category <preg cat="X">X</preg></class>
			</info>
			<section type="confusion" id="sidelem4x12564">
				<para>
					<confusion>
						<tradename id="tnidelem4x125640">Pravachol</tradename>
						<drug type="generic" refid="idelem4x125640">Prevacid/propranolol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x12568">
				<sec_title>Action:</sec_title>
				<para>Inhibits HMG-CoA reductase enzyme, which reduces cholesterol synthesis</para>
			</section>
			<section type="uses" id="sidelem4x12573">
				<sec_title>Uses:</sec_title>
				<para>As an adjunct for primary hypercholesterolemia (types IIa, IIb, III, IV), to reduce the risk for recurrent MI, atherosclerosis, primary/secondary CV events, stroke, TIAs</para>
			</section>
			<section type="contra" id="sidelem4x12578">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="X">X</preg>), breastfeeding, hypersensitivity, active hepatic disease</para>
				<section type="none" id="sidelem4x12584">
					<section type="none" id="sidelem4x12585">
						<sec_title>Precautions:</sec_title>
						<para> Past hepatic disease, alcoholism, severe acute infections, trauma, severe metabolic disorders, electrolyte imbalances, renal disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12590">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12598">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12598">
							<item>
								<label>•</label>
								<para> 40 mg/day at bedtime (range 10-80 mg/day); start at 10 mg/day if patient also taking immunosuppressants</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12605">
					<label>•</label>
					<sec_title>Adolescent 14-18 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12605">
							<item>
								<label>•</label>
								<para> 40 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12612">
					<label>•</label>
					<sec_title>Child 8-13 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12612">
							<item>
								<label>•</label>
								<para> 20 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12619">
					<label>•</label>
					<sec_title>Geriatric/renal/hepatic disease<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x12619">
							<item>
								<label>•</label>
								<para> 10 mg/day initially</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x12623">
					<section type="none" id="sidelem4x12624">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x12632">
							<label>•</label>
							<sec_title>Adult<route> PO 10-20 mg daily at bedtime, increase at 4-wk intervals</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x12635">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 20, 40, 80 mg</para>
					</section>
					<section type="none" id="sidelem4x12640">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12644">
								<item>
									<label>•</label>
									<para>Without regard to meals, at bedtime</para>
								</item>
								<item>
									<label>•</label>
									<para>Give 4 hr after bile acid sequestrants</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in cool environment in tight container protected from light</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12660">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12663">
					<section type="none" id="sidelem4x12664">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, fatigue, confusion</para>
					</section>
					<section type="none" id="sidelem4x12669">
						<sec_title>CV:</sec_title>
						<para> Chest pain</para>
					</section>
					<section type="none" id="sidelem4x12674">
						<sec_title>EENT:</sec_title>
						<para> Lens opacities</para>
					</section>
					<section type="none" id="sidelem4x12679">
						<sec_title>GI:</sec_title>
						<para> Nausea, constipation, diarrhea, flatus, abdominal pain, heartburn, <emphasis style="bold">hepatic dysfunction,</emphasis> pancreatitis, <emphasis style="bold">hepatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12689">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Renal failure (myoglobinuria)</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12696">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus</para>
					</section>
					<section type="none" id="sidelem4x12701">
						<sec_title>MS:</sec_title>
						<para> Muscle cramps, myalgia, <emphasis style="bold">myositis, rhabdomyolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x12708">
						<sec_title>RESP:</sec_title>
						<para> Common cold, rhinitis, cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x12713">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; metabolized by liver; protein binding 50%; excreted in urine 20%, feces 70%, breast milk; crosses placenta; half-life 1.25-2.25 hr</para>
			</section>
			<section type="interactions" id="sidelem4x12724">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: myopathy, rhabdomyolysis risk—erythromycin, niacin, cycloSPORINE, gemfibrozil, clofibrate, clarithromycin, itraconazole, protease inhibitors</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> bioavailability of pravastatin —bile acid sequestrants</para>
				<section type="none" id="sidelem4x12734">
					<section type="none" id="sidelem4x12735">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> adverse reactions—red yeast rice</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> hepatotoxicity—eucalyptus</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x12750">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CK, LFTs</para>
						<para>
							<emphasis style="bold">Altered:</emphasis> thyroid function tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x12761">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x12764">
					<section type="none" id="sidelem4x12765">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x12770">
								<item>
									<label>•</label>
									<para>Fasting lipid profile: LDL, HDL, triglycerides, cholesterol at baseline, q12wk, then q6mo when stable; obtain diet history</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12775">
								<item>
									<label>•</label>
									<para>Hepatic studies: baseline, q12wk, then q6mo for remainder of yr; AST, ALT, LFTs may increase</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12780">
								<item>
									<label>•</label>
									<para>Renal studies of patients with compromised renal systems: BUN, I&amp;O ratio, creatinine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12786">
								<item>
									<para>
										<emphasis alert="nurse">Rhabdomyolysis: muscle tenderness, pain; obtain CPK at baseline and if these occur, therapy should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12791">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x12795">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in LDL total cholesterol, triglycerides; increase in HDL</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x12801">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x12806">
								<item>
									<label>•</label>
									<para>That blood work will be necessary during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12812">
								<item>
									<para>
										<emphasis alert="nurse">To report blurred vision, severe GI symptoms, dizziness, headache, muscle pain, weakness, fever</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12817">
								<item>
									<label>•</label>
									<para>That regimen will continue: low-cholesterol diet, exercise program</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x12823">
								<item>
									<para>
										<emphasis alert="nurse">To report suspected, planned pregnancy; not to use product during pregnancy, pregnancy category (X); not to breastfeed</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x12831">
							<label>•</label>
							<sec_title>Hepatic disease</sec_title>
							<para>
								<list id="lidelem4x12831">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hepatic disease:</emphasis> to notify prescriber of lack of appetite, yellow sclera/skin, dark urine, abdominal pain, weakness</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="36" status="active">
			<mono_name>prazosin (Rx)</mono_name>
			<info>
				<pronunciation>(pray′zoe-sin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x128410">Minipress</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> α-Adrenergic blocker, peripheral</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x12854">
				<sec_title>Action:</sec_title>
				<para>Blocks α-mediated vasoconstriction of adrenergic receptors, thereby inducing peripheral vasodilation</para>
			</section>
			<section type="uses" id="sidelem4x12859">
				<sec_title>Uses:</sec_title>
				<para>Hypertension</para>
				<section type="none" id="sidelem4x12864">
					<section type="none" id="sidelem4x12865">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Benign prostatic hypertrophy to decrease urine outflow obstruction, heart failure, hypertensive urgency, Raynaud’s phenomenon, posttraumatic stress disorder (PTSD), scorpion venom poisoning</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x12870">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x12875">
					<section type="none" id="sidelem4x12876">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, prostate cancer, ocular surgery, orthostatic hypotension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x12881">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x12884">
					<section type="none" id="sidelem4x12885">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x12893">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12893">
									<item>
										<label>•</label>
										<para> 1 mg bid or tid increasing to 20 mg/day in divided doses, if required; usual range 6-15 mg/day, max 1 mg initially; max 20 mg/day, some may require 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12900">
							<label>•</label>
							<sec_title>Child (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12900">
									<item>
										<label>•</label>
										<para> 5 mcg/kg q6hr; max 400 mcg/kg/day or 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12904">
						<sec_title>Benign prostatic hyperplasia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12912">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12912">
									<item>
										<label>•</label>
										<para> 2 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12916">
						<sec_title>Raynaud’s phenomenon (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12924">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12924">
									<item>
										<label>•</label>
										<para> 0.5-3 mg bid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12928">
						<sec_title>CHF (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12936">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12936">
									<item>
										<label>•</label>
										<para> 1 mg bid-tid, may gradually increase to max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x12943">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12943">
									<item>
										<label>•</label>
										<para> 5 mcg/kg q6hr, may gradually increase to 25 mcg/kg q6hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12947">
						<sec_title>Hypertensive urgency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x12955">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x12955">
									<item>
										<label>•</label>
										<para> 10-20 mg, may repeat after 30 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x12959">
						<sec_title>Post-traumatic Stress Disorder (unlabeled)</sec_title>
						<para>
							<emphasis style="bold">Adult: PO</emphasis> up to 15 mg/day</para>
						<para>
							<emphasis style="bold">Adolescents ≥15 yr: PO</emphasis> 1 mg at bedtime, then titrated to 1.5-4 mg at bedtime (to relieve nightmares)</para>
					</section>
					<section type="none" id="sidelem4x12970">
						<sec_title>Available forms:</sec_title>
						<para> Caps 1, 2, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x12975">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x12979">
								<item>
									<label>•</label>
									<para>1st dose at bedtime to avoid fainting</para>
								</item>
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
								<item>
									<label>•</label>
									<para>Store at room temperature</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x12995">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x12998">
					<section type="none" id="sidelem4x12999">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache, drowsiness,</emphasis> anxiety, depression, vertigo, <emphasis style="italic">weakness,</emphasis> fatigue, syncope</para>
					</section>
					<section type="none" id="sidelem4x13010">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Palpitations, orthostatic hypotension,</emphasis> tachycardia, edema, rebound hypertension</para>
					</section>
					<section type="none" id="sidelem4x13018">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, epistaxis, tinnitus, dry mouth, red sclera</para>
					</section>
					<section type="none" id="sidelem4x13023">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, diarrhea, constipation, abdominal pain, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13033">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, incontinence, impotence, priapism; water, sodium retention</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13038">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 2 hr, peak 2-4 hr, duration 6-12 hr, half-life 2-4 hr; metabolized in liver, excreted via bile, feces (&gt;90%), urine (&lt;10%); protein binding 97%</para>
			</section>
			<section type="interactions" id="sidelem4x13043">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotensive effects—β-blockers, nitroglycerin, alcohol, phosphodiesterase inhibitors (vardenafil, tadalafil, sildenafil); diuretics, other antihypertensives, MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—NSAIDs</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
				<section type="none" id="sidelem4x13058">
					<section type="none" id="sidelem4x13059">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> urinary norepinephrine, VMA</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13066">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13069">
					<section type="none" id="sidelem4x13070">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x13078">
							<label>•</label>
							<sec_title>Hypertension/CHF</sec_title>
							<para>
								<list id="lidelem4x13078">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension/CHF:</emphasis> B/P (sitting, standing) during initial treatment, periodically thereafter; pulse, jugular venous distention</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13083">
								<item>
									<label>•</label>
									<para>BUN, uric acid if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13088">
								<item>
									<label>•</label>
									<para>Weight daily, I&amp;O; edema in feet, legs daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13096">
							<label>•</label>
							<sec_title>Benign prostatic hypertrophy (unlabeled)</sec_title>
							<para>
								<list id="lidelem4x13096">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Benign prostatic hypertrophy (unlabeled):</emphasis> urinary patterns, frequency, stream, dribbling; flow before, during, and after therapy</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13100">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13104">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13110">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13114">
								<item>
									<label>•</label>
									<para>That fainting occasionally occurs after 1st dose; to take 1st dose at bedtime; not to drive or operate machinery for 4 hr after 1st dose; that full effect may take 4-6 wk</para>
								</item>
								<item>
									<label>•</label>
									<para>To change positions slowly to prevent orthostatic hypotension</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid OTC medications, alcohol unless approved by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="37" status="active">
			<mono_name>prednisoLONE (Rx)</mono_name>
			<info>
				<pronunciation>(pred-niss′oh-lone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x131452">Flo-Pred</tradename>
					<tradename id="tnidelem4x131451">Orapred</tradename>
					<tradename id="tnidelem4x131450">Prelone</tradename>
				</tradenames>
				<class type="func"> Corticosteroid, synthetic</class>
				<class type="chem"> Glucocorticoid, immediate acting</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13155">
				<para>
					<confusion>
						<tradename id="tnidelem4x131550">prednisoLONE</tradename>
						<drug type="generic" refid="idelem4x131550">predniSONE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13159">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by the suppression of migration of polymorphonuclear leukocytes, fibroblasts; reversal to increase capillary permeability and lysosomal stabilization</para>
			</section>
			<section type="uses" id="sidelem4x13164">
				<sec_title>Uses:</sec_title>
				<para>Severe inflammation, immunosuppression, neoplasms, asthma</para>
			</section>
			<section type="contra" id="sidelem4x13169">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, fungal infections, viral infection, varicella</para>
				<section type="none" id="sidelem4x13174">
					<section type="none" id="sidelem4x13175">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, diabetes mellitus, glaucoma, osteoporosis, seizure disorders, ulcerative colitis, CHF, myasthenia gravis, abrupt discontinuation, children, acute MI, GI ulcers, hypertension, hepatitis, psychosis, thromboembolism, peptic ulcer disease, renal disease, Cushing syndrome</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13180">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13183">
					<section type="none" id="sidelem4x13184">
						<sec_title>Primary (Addison’s disease)/secondary adrenocortical insufficiency or for the treatment of congenital adrenal hyperplasia</sec_title>
						<section type="none" id="sidelem4x13192">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13192">
									<item>
										<label>•</label>
										<para> 5-60 mg  per day as a single dose or divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13202">
							<label>•</label>
							<sec_title>Infants, children, and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13202">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13209">
						<sec_title>Nonsuppurative thyroiditis</sec_title>
						<section type="none" id="sidelem4x13217">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13217">
									<item>
										<label>•</label>
										<para> 5-60 mg/day as a single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13224">
							<label>•</label>
							<sec_title>Infants, children, and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13224">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day given in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13233">
						<sec_title>Management of symptomatic sarcoidosis; or treatment of hypercalcemia associated with sarcoidosis or with various cancers</sec_title>
						<section type="none" id="sidelem4x13241">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13241">
									<item>
										<label>•</label>
										<para> 5-60 mg/day as a single dose or divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13248">
							<label>•</label>
							<sec_title>Infants, children, and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13248">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13255">
						<sec_title>Adjunct in rheumatic disorders (ankylosing spondylitis, gout with gouty arthritis, juvenile rheumatoid arthritis (JRA)/juvenile idiopathic arthritis (JIA), post-traumatic osteoarthritis psoriatic arthritis, rheumatoid arthritis) or acute episodes or exacerbation of nonrheumatic inflammation (acute and subacute bursitis, epicondylitis, and acute non-specific tenosynovitis)</sec_title>
						<section type="none" id="sidelem4x13263">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13263">
									<item>
										<label>•</label>
										<para> 5-60 mg/day as a single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13270">
							<label>•</label>
							<sec_title>Infants, children, and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13270">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13278">
						<sec_title>Adjunct in carpal tunnel syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13286">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13286">
									<item>
										<label>•</label>
										<para> 20 mg/day × 2 wk, then 10 mg/day for an additional 2 wk relief</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13290">
						<sec_title>For maintenance therapy in selected cases of acute rheumatic carditis, systemic dermatomyositis (polymyositis), systemic lupus erythematosus (SLE); (Unlabeled): temporal arteritis, Churg-Strauss syndrome, mixed connective tissue disease, polyarteritis nodosa, relapsing polychondritis, polymyalgia rheumatica, vasculitis, or Wegener’s granulomatosis:</sec_title>
						<section type="none" id="sidelem4x13298">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13298">
									<item>
										<label>•</label>
										<para> 5-60 mg per day as a single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13305">
							<label>•</label>
							<sec_title>Infants, children, and adolescents</sec_title>
							<para>
								<list id="lidelem4x13305">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infants, children, and adolescents:</emphasis> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day given in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13314">
						<sec_title>Corticosteroid-responsive respiratory disorders (airway-obstructing hemangioma in infants (unlabeled), aspiration pneumonitis, berylliosis, chronic obstructive pulmonary disease (COPD), laryngotracheobronchitis (croup), Loeffler’s syndrome, noncardiogenic pulmonary edema (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13322">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13322">
									<item>
										<label>•</label>
										<para> 5-60 mg/day as a single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13329">
							<label>•</label>
							<sec_title>Infants, children, and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13329">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day given in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13336">
						<sec_title>Asthma; bronchospasm prophylaxis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x13344">
							<label>•</label>
							<sec_title>Adults and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13344">
									<item>
										<label>•</label>
										<para> 40-80 mg  per day in 1-2 divided doses until the peak expiratory flow (PEF) reaches 70% of predicted or personal best; total course of treatment is 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13354">
							<label>•</label>
							<sec_title>Children<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13354">
									<item>
										<label>•</label>
										<para> 1 mg/kg (up to 60 mg) per day in 2 divided doses until PEF reaches 70% of predicted or personal best; if a patient is given systemic corticosteroids, continue  corticosteroids for a total course of 3-10 days; tapering is not necessary for courses &lt;1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13361">
						<sec_title>Acute asthma exacerbation on an outpatient basis</sec_title>
						<section type="none" id="sidelem4x13369">
							<label>•</label>
							<sec_title>Adults and adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13369">
									<item>
										<label>•</label>
										<para> 40-60 mg  per day as a single dose or in 2 divided doses for 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13379">
							<label>•</label>
							<sec_title>Children 5-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13379">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg (up to 60 mg)  per day in 2 divided doses for 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13389">
							<label>•</label>
							<sec_title>Infants and children ≤4 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13389">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg (up to 30 mg)  per day in 2 divided doses for 3-10 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13396">
						<sec_title>Long-term prevention of symptoms in severe persistent asthma</sec_title>
						<section type="none" id="sidelem4x13404">
							<label>•</label>
							<sec_title>Adults, adolescents, and children ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13404">
									<item>
										<label>•</label>
										<para> 7.5-60 mg once daily in the morning or every other day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13411">
							<label>•</label>
							<sec_title>Infants and children ≤11 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13411">
									<item>
										<label>•</label>
										<para> 0.25-2 mg/kg  daily given as a single dose each morning or every other day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13418">
						<sec_title>Hematologic disorders with thrombocytopenia (immune thrombocytopenia/idiopathic thrombocytopenic purpura (ITP), or secondary thrombocytopenia)</sec_title>
						<section type="none" id="sidelem4x13426">
							<label>•</label>
							<sec_title>Adults<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13426">
									<item>
										<label>•</label>
										<para> 5-60 mg/day as a single dose or in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13433">
							<label>•</label>
							<sec_title>Children and adolescents (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13433">
									<item>
										<label>•</label>
										<para> 0.14-2 mg/kg or 4-60 mg/m<emphasis style="sup">2</emphasis> per day in 3-4 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13440">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5 mg; oral dissolving tab 10, 15, 30 mg; oral sol 5 mg/5 ml, 10 mg/5 ml, 15 mg/5 ml, 25 mg/5 ml; syrup 5 mg/5 ml</para>
					</section>
					<section type="none" id="sidelem4x13445">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x13453">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x13453">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> use calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13460">
							<label>•</label>
							<sec_title>Orally disintegrating tabs</sec_title>
							<para>
								<list id="lidelem4x13460">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Orally disintegrating tabs:</emphasis> place on tongue; allow to dissolve, swallow or swallow whole; do not cut, split</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13464">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13467">
					<section type="none" id="sidelem4x13468">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Depression,</emphasis> headache, mood changes</para>
					</section>
					<section type="none" id="sidelem4x13476">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypertension,</emphasis><emphasis style="bold">circulatory collapse, thrombophlebitis, embolism,</emphasis> tachycardia</para>
					</section>
					<section type="none" id="sidelem4x13486">
						<sec_title>EENT:</sec_title>
						<para> Fungal infections, increased intraocular pressure, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x13491">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Diarrhea, nausea, abdominal distention,</emphasis><emphasis style="bold">GI hemorrhage,</emphasis> increased appetite, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x13504">
						<sec_title>INTEG:</sec_title>
						<para> Acne, poor wound healing, ecchymosis, petechiae, sweating</para>
					</section>
					<section type="none" id="sidelem4x13509">
						<sec_title>MS:</sec_title>
						<para> Fractures, osteoporosis, weakness, arthralgia, myopathy, <emphasis style="bold">tendon rupture</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13516">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13519">
					<section type="none" id="sidelem4x13520">
						<sec_title>PO:</sec_title>
						<para> Peak 1-2 hr, duration 2 days</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13525">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> tendon rupture—quinolones</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—alcohol, salicylates, indomethacin, amphotericin B, digitalis, cycloSPORINE, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> prednisoLONE action—salicylates, estrogens, indomethacin, oral contraceptives, ketoconazole, macrolide antibiotics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> prednisoLONE effect—CYP3A4 inhibitors</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—azole antifungals, cycloSPORINE, NSAIDs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> prednisoLONE action—cholestyramine, colestipol, barbiturates, rifampin, ePHEDrine, phenytoin, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of anticoagulants, anticonvulsants, antidiabetics, ambenonium, neostigmine, isoniazid, toxoids, vaccines, anticholinesterases, salicylates, somatrem</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> prednisoLONE effect—CYP3A4 inducers</para>
				<section type="none" id="sidelem4x13559">
					<section type="none" id="sidelem4x13560">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, sodium, blood glucose, uric acid, calcium, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS, PBI</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13584">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13587">
					<section type="none" id="sidelem4x13588">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x13593">
								<item>
									<label>•</label>
									<para>Potassium, blood glucose, urine glucose while patient receiving long-term therapy; hypokalemia, hyperglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13598">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber if weekly gain of &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13603">
								<item>
									<label>•</label>
									<para>B/P q4hr, pulse; notify prescriber if chest pain occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13608">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13613">
								<item>
									<label>•</label>
									<para>Plasma cortisol levels with long-term therapy; normal level: 138-635 nmol/L SI units when drawn at 8 <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13623">
							<label>•</label>
							<sec_title>Infection</sec_title>
							<para>
								<list id="lidelem4x13623">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Infection:</emphasis> increased temperature, WBC, even after withdrawal of medication; product masks infection</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13630">
							<label>•</label>
							<sec_title>Potassium depletion</sec_title>
							<para>
								<list id="lidelem4x13630">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Potassium depletion:</emphasis> paresthesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x13634">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13639">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13647">
							<label>•</label>
							<sec_title>Adrenal insufficiency<route> nausea, vomiting, lethargy, restlessness, confusion, weight loss, hypotension before, during treatment; HPA suppression may be precipitated by abrupt withdrawal</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x13650">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x13654">
								<item>
									<label>•</label>
									<para>Therapeutic response: ease of respirations, decreased inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x13660">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x13665">
								<item>
									<label>•</label>
									<para>That emergency ID as steroid user should be carried</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13670">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases; that dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13675">
								<item>
									<label>•</label>
									<para>Not to discontinue abruptly; that adrenal crisis can result; to take product exactly as prescribed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13680">
								<item>
									<label>•</label>
									<para>To avoid OTC products: salicylates, cough products with alcohol, cold preparations unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13685">
								<item>
									<label>•</label>
									<para>About cushingoid symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13694">
							<label>•</label>
							<sec_title>About the symptoms of adrenal insufficiency<route> nausea, anorexia, fatigue, dizziness, dyspnea, weakness, joint pain</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="38" status="active">
			<mono_name>prednisoLONE ophthalmic (Rx)</mono_name>
			<section type="none" id="sidelem4x13700">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="39" status="active">
			<mono_name>predniSONE (Rx)</mono_name>
			<info>
				<pronunciation>(pred′ni-sone)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x137091">Rayos</tradename>
					<tradename id="tnidelem4x137090">
						<country code="CAN">Winpred </country>
					</tradename>
				</tradenames>
				<class type="func"> Corticosteroid</class>
				<class type="chem"> Intermediate-acting glucocorticoid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x13721">
				<para>
					<confusion>
						<tradename id="tnidelem4x137210">predniSONE</tradename>
						<drug type="generic" refid="idelem4x137210">methylPREDNISolone/ prednisoLONE/PriLOSEC</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x13725">
				<sec_title>Action:</sec_title>
				<para>Decreases inflammation by increasing capillary permeability and lysosomal stabilization, minimal mineralocorticoid activity</para>
			</section>
			<section type="uses" id="sidelem4x13730">
				<sec_title>Uses:</sec_title>
				<para>Severe inflammation, neoplasms, multiple sclerosis, collagen disorders, dermatologic disorders, pulmonary fibrosis, asthma</para>
				<section type="none" id="sidelem4x13735">
					<section type="none" id="sidelem4x13736">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Adjunct for refractory seizures, infantile spasms, acute interstitial nephritis, amyloidosis, autoimmune hepatitis, Behçet’s syndrome, Bell’s palsy, carpal tunnel syndrome, Churg-Strauss syndrome, dermatomyositis, Duchenne muscular dystrophy, endophthalmitis, Lennox-Gastaut syndrome, lupus nephritis, mixed connective-tissue disease, pericarditis, pneumonia, polyarteritis nodosa, polychondritis, polymyositis, rheumatic carditis, temporal arteritis, TB, Wegener’s granulomatosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x13741">
				<sec_title>Contraindications:</sec_title>
				<para>Fungal infections, hypersensitivity</para>
				<section type="none" id="sidelem4x13746">
					<section type="none" id="sidelem4x13747">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), diabetes mellitus, glaucoma, osteoporosis, seizure disorders, ulcerative colitis, CHF, myasthenia gravis, renal disease, esophagitis, peptic ulcer, cataracts, coagulopathy, abrupt discontinuation, children, corticosteroid hypertensitivity, Cushing syndrome, diabetes mellitus, ulcerative colitis, thromboembolism, geriatric patients, acute MI</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x13752">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x13760">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13760">
							<item>
								<label>•</label>
								<para> 5-60 mg/day or divided bid-qid</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13767">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x13767">
							<item>
								<label>•</label>
								<para> 0.05-2 mg/kg/day divided 1-4×/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x13771">
					<section type="none" id="sidelem4x13772">
						<sec_title>Nephrotic syndrome</sec_title>
						<section type="none" id="sidelem4x13780">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13780">
									<item>
										<label>•</label>
										<para> 2 mg/kg/day in divided doses, until urine is protein-free for 3 consecutive days, then 1-1.5 mg/kg/day every other day × 4 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13784">
						<sec_title>Multiple sclerosis</sec_title>
						<section type="none" id="sidelem4x13792">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13792">
									<item>
										<label>•</label>
										<para> 200 mg/day × 1 wk, then 80 mg every other day × 1 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13796">
						<sec_title>Asthma</sec_title>
						<section type="none" id="sidelem4x13804">
							<label>•</label>
							<sec_title>Adult/adolescent<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13804">
									<item>
										<label>•</label>
										<para> 40-80 mg/day in 1-2 divided doses until PEF is 70% of predicted or best</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13811">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x13811">
									<item>
										<label>•</label>
										<para> 1 mg/kg (max 60 mg)/day in 2 divided doses until PEF is 70% of predicted or personal best</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x13815">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 1, 2.5, 5, 10, 20, 50 mg; oral sol 5 mg/5 ml; syr 5 mg/5 ml, del rel tab 1, 2, 5 mg</para>
					</section>
					<section type="none" id="sidelem4x13820">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x13825">
								<item>
									<label>•</label>
									<para>For long-term use, alternate-day therapy recommended to decrease adverse reactions; give in <emphasis style="smallcaps">am</emphasis> to coincide with normal cortisol secretion</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13833">
								<item>
									<label>•</label>
									<para>Titrated dose; use lowest effective dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x13838">
								<item>
									<label>•</label>
									<para>With food or milk to decrease GI symptoms</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x13846">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x13846">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> use calibrated measuring device</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x13853">
							<label>•</label>
							<sec_title>Del rel tab</sec_title>
							<para>
								<list id="lidelem4x13853">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Del rel tab:</emphasis> swallow whole; do not break, crush, chew; give once a day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x13857">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x13860">
					<section type="none" id="sidelem4x13861">
						<sec_title>CNS:</sec_title>
						<para> Depression, flushing, sweating, headache, mood changes</para>
					</section>
					<section type="none" id="sidelem4x13866">
						<sec_title>CV:</sec_title>
						<para> Hypertension, <emphasis style="bold">thrombophlebitis, embolism,</emphasis> tachycardia, fluid retention</para>
					</section>
					<section type="none" id="sidelem4x13874">
						<sec_title>EENT:</sec_title>
						<para> Fungal infections, increased intraocular pressure, blurred vision</para>
					</section>
					<section type="none" id="sidelem4x13879">
						<sec_title>GI:</sec_title>
						<para> Diarrhea, nausea, abdominal distention, <emphasis style="bold">GI hemorrhage,</emphasis> increased appetite, pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x13888">
						<sec_title>INTEG:</sec_title>
						<para> Acne, poor wound healing, ecchymosis, petechiae</para>
					</section>
					<section type="none" id="sidelem4x13893">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x13898">
						<sec_title>MS:</sec_title>
						<para> Fractures, osteoporosis, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x13903">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x13906">
					<section type="none" id="sidelem4x13907">
						<sec_title>PO:</sec_title>
						<para> Well absorbed PO, peak 1-2 hr, duration; del rel peak 6-6<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr; 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> days, half-life 3<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr, crosses placenta, enters breast milk, metabolized by liver after conversion, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x13930">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase: tendon rupture quinolones</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> side effects—alcohol, salicylates, NSAIDs, amphotericin B, digoxin, cycloSPORINE, diuretics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> predniSONE action—salicylates, estrogens, NSAIDs, oral contraceptives, ketoconazole, macrolide antiinfectives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> predniSONE effect—CYP3A4 inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> predniSONE effect—CYP3A4 inducers</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> predniSONE action—cholestyramine, colestipol, barbiturates, rifampin, phenytoin, theophylline</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of anticoagulants, anticonvulsants, antidiabetics, ambenonium, neostigmine, isoniazid, toxoids, vaccines, anticholinesterases, salicylates, somatrem</para>
				<section type="none" id="sidelem4x13960">
					<section type="none" id="sidelem4x13961">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> predniSONE effect—ephedra (ma huang)</para>
					</section>
					<section type="none" id="sidelem4x13968">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, sodium, blood glucose, uric acid, calcium, urine glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> calcium, potassium, T<emphasis style="inf">4</emphasis>, T<emphasis style="inf">3</emphasis>, thyroid <emphasis style="sup">131</emphasis>I uptake test, urine 17-OHCS, 17-KS, PBI</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x13992">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x13995">
					<section type="none" id="sidelem4x13996">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14004">
							<label>•</label>
							<sec_title>Adrenal insufficiency<route> nausea, vomiting, anorexia, confusion, hypotension, weight loss before, during treatment; HPA suppression may be precipitated by abrupt withdrawal</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x14007">
								<item>
									<label>•</label>
									<para>Potassium, blood glucose, urine glucose while patient receiving long-term therapy; hypokalemia and hyperglycemia; plasma cortisol with long-term therapy, normal: 138-635 nmol/L SI units drawn at 8 <emphasis style="smallcaps">am</emphasis></para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14014">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly gain of &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14019">
								<item>
									<label>•</label>
									<para>B/P, pulse; notify prescriber of chest pain; monitor for crackles, dyspnea if edema is present; hypertension, cardiac symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14024">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14032">
							<label>•</label>
							<sec_title>Infection<route> increased temperature, WBC, even after withdrawal of medication; product masks infection</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x14035">
								<item>
									<label>•</label>
									<para>Potassium depletion: paresthesias, fatigue, nausea, vomiting, depression, polyuria, dysrhythmias, weakness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14040">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, aggression</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14045">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14049">
								<item>
									<label>•</label>
									<para>Therapeutic response: ease of respirations, decreased inflammation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14055">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14060">
								<item>
									<label>•</label>
									<para>That emergency ID as corticosteroid user should be carried; provide information about product being taken and condition</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14065">
								<item>
									<label>•</label>
									<para>To notify prescriber if therapeutic response decreases; that dosage adjustment may be needed</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14070">
								<item>
									<label>•</label>
									<para>To avoid vaccinations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14076">
								<item>
									<para>
										<emphasis alert="nurse">Not to discontinue abruptly because adrenal crisis can result</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14081">
								<item>
									<label>•</label>
									<para>To avoid OTC products: salicylates, cough products with alcohol, cold preparations unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14089">
							<label>•</label>
							<sec_title>Cushingoid symptoms<route> moon face, weight gain; symptoms of adrenal insufficiency</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x14092">
								<item>
									<label>•</label>
									<para>That product causes immunosuppression; to report any symptoms of infection (fever, sore throat, cough)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14101">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy is planned or suspected; cleft palate, stillbirth, abortion reported</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="40" status="active">
			<mono_name>pregabalin (Rx)</mono_name>
			<info>
				<pronunciation>(pre-gab′a-lin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x141090">Lyrica</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> γ-Aminobutyric acid (GABA) analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
				<class type="schedule">Controlled Substance Schedule <schedule num="5">V</schedule></class>
			</info>
			<section type="actions" id="sidelem4x14121">
				<sec_title>Action:</sec_title>
				<para>Binds to high-voltage–gated calcium channels in CNS tissues; this may lead to anticonvulsant action similar to the inhibitory neurotransmitter GABA; anxiolytic, analgesics, and antiepileptic properties</para>
			</section>
			<section type="uses" id="sidelem4x14126">
				<sec_title>Uses:</sec_title>
				<para>Neuropathic pain associated with spinal cord injury/diabetic peripheral neuropathy, partial-onset seizures, postherpetic neuralgia, fibromyalgia</para>
				<section type="none" id="sidelem4x14131">
					<section type="none" id="sidelem4x14132">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Moderate pain, social anxiety disorder</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x14137">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or gabapentin, abrupt discontinuation</para>
				<section type="none" id="sidelem4x14142">
					<section type="none" id="sidelem4x14143">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children &lt;12 yr, geriatric patients, renal disease, PR interval prolongation, creatine kinase elevations, CHF (class III, IV), decreased platelets, substance abuse, dependence, glaucoma, myopathy, angioedema history, suicidal behavior</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14148">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14151">
					<section type="none" id="sidelem4x14152">
						<sec_title>Diabetic peripheral neuropathic pain</sec_title>
						<section type="none" id="sidelem4x14160">
							<label>•</label>
							<sec_title>ADULT<route> PO/ORAL SOL</route></sec_title>
							<para>
								<list id="lidelem4x14160">
									<item>
										<label>•</label>
										<para> 50 mg tid, may increase to 300 mg/day (max) within 1 wk, adjust in patients with renal disease</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14164">
						<sec_title>Partial-onset seizures</sec_title>
						<section type="none" id="sidelem4x14172">
							<label>•</label>
							<sec_title>ADULT<route> PO/ORAL SOL</route></sec_title>
							<para>
								<list id="lidelem4x14172">
									<item>
										<label>•</label>
										<para> 75 mg bid or 50 mg tid; may increase to 600 mg/day (max)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14176">
						<sec_title>Postherpetic neuralgia</sec_title>
						<section type="none" id="sidelem4x14184">
							<label>•</label>
							<sec_title>Adult<route> PO/ORAL SOL</route></sec_title>
							<para>
								<list id="lidelem4x14184">
									<item>
										<label>•</label>
										<para> 150 mg/day in 2-3 divided doses, may increase to 300 mg/day in 2-3 divided doses; if higher dose is required after 2-4 wk, may increase to 600 mg/day in 2-3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14188">
						<sec_title>Fibromyalgia spinal cord injury, pain</sec_title>
						<section type="none" id="sidelem4x14196">
							<label>•</label>
							<sec_title>Adult<route> PO/ORAL SOL</route></sec_title>
							<para>
								<list id="lidelem4x14196">
									<item>
										<label>•</label>
										<para> 75 mg bid, may increase to 150 mg bid within 1 wk and 225 mg bid after 1 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14200">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x14208">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 30-60 ml/min, 75-300 mg/day in 2-3 divided doses; CCr 15-30 ml/min, 25-150 mg/day in 1-2 divided doses; CCr &lt;15 ml/min, 25-75 mg/day as a single dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14211">
						<sec_title>Social phobia (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14219">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14219">
									<item>
										<label>•</label>
										<para> 150-600 mg/day in 3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14223">
						<sec_title>Available forms:</sec_title>
						<para> Caps 25, 50, 75, 100, 150, 200, 225, 300 mg; oral sol 20 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x14228">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14233">
								<item>
									<label>•</label>
									<para>Do not crush or chew caps; caps may be opened and contents put in applesauce or dissolved in juice</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14238">
								<item>
									<label>•</label>
									<para>Give without regard to meals</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14243">
								<item>
									<label>•</label>
									<para>Gradually withdraw over 7 days; abrupt withdrawal may precipitate seizures</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14251">
							<label>•</label>
							<sec_title>Oral sol</sec_title>
							<para>
								<list id="lidelem4x14251">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Oral sol:</emphasis> should be written in mg and calculated to mL</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14255">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14258">
					<section type="none" id="sidelem4x14259">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, fatigue, confusion, euphoria, incoordination, nervousness, neuropathy, tremor, vertigo, somnolence, ataxia, amnesia, abnormal thinking, <emphasis style="bold">suicidal ideation,</emphasis> drowsiness</para>
					</section>
					<section type="none" id="sidelem4x14267">
						<sec_title>EENT:</sec_title>
						<para> Dry mouth, blurred vision, nystagmus, amblyopia, sinusitis</para>
					</section>
					<section type="none" id="sidelem4x14272">
						<sec_title>GI:</sec_title>
						<para> Constipation, flatulence, abdominal pain, weight gain, nausea, vomiting, increased appetite</para>
					</section>
					<section type="none" id="sidelem4x14277">
						<sec_title>GU:</sec_title>
						<para> Gynecomastia</para>
					</section>
					<section type="none" id="sidelem4x14282">
						<sec_title>HEMA:</sec_title>
						<para> Ecchymosis, <emphasis style="bold">thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14289">
						<sec_title>MS:</sec_title>
						<para> Back pain, <emphasis style="bold">rhabdomyolysis,</emphasis> myopathy</para>
					</section>
					<section type="none" id="sidelem4x14297">
						<sec_title>OTHER:</sec_title>
						<para> Pruritus, orgasm/erectile dysfunction, peripheral edema, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14304">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14309">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Well absorbed, peak 1.5 hr; 90% recovered in urine unchanged; negligible metabolism; not bound to plasma proteins; half-life 6 hr</para>
			</section>
			<section type="interactions" id="sidelem4x14316">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> weight gain/fluid retention—thiazolidinedione; avoid use if possible</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—anxiolytics, sedatives, hypnotics, barbiturates, general anesthetics, opiate agonists, phenothiazines, sedating H<emphasis style="inf">1</emphasis> blockers, thiazolidinediones, tricyclics, alcohol</para>
				<section type="none" id="sidelem4x14330">
					<section type="none" id="sidelem4x14331">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> creatine kinase</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14342">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14345">
					<section type="none" id="sidelem4x14346">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x14354">
							<label>•</label>
							<sec_title>Seizures<route> aura, location, duration, activity at onset, use seizure precaution</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14360">
							<label>•</label>
							<sec_title>Pain</sec_title>
							<para>
								<list id="lidelem4x14360">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pain:</emphasis> location, duration, characteristics if using for diabetic neuropathy</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x14364">
								<item>
									<label>•</label>
									<para>Renal studies: urinalysis, BUN, urine creatinine q3mo, creatine kinase; if markedly increased, discontinue product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14370">
								<item>
									<para>
										<emphasis alert="nurse">Mental status: mood, sensorium, affect, behavioral changes, suicidal thoughts/behaviors; if mental status changes, notify prescriber</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14378">
							<label>•</label>
							<sec_title>Angioedema/hypersensitivity<route> monitor for blisters, hives, rash, dyspnea, wheezing; angioedema; if these occur, discontinue; cross-hypersensitivity with this product and gabapentin may occur</route></sec_title>
						</section>
						<section type="none" id="sidelem4x14384">
							<label>•</label>
							<sec_title>Rhabdomyolysis and creatinine kinase elevations<route> monitor for muscle pain, tenderness, weakness accompanied by malaise or fever; product should be discontinued</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14387">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14391">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased seizure activity; decrease in neuropathic pain</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14397">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x14402">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating patient’s name, products taken, condition, prescriber’s name and phone number</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14407">
								<item>
									<label>•</label>
									<para>To avoid driving, other activities that require alertness because dizziness, drowsiness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14415">
							<label>•</label>
							<sec_title>
								<route>Not to discontinue medication quickly after long-term use, to taper over ≥1 wk; that withdrawal-precipitated seizures may occur; not to double doses if dose is missed, to take if 2 hr or more before next dose</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14418">
								<item>
									<label>•</label>
									<para>To notify prescriber if pregnancy planned or suspected; to avoid breastfeeding</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x14426">
							<label>•</label>
							<sec_title>
								<route>To report muscle pain, tenderness, weakness when accompanied by fever, malaise, suicidal thoughts/behaviors</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14429">
								<item>
									<label>•</label>
									<para>To avoid alcohol, live virus vaccines</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="41" status="active">
			<mono_name>primaquine (Rx)</mono_name>
			<info>
				<pronunciation>(prim′a-kween)</pronunciation>
				<class type="func"> Antimalarial</class>
				<class type="chem"> Synthetic 8-aminoquinolone</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x14452">
				<sec_title>Action:</sec_title>
				<para>Unknown; thought to destroy exoerythrocytic forms by gametocidal action</para>
			</section>
			<section type="uses" id="sidelem4x14457">
				<sec_title>Uses:</sec_title>
				<para>Malaria caused by <emphasis style="italic">Plasmodium vivax;</emphasis> in combination with clindamycin for <emphasis style="italic">Pneumocystis jiroveci</emphasis> pneumonia</para>
			</section>
			<section type="contra" id="sidelem4x14468">
				<sec_title>Contraindications:</sec_title>
				<para>Lupus erythematosus, rheumatoid arthritis; hypersensitivity to this product or idoquinol</para>
				<section type="none" id="sidelem4x14473">
					<section type="none" id="sidelem4x14474">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, methemoglobin reductase deficiency</para>
						<para>
							<bbw>Bone marrow suppression, hemolytic anemia, G6PD deficiency</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14489">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14497">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14497">
							<item>
								<label>•</label>
								<para> 15-30 mg (base)/day × 2 wk or 45 mg (base)/wk × 8 wk; 26.3-mg tab is 15-mg base</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14504">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14504">
							<item>
								<label>•</label>
								<para> 0.5 mg/kg (0.3 mg/base/day) daily × 2 wk</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14508">
					<section type="none" id="sidelem4x14509">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 26.3 mg</para>
					</section>
					<section type="none" id="sidelem4x14515">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x14518">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x14522">
									<item>
										<label>•</label>
										<para>Before or after meals at same time each day to maintain product level; take with food to decrease GI upset</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14528">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14531">
					<section type="none" id="sidelem4x14532">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness</para>
					</section>
					<section type="none" id="sidelem4x14537">
						<sec_title>CV:</sec_title>
						<para> Hypertension, dysrhythmias</para>
					</section>
					<section type="none" id="sidelem4x14542">
						<sec_title>EENT:</sec_title>
						<para> <emphasis style="italic">Blurred vision, difficulty focusing</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14549">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia,</emphasis> cramps</para>
					</section>
					<section type="none" id="sidelem4x14557">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, granulocytopenia, leukopenia, hemolytic anemia, leukocytosis,</emphasis> mild anemia, <emphasis style="bold">methemoglobinemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14567">
						<sec_title>INTEG:</sec_title>
						<para> Pruritus, skin eruptions, pallor, weakness</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14572">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x14575">
					<section type="none" id="sidelem4x14576">
						<sec_title>PO:</sec_title>
						<para> Metabolized by liver (metabolites), half-life 3.7-9.6 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x14581">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x14585">
						<item>
							<label>•</label>
							<para>Toxicity: quinacrine</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of carBAMazepine, PHENobarbital, phenytoins, rifamycins, nafcillin</para>
				<section type="none" id="sidelem4x14595">
					<section type="none" id="sidelem4x14596">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> primaquine effect—food</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> primaquine effect—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x14607">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> WBC</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> WBC, RBC, Hgb</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14618">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14621">
					<section type="none" id="sidelem4x14622">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14627">
								<item>
									<label>•</label>
									<para>Ophthalmic test if patient receiving long-term treatment or product dosage of &gt;150 mg/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14632">
								<item>
									<label>•</label>
									<para>Hepatic studies weekly: AST, ALT, bilirubin if patient receiving long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14637">
								<item>
									<label>•</label>
									<para>Blood studies: CBC; blood dyscrasias occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14642">
								<item>
									<label>•</label>
									<para>Allergic reactions: pruritus, rash, urticaria</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14647">
								<item>
									<label>•</label>
									<para>Blood dyscrasias: malaise, fever, bruising, bleeding (rare)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14652">
								<item>
									<label>•</label>
									<para>Renal status: dark urine, hematuria, decreased output</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14658">
								<item>
									<para>
										<emphasis alert="nurse">Hemolytic reaction: chills, fever, chest pain, cyanosis; product should be discontinued immediately; hemolytic anemia may be severe in patients of Asian, Mediterranean descent</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14663">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x14667">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of malaria</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x14673">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x14681">
							<label>•</label>
							<sec_title>
								<route>To report visual problems, fever, fatigue, dark urine, bruising, bleeding; may indicate blood dyscrasias</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x14684">
								<item>
									<label>•</label>
									<para>To complete full course of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14689">
								<item>
									<label>•</label>
									<para>That an eye exam will be needed q4-6mo if using product for an extended period of time</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="42" status="active" ru="yes">
			<mono_name> primidone (Rx)</mono_name>
			<info>
				<pronunciation>(pri′mi-done)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x147011">Mysoline</tradename>
					<tradename id="tnidelem4x147010">
						<country code="CAN">Sertan </country>
					</tradename>
				</tradenames>
				<class type="func"> Anticonvulsant</class>
				<class type="chem"> Barbiturate derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="uses" id="sidelem4x14713">
				<sec_title>Uses:</sec_title>
				<para>Generalized tonic-clonic (grand mal), complex seizures</para>
			</section>
			<section type="contra" id="sidelem4x14718">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity to this product or barbiturates, porphyria</para>
			</section>
			<section type="doses" id="sidelem4x14723">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14731">
					<label>•</label>
					<sec_title>Adult and child &gt;8 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14731">
							<item>
								<label>•</label>
								<para> 125-250 mg at bedtime, increase by 125-250 mg/day q3-7days, usual dose 750-1500 mg/day in 3-4 divided doses, max 2 g/day in divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14738">
					<label>•</label>
					<sec_title>Child &lt;8 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14738">
							<item>
								<label>•</label>
								<para> 50-125 mg at bedtime, increase by 50-125 mg/day q3-7days, usual dose 10-25 mg/kg/day in 3-4 divided doses</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14745">
					<label>•</label>
					<sec_title>Neonate<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x14745">
							<item>
								<label>•</label>
								<para> 12-20 mg/kg/day in 2-4 divided doses, start at lower dose and titrate</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x14749">
					<section type="none" id="sidelem4x14750">
						<sec_title>Benign familial tremor/essential tremor (unlabeled)</sec_title>
						<section type="none" id="sidelem4x14758">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14758">
									<item>
										<label>•</label>
										<para> 50-62.5 mg, increase as tolerated up to 750 mg/day in 3 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14763">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x14771">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 10-50 ml/min, increase interval between doses to 8-12 hr; CCr &lt;10 ml/min, increase interval to 12-24 hr</route></sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="43" status="active">
			<mono_name>probenecid (Rx)</mono_name>
			<info>
				<pronunciation>(proe-ben′e-sid)</pronunciation>
				<class type="func"> Uricosuric, antigout agent</class>
				<class type="chem"> Sulfonamide derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x14787">
				<sec_title>Action:</sec_title>
				<para>Inhibits tubular reabsorption of urates, with increased excretion of uric acids</para>
			</section>
			<section type="uses" id="sidelem4x14792">
				<sec_title>Uses:</sec_title>
				<para>Hyperuricemia in gout, gouty arthritis, adjunct to penicillin treatment</para>
			</section>
			<section type="contra" id="sidelem4x14797">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe renal/hepatic disease, CCr &lt;50 mg/min, history of uric acid calculus</para>
				<section type="none" id="sidelem4x14802">
					<section type="none" id="sidelem4x14803">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), children &lt;2 yr, sulfonamide hypersensitivity, pepticular</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x14808">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x14811">
					<section type="none" id="sidelem4x14812">
						<sec_title>Adjunct to penicillin</sec_title>
						<section type="none" id="sidelem4x14820">
							<label>•</label>
							<sec_title>Adult/adolescent &gt;15 yr, &gt;50 kg (110 lb)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14820">
									<item>
										<label>•</label>
										<para> 500 mg qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14824">
						<sec_title>Gout/gouty arthritis</sec_title>
						<section type="none" id="sidelem4x14832">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14832">
									<item>
										<label>•</label>
										<para> 250 mg bid for 1 wk, then 500 mg bid, max 2 g/day; maintenance 500 mg/day × 6 mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14836">
						<sec_title>Adjunct in penicillin treatment</sec_title>
						<section type="none" id="sidelem4x14844">
							<label>•</label>
							<sec_title>Adult and adolescent &gt;50 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14844">
									<item>
										<label>•</label>
										<para> 500 mg qid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x14851">
							<label>•</label>
							<sec_title>Child &lt;50 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x14851">
									<item>
										<label>•</label>
										<para> 25 mg/kg, then 40 mg/kg in divided doses qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x14855">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x14863">
							<label>•</label>
							<sec_title>
								<route>Avoid use if CCr &lt;50 ml/min</route>
							</sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x14866">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 500 mg</para>
					</section>
					<section type="none" id="sidelem4x14871">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x14875">
								<item>
									<label>•</label>
									<para>After meals or with milk if GI symptoms occur</para>
								</item>
								<item>
									<label>•</label>
									<para>Increase ﬂuid intake to 2-3 L/day to prevent urinary calculi</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x14886">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x14889">
					<section type="none" id="sidelem4x14890">
						<sec_title>CNS:</sec_title>
						<para> Drowsiness, headache, flushing</para>
					</section>
					<section type="none" id="sidelem4x14895">
						<sec_title>CV:</sec_title>
						<para> Bradycardia</para>
					</section>
					<section type="none" id="sidelem4x14900">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Gastric irritation, nausea, vomiting, anorexia,</emphasis><emphasis style="bold">hepatic necrosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14909">
						<sec_title>GU:</sec_title>
						<para> Glycosuria, thirst, frequency, <emphasis style="bold">nephrotic syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x14916">
						<sec_title>INTEG:</sec_title>
						<para> Rash, dermatitis, pruritus, fever</para>
					</section>
					<section type="none" id="sidelem4x14921">
						<sec_title>META:</sec_title>
						<para> <emphasis style="italic">Acidosis, hypokalemia, hyperchloremia,</emphasis> hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x14929">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Apnea,</emphasis> irregular respirations</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x14937">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 2-4 hr, duration 8 hr, half-life 5-8 hr; metabolized by liver; excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x14942">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of acyclovir, barbiturates, allopurinol, benzodiazepines, dyphylline, zidovudine, cephalosporins, penicillins, sulfonamides</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—sulfa products, dapsone, clofibrate, indomethacin, rifampin, naproxen, methotrexate</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action of probenecid—salicylates</para>
				<section type="none" id="sidelem4x14956">
					<section type="none" id="sidelem4x14957">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> theophylline levels</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x14964">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x14967">
					<section type="none" id="sidelem4x14968">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x14973">
								<item>
									<label>•</label>
									<para>Uric acid levels (3-7 mg/dl); mobility, joint pain, swelling, maintain fluid intake at 2-3 L/day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14978">
								<item>
									<label>•</label>
									<para>Respiratory rate, rhythm, depth; notify prescriber of abnormalities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14983">
								<item>
									<label>•</label>
									<para>Electrolytes; CO<emphasis style="inf">2</emphasis> before, during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14991">
								<item>
									<label>•</label>
									<para>Urine pH, output, glucose during beginning treatment, poor effect in GFR &lt;30 ml/min</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x14997">
								<item>
									<para>
										<emphasis alert="nurse">For CNS symptoms: confusion, twitching, hyperreﬂexia, stimulation, headache; may indicate overdose</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15002">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15006">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of pain, stiffness in joints</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15012">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15016">
								<item>
									<label>•</label>
									<para>To avoid OTC preparations (aspirin) unless directed by prescriber; to increase water intake, avoid alcohol, caffeine</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="44" status="active" ha="yes">
			<mono_name> procainamide (Rx)</mono_name>
			<info>
				<pronunciation>(proe-kane-ah′mide)</pronunciation>
				<class type="func"> Antidysrhythmic (class IA)</class>
				<class type="chem"> Procaine HCl amide analog</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x15038">
				<sec_title>Action:</sec_title>
				<para>Depresses excitability of cardiac muscle to electrical stimulation and slows conduction velocity in atrium, bundle of His, and ventricle; increases refractory period</para>
			</section>
			<section type="uses" id="sidelem4x15043">
				<sec_title>Uses:</sec_title>
				<para>Life-threatening ventricular dysrhythmias</para>
				<section type="none" id="sidelem4x15048">
					<section type="none" id="sidelem4x15049">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Atrial fibrillation/flutter, paroxysmal atrial tachycardia, PSVT, Wolff-Parkinson-White (WPW) syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15054">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, severe heart block, torsades de pointes</para>
				<para>
					<bbw>Lupus erythematosus</bbw>
				</para>
				<section type="none" id="sidelem4x15069">
					<section type="none" id="sidelem4x15070">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, renal/hepatic disease, CHF, respiratory depression, cytopenia, dysrhythmia associated with digoxin toxicity, myasthenia gravis, digoxin toxicity</para>
						<para>
							<bbw>Bone marrow failure, cardiac arrhythmias</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15085">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15088">
					<section type="none" id="sidelem4x15089">
						<sec_title>Ventricular tachycardia during CPR</sec_title>
						<section type="none" id="sidelem4x15097">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15097">
									<item>
										<label>•</label>
										<para> loading dose 20 mg/min; either ventricular tachycardia resolves or patient becomes hypotensive; QRS complex is widened by 50% of original width or total is 17 mg/kg (1.2 g for a 70-kg patient); may give up to 50 mg/min in urgent situations; maintenance: 1-4 mg/min  50 mg/kg/day in divided doses q3-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15107">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x15107">
									<item>
										<label>•</label>
										<para> PALS 15 mg/kg over 30-60 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15111">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x15119">
							<label>•</label>
							<sec_title>Adult<route> IV CCr 35-59 ml/min, give 70% maintenance dose; CCr 15-34 ml/min, give 40%-60% maintenance dose; CCr &lt;15 ml/min, individualize dose</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x15122">
						<sec_title>Available forms:</sec_title>
						<para>  Inj 100, 500 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x15127">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x15130">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x15134">
									<item>
										<label>•</label>
										<para>IM inj in deltoid; aspirate to avoid intravascular administration; use only when unable to use IV</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15140">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x15144">
									<item>
										<label>•</label>
										<para>Dilute each 100 mg/10 ml of 0.9% NaCl; give at max 50 mg/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15150">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15154">
									<item>
										<label>•</label>
										<para>Dilute 0.2-1 g/50-500 ml of D<emphasis style="inf">5</emphasis>W (2-4 mg/ml); give over 30-60 min at max 25-50 mg/min; use infusion pump</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, aminocaproic acid, aminophylline, amiodarone, amphotericin B lipid complex, amphotericin B liposome, anidulafungin, ascorbic acid, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, caspofungin, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, cefTRIAXone, cefuroxime, cephalothin, chlorproMAZINE, cimetidine, cisatracurium, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, IDArubicin, ifosfamide, indomethacin, insulin (regular), irinotecan, isoproterenol, ketorolac, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, mezlocillin, miconazole, midazolam, mitoXANtrone, morphine, moxalactam, multivitamins, mycophenolate, nafcillin, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, pantoprazole, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, piperacillin-tazobactam, polymyxin B, potassium chloride, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, ritodrine, rocuronium, sodium bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15169">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15172">
					<section type="none" id="sidelem4x15173">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> confusion, psychosis, restlessness, irritability, weakness, depression</para>
					</section>
					<section type="none" id="sidelem4x15181">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis><emphasis style="bold">heart block, cardiovascular collapse, arrest, torsades de pointes</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15190">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, diarrhea, hepatomegaly, pain, bitter taste</para>
					</section>
					<section type="none" id="sidelem4x15195">
						<sec_title>HEMA:</sec_title>
						<para> SLE syndrome, <emphasis style="bold">agranulocytosis, thrombocytopenia, neutropenia, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15202">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, edema, swelling (rare), pruritus, flushing, <emphasis style="bold">angioedema</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15209">
						<sec_title>SYST:</sec_title>
						<para> SLE</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15214">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver to active metabolites, excreted unchanged by kidneys (60%), protein binding 15%</para>
				<section type="none" id="sidelem4x15219">
					<section type="none" id="sidelem4x15220">
						<sec_title>IM:</sec_title>
						<para> Peak 10-60 min, half-life 3 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x15225">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of neuromuscular blockers</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> procainamide effects—cimetidine, quiNIDine, trimethoprim, β-blockers, ranitidine</para>
				<para>
					<emphasis alert="lifethreat">Increase: toxicity—other antidysrhythmics, thioridazine, quinolones</emphasis>
				</para>
				<section type="none" id="sidelem4x15239">
					<section type="none" id="sidelem4x15240">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> ALT, AST, alk phos, LDH, bilirubin</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15247">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15250">
					<section type="none" id="sidelem4x15251">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Cardiac dysrhythmias:</emphasis> ECG continuously if using IV to determine increased PR or QRS segments; discontinue immediately; watch for increased ventricular ectopic beats, maximum need to rebolus</bbw>
						</para>
						<para>
							<list id="lidelem4x15266">
								<item>
									<label>•</label>
									<para>Therapeutic blood levels, 4-10 mcg/ml or NAPA levels 10-20 mcg/ml</para>
								</item>
							</list>
						</para>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Bone marrow suppression:</emphasis> CBC q2wk × 3 mo; leukocyte, neutrophil, platelet counts may be decreased, treatment may need to be discontinued</bbw>
						</para>
						<para>
							<list id="lidelem4x15284">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; electrolytes (K, Na, Cl), weight weekly, report gain of &gt;2 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15290">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: confusion, drowsiness, nausea, vomiting, tachydysrhythmias, oliguria</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15295">
								<item>
									<label>•</label>
									<para>ANA titer; during long-term treatment, watch for lupuslike symptoms</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15300">
								<item>
									<label>•</label>
									<para>Cardiac rate, rhythm, character, B/P continuously for fluctuations</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15305">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, character, lung fields; bilateral crackles may occur in CHF patient; watch for respiratory depression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15311">
								<item>
									<para>
										<emphasis alert="nurse">CNS effects: dizziness, confusion, psychosis, paresthesias, seizures; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15316">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15320">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15326">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x15330">
								<item>
									<label>•</label>
									<para>That wax matrix may appear in stools</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to discontinue without provider’s approval
<bbw>To notify prescriber immediately if lupuslike symptoms appear (joint pain, butterfly rash, fever, chills, dyspnea)</bbw>

<bbw>To notify prescriber of leukopenia (sore mouth, gums, throat) or thrombocytopenia (bleeding, bruising)</bbw>
</para>
								</item>
								<item>
									<label>•</label>
									<para>How to take pulse and when to report to prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until product effect is known</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="45" status="active" ha="yes">
			<mono_name> procarbazine (Rx)</mono_name>
			<info>
				<pronunciation>(proe-kar′ba-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x153850">Matulane</tradename>
				</tradenames>
				<class type="func"> Antineoplastic, alkylating agent</class>
				<class type="chem"> Hydrazine derivative</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x15395">
				<sec_title>Action:</sec_title>
				<para>Inhibits DNA, RNA, protein synthesis; has multiple sites of action; nonvesicant</para>
			</section>
			<section type="uses" id="sidelem4x15400">
				<sec_title>Uses:</sec_title>
				<para>Lymphoma, Hodgkin’s disease, cancers resistant to other therapy</para>
				<section type="none" id="sidelem4x15405">
					<section type="none" id="sidelem4x15406">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Brain, lung malignancies; other lymphomas; multiple myeloma, malignant melanoma, polycythemia vera</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15411">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, thrombocytopenia, bone marrow depression</para>
				<section type="none" id="sidelem4x15416">
					<section type="none" id="sidelem4x15417">
						<sec_title>Precautions:</sec_title>
						<para> Cardiac/renal/hepatic disease, radiation therapy, seizure disorder, anemia, bipolar disorder, Parkinson’s disease</para>
						<para>
							<bbw>Requires a specialized care setting and an experienced clinician</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15432">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15440">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15440">
							<item>
								<label>•</label>
								<para> 2-4 mg/kg/day for 1st wk; maintain dosage of 4-6 mg/kg/day until platelets, WBC fall; after recovery, 1-2 mg/kg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15447">
					<label>•</label>
					<sec_title>Child<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x15447">
							<item>
								<label>•</label>
								<para> 50 mg/m<emphasis style="sup">2</emphasis>/day for 7 days, then 100 mg/m<emphasis style="sup">2</emphasis> until desired response, leukopenia, or thrombocytopenia occurs; 50 mg/m<emphasis style="sup">2</emphasis>/day maintenance after bone marrow recovery</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x15460">
					<section type="none" id="sidelem4x15461">
						<sec_title>Available forms:</sec_title>
						<para> Caps 50 mg</para>
					</section>
					<section type="none" id="sidelem4x15466">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15470">
								<item>
									<label>•</label>
									<para>In divided doses and at bedtime to minimize nausea and vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>Nonphenothiazine antiemetic 30-60 min before product and 4-10 hr after treatment to prevent vomiting</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x15481">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x15484">
					<section type="none" id="sidelem4x15485">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, insomnia, hallucinations, confusion, <emphasis style="bold">coma,</emphasis> pain, chills, fever, sweating, paresthesias, <emphasis style="bold">seizures,</emphasis> peripheral neuropathy</para>
					</section>
					<section type="none" id="sidelem4x15496">
						<sec_title>EENT:</sec_title>
						<para> Retinal hemorrhage, nystagmus, photophobia, diplopia, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x15501">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> anorexia, diarrhea, constipation, dry mouth, stomatitis, elevated hepatic enzymes</para>
					</section>
					<section type="none" id="sidelem4x15509">
						<sec_title>GU:</sec_title>
						<para> Azoospermia, cessation of menses</para>
					</section>
					<section type="none" id="sidelem4x15514">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, anemia, leukopenia, myelosuppression, bleeding tendencies,</emphasis> purpura, petechiae, epistaxis, <emphasis style="bold">hemolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x15524">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> pruritus, dermatitis, alopecia, herpes, hyperpigmentation</para>
					</section>
					<section type="none" id="sidelem4x15532">
						<sec_title>MS:</sec_title>
						<para> Arthralgias, myalgias</para>
					</section>
					<section type="none" id="sidelem4x15537">
						<sec_title>RESP:</sec_title>
						<para> Cough, pneumonitis, hemoptysis</para>
					</section>
					<section type="none" id="sidelem4x15542">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Secondary malignancy</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x15549">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Half-life 1 hr; concentrates in liver, kidney, skin; metabolized in liver, excreted in urine</para>
			</section>
			<section type="interactions" id="sidelem4x15555">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: hypotension—meperidine; do not use together</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: neuroleptic malignant syndrome, seizures, hyperpyrexia—alcohol, MAOIs, tricyclics, sympathomimetic products, SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypertension—guanethidine, levodopa, methyldopa, reserpine, caffeine</para>
				<para>
					<emphasis alert="nurse">Life-threatening hypertension: sympathomimetics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> bleeding risk—NSAIDs, anticoagulants, platelet inhibitors, thrombolytics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—barbiturates, antihistamines, opioids, hypotensive agents, phenothiazines</para>
				<section type="none" id="sidelem4x15583">
					<section type="none" id="sidelem4x15584">
						<sec_title>Drug/Food</sec_title>
						<section type="none" id="sidelem4x15592">
							<label>•</label>
							<sec_title>Hypertensive crisis<route> tyramine foods</route></sec_title>
						</section>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x15595">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x15598">
					<section type="none" id="sidelem4x15599">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x15607">
							<label>•</label>
							<sec_title>Bone marrow suppression<route> CBC, differential, platelet count weekly; withhold product if WBC is &lt;4000/mm3 or platelet count is &lt;100,000/mm3; notify prescriber</route></sec_title>
						</section>
						<section type="none" id="sidelem4x15619">
							<label>•</label>
							<sec_title>Hepatic/renal disease<route> can cause accumulation of drug, increased toxicity; renal studies</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15622">
								<item>
									<label>•</label>
									<para>Monitor temperature; fever may indicate beginning infection
<bbw>To be used only in a specialized care setting with emergency equipment</bbw>

<bbw>To be given only by an experienced clinician knowledgeable in cytotoxic products</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15645">
								<item>
									<label>•</label>
									<para>CNS changes: confusion, paresthesias, neuropathies; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15651">
								<item>
									<para>
										<emphasis alert="nurse">Tyramine foods in diet; hypertensive crisis can occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15657">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: facial flushing, epistaxis, increased PT, thrombocytopenia; product should be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15665">
							<label>•</label>
							<sec_title>Bleeding</sec_title>
							<para>
								<list id="lidelem4x15665">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bleeding:</emphasis> hematuria, guaiac stools, bruising or petechiae, mucosa or orifices q8hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x15669">
								<item>
									<label>•</label>
									<para>Effects of alopecia on body image; discuss feelings about body changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15674">
								<item>
									<label>•</label>
									<para>Jaundiced skin, sclera; dark urine, clay-colored stools, itchy skin, abdominal pain, fever, diarrhea</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15679">
								<item>
									<label>•</label>
									<para>Buccal cavity for dryness, sores or ulceration, white patches, oral pain, bleeding, dysphagia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15684">
								<item>
									<label>•</label>
									<para>GI symptoms: frequency of stools, cramping</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15692">
							<label>•</label>
							<sec_title>Acidosis, signs of dehydration</sec_title>
							<para>
								<list id="lidelem4x15692">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Acidosis, signs of dehydration:</emphasis> rapid respirations, poor skin turgor, decreased urine output, dry skin, restlessness, weakness</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15696">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x15700">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreasing malignancy</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x15706">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x15714">
							<label>•</label>
							<sec_title>To report any complaints, side effects to nurse or prescriber<route> CNS changes, diarrhea, cough, SOB, fever, chills, sore throat, bleeding, bruising, vomiting blood; black, tarry stools</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x15717">
								<item>
									<label>•</label>
									<para>That hair may be lost during treatment and wig or hairpiece may make patient feel better; that new hair may be different in color, texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15722">
								<item>
									<label>•</label>
									<para>To avoid sunlight or UV exposure; to wear sunscreen or protective clothing</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15727">
								<item>
									<label>•</label>
									<para>To avoid foods with citric acid, hot or rough texture</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15732">
								<item>
									<label>•</label>
									<para>To report any bleeding, white spots, ulcerations in mouth to prescriber; to examine mouth daily</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15737">
								<item>
									<label>•</label>
									<para>To avoid driving, activities requiring alertness because dizziness may occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15745">
							<label>•</label>
							<sec_title>
								<route>To use effective contraception; to avoid breastfeeding; that product may cause infertility</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x15748">
								<item>
									<label>•</label>
									<para>To avoid the ingestion of alcohol, caffeine, tyramine-containing foods; that cold, hay fever, and weight-reducing products may cause serious product interactions; to avoid smoking</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15753">
								<item>
									<label>•</label>
									<para>To avoid crowds, persons with infections if granulocytes are low</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x15758">
								<item>
									<label>•</label>
									<para>To avoid vaccines</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="46" status="active">
			<mono_name>prochlorperazine (Rx)</mono_name>
			<info>
				<pronunciation>(proe-klor-pair′a-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x157690">Compro</tradename>
				</tradenames>
				<class type="func"> Antiemetic, antipsychotic</class>
				<class type="chem"> Phenothiazine, piperazine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x15779">
				<para>
					<confusion>
						<tradename id="tnidelem4x157790">prochlorperazine</tradename>
						<drug type="generic" refid="idelem4x157790">chlorproMAZINE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x15783">
				<sec_title>Action:</sec_title>
				<para>Decreases DOPamine neurotransmission by increasing DOPamine turnover through the blockade of the D<emphasis style="inf">2</emphasis> somatodendritic autoreceptor in the mesolimbic system</para>
			</section>
			<section type="uses" id="sidelem4x15791">
				<sec_title>Uses:</sec_title>
				<para>Nausea, vomiting, psychotic disorders</para>
				<section type="none" id="sidelem4x15796">
					<section type="none" id="sidelem4x15797">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Migraine</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x15802">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to phenothiazines, coma; infants, neonates, children &lt;2 yr or &lt;20 lb; surgery</para>
				<section type="none" id="sidelem4x15807">
					<section type="none" id="sidelem4x15808">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, seizure, encephalopathy, glaucoma, hepatic disease, Parkinson’s disease, BPH</para>
						<para>
							<bbw>Increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x15823">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x15826">
					<section type="none" id="sidelem4x15827">
						<sec_title>Postoperative nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x15835">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x15835">
									<item>
										<label>•</label>
										<para> 5-10 mg 1-2 hr before anesthesia; may repeat after 30 min;  5-10 mg 15-30 min before anesthesia;  20 mg/L D<emphasis style="inf">5</emphasis>W or  15-30 min before anesthesia, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15851">
						<sec_title>Severe nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x15859">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15859">
									<item>
										<label>•</label>
										<para> 5-10 mg tid-qid;  15 mg/day in <emphasis style="smallcaps">am</emphasis> or 10 mg q12hr;  25 mg/bid;  5-10 mg q3-4hr prn, max 40 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15878">
							<label>•</label>
							<sec_title>Child 18-39 kg<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15878">
									<item>
										<label>•</label>
										<para> 2.5 mg tid or 5 mg bid;  0.132 mg/kg q3-4hr prn, max 15 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15888">
							<label>•</label>
							<sec_title>Child 14-17 kg<route> PO/RECT</route></sec_title>
							<para>
								<list id="lidelem4x15888">
									<item>
										<label>•</label>
										<para> 2.5 mg bid-tid;  0.132 mg/kg q3-4hr prn, max 10 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15898">
							<label>•</label>
							<sec_title>Child 9-13 kg<route> PO/RECT</route></sec_title>
							<para>
								<list id="lidelem4x15898">
									<item>
										<label>•</label>
										<para> 2.5 mg/day-bid;  0.132 mg/kg q3-4hr prn, max 7.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15905">
						<sec_title>Antipsychotic</sec_title>
						<section type="none" id="sidelem4x15913">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15913">
									<item>
										<label>•</label>
										<para> 5-10 mg tid-qid; may increase q2-3days, max 150 mg/day;  10-20 mg q2-4hr up to 4 doses, then 10-20 mg q4-6hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15923">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15923">
									<item>
										<label>•</label>
										<para> 2.5 mg bid-tid;  0.132 mg/kg change to oral ASAP</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15930">
						<sec_title>Antianxiety</sec_title>
						<section type="none" id="sidelem4x15938">
							<label>•</label>
							<sec_title>Adult and child ≥12 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x15938">
									<item>
										<label>•</label>
										<para> 5 mg tid-qid, max 20 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15945">
							<label>•</label>
							<sec_title>Child 2-12 yr<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x15945">
									<item>
										<label>•</label>
										<para> 0.132 mg/kg change to oral ASAP</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x15949">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 25 mg; supp 25 mg</para>
					</section>
					<section type="none" id="sidelem4x15954">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x15958">
								<item>
									<label>•</label>
									<para>Avoid other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x15964">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x15968">
									<item>
										<label>•</label>
										<para>IM inj in large muscle mass; aspirate to avoid IV administration</para>
									</item>
									<item>
										<label>•</label>
										<para>Keep patient recumbent for <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15985">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x15989">
									<item>
										<label>•</label>
										<para>No dilution needed; inject directly in a vein ≤5 mg/min; do not give as bolus</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x15995">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x15999">
									<item>
										<label>•</label>
										<para>May dilute 20 mg/L NaCl and give as infusion 15-30 min before anesthesia induction</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Amsacrine, calcium gluconate, cisatracurium, CISplatin, cladribine, cyclophosphamide, cytarabine, DOXOrubicin, DOXOrubicin liposome, fluconazole, granisetron, heparin, hydrocortisone, melphalan, methotrexate, ondansetron, PACLitaxel, potassium chloride, propofol, remifentanil, sargramostim, SUFentanil, teniposide, thiotepa, vinorelbine, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16009">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16012">
					<section type="none" id="sidelem4x16013">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="bold">Neuroleptic malignant syndrome,</emphasis><emphasis style="italic">extrapyramidal reactions, tardive dyskinesia, euphoria,</emphasis><emphasis style="bold">depression,</emphasis><emphasis style="italic">drowsiness,</emphasis> restlessness, tremor, dizziness, headache</para>
					</section>
					<section type="none" id="sidelem4x16028">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Circulatory failure, tachycardia,</emphasis> hypotension, ECG changes</para>
					</section>
					<section type="none" id="sidelem4x16036">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision</para>
					</section>
					<section type="none" id="sidelem4x16041">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, dry mouth, diarrhea, constipation, weight loss, metallic taste, cramps</para>
					</section>
					<section type="none" id="sidelem4x16046">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16053">
						<sec_title>MISC:</sec_title>
						<para> Impotence</para>
					</section>
					<section type="none" id="sidelem4x16058">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16065">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; excreted in urine, breast milk; crosses placenta; 91%-99% protein binding</para>
				<section type="none" id="sidelem4x16070">
					<section type="none" id="sidelem4x16071">
						<sec_title>IM:</sec_title>
						<para> Onset 10-20 min, duration 4-6 hr; children: 12 hr</para>
					</section>
					<section type="none" id="sidelem4x16076">
						<sec_title>PO:</sec_title>
						<para> Onset 30-40 min, duration 3-4 hr</para>
					</section>
					<section type="none" id="sidelem4x16081">
						<sec_title>RECT:</sec_title>
						<para> Onset 60 min, duration 3-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x16086">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticholinergic action—anticholinergics, antiparkinson products, antidepressants</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—CNS depressants</para>
				<para>
					<emphasis alert="lifethreat">Increase: serotonin syndrome, neuroleptic malignant syndrome—SSRIs, SNRIs</emphasis>
				</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> prochlorperazine effect—barbiturates, antacids, lithium</para>
				<section type="none" id="sidelem4x16104">
					<section type="none" id="sidelem4x16105">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CNS depression—chamomile, hops, kava, St. John’s wort, valerian</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> EPS—kava</para>
					</section>
					<section type="none" id="sidelem4x16116">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> LFTs, cardiac enzymes, cholesterol, blood glucose, prolactin, bilirubin, PBI, <emphasis style="sup">131</emphasis>I, alk phos, leukocytes, granulocytes, platelets</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> hormones (blood and urine)</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> pregnancy tests, urine bilirubin</para>
						<para>
							<emphasis style="bold">False negative:</emphasis> urinary steroids, 17-OHCS, pregnancy tests</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16138">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16141">
					<section type="none" id="sidelem4x16142">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x16150">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x16150">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> abnormal movement, tardive dyskinesia, akathisia</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16154">
								<item>
									<label>•</label>
									<para>VS, B/P; check patients with cardiac disease more often</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16160">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: seizures, hypo/hypertension, fever, tachycardia, dyspnea, fatigue, muscle stiffness, loss of bladder control; notify prescriber immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16166">
								<item>
									<para>
										<emphasis alert="nurse">CBC, LFTs during course of treatment; blood dyscrasias, hepatotoxicity may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16171">
								<item>
									<label>•</label>
									<para>Respiratory status before, during, after administration of emetic; check rate, rhythm, character; respiratory depression can occur rapidly among geriatric or debilitated patients</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16176">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16180">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting; reduced anxiety, agitation, excitability</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16186">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16190">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities, activities requiring alertness because dizziness may occur</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid alcohol</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to double or skip doses</para>
								</item>
								<item>
									<label>•</label>
									<para>That urine may be pink to reddish brown</para>
								</item>
								<item>
									<label>•</label>
									<para>That suppositories may contain coconut/palm oil</para>
								</item>
								<item>
									<label>•</label>
									<para>To report dark urine, clay-colored stools, bleeding, bruising, rash, blurred vision</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid sun; wear sunscreen, protective clothing</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="47" status="active">
			<mono_name>progesterone (Rx)</mono_name>
			<info>
				<pronunciation>(proe-jess′ter-one)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x162313">Crinone</tradename>
					<tradename id="tnidelem4x162312">Endometrin</tradename>
					<tradename id="tnidelem4x162311">Prochieve</tradename>
					<tradename id="tnidelem4x162310">Prometrium</tradename>
				</tradenames>
				<class type="func"> Progestogen</class>
				<class type="chem"> Progesterone derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x16241">
				<sec_title>Action:</sec_title>
				<para>Inhibits secretion of pituitary gonadotropins, which prevents follicular maturation, ovulation; stimulates growth of mammary tissue; antineoplastic action against endometrial cancer</para>
			</section>
			<section type="uses" id="sidelem4x16246">
				<sec_title>Uses:</sec_title>
				<para>Contraception, amenorrhea, premenstrual syndrome, abnormal uterine bleeding, endometrial hyperplasia prevention, assisted reproductive technology (ART) gel</para>
				<section type="none" id="sidelem4x16253">
					<section type="none" id="sidelem4x16254">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Corpus luteum insufficiency, early pregnancy failure, PMS, preterm delivery prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16259">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="B">B</preg>), ectopic pregnancy; hypersensitivity to this product, peanuts, or peanut oil; thromboembolic disorders, reproductive cancer, genital bleeding (abnormal, undiagnosed), cerebral hemorrhage, PID, STDs, thrombophlebitis</para>
				<para>
					<bbw>Breast cancer</bbw>
				</para>
				<section type="none" id="sidelem4x16274">
					<section type="none" id="sidelem4x16275">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, hypertension, asthma, blood dyscrasias, CHF, diabetes mellitus, bone disease, depression, migraine headache, seizure disorders, gallbladder/renal/hepatic disease, family history of breast/reproductive tract cancer</para>
						<para>
							<bbw>Cardiac disease, dementia</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16290">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16293">
					<section type="none" id="sidelem4x16294">
						<sec_title>Infertility</sec_title>
						<section type="none" id="sidelem4x16302">
							<label>•</label>
							<sec_title>Adult<route> VAG</route></sec_title>
							<para>
								<list id="lidelem4x16302">
									<item>
										<label>•</label>
										<para> 90 mg/day (micronized gel); 100 mg 2-3 times/day starting day after oocyte retrieval and for ≤10 wk total (insert)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16306">
						<sec_title>Amenorrhea/functional uterine bleeding</sec_title>
						<section type="none" id="sidelem4x16314">
							<label>•</label>
							<sec_title>Adult<route> IM</route></sec_title>
							<para>
								<list id="lidelem4x16314">
									<item>
										<label>•</label>
										<para> 5-10 mg/day × 6-8 doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16318">
						<sec_title>Endometrial hyperplasia prevention</sec_title>
						<section type="none" id="sidelem4x16326">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16326">
									<item>
										<label>•</label>
										<para> 200 mg/day × 12 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16330">
						<sec_title>Assisted reproductive therapy</sec_title>
						<section type="none" id="sidelem4x16338">
							<label>•</label>
							<sec_title>Adult<route> GEL</route></sec_title>
							<para>
								<list id="lidelem4x16338">
									<item>
										<label>•</label>
										<para> 90 mg (8%) vaginally daily for supplementation; 90 mg (8%) vaginally bid for replacement; if pregnancy occurs, continue × 10-12 wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16342">
						<sec_title>Corpus luteum insufficiency (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16350">
							<label>•</label>
							<sec_title>Adult<route> VAG INSERT</route></sec_title>
							<para>
								<list id="lidelem4x16350">
									<item>
										<label>•</label>
										<para> 90-100 mg bid-tid starting at oocyte retrieval and continuing up to 10-12 wk gestation</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16354">
						<sec_title>Available forms:</sec_title>
						<para> Inj 50 mg/ml; vag gel 4%, 8%; caps 100, 200 mg; vag insert 100 mg; vag supp 25, 100, 200, 500 mg; compounding kit 25, 50, 100, 200, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x16359">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x16362">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x16366">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew caps</para>
									</item>
									<item>
										<label>•</label>
										<para>Titrated dose; use lowest effective dose</para>
									</item>
									<item>
										<label>•</label>
										<para>In 1 dose in <emphasis style="smallcaps">am</emphasis></para>
									</item>
									<item>
										<label>•</label>
										<para>With food or milk to decrease GI symptoms</para>
									</item>
									<item>
										<label>•</label>
										<para>Start progesterone 14 days after estrogen dose if given concomitantly</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16394">
							<sec_title>Vaginal route</sec_title>
							<para>
								<list id="lidelem4x16398">
									<item>
										<label>•</label>
										<para>Wait at least 6 hr after any vaginal treatment before using vaginal gel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16404">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x16408">
									<item>
										<label>•</label>
										<para>Shake vial, inject deeply into large muscle, aspirate</para>
									</item>
									<item>
										<label>•</label>
										<para>Check for particulate matter and discoloration before injecting</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16419">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16422">
					<section type="none" id="sidelem4x16423">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, headache,</emphasis> migraines, depression, <emphasis style="italic">fatigue,</emphasis> mood swings, dementia, drowsiness</para>
					</section>
					<section type="none" id="sidelem4x16434">
						<sec_title>CV:</sec_title>
						<para> Hypotension, <emphasis style="bold">thrombophlebitis,</emphasis> edema, <emphasis style="bold">thromboembolism, stroke, pulmonary embolism, MI</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16444">
						<sec_title>EENT:</sec_title>
						<para> Diplopia, retinal thrombosis</para>
					</section>
					<section type="none" id="sidelem4x16449">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> vomiting, anorexia, cramps, increased weight, <emphasis style="bold">cholestatic jaundice,</emphasis><emphasis style="italic">constipation,</emphasis> abdominal pain</para>
					</section>
					<section type="none" id="sidelem4x16462">
						<sec_title>GU:</sec_title>
						<para> Amenorrhea, cervical erosion, breakthrough bleeding, dysmenorrhea, vaginal candidiasis, nocturia, breast changes, <emphasis style="italic">gynecomastia, testicular atrophy, impotence,</emphasis> endometriosis, <emphasis style="bold">spontaneous abortion,</emphasis> breast pain, ectopic pregnancy</para>
					</section>
					<section type="none" id="sidelem4x16473">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, acne, hirsutism, alopecia, oily skin, seborrhea, purpura, melasma</para>
					</section>
					<section type="none" id="sidelem4x16478">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x16483">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Angioedema, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16490">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Excreted in urine, feces; metabolized in liver</para>
				<section type="none" id="sidelem4x16495">
					<section type="none" id="sidelem4x16496">
						<sec_title>IM/RECT/VAG:</sec_title>
						<para> Duration 24 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x16501">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> progesterone effect—CYP3A4 inhibitors (ketoconazole, cimetidine, clarithromycin, danazol, diltiazem, erythromycin, fluconazole, itraconazole, troleandomycin, verapamil, voriconazole)</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> progesterone effect—barbiturates, phenytoin</para>
				<section type="none" id="sidelem4x16514">
					<section type="none" id="sidelem4x16515">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> alk phos, nitrogen (urine), pregnanediol, amino acids, factors VII, VIII, IX, X</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> GTT, HDL</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x16526">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x16529">
					<section type="none" id="sidelem4x16530">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x16538">
							<label>•</label>
							<sec_title>Abnormal uterine bleeding</sec_title>
							<para>
								<list id="lidelem4x16538">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Abnormal uterine bleeding:</emphasis> vaginal bleeding; obtain pad count, patient menstrual history, breast exam, cervical cytology</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x16542">
								<item>
									<label>•</label>
									<para>Weight daily; notify prescriber of weekly weight gain of &gt;5 lb</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16547">
								<item>
									<label>•</label>
									<para>B/P at beginning of treatment and periodically</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16552">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for decreasing urinary output, increasing edema</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16557">
								<item>
									<label>•</label>
									<para>Hepatic studies: ALT, AST, bilirubin periodically during long-term therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16562">
								<item>
									<label>•</label>
									<para>Edema, hypertension, cardiac symptoms, jaundice, thromboembolism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16567">
								<item>
									<label>•</label>
									<para>Mental status: affect, mood, behavioral changes, depression</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16572">
								<item>
									<label>•</label>
									<para>Hypercalcemia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16577">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x16581">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased abnormal uterine bleeding, absence of amenorrhea</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x16587">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x16593">
								<item>
									<para>
										<emphasis alert="nurse">To report breast lumps, vaginal bleeding, edema, jaundice, dark urine, clay-colored stools, dyspnea, headache, blurred vision, abdominal pain, numbness or stiffness in legs, chest pain</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16598">
								<item>
									<label>•</label>
									<para>To avoid gel with other vaginal products; if to be used together, to separate by ≥6 hr; for vaginal route, on proper insertion technique</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16603">
								<item>
									<label>•</label>
									<para>To report suspected pregnancy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16608">
								<item>
									<label>•</label>
									<para>To monitor blood glucose if diabetic</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x16613">
								<item>
									<label>•</label>
									<para>To avoid activities requiring mental alertness until effects are realized; can cause dizziness</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="48" status="active" ha="yes">
			<mono_name> promethazine (Rx)</mono_name>
			<info>
				<pronunciation>(proe-meth′a-zeen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x166250">Promethegan</tradename>
				</tradenames>
				<class type="func"> Antihistamine, H-receptor antagonist, antiemetic</class>
				<class type="chem"> Phenothiazine derivative</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x16638">
				<sec_title>Action:</sec_title>
				<para>Acts on blood vessels, GI, respiratory system by competing with histamine for H<emphasis style="inf">1</emphasis>-receptor sites; decreases allergic response by blocking histamine</para>
			</section>
			<section type="uses" id="sidelem4x16646">
				<sec_title>Uses:</sec_title>
				<para>Motion sickness, rhinitis, allergy symptoms, sedation, nausea, preoperative and postoperative sedation</para>
				<section type="none" id="sidelem4x16651">
					<section type="none" id="sidelem4x16652">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Allergic rhinitis, acute peripheral vestibular nystagmus, hyperemesis gravidarum</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x16657">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding, agranulocytosis, bone marrow suppression, coma, jaundice, Reye’s syndrome</para>
				<para>
					<bbw>Infants, neonates, children, intraarterial/SUBCUT administration, extravasation</bbw>
				</para>
				<section type="none" id="sidelem4x16672">
					<section type="none" id="sidelem4x16673">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), cardiac/renal/hepatic disease, asthma, seizure disorder, prostatic hypertrophy, bladder obstruction, glaucoma, COPD, GI obstruction, ileus, CNS depression, diabetes, sleep apnea, urinary retention</para>
						<para>
							<bbw>IV use</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x16688">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x16691">
					<section type="none" id="sidelem4x16692">
						<sec_title>Nausea/vomiting</sec_title>
						<section type="none" id="sidelem4x16700">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV/RECT</route></sec_title>
							<para>
								<list id="lidelem4x16700">
									<item>
										<label>•</label>
										<para> 12.5-25 mg; q4-6hr prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16707">
							<label>•</label>
							<sec_title>Child &gt;2 yr<route> PO/IM/IV/RECT</route></sec_title>
							<para>
								<list id="lidelem4x16707">
									<item>
										<label>•</label>
										<para> 0.25-0.5 mg/kg q4-6hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16711">
						<sec_title>Motion sickness</sec_title>
						<section type="none" id="sidelem4x16719">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16719">
									<item>
										<label>•</label>
										<para> 25 mg bid, give <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before departure, then q8-12hr prn</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16733">
							<label>•</label>
							<sec_title>Child ≥2 yr<route> PO/IM/RECT</route></sec_title>
							<para>
								<list id="lidelem4x16733">
									<item>
										<label>•</label>
										<para> 12.5-25 mg bid, give <emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-1 hr before departure, then q8-12hr prn</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16743">
						<sec_title>Sedation</sec_title>
						<section type="none" id="sidelem4x16751">
							<label>•</label>
							<sec_title>Adult<route> PO/IM</route></sec_title>
							<para>
								<list id="lidelem4x16751">
									<item>
										<label>•</label>
										<para> 25-50 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16758">
							<label>•</label>
							<sec_title>Child ≥2 yr<route> PO/IM/RECT</route></sec_title>
							<para>
								<list id="lidelem4x16758">
									<item>
										<label>•</label>
										<para> 12.5-25 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16762">
						<sec_title>Sedation (preoperative/postoperative)</sec_title>
						<section type="none" id="sidelem4x16770">
							<label>•</label>
							<sec_title>Adult<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x16770">
									<item>
										<label>•</label>
										<para> 25-50 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16777">
							<label>•</label>
							<sec_title>Child &gt;2 yr<route> PO/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x16777">
									<item>
										<label>•</label>
										<para> 0.5-1.1 mg/kg</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16781">
						<sec_title>Allergy/rhinitis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16789">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16789">
									<item>
										<label>•</label>
										<para> 12.5 mg qid or 25 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16796">
							<label>•</label>
							<sec_title>Child ≥2 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16796">
									<item>
										<label>•</label>
										<para> 6.25-12.5 mg tid or 25 mg at bedtime</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16800">
						<sec_title>Hyperemesis gravidarum (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16808">
							<label>•</label>
							<sec_title>Pregnant females<route> PO/RECT/IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x16808">
									<item>
										<label>•</label>
										<para> 12.5-25 mg q4hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16812">
						<sec_title>Nystagmus (unlabeled)</sec_title>
						<section type="none" id="sidelem4x16820">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x16820">
									<item>
										<label>•</label>
										<para> 12.5-25 mg q4-6hr for ≤48 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x16824">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 12.5, 25, 50 mg; supp 12.5, 25, 50 mg; inj 25, 50 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x16829">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x16833">
								<item>
									<label>•</label>
									<para>Avoid use with other CNS depressants</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x16839">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x16843">
									<item>
										<label>•</label>
										<para>With meals for GI symptoms; absorption may slightly decrease</para>
									</item>
									<item>
										<label>•</label>
										<para>When used for motion sickness, 30 min-1 hr before travel</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16854">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x16858">
									<item>
										<label>•</label>
										<para>IM inj deep in large muscle; rotate site</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x16864">
							<sec_title>Direct IV route</sec_title>
							<para>
								<bbw>Check for extravasation: burning, pain, swelling at IV site; can cause tissue necrosis</bbw>
							</para>
							<para>
								<list id="lidelem4x16877">
									<item>
										<label>•</label>
										<para>Do not use if precipitate is present</para>
									</item>
									<item>
										<label>•</label>
										<para>Rapid administration may cause transient decrease in B/P</para>
									</item>
									<item>
										<label>•</label>
										<para>After diluting each 25-50 mg/9 ml of NaCl for inj; give ≤25 mg/2 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amifostine, amikacin, aminocaproic acid, amsacrine, anidulafungin, ascorbic acid, atenolol, atracurium, atropine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, caspofungin, chlorproMAZINE, cimetidine, ciprofloxacin, cisatracurium, CISplatin, cladribine, codeine, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexmedetomidine, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin, eptifibatide, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, filgrastim, fluconazole, fludarabine, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, insulin (regular), irinotecan, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, melphalan, meperidine, metaraminol, methoxamine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, midazolam, milrinone, mitoXANtrone, morphine, mycophenolate, nalbuphine, naloxone, netilmicin, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, oxytocin, PACLitaxel, palonosetron, pamidronate, pancuronium, PEMEtrexed, pentamidine, pentazocine, phenylephrine, polymyxin B, procainamide, prochlorperazine, propranolol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, remifentanil, Ringer’s, ritodrine, riTUXimab, rocuronium, sargramostim, sodium acetate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, tigecycline, tirofiban, TNA, tobramycin, tolazoline, trastuzumab, trimetaphan, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, voriconazole</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x16897">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x16900">
					<section type="none" id="sidelem4x16901">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Dizziness, drowsiness,</emphasis> poor coordination, fatigue, anxiety, euphoria, confusion, paresthesia, neuritis, EPS, <emphasis style="bold">neuroleptic malignant syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16911">
						<sec_title>CV:</sec_title>
						<para> Hypo/hypertension, palpitations, tachycardia</para>
					</section>
					<section type="none" id="sidelem4x16917">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, dilated pupils, tinnitus, nasal stuffiness; dry nose, throat, mouth; photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x16922">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Constipation,</emphasis> dry mouth, nausea, vomiting, anorexia, diarrhea</para>
					</section>
					<section type="none" id="sidelem4x16930">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="italic">Urinary retention,</emphasis> dysuria, frequency</para>
					</section>
					<section type="none" id="sidelem4x16938">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, agranulocytosis, hemolytic anemia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x16945">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, photosensitivity</para>
					</section>
					<section type="none" id="sidelem4x16950">
						<sec_title>RESP:</sec_title>
						<para> Increased thick secretions, wheezing, chest tightness; <emphasis style="bold">apnea in neonates, infants, young children</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x16957">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver; excreted by kidneys, GI tract (inactive metabolites)</para>
				<section type="none" id="sidelem4x16962">
					<section type="none" id="sidelem4x16963">
						<sec_title>PO:</sec_title>
						<para> Onset 20 min, duration 4-12 hr</para>
					</section>
					<section type="none" id="sidelem4x16968">
						<sec_title>IV:</sec_title>
						<para> Onset 3-5 min</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x16973">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—barbiturates, opioids, hypnotics, tricyclics, alcohol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> promethazine effect—MAOIs</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> oral anticoagulants effect—heparin</para>
				<section type="none" id="sidelem4x16988">
					<section type="none" id="sidelem4x16989">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">False negative:</emphasis> skin allergy test</para>
						<para>
							<emphasis style="bold">False positive:</emphasis> urine pregnancy test</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> blood grouping (ABO), GTT</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17004">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17007">
					<section type="none" id="sidelem4x17008">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>Not to be used in children &lt;2 yr, fatal respiratory depression may occur; use cautiously in children &gt;2 yr, seizures, paradoxical CNS stimulation may occur</bbw>
						</para>
						<section type="none" id="sidelem4x17025">
							<label>•</label>
							<sec_title>Antiemetic/motion sickness</sec_title>
							<para>
								<list id="lidelem4x17025">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Antiemetic/motion sickness:</emphasis> nausea, vomiting before, after dose</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17029">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; be alert for urinary retention, frequency, dysuria; product should be discontinued</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17035">
								<item>
									<para>
										<emphasis alert="nurse">CBC with differential, LFTs during long-term therapy; blood dyscrasias, jaundice may occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17040">
								<item>
									<label>•</label>
									<para>Respiratory status: rate, rhythm, increase in bronchial secretions, wheezing, chest tightness</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17045">
								<item>
									<label>•</label>
									<para>Cardiac status: palpitations, increased pulse, hypo/hypertension, B/P in those receiving IV doses</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17053">
							<label>•</label>
							<sec_title>Neuroleptic malignant syndrome<route> fever, confusion, diaphoresis, rigid muscles, elevated CPK, encephalopathy; discontinue product, notify prescriber</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x17056">
								<item>
									<label>•</label>
									<para>Hard candy, gum, frequent rinsing of mouth for dryness</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17061">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17065">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of running, congested nose; rashes; absence of motion sickness, nausea; sedation</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17071">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17075">
								<item>
									<label>•</label>
									<para>That product may cause photosensitivity; to avoid prolonged exposure to sunlight</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber of confusion, sedation, hypotension, jaundice, fever</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activity if drowsy</para>
								</item>
								<item>
									<label>•</label>
									<para>To avoid concurrent use of alcohol or other CNS depressants</para>
								</item>
								<item>
									<label>•</label>
									<para>That product may reduce sweating; that there is a risk of heat stroke</para>
								</item>
								<item>
									<label>•</label>
									<para>How to use frequent sips of water, gum to decrease dry mouth</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="49" status="active" ha="yes">
			<mono_name> propafenone (Rx)</mono_name>
			<info>
				<pronunciation>(pro-paff′e-nown)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x171131">Rythmol</tradename>
					<tradename id="tnidelem4x171130">Rythmol SR</tradename>
				</tradenames>
				<class type="func"> Antidysrhythmic (class IC)</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x17119">
				<sec_title>Action:</sec_title>
				<para>Slows conduction velocity; reduces membrane responsiveness; inhibits automaticity; increases ratio of effective refractory period to action potential duration; β-blocking activity</para>
			</section>
			<section type="uses" id="sidelem4x17124">
				<sec_title>Uses:</sec_title>
				<para>Sustained ventricular tachycardia, atrial fibrillation (single dose), paroxysmal supraventricular tachycardia (PSVT) prophylaxis, supraventricular dysrhythmias</para>
				<section type="none" id="sidelem4x17129">
					<section type="none" id="sidelem4x17130">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Wolff-Parkinson-White (WPW) syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17136">
				<sec_title>Contraindications:</sec_title>
				<para>2nd/3rd-degree AV block, right bundle branch block, cardiogenic shock, hypersensitivity, bradycardia, uncontrolled CHF, sick-sinus syndrome, marked hypotension, bronchospastic disorders, electrolyte imbalance, Brugada syndrome</para>
				<section type="none" id="sidelem4x17141">
					<section type="none" id="sidelem4x17142">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, CHF, hypo/hyperkalemia, nonallergic bronchospasm, renal/hepatic disease, hematologic disorders, myasthenia gravis, COPD</para>
						<para>
							<bbw>Recent MI, cardiac arrhythmias, QT prolongation, torsades de pointes</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17157">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17160">
					<section type="none" id="sidelem4x17161">
						<sec_title>PSVT</sec_title>
						<section type="none" id="sidelem4x17169">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17169">
									<item>
										<label>•</label>
										<para> 150 mg q8hr; allow 3-4 day interval before increasing dose, max 900 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17173">
						<sec_title>Atrial fibrillation</sec_title>
						<section type="none" id="sidelem4x17181">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17181">
									<item>
										<label>•</label>
										<para> 450 or 600 mg as single dose; SR 225 mg q12hr, may increase to 325 q12hr, max 425 mg q12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17185">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 150, 225, 300 mg; SR cap 225, 325, 425 mg</para>
					</section>
					<section type="none" id="sidelem4x17190">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x17195">
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew tabs; swallow whole</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17203">
							<label>•</label>
							<sec_title>
								<route>To hospitalized patients because heart monitoring is required</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17206">
								<item>
									<label>•</label>
									<para>After hypo/hyperkalemia is corrected</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17211">
								<item>
									<label>•</label>
									<para>With dosage adjustment q3-4days</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17216">
								<item>
									<label>•</label>
									<para>Without regard to meals</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17221">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17224">
					<section type="none" id="sidelem4x17225">
						<sec_title>CNS:</sec_title>
						<para> Headache, dizziness, abnormal dreams, syncope, confusion, <emphasis style="bold">seizures,</emphasis> insomnia, tremor, anxiety, fatigue</para>
					</section>
					<section type="none" id="sidelem4x17233">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Supraventricular dysrhythmia, ventricular dysrhythmia, bradycardia,</emphasis> prodysrhythmia, palpitations, AV block, intraventricular conduction delay, AV dissociation, hypotension, chest pain, <emphasis style="bold">asystole</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17243">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, altered taste, tinnitus</para>
					</section>
					<section type="none" id="sidelem4x17248">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting,</emphasis> constipation, dyspepsia, cholestasis, abnormal hepatic studies, dry mouth, diarrhea, anorexia</para>
					</section>
					<section type="none" id="sidelem4x17256">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, agranulocytosis, granulocytopenia, thrombocytopenia,</emphasis> anemia, bruising</para>
					</section>
					<section type="none" id="sidelem4x17264">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x17269">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17274">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Peak 3-8 hr, half-life 2-10 hr, poor metabolizers 10-32 hr; metabolized in liver; excreted in urine (metabolite)</para>
			</section>
			<section type="interactions" id="sidelem4x17279">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> propafenone effects—CYP1A2, CYP2D6, CYP3A4 inhibitors (protease inhibitors, quiNINE, PARoxetine, saquinavir, erythromycin, azole antifungals, sertraline, tricyclics)</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—other class IA/IC antidysrhythmics, arsenic trioxide, chloroquine, clarithromycin, droperidol, erythromycin, haloperidol, levomethadyl, methadone, pentamidine, chlorproMAZINE, mesoridazine, thioridazine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> anticoagulation—warfarin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS effects—local anesthetics</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> digoxin level—digoxin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> β-blocker effect—propranolol, metoprolol</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cycloSPORINE levels—cycloSPORINE</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> propafenone effect—rifampin, cimetidine, quiNIDine</para>
				<section type="none" id="sidelem4x17313">
					<section type="none" id="sidelem4x17314">
						<sec_title>Drug/Food</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> propafenone effect—grapefruit juice</para>
					</section>
					<section type="none" id="sidelem4x17321">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> propafenone effect—St. John’s wort</para>
					</section>
					<section type="none" id="sidelem4x17328">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> CPK</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17335">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17338">
					<section type="none" id="sidelem4x17339">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x17347">
							<para>
								<list id="lidelem4x17347">
									<item>
										<label>•</label>
										<para>GI status: bowel pattern, number of stools
<bbw>
												<emphasis alert="lifethreat">QT/PR prolongation:</emphasis> ECG or Holter monitor before and during therapy</bbw>

<bbw>
												<emphasis alert="lifethreat">CHF:</emphasis> dyspnea, jugular venous distention, crackles, edema in extremities, I&amp;O ratio; check for decreasing output; daily weight</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17372">
								<item>
									<label>•</label>
									<para>CBC, ANA titer, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17377">
								<item>
									<label>•</label>
									<para>Chest x-ray, pulmonary function test during treatment</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17382">
								<item>
									<label>•</label>
									<para>Lung fields; bilateral crackles, dyspnea, peripheral edema, weight gain; jugular venous distention may occur in patient with CHF</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17388">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: fine tremors, dizziness, hypotension, drowsiness, abnormal heart rate</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17393">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17397">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of ventricular dysrhythmias; decreasing recurrence of PAF, PSVT</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17403">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17408">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities until response is known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17416">
							<label>•</label>
							<sec_title>
								<route>To report fever, chills, sore throat, bleeding, SOB, chest pain, palpitations, blurred vision</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x17419">
								<item>
									<label>•</label>
									<para>To take tab with food, not to use with grapefruit juice or St. John’s wort</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17424">
								<item>
									<label>•</label>
									<para>To carry emergency ID identifying medication and prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17429">
								<item>
									<label>•</label>
									<para>To avoid abrupt discontinuation of product; to take as prescribed; not to miss, double doses</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="50" status="active">
			<mono_name>proparacaine ophthalmic</mono_name>
			<section type="none" id="sidelem4x17445">
				<para>See <see refid="tra">Appendix B</see></para>
			</section>
		</monograph>
<monograph id="51" status="active" ha="yes">
			<mono_name> propofol (Rx)</mono_name>
			<info>
				<pronunciation>(pro′poh-fole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x174560">Diprivan</tradename>
				</tradenames>
				<class type="func"> Hypnotic</class>
				<class type="chem"> Phenol derivative</class>
				<class type="preg">Pregnancy category <preg cat="B">B</preg></class>
			</info>
			<section type="actions" id="sidelem4x17466">
				<sec_title>Action:</sec_title>
				<para>Produces dose-dependent CNS depression by activation of GABA receptor</para>
			</section>
			<section type="uses" id="sidelem4x17471">
				<sec_title>Uses:</sec_title>
				<para>Induction or maintenance of anesthesia as part of balanced anesthetic technique; sedation in mechanically ventilated patients</para>
			</section>
			<section type="contra" id="sidelem4x17476">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product or soybean oil, egg, benzyl alcohol (some products)</para>
				<section type="none" id="sidelem4x17481">
					<section type="none" id="sidelem4x17482">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="B">B</preg>), breastfeeding, children, geriatric patients, respiratory depression, severe respiratory disorders, cardiac dysrhythmias, labor and delivery, renal disease, hyperlipidemia</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17487">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17490">
					<section type="none" id="sidelem4x17491">
						<sec_title>Anesthesia</sec_title>
						<section type="none" id="sidelem4x17499">
							<label>•</label>
							<sec_title>Adult &lt;55 yr and ASA I/II IV (Diprivan or generic)<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17499">
									<item>
										<label>•</label>
										<para> 40 mg q10sec until induction onset, maintenance 100-200 mcg/kg/min or  20-50 mg prn, allow 3-5 min between adjustments; Fresenius Propoven 1%  20-40 mg q10sec until induction, then 3-6 mg/kg/hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17512">
							<label>•</label>
							<sec_title>Child ≥3 yr or ASA I or II<route> IV induction</route></sec_title>
							<para>
								<list id="lidelem4x17512">
									<item>
										<label>•</label>
										<para> 2.5-3.5 mg/kg over 20-30 sec when not premedicated or lightly premedicated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17519">
							<label>•</label>
							<sec_title>Child 2 mo-16 yr maintenance<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17519">
									<item>
										<label>•</label>
										<para> 125-300 mcg/kg/min, lower dose for ASA III or </para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17525">
						<sec_title>ICU sedation</sec_title>
						<section type="none" id="sidelem4x17533">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x17533">
									<item>
										<label>•</label>
										<para> 5 mcg/kg/min over 5 min; may increase by 5-10 mcg/kg/min over 5-10 min until desired response (Diprivan or generic): 0.3-4 mg/kg/hr, max 4 mg/kg/hr (Fresenius Propoven)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17537">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml in 20-ml ampule, vials, syringes</para>
					</section>
					<section type="none" id="sidelem4x17543">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x17546">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x17550">
									<item>
										<label>•</label>
										<para>Shake well before use; dilution is not necessary but, if diluted, use only D<emphasis style="inf">5</emphasis>W to ≥2 mg/ml; give over 3-5 min, titrate to needed level of sedation; use only glass containers when mixing, not stable in plastic; use aseptic technique when transferring from original container</para>
									</item>
									<item>
										<label>•</label>
										<para>Only with resuscitative equipment available; only by qualified persons trained in anesthesia</para>
									</item>
									<item>
										<label>•</label>
										<para>Store in light-resistant area at room temperature, use within 6 hr of opening</para>
									</item>
									<item>
										<label>•</label>
										<para>If transferred from original container to another container, complete infusion within 12 hr (Diprivan), 6 hr (generic propofol)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, aminophylline, ampicillin, aztreonam, bumetanide, buprenorphine, butorphanol, calcium gluconate, CARBOplatin, ceFAZolin, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, ceftizoxime, cefTRIAXone, cefuroxime, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyclophosphamide, cycloSPORINE, cytarabine, dexamethasone, diphenhydrAMINE, DOBUTamine, DOPamine, doxycycline, droperidol, enalaprilat, ePHEDrine, EPINEPHrine, esmolol, famotidine, fentaNYL, fluconazole, fluorouracil, furosemide, ganciclovir, glycopyrrolate, granisetron, haloperidol, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, ifosfamide, imipenem/cilastatin, inamrinone, regular insulin, isoproterenol, ketamine, labetalol, levorphanol, lidocaine, LORazepam, magnesium sulfate, mannitol, meperidine, mezlocillin, miconazole, morphine, nafcillin, nalbuphine, naloxone, nitroglycerin, norepinephrine, ofloxacin, PACLitaxel, PENTobarbital, PHENobarbital, piperacillin, potassium chloride, prochlorperazine, propranolol, ranitidine, scopolamine, sodium bicarbonate, sodium nitroprusside, succinylcholine, SUFentanil, thiopental ticarcillin, ticarcillin/clavulanate, vecuronium, verapamil</para>
							<para>
								<emphasis style="bold">Solution compatibilities:</emphasis> if given together via <emphasis style="sans-serif">Y</emphasis>-site: D<emphasis style="inf">5</emphasis>W, D<emphasis style="inf">5</emphasis>LR, LR, D<emphasis style="inf">5</emphasis>/0.45% NaCl, D<emphasis style="inf">5</emphasis>/0.2% NaCl</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x17597">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x17600">
					<section type="none" id="sidelem4x17601">
						<sec_title>CNS:</sec_title>
						<para> Involuntary movement, headache, jerking, fever, dizziness, shivering, tremor, confusion, somnolence, paresthesia, agitation, abnormal dreams, euphoria fatigue, <emphasis style="bold">increased intracranial pressure, impaired cerebral flow, seizures</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17608">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Bradycardia, hypotension,</emphasis> hypertension, PVC, PAC, tachycardia, abnormal ECG, ST segment depression, <emphasis style="bold">asystole, bradydysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17618">
						<sec_title>EENT:</sec_title>
						<para> Blurred vision, tinnitus, eye pain, strange taste, diplopia</para>
					</section>
					<section type="none" id="sidelem4x17623">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, abdominal cramping,</emphasis> dry mouth, swallowing, hypersalivation, <emphasis style="bold">pancreatitis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x17633">
						<sec_title>GU:</sec_title>
						<para> Urine retention, green urine, cloudy urine, oliguria</para>
					</section>
					<section type="none" id="sidelem4x17638">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Flushing, phlebitis, hives, burning/stinging at inj site,</emphasis> rash, pain of extremities</para>
					</section>
					<section type="none" id="sidelem4x17646">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x17651">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Apnea,</emphasis><emphasis style="italic">cough, hiccups,</emphasis> dyspnea, hypoventilation, sneezing, wheezing, tachypnea, hypoxia, respiratory acidosis</para>
					</section>
					<section type="none" id="sidelem4x17661">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Propofol infusion syndrome</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x17668">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 15-30 sec, rapid distribution, half-life 1-8 min, terminal half-life 3-12 hr; 70% excreted in urine; metabolized in liver by conjugation to inactive metabolites, 95%-99% protein binding</para>
			</section>
			<section type="interactions" id="sidelem4x17673">
				<sec_title>Interactions</sec_title>
				<section type="none" id="sidelem4x17681">
					<label>•</label>
					<sec_title>
						<route>Do not use within 10 days of MAOIs</route>
					</sec_title>
				</section>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants, inhalational anesthetics</para>
				<section type="none" id="sidelem4x17688">
					<section type="none" id="sidelem4x17689">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> propofol effect—St. John’s wort</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x17696">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x17699">
					<section type="none" id="sidelem4x17700">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x17705">
								<item>
									<label>•</label>
									<para>Inj site: phlebitis, burning, stinging</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17714">
							<label>•</label>
							<sec_title>ECG for changes<route> PVC, PAC, ST segment changes; monitor VS</route></sec_title>
						</section>
						<section type="none" id="sidelem4x17720">
							<label>•</label>
							<sec_title>Neurologic excitatory symptoms</sec_title>
							<para>
								<list id="lidelem4x17720">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Neurologic excitatory symptoms:</emphasis> movement, tremors, dizziness, LOC, pupil reaction</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x17724">
								<item>
									<label>•</label>
									<para>Allergic reactions: hives</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x17730">
								<item>
									<para>
										<emphasis alert="nurse">Respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are &lt;10/min</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x17738">
							<label>•</label>
							<sec_title>Propofol infusion syndrome<route> rhabdomyolysis, renal failure, hyperkalemia, metabolic acidosis, cardiac dysrhythmias, heart failure usually between 35 and 93 hr after infusion begun at &gt;5 mg/kg/hr for &gt;58 hr</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x17741">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x17745">
								<item>
									<label>•</label>
									<para>Therapeutic response: induction of anesthesia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x17751">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x17755">
								<item>
									<label>•</label>
									<para>That product will cause dizziness, drowsiness, sedation; to avoid hazardous activities until drug effect wears off</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="52" status="active" ha="yes">
			<mono_name> propranolol (Rx)</mono_name>
			<info>
				<pronunciation>(proe-pran′oh-lole)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x177732">Inderal</tradename>
					<tradename id="tnidelem4x177731">Inderal LA</tradename>
					<tradename id="tnidelem4x177730">InnoPran XL</tradename>
				</tradenames>
				<class type="func"> Antihypertensive, antianginal, antidysrhythmic (class II)</class>
				<class type="chem"> β-Adrenergic blocker</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x17783">
				<para>
					<confusion>
						<tradename id="tnidelem4x177830">propranolol</tradename>
						<drug type="generic" refid="idelem4x177830">Pravachol</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x17790">
				<sec_title>Action:</sec_title>
				<para>Nonselective β-blocker with negative inotropic, chronotropic, dromotropic properties</para>
			</section>
			<section type="uses" id="sidelem4x17795">
				<sec_title>Uses:</sec_title>
				<para>Chronic stable angina pectoris, hypertension, supraventricular dysrhythmias, migraine prophylaxis, pheochromocytoma, cyanotic spells related to hypertrophic subaortic stenosis, essential tremor, acute MI</para>
				<section type="none" id="sidelem4x17800">
					<section type="none" id="sidelem4x17801">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Anxiety, prevention of variceal bleeding caused by portal hypertension, akathisia induced by antipsychotics, portal hypertension, sclerodermal renal crisis, unstable angina, infantile capillary hemangioma, lithium-induced tremor</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x17806">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to this product; cardiogenic shock, AV heart block; bronchospastic disease; sinus bradycardia; bronchospasm; asthma</para>
				<section type="none" id="sidelem4x17811">
					<section type="none" id="sidelem4x17812">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, diabetes mellitus, hyperthyroidism, COPD, renal/hepatic disease, myasthenia gravis, peripheral vascular disease, hypotension, cardiac failure, Raynaud’s disease, sick sinus syndrome, vasospastic angina, smoking, Wolff-Parkinson-White syndrome, thyrotoxicosis</para>
						<para>
							<bbw>Abrupt discontinuation</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x17827">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x17830">
					<section type="none" id="sidelem4x17831">
						<sec_title>Dysrhythmias</sec_title>
						<section type="none" id="sidelem4x17839">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17839">
									<item>
										<label>•</label>
										<para> 10-30 mg tid-qid;  1-3 mg give 1 mg/min; may repeat after 2 min, may repeat q4hr thereafter</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17849">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17849">
									<item>
										<label>•</label>
										<para> 1 mg/kg/day in 2 divided doses;  0.01-0.1 mg/kg over 5 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17856">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x17864">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17864">
									<item>
										<label>•</label>
										<para> 40 mg bid or 80 mg/day (ext rel) initially; usual dose 120-240 mg/day bid-tid or 120-160 mg/day (ext rel)</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17871">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17871">
									<item>
										<label>•</label>
										<para> 0.5-1 mg/kg/day divided q6-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17875">
						<sec_title>Angina</sec_title>
						<section type="none" id="sidelem4x17883">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17883">
									<item>
										<label>•</label>
										<para> 10-20 mg bid-qid, increase at 3-7 day intervals up to 160-320 mg/day or 80 mg daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17887">
						<sec_title>MI prophylaxis</sec_title>
						<section type="none" id="sidelem4x17895">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17895">
									<item>
										<label>•</label>
										<para> 180-240 mg/day tid-qid starting 5 days to 2 wk after MI</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17900">
						<sec_title>Pheochromocytoma</sec_title>
						<section type="none" id="sidelem4x17908">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17908">
									<item>
										<label>•</label>
										<para> 60 mg/day × 3 days preoperatively in divided doses or 30 mg/day in divided doses (inoperable tumor)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17912">
						<sec_title>Migraine</sec_title>
						<section type="none" id="sidelem4x17920">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17920">
									<item>
										<label>•</label>
										<para> 80 mg/day (ext rel) or in divided doses; may increase to 160-240 mg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17927">
							<label>•</label>
							<sec_title>Child &gt;35 kg (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17927">
									<item>
										<label>•</label>
										<para> 20-40 mg tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x17934">
							<label>•</label>
							<sec_title>Child ≤35 kg (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17934">
									<item>
										<label>•</label>
										<para> 10-20 mg tid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17938">
						<sec_title>Essential tremor</sec_title>
						<section type="none" id="sidelem4x17946">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17946">
									<item>
										<label>•</label>
										<para> 40 mg bid; usual dose 120 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17950">
						<sec_title>Acute MI</sec_title>
						<section type="none" id="sidelem4x17958">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17958">
									<item>
										<label>•</label>
										<para> 180-320 mg/day in 3-4 divided doses; IV 0.1 mg/kg in 3 divided doses at 2-3 min intervals</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17962">
						<sec_title>Anxiety (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17970">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17970">
									<item>
										<label>•</label>
										<para> 10-80 mg given 1 hr before anxiety-producing event</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17974">
						<sec_title>Scleroderma renal crisis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17982">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17982">
									<item>
										<label>•</label>
										<para> 40 mg bid, may increase q3-7days, max 160-480 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17986">
						<sec_title>Esophageal varices (portal hypertension) (unlabeled)</sec_title>
						<section type="none" id="sidelem4x17994">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x17994">
									<item>
										<label>•</label>
										<para> 40 mg bid, titrate to heart rate reduction of 25%</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x17998">
						<sec_title>Infantile capillary hemangioma (unlabeled)</sec_title>
						<section type="none" id="sidelem4x18006">
							<label>•</label>
							<sec_title>Infant<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18006">
									<item>
										<label>•</label>
										<para> 2-3 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18010">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel caps 60, 80, 120, 160 mg; tabs 10, 20, 40, 60, 80, 90 mg; inj 1 mg/ml; oral sol 4 mg/ml, 8 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x18015">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x18018">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x18022">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew, or open ext rel cap</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not use ext rel cap for essential tremor, MI, cardiac dysrhythmias; do not use InnoPran XL in hypertropic subaortic stenosis, migraine, angina pectoris</para>
									</item>
									<item>
										<label>•</label>
										<para>Ext rel caps should be taken daily; InnoPran XL should be taken at bedtime</para>
									</item>
									<item>
										<label>•</label>
										<para>May mix oral sol with liquid or semisolid food; rinse container to get entire dose</para>
									</item>
									<item>
										<label>•</label>
										<para>With 8 oz water with food; food enhances bioavailability</para>
									</item>
									<item>
										<label>•</label>
										<para>Do not give with aluminum-containing antacid; may decrease GI absorption</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18053">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x18057">
									<item>
										<label>•</label>
										<para>IV undiluted or diluted 10 ml D<emphasis style="inf">5</emphasis>W for inj; give ≤1 mg/min</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18066">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x18070">
									<item>
										<label>•</label>
										<para>May be diluted in 50 ml NaCl and run 1 mg over 10-15 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Acyclovir, alfentanil, alteplase, amikacin, aminocaproic acid, aminophylline, anidulafungin, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bivalirudin, bleomycin, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, CARBOplatin, carmustine, caspofungin, cefamandole, ceFAZolin, cefmetazole, cefonicid, cefoperazone, cefotaxime, cefoTEtan, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cephalothin, cephapirin, chloramphenicol, chlorproMAZINE, cimetidine, CISplatin, clindamycin, cyanocobalamin, cyclophosphamide, cycloSPORINE, cytarabine, DACTINomycin, DAPTOmycin, dexamethasone, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxacurium, DOXOrubicin, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epirubicin, epoetin alfa, eptifibatide, ertapenem, erythromycin, esmolol, etoposide, etoposide phosphate, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, fluorouracil, folic acid, furosemide, ganciclovir, gatifloxacin, gemcitabine, gemtuzumab, gentamicin, glycopyrrolate, granisetron, heparin, hydrocortisone, HYDROmorphone, hydrOXYzine, IDArubicin, ifosfamide, imipenem-cilastatin, inamrinone, irinotecan, isoproterenol, ketorolac, labetalol, levofloxacin, lidocaine, linezolid, LORazepam, magnesium, mannitol, mechlorethamine, meperidine, metaraminol, methicillin, methotrexate, methoxamine, methyldopate, methylPREDNISolone, metoclopramide, metoprolol, metroNIDAZOLE, mezlocillin, miconazole, midazolam, milrinone, minocycline, mitoXANtrone, morphine, moxalactam, multiple vitamins, mycophenolate, nafcillin, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, nitroprusside, norepinephrine, octreotide, ondansetron, oxacillin, oxaliplatin, oxytocin, palonosetron, pamidronate, pancuronium, papaverine, PEMEtrexed, penicillin G potassium/sodium, pentamidine, pentazocine, PENTobarbital, PHENobarbital, phenylephrine, phytonadione, piperacillin, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propofol, protamine, pyridoxine, quiNIDine, quinupristin-dalfopristin, ranitidine, ritodrine, rocuronium, sodium acetate/bicarbonate, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, ticarcillin, ticarcillin-clavulanate, tigecycline, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, vecuronium, verapamil, vinCRIStine, vinorelbine, vitamin B complex/C, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18082">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18085">
					<section type="none" id="sidelem4x18086">
						<sec_title>CNS:</sec_title>
						<para> Depression, hallucinations, <emphasis style="italic">dizziness, fatigue,</emphasis> lethargy, paresthesias, bizarre dreams, disorientation</para>
					</section>
					<section type="none" id="sidelem4x18094">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Bradycardia,</emphasis> hypotension, <emphasis style="bold">CHF,</emphasis> palpitations, AV block, peripheral vascular insufficiency, vasodilation, cold extremities, <emphasis style="bold">pulmonary edema, dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18107">
						<sec_title>EENT:</sec_title>
						<para> Sore throat, <emphasis style="bold">laryngospasm,</emphasis> blurred vision, dry eyes</para>
					</section>
					<section type="none" id="sidelem4x18115">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, diarrhea, colitis, constipation, cramps, dry mouth, hepatomegaly, gastric pain, acute pancreatitis</para>
					</section>
					<section type="none" id="sidelem4x18120">
						<sec_title>GU:</sec_title>
						<para> Impotence, decreased libido, UTIs</para>
					</section>
					<section type="none" id="sidelem4x18125">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, thrombocytopenia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18132">
						<sec_title>INTEG:</sec_title>
						<para> Rash, pruritus, fever, <emphasis style="bold">Stevens-Johnson syndrome, toxic epidermal necrolysis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18139">
						<sec_title>META:</sec_title>
						<para> Hyperglycemia, hypoglycemia</para>
					</section>
					<section type="none" id="sidelem4x18144">
						<sec_title>MISC:</sec_title>
						<para> Facial swelling, weight change, Raynaud’s phenomenon</para>
					</section>
					<section type="none" id="sidelem4x18149">
						<sec_title>MS:</sec_title>
						<para> Joint pain, arthralgia, muscle cramps, pain</para>
					</section>
					<section type="none" id="sidelem4x18154">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, respiratory dysfunction, <emphasis style="italic">bronchospasm,</emphasis> cough</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18162">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized by liver; crosses placenta, blood-brain barrier; excreted in breast milk; protein binding 90%</para>
				<section type="none" id="sidelem4x18167">
					<section type="none" id="sidelem4x18168">
						<sec_title>PO:</sec_title>
						<para> Onset 30 min, peak 1-1<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis> hr, duration 12 hr, half-life 3-8 hr</para>
					</section>
					<section type="none" id="sidelem4x18179">
						<sec_title>PO-ER:</sec_title>
						<para> Peak 6 hr, duration 24 hr, half-life 8-11 hr</para>
					</section>
					<section type="none" id="sidelem4x18184">
						<sec_title>IV:</sec_title>
						<para> Onset 2 min, peak 1 min, duration 2-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x18189">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="lifethreat">Increase:</emphasis>
					<emphasis alert="lifethreat">toxicity—phenothiazines</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> propranolol level—propafenone</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of calcium channel blockers, neuromuscular blocker</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> negative inotropic effects—disopyramide</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> β-blocking effect—cimetidine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—quiNIDine, haloperidol, prazosin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> β-blocking effects—barbiturates</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> propranolol levels—smoking</para>
				<section type="none" id="sidelem4x18225">
					<section type="none" id="sidelem4x18226">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x18230">
								<item>
									<label>•</label>
									<para>Avoid use with feverfew</para>
								</item>
							</list>
						</para>
						<para>
							<emphasis style="bold">Increase:</emphasis> antihypertensive effect—hawthorn</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ma huang</para>
					</section>
					<section type="none" id="sidelem4x18244">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> serum potassium, serum uric acid, ALT, AST, alk phos, LDH</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> blood glucose</para>
						<para>
							<emphasis style="bold">Interference:</emphasis> glaucoma testing</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18259">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18262">
					<section type="none" id="sidelem4x18263">
						<sec_title>Assess:</sec_title>
						<para>
							<bbw>
								<emphasis alert="lifethreat">Abrupt withdrawal:</emphasis> taper over a few weeks, do not discontinue abruptly; dysrhythmias, angina, myocardial ischemia, or MI may occur, taper over at least a few weeks</bbw>
						</para>
						<para>
							<list id="lidelem4x18279">
								<item>
									<label>•</label>
									<para>B/P, pulse, respirations during beginning therapy; notify prescriber if pulse &lt;50 bpm or systolic B/P &lt;90 mm Hg</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18286">
								<item>
									<para>
										<emphasis alert="nurse">ECG continuously if using as antidysrhythmic IV, PCWP (pulmonary capillary wedge pressure), CVP (central venous pressure)</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18291">
								<item>
									<label>•</label>
									<para>Hepatic enzymes: AST, ALT, bilirubin; blood glucose (diabetes mellitus)</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18296">
								<item>
									<label>•</label>
									<para>Angina pain: duration, time started, activity being performed, character</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18301">
								<item>
									<label>•</label>
									<para>Tolerance with long-term use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18306">
								<item>
									<label>•</label>
									<para>Headache, lightheadedness, decreased B/P; may indicate need for decreased dosage; may aggravate symptoms of arterial insufficiency</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18314">
							<label>•</label>
							<sec_title>Fluid overload</sec_title>
							<para>
								<list id="lidelem4x18314">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Fluid overload:</emphasis> weight daily; report gain of &gt;5 lb</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18319">
								<item>
									<para>
										<emphasis alert="nurse">I&amp;O ratio, CCr if kidney damage is diagnosed; fatigue, weight gain, jugular distention, dyspnea, peripheral edema, crackles</emphasis>
									</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18324">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18328">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased B/P, dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18334">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18340">
								<item>
									<para>
										<emphasis alert="nurse">Not to discontinue abruptly; may precipitate life-threatening dysrhythmias, exacerbation of angina, MI; to take product at same time each day, either with or without food consistently; to decrease dosage over 2 wk</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18345">
								<item>
									<label>•</label>
									<para>To avoid OTC products unless approved by prescriber; to avoid alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18350">
								<item>
									<label>•</label>
									<para>To avoid hazardous activities if dizzy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18355">
								<item>
									<label>•</label>
									<para>About the importance of compliance with complete medical regimen; to monitor blood glucose, may mask symptoms of hypoglycemia</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18360">
								<item>
									<label>•</label>
									<para>To make position changes slowly to prevent fainting</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18365">
								<item>
									<label>•</label>
									<para>That sensitivity to cold may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18370">
								<item>
									<label>•</label>
									<para>How to take pulse, B/P; to withhold product if &lt;50 bpm or systolic B/P &lt;90 mm Hg</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="53" status="active" ha="yes">
			<mono_name> propylthiouracil (Rx)</mono_name>
			<info>
				<pronunciation>(proe-pill-thye-oh-yoor′a-sill)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x183820">
						<country code="CAN">Propyl-Thyracil </country>
					</tradename>
				</tradenames>
				<class type="func"> Thyroid hormone antagonist (antithyroid)</class>
				<class type="chem"> Thioamide</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="actions" id="sidelem4x18394">
				<sec_title>Action:</sec_title>
				<para>Blocks synthesis peripherally of T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis> (triiodothyronine, thyroxine), inhibits organification of iodine</para>
			</section>
			<section type="uses" id="sidelem4x18405">
				<sec_title>Uses:</sec_title>
				<para>Preparation for thyroidectomy, thyrotoxic crisis, hyperthyroidism, thyroid storm</para>
			</section>
			<section type="contra" id="sidelem4x18410">
				<sec_title>Contraindications:</sec_title>
				<para>Pregnancy (<preg cat="D">D</preg>), breastfeeding, hypersensitivity, agranulocytosis, hepatitis, jaundice</para>
				<section type="none" id="sidelem4x18415">
					<section type="none" id="sidelem4x18416">
						<sec_title>Precautions:</sec_title>
						<para> Infants, bone marrow depression, fever</para>
						<para>
							<bbw>Hepatic disease</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18431">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18434">
					<section type="none" id="sidelem4x18435">
						<sec_title>Thyrotoxic crisis</sec_title>
						<section type="none" id="sidelem4x18443">
							<label>•</label>
							<sec_title>Adult and child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18443">
									<item>
										<label>•</label>
										<para> 200-400 mg q4hr for 1st 24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18447">
						<sec_title>Preparation for thyroidectomy</sec_title>
						<section type="none" id="sidelem4x18455">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18455">
									<item>
										<label>•</label>
										<para> 600-1200 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18462">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18462">
									<item>
										<label>•</label>
										<para> 10 mg/kg/day in divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18466">
						<sec_title>Hyperthyroidism</sec_title>
						<section type="none" id="sidelem4x18474">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18474">
									<item>
										<label>•</label>
										<para> 100 mg tid increasing to 300 mg q8hr if condition is severe; continue to euthyroid state, then 100 mg daily tid</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18481">
							<label>•</label>
							<sec_title>Child &gt;6 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18481">
									<item>
										<label>•</label>
										<para> 50 mg/day divided q8hr, titrate based on TSH/free T<emphasis style="inf">4</emphasis> levels</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x18491">
							<label>•</label>
							<sec_title>Neonate (unlabeled)<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x18491">
									<item>
										<label>•</label>
										<para> 5-10 mg/kg/day in divided doses q8hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18495">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 50 mg</para>
					</section>
					<section type="none" id="sidelem4x18500">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18504">
								<item>
									<label>•</label>
									<para>With meals to decrease GI upset</para>
								</item>
								<item>
									<label>•</label>
									<para>At same time each day to maintain product level</para>
								</item>
								<item>
									<label>•</label>
									<para>At lowest dose that relieves symptoms</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18521">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18524">
					<section type="none" id="sidelem4x18525">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Drowsiness, headache, vertigo, fever,</emphasis> paresthesias, neuritis</para>
					</section>
					<section type="none" id="sidelem4x18533">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting,</emphasis><emphasis style="bold">jaundice, hepatitis,</emphasis> loss of taste, <emphasis style="bold">liver failure, death</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18545">
						<sec_title>GU:</sec_title>
						<para> <emphasis style="bold">Nephritis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x18552">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Agranulocytosis, leukopenia, thrombocytopenia, hypothrombinemia, lymphadenopathy,</emphasis> bleeding, vasculitis, periarteritis</para>
					</section>
					<section type="none" id="sidelem4x18560">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash, urticaria, pruritus, alopecia, hyperpigmentation,</emphasis> lupuslike syndrome</para>
					</section>
					<section type="none" id="sidelem4x18568">
						<sec_title>MS:</sec_title>
						<para> Myalgia, arthralgia, nocturnal muscle cramps, osteoporosis</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18573">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset up to 3 wk, peak 6-10 wk, duration 1 wk to 1 mo, half-life 1-2 hr; excreted in urine, bile, breast milk; crosses placenta; concentration in thyroid gland</para>
			</section>
			<section type="interactions" id="sidelem4x18578">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x18582">
						<item>
							<label>•</label>
							<para>Bone marrow suppression: radiation, antineoplastics</para>
						</item>
						<item>
							<label>•</label>
							<para>Agranulocytosis: phenothiazines</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects—potassium/sodium iodide, lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> anticoagulant effect—heparin, oral anticoagulants</para>
				<section type="none" id="sidelem4x18601">
					<section type="none" id="sidelem4x18602">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> PT, AST, ALT, alk phos</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18609">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18612">
					<section type="none" id="sidelem4x18613">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x18621">
							<label>•</label>
							<sec_title>Hyperthyroidism</sec_title>
							<para>
								<list id="lidelem4x18621">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperthyroidism:</emphasis> weight loss, nervousness, insomnia, fever, diaphoresis, tremors; <emphasis style="bold">hypothyroidism:</emphasis> constipation, dry skin, weakness, headache; monitor T<emphasis style="inf">3</emphasis>, T<emphasis style="inf">4</emphasis>, which are increased; serum TSH, which is decreased; free thyroxine index, which is increased if dosage is too low; discontinue product 3-4 wk before RAIU</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18634">
								<item>
									<label>•</label>
									<para>Pulse, B/P, temperature</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18639">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for edema: puffy hands, feet, periorbits; indicates hypothyroidism</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18644">
								<item>
									<label>•</label>
									<para>Weight daily; same clothing, scale, time of day</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18650">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: CBC with differential; leukopenia, thrombocytopenia, agranulocytosis</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18656">
								<item>
									<para>
										<emphasis alert="nurse">Overdose: peripheral edema, heat intolerance, diaphoresis, palpitations, dysrhythmias, severe tachycardia, increased temperature, delirium, CNS irritability</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18662">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity: rash, enlarged cervical lymph nodes; product may have to be discontinued</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18670">
							<label>•</label>
							<sec_title>Hypoprothrombinemia</sec_title>
							<para>
								<list id="lidelem4x18670">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypoprothrombinemia:</emphasis> bleeding, petechiae, ecchymosis</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18674">
								<item>
									<label>•</label>
									<para>Clinical response: after 3 wk should include increased weight, pulse; decreased T<emphasis style="inf">4</emphasis></para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18684">
							<label>•</label>
							<sec_title>Bone marrow suppression</sec_title>
							<para>
								<list id="lidelem4x18684">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Bone marrow suppression:</emphasis> sore throat, fever, fatigue
<bbw>
												<emphasis alert="lifethreat">Hepatotoxicity:</emphasis> LFTs before, during treatment; jaundice, nausea, vomiting, abdominal pain, anorexia, diarrhea, fatigue</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x18699">
								<item>
									<label>•</label>
									<para>Fluids to 3-4 L/day unless contraindicated</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18704">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18708">
								<item>
									<label>•</label>
									<para>Therapeutic response: weight gain, decreased pulse, decreased T<emphasis style="inf">4</emphasis>, decreased B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18717">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x18722">
								<item>
									<label>•</label>
									<para>To abstain from breastfeeding after delivery</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18727">
								<item>
									<label>•</label>
									<para>To take pulse daily</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18735">
							<label>•</label>
							<sec_title>
								<route>To report redness, swelling, sore throat, mouth lesions, which indicate blood dyscrasias; to report symptoms of hepatic dysfunction</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x18738">
								<item>
									<label>•</label>
									<para>To keep graph of weight, pulse, mood</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18743">
								<item>
									<label>•</label>
									<para>To avoid OTC products that contain iodine</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18748">
								<item>
									<label>•</label>
									<para>That seafood, other iodine products may be restricted</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18753">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly because thyroid crisis may occur; about stress response</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18758">
								<item>
									<label>•</label>
									<para>That response may take several months if thyroid is large</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18767">
							<label>•</label>
							<sec_title>About the symptoms/signs of overdose<route> periorbital edema, cold intolerance, mental depression</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x18770">
								<item>
									<label>•</label>
									<para>About the symptoms of an inadequate dose: tachycardia, diarrhea, fever, irritability</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18775">
								<item>
									<label>•</label>
									<para>To take medication as prescribed; not to skip or double dose; that missed doses should be taken when remembered up to 1 hr before next dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18780">
								<item>
									<label>•</label>
									<para>To carry emergency ID listing condition, medication</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="54" status="active">
			<mono_name>protamine (Rx)</mono_name>
			<info>
				<pronunciation>(proe′ta-meen)</pronunciation>
				<class type="func"> Heparin antagonist</class>
				<class type="chem"> Low-molecular-weight protein</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x18798">
				<sec_title>Action:</sec_title>
				<para>Binds heparin, thereby making it ineffective</para>
			</section>
			<section type="uses" id="sidelem4x18803">
				<sec_title>Uses:</sec_title>
				<para>Heparin, LMWH toxicity, hemorrhage</para>
			</section>
			<section type="contra" id="sidelem4x18808">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x18813">
					<section type="none" id="sidelem4x18814">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, fish allergy, diabetes, previous exposure to protamine, insulins, heparin rebound or bleeding</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x18819">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x18822">
					<section type="none" id="sidelem4x18823">
						<sec_title>Heparin overdose</sec_title>
						<section type="none" id="sidelem4x18831">
							<label>•</label>
							<sec_title>Adult and child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18831">
									<item>
										<label>•</label>
										<para> 1 mg of protamine/100 units heparin given; administer slowly over 1-3 min; max 50 mg/10 min</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18835">
						<sec_title>Enoxaparin overdose</sec_title>
						<section type="none" id="sidelem4x18843">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18843">
									<item>
										<label>•</label>
										<para> 1 mg protamine/1 mg enoxaparin</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18847">
						<sec_title>Dalteparin/tinzaparin overdose</sec_title>
						<section type="none" id="sidelem4x18855">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x18855">
									<item>
										<label>•</label>
										<para> 1 mg protamine/100 anti-Xa unit</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x18859">
						<sec_title>Available forms:</sec_title>
						<para> Inj 10 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x18864">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x18868">
								<item>
									<label>•</label>
									<para>Store at 36° F-46° F (2° C-8° C)</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x18874">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x18878">
									<item>
										<label>•</label>
										<para>After reconstituting 50 mg/5 ml sterile bacteriostatic water for inj; shake, give ≤20 mg over 1-3 min</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, aminophylline, ascorbic acid, atracurium, atropine, azaTHIOprine, aztreonam, benztropine, bumetanide, buprenorphine, butorphanol, calcium chloride/gluconate, cefTAZidime, chlorproMAZINE, cimetidine, clindamycin, cyanocobalamin, cycloSPORINE, digoxin, diphenhydrAMINE, DOBUTamine, DOPamine, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, erythromycin, esmolol, famotidine, fentaNYL, fluconazole, ganciclovir, gentamicin, glycopyrrolate, hydrOXYzine, imipenem-cilastatin, inamrinone, iohexol, iopamidol, iothalamate, isoproterenol, labetalol, lidocaine, magnesium, mannitol, meperidine, metaraminol, methoxamine, methyldopate, metoclopramide, metoprolol, miconazole, midazolam, minocycline, morphine, multiple vitamins, nalbuphine, naloxone, netilmicin, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxytocin, papaverine, pentazocine, phenylephrine, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, pyridoxine, quiNIDine, ranitidine, Ringer’s, ritodrine, sodium bicarbonate, succinylcholine, SUFentanil, theophylline, thiamine, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, verapamil</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x18888">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x18891">
					<section type="none" id="sidelem4x18892">
						<sec_title>CNS:</sec_title>
						<para> Lassitude, flushing</para>
					</section>
					<section type="none" id="sidelem4x18897">
						<sec_title>CV:</sec_title>
						<para> Hypotension, bradycardia, <emphasis style="bold">circulatory collapse,</emphasis> capillary leak</para>
					</section>
					<section type="none" id="sidelem4x18905">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia</para>
					</section>
					<section type="none" id="sidelem4x18910">
						<sec_title>HEMA:</sec_title>
						<para> Bleeding</para>
					</section>
					<section type="none" id="sidelem4x18915">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="italic">Rash,</emphasis> dermatitis, urticaria</para>
					</section>
					<section type="none" id="sidelem4x18923">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">pulmonary edema, severe respiratory distress,</emphasis> bronchospasm</para>
					</section>
					<section type="none" id="sidelem4x18931">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Anaphylaxis, angioedema</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x18938">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x18941">
					<section type="none" id="sidelem4x18942">
						<sec_title>IV:</sec_title>
						<para> Onset 5 min, duration 2 hr</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x18948">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x18951">
					<section type="none" id="sidelem4x18952">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x18958">
								<item>
									<para>
										<emphasis alert="nurse">Hypersensitivity: urticaria, cough, wheezing, have emergency equipment nearby; allergy to fish; use with caution; men who have had vasectomies may be more prone to hypersensitivity</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18963">
								<item>
									<label>•</label>
									<para>Blood studies (Hct, platelets, occult blood in stools) q3mo</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18968">
								<item>
									<label>•</label>
									<para>Coagulation tests (aPTT, ACT) 15 min after dose, then again after several hours</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18973">
								<item>
									<label>•</label>
									<para>VS, B/P, pulse after 30 min, then 3 hr after dose</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x18978">
								<item>
									<label>•</label>
									<para>Skin rash, urticaria, dermatitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18983">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x18987">
								<item>
									<label>•</label>
									<para>Therapeutic response: reversal of heparin overdose</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x18993">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x19001">
							<label>•</label>
							<sec_title>
								<route>Not to take if allergic to fish</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="55" status="active">
			<mono_name>pseudoephedrine (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(soo-doh-eh-fed′rin)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x190125">Elix Sure Cold</tradename>
					<tradename id="tnidelem4x190124">
						<country code="CAN">Eltor </country>
					</tradename>
					<tradename id="tnidelem4x190123">Nasofed</tradename>
					<tradename id="tnidelem4x190122">Sudafed</tradename>
					<tradename id="tnidelem4x190121">Sudafed 24 Hour</tradename>
					<tradename id="tnidelem4x190120">Sudogest</tradename>
				</tradenames>
				<class type="func"> Adrenergic</class>
				<class type="chem"> Substituted phenylethylamine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x19025">
				<sec_title>Action:</sec_title>
				<para>Primary activity through α-effects on respiratory mucosal membranes reducing congestion hyperemia, edema; minimal bronchodilation secondary to β-effects</para>
			</section>
			<section type="uses" id="sidelem4x19030">
				<sec_title>Uses:</sec_title>
				<para>Nasal decongestant, adjunct for otitis media; with antihistamines</para>
			</section>
			<section type="contra" id="sidelem4x19035">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity to sympathomimetics, closed-angle glaucoma</para>
				<section type="none" id="sidelem4x19040">
					<section type="none" id="sidelem4x19041">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, cardiac disorders, hyperthyroidism, diabetes mellitus, prostatic hypertrophy, hypertension</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19046">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19054">
					<label>•</label>
					<sec_title>Adult and child &gt;12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19054">
							<item>
								<label>•</label>
								<para> 60 mg q6hr;  120 mg q12hr or 240 mg q24hr</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19064">
					<label>•</label>
					<sec_title>Geriatric<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19064">
							<item>
								<label>•</label>
								<para> 30-60 mg q6hr prn</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19071">
					<label>•</label>
					<sec_title>Child 6-12 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19071">
							<item>
								<label>•</label>
								<para> 30 mg q6hr, max 120 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19078">
					<label>•</label>
					<sec_title>Child 2-6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19078">
							<item>
								<label>•</label>
								<para> 15 mg q6hr, max 60 mg/day</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19082">
					<section type="none" id="sidelem4x19083">
						<sec_title>Available forms:</sec_title>
						<para> Ext rel caps 120, 240 mg; oral sol 15 mg, 30 mg/5 ml; tabs 30, 60 mg; ext rel tabs 120, 240 mg</para>
					</section>
					<section type="none" id="sidelem4x19088">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x19092">
								<item>
									<label>•</label>
									<para>Avoid taking at or near bedtime; stimulation can occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19098">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19101">
					<section type="none" id="sidelem4x19102">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Tremors, anxiety,</emphasis> stimulation, insomnia, headache, dizziness, hallucinations, <emphasis style="bold">seizures</emphasis> (geriatric patients)</para>
					</section>
					<section type="none" id="sidelem4x19113">
						<sec_title>CV:</sec_title>
						<para> Palpitations, tachycardia, hypertension, chest pain, <emphasis style="bold">dysrhythmias, CV collapse</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19120">
						<sec_title>EENT:</sec_title>
						<para> Dry nose; irritation of nose and throat</para>
					</section>
					<section type="none" id="sidelem4x19125">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Anorexia, nausea, vomiting,</emphasis> dry mouth, ischemic colitis</para>
					</section>
					<section type="none" id="sidelem4x19133">
						<sec_title>GU:</sec_title>
						<para> Dysuria</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19138">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x19141">
					<section type="none" id="sidelem4x19142">
						<sec_title>PO:</sec_title>
						<para> Onset 15-30 min; duration 4-6 hr, 8-12 hr (ext rel); metabolized in liver; excreted in feces and breast milk; terminal half-life 9-16 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19147">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Do not use with MAOIs or tricyclics; hypertensive crisis may occur</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effect of this product—urinary alkalizers, adrenergics, β-blockers, phenothiazines, tricyclics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effect of this product—urinary acidifiers</para>
			</section>
			<section type="considerations" id="sidelem4x19163">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19166">
					<section type="none" id="sidelem4x19167">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19171">
								<item>
									<label>•</label>
									<para>Nasal congestion: auscultate lung sounds; check for tenacious bronchial secretions</para>
								</item>
								<item>
									<label>•</label>
									<para>B/P, pulse throughout treatment</para>
								</item>
								<item>
									<label>•</label>
									<para>CNS side effects in geriatric patients: excitation, seizures, hallucinations</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19187">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19191">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased nasal congestion</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19197">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19202">
								<item>
									<label>•</label>
									<para>About the reason for product administration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19208">
								<item>
									<label>•</label>
									<para>Ext rel: do not divide, crush, chew, or dissolve</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19213">
								<item>
									<label>•</label>
									<para>Do not use within 14 days of MAOIs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19218">
								<item>
									<label>•</label>
									<para>Not to use continuously or to take more than recommended dose because rebound congestion may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19224">
								<item>
									<para>
										<emphasis alert="nurse">To notify prescriber immediately of anxiety; slow or fast heart rate; dyspnea; seizures</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19229">
								<item>
									<label>•</label>
									<para>To check with prescriber before using other products because product interactions may occur</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19234">
								<item>
									<label>•</label>
									<para>To avoid taking near bedtime because stimulation can occur</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19242">
							<label>•</label>
							<sec_title>
								<route>Not to use if stimulation, restlessness, tremors occur</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x19248">
							<label>•</label>
							<sec_title>
								<route>That use in children may cause excessive agitation</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="56" status="active">
			<mono_name>psyllium (<emphasis style="smallcaps">otc</emphasis>, Rx)</mono_name>
			<info>
				<pronunciation>(sill′ee-um)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x192596">Hydrocil</tradename>
					<tradename id="tnidelem4x192595">Leader Fiber Laxative</tradename>
					<tradename id="tnidelem4x192594">Metamucil</tradename>
					<tradename id="tnidelem4x192593">Natural Fiber</tradename>
					<tradename id="tnidelem4x192592">Natural Vegetable Fiber</tradename>
					<tradename id="tnidelem4x192591">Reguloid</tradename>
					<tradename id="tnidelem4x192590">Wal-Mucil</tradename>
				</tradenames>
				<class type="func"> Bulk laxative</class>
				<class type="chem"> Psyllium colloid</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x19269">
				<sec_title>Action:</sec_title>
				<para>Bulk-forming laxative</para>
			</section>
			<section type="uses" id="sidelem4x19274">
				<sec_title>Uses:</sec_title>
				<para>Chronic constipation, ulcerative colitis</para>
				<section type="none" id="sidelem4x19279">
					<section type="none" id="sidelem4x19280">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Diarrhea, diverticulosis, irritable bowel syndrome, hypercholesterolemia</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19285">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, intestinal obstruction, abdominal pain, nausea, vomiting, fecal impaction</para>
				<section type="none" id="sidelem4x19290">
					<section type="none" id="sidelem4x19291">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>)</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19296">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19304">
					<label>•</label>
					<sec_title>Adult<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19304">
							<item>
								<label>•</label>
								<para> 1-2 tsp in 8 oz water bid or tid, then 8 oz water or 1 premeasured packet in 8 oz water bid or tid, then 8 oz water</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19311">
					<label>•</label>
					<sec_title>Child &gt;6 yr<route> PO</route></sec_title>
					<para>
						<list id="lidelem4x19311">
							<item>
								<label>•</label>
								<para> 1 tsp in 4 oz water at bedtime</para>
							</item>
						</list>
					</para>
				</section>
				<section type="none" id="sidelem4x19315">
					<section type="none" id="sidelem4x19316">
						<sec_title>Available forms:</sec_title>
						<para> Chew pieces 1.7, 3.4 g/piece; effervescent powder 3.4, 3.7 g/packet; powder 3.3, 3.4, 3.5, 4.94 g/tsp; wafers 3.4 g/wafer</para>
					</section>
					<section type="none" id="sidelem4x19321">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x19324">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19328">
									<item>
										<label>•</label>
										<para>Alone for better absorption, separate from other products by 1-2 hr</para>
									</item>
									<item>
										<label>•</label>
										<para>In morning or evening (oral dose)</para>
									</item>
									<item>
										<label>•</label>
										<para>Immediately after mixing with water or will congeal</para>
									</item>
									<item>
										<label>•</label>
										<para>With 8 oz water or juice followed by another 8 oz of fluid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19349">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19352">
					<section type="none" id="sidelem4x19353">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, anorexia, diarrhea,</emphasis> cramps, intestinal esophageal blockage</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19361">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Onset 12-72 hr, excreted in feces, not absorbed in GI tract</para>
			</section>
			<section type="interactions" id="sidelem4x19366">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of cardiac glycosides, oral anticoagulants, salicylates</para>
				<section type="none" id="sidelem4x19373">
					<section type="none" id="sidelem4x19374">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> laxative effect—flax, senna</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x19381">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19384">
					<section type="none" id="sidelem4x19385">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x19390">
								<item>
									<label>•</label>
									<para>Blood, urine electrolytes if used often</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19395">
								<item>
									<label>•</label>
									<para>I&amp;O ratio to identify fluid loss</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19403">
							<label>•</label>
							<sec_title>Constipation</sec_title>
							<para>
								<list id="lidelem4x19403">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Constipation:</emphasis> cause of constipation; fluids, bulk, exercise missing; bowel sounds, distention, usual bowel function; color, consistency, amount</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19407">
								<item>
									<label>•</label>
									<para>Cramping, rectal bleeding, nausea, vomiting; product should be discontinued</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19412">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19416">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in constipation, decreased diarrhea with colitis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19422">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x19426">
								<item>
									<label>•</label>
									<para>To maintain adequate fluid consumption</para>
								</item>
								<item>
									<label>•</label>
									<para>That normal bowel movements do not always occur daily</para>
								</item>
								<item>
									<label>•</label>
									<para>Not to use in presence of abdominal pain, nausea, vomiting</para>
								</item>
								<item>
									<label>•</label>
									<para>To notify prescriber if constipation unrelieved or if symptoms of electrolyte imbalance occur: muscle cramps, pain, weakness, dizziness, excessive thirst</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="57" status="active">
			<mono_name>pyridostigmine (Rx)</mono_name>
			<info>
				<pronunciation>(peer-id-oh-stig′meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x194532">Mestinon</tradename>
					<tradename id="tnidelem4x194531">Mestinon SR</tradename>
					<tradename id="tnidelem4x194530">Regonol</tradename>
				</tradenames>
				<class type="func"> Cholinergic; anticholinesterase</class>
				<class type="chem"> Tertiary amine carbamate</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x19463">
				<sec_title>Action:</sec_title>
				<para>Inhibits destruction of acetylcholine, which increases concentration at sites where acetylcholine is released; this facilitates the transmission of impulses across the myoneural junction</para>
			</section>
			<section type="uses" id="sidelem4x19468">
				<sec_title>Uses:</sec_title>
				<para>Nondepolarizing muscle relaxant antagonist, myasthenia gravis, pretreatment for nerve gas exposure (military only)</para>
			</section>
			<section type="contra" id="sidelem4x19473">
				<sec_title>Contraindications:</sec_title>
				<para>Bradycardia; hypotension; obstruction of intestine, renal system; bromide, benzyl alcohol sensitivity; adrenal insufficiency; cholinesterase inhibitor toxicity</para>
				<section type="none" id="sidelem4x19478">
					<section type="none" id="sidelem4x19479">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), seizure disorders, bronchial asthma, coronary occlusion, hyperthyroidism, dysrhythmias, peptic ulcer, megacolon, poor GI motility</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19484">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19487">
					<section type="none" id="sidelem4x19488">
						<sec_title>Myasthenia gravis</sec_title>
						<section type="none" id="sidelem4x19496">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19496">
									<item>
										<label>•</label>
										<para> 600 mg/day in 5-6 divided doses, max 1.5 g/day;  2 mg or <emphasis style="sup">1</emphasis>/<emphasis style="inf">30</emphasis> of  dose;  180-540 mg/day or bid at intervals of ≥6 hr</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19518">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19518">
									<item>
										<label>•</label>
										<para> 7 mg/kg/day in 5-6 divided doses;  0.05-0.15 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19525">
						<sec_title>Nondepolarizing neuromuscular blocker antagonist</sec_title>
						<section type="none" id="sidelem4x19533">
							<label>•</label>
							<sec_title>Adult</sec_title>
							<para>
								<list id="lidelem4x19533">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Adult:</emphasis> 0.6-1.2 mg  atropine, then 0.1-0.25 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19543">
							<label>•</label>
							<sec_title>Child<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x19543">
									<item>
										<label>•</label>
										<para> 0.1-0.25 mg/kg/dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19547">
						<sec_title>Nerve gas exposure prophylaxis (military)</sec_title>
						<section type="none" id="sidelem4x19555">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19555">
									<item>
										<label>•</label>
										<para> 30 mg q8hr if threat of exposure to Soman gas is anticipated; start several hours before exposure and discontinue upon exposure; after product is discontinued, give antidotes (atropine, pralidoxime)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19559">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 60 mg; ext rel tabs 180 mg; syr 60 mg/5 ml; inj 5 mg/ml</para>
					</section>
					<section type="none" id="sidelem4x19564">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x19568">
								<item>
									<label>•</label>
									<para>Only with atropine sulfate available for cholinergic crisis</para>
								</item>
								<item>
									<label>•</label>
									<para>Only after all other cholinergics have been discontinued</para>
								</item>
								<item>
									<label>•</label>
									<para>Increased doses for tolerance as ordered</para>
								</item>
								<item>
									<label>•</label>
									<para>Larger doses after exercise or fatigue as ordered</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not break, crush, or chew sus rel tabs</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19594">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x19598">
									<item>
										<label>•</label>
										<para>On empty stomach for better absorption</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19604">
							<sec_title>Direct IV route</sec_title>
							<para>
								<list id="lidelem4x19608">
									<item>
										<label>•</label>
										<para>Undiluted (5 mg/ml), give through <emphasis style="sans-serif">Y</emphasis>-tube or 3-way stopcock, give ≤0.5 mg/min (myasthenia gravis); 5 mg/min (reversal of nondepolarizing neuromuscular blockers)</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Heparin, hydrocortisone, potassium chloride, vit B/C</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x19621">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x19624">
					<section type="none" id="sidelem4x19625">
						<sec_title>CNS:</sec_title>
						<para> Dizziness, headache, sweating, weakness, <emphasis style="bold">seizures,</emphasis> incoordination, <emphasis style="bold">paralysis,</emphasis> drowsiness, LOC</para>
					</section>
					<section type="none" id="sidelem4x19636">
						<sec_title>CV:</sec_title>
						<para> Tachycardia, dysrhythmias, bradycardia, AV block, hypotension, ECG changes, <emphasis style="bold">cardiac arrest,</emphasis> syncope</para>
					</section>
					<section type="none" id="sidelem4x19644">
						<sec_title>EENT:</sec_title>
						<para> Miosis, blurred vision, lacrimation, visual changes</para>
					</section>
					<section type="none" id="sidelem4x19649">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, diarrhea, vomiting, cramps, increased salivary and gastric secretions, peristalsis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19656">
						<sec_title>GU:</sec_title>
						<para> Urinary frequency, incontinence, urgency</para>
					</section>
					<section type="none" id="sidelem4x19661">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, flushing</para>
					</section>
					<section type="none" id="sidelem4x19667">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory depression, bronchospasm, constriction, laryngospasm, respiratory arrest</emphasis></para>
					</section>
					<section type="none" id="sidelem4x19674">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Cholinergic crisis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x19681">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Metabolized in liver, excreted in urine (unchanged)</para>
				<section type="none" id="sidelem4x19686">
					<section type="none" id="sidelem4x19687">
						<sec_title>PO:</sec_title>
						<para> Onset 20-30 min, duration 3-6 hr</para>
					</section>
					<section type="none" id="sidelem4x19692">
						<sec_title>PO-EXT REL:</sec_title>
						<para> Onset 30-60 min, duration 6-12 hr</para>
					</section>
					<section type="none" id="sidelem4x19697">
						<sec_title>IM/IV/SUBCUT:</sec_title>
						<para> Onset 2-15 min, duration 2<emphasis style="sup">1</emphasis>/<emphasis style="inf">2</emphasis>-4 hr</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x19708">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> action—succinylcholine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> action—gallamine, metocurine, pancuronium, tubocurarine, atropine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> pyridostigmine action—aminoglycosides, anesthetics, procainamide, quiNIDine, mecamylamine, polymyxin, magnesium, corticosteroids, antidysrhythmics, quinolones</para>
			</section>
			<section type="considerations" id="sidelem4x19723">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x19726">
					<section type="none" id="sidelem4x19727">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x19735">
							<label>•</label>
							<sec_title>Myasthenia gravis</sec_title>
							<para>
								<list id="lidelem4x19735">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Myasthenia gravis:</emphasis> fatigue, ptosis, diplopia, difficulty swallowing, SOB, hand/gait before, after product; improvement should be seen after 1 hr</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19739">
								<item>
									<label>•</label>
									<para>VS, respiration q8hr</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19744">
								<item>
									<label>•</label>
									<para>I&amp;O ratio; check for urinary retention or incontinence</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19752">
							<label>•</label>
							<sec_title>Toxicity<route> bradycardia, hypotension, bronchospasm, headache, dizziness, seizures, respiratory depression; product should be discontinued if toxicity occurs</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x19755">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x19759">
								<item>
									<label>•</label>
									<para>Therapeutic response: increased muscle strength, hand grasp, improved gait, absence of labored breathing (if severe); reversal of nondepolarizing neuromuscular blockers; prevention of nerve gas toxicity</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x19765">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x19773">
							<label>•</label>
							<sec_title>Myasthenia gravis</sec_title>
							<para>
								<list id="lidelem4x19773">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Myasthenia gravis:</emphasis> that product is not a cure, only relieves symptoms</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x19777">
								<item>
									<label>•</label>
									<para>To wear emergency ID specifying myasthenia gravis, products taken</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19782">
								<item>
									<label>•</label>
									<para>To avoid driving, other hazardous activities until effect is known</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x19790">
							<label>•</label>
							<sec_title>
								<route>To report muscle weakness (cholinergic crisis or underdosage), bradycardia</route>
							</sec_title>
						</section>
						<para>
							<list id="lidelem4x19793">
								<item>
									<label>•</label>
									<para>Not to drink alcohol</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x19798">
								<item>
									<label>•</label>
									<para>To take with food to decrease gastric side effects</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="58" status="active">
			<mono_name>pyridoxine (vit B6) (Rx, <emphasis style="smallcaps">otc</emphasis>)</mono_name>
			<info>
				<pronunciation>(peer-i-dox′een)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x198193">Equaline Vitamin B6</tradename>
					<tradename id="tnidelem4x198192">Neuro-K</tradename>
					<tradename id="tnidelem4x198191">Walgreens Finest B-6</tradename>
					<tradename id="tnidelem4x198190">Walgreens Gold Seal Vitamin B6</tradename>
				</tradenames>
				<class type="func"> Vit B, water soluble</class>
				<class type="preg">Pregnancy category <preg cat="A">A</preg></class>
			</info>
			<section type="actions" id="sidelem4x19828">
				<sec_title>Action:</sec_title>
				<para>Needed for fat, protein, carbohydrate metabolism; enhances glycogen release from liver and muscle tissue; needed as coenzyme for metabolic transformations of a variety of amino acids</para>
			</section>
			<section type="uses" id="sidelem4x19833">
				<sec_title>Uses:</sec_title>
				<para>Vit B<emphasis style="inf">6</emphasis> deficiency of inborn errors of metabolism, seizures, isoniazid therapy, oral contraceptives, alcoholic polyneuritis</para>
				<section type="none" id="sidelem4x19841">
					<section type="none" id="sidelem4x19842">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Palmar-plantar erythrodysesthesia syndrome</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x19847">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity</para>
				<section type="none" id="sidelem4x19852">
					<section type="none" id="sidelem4x19853">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="A">A</preg>), breastfeeding, children, Parkinson’s disease; patients taking levodopa should avoid supplemental vitamins with &gt;5 mg pyridoxine</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x19858">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x19861">
					<section type="none" id="sidelem4x19862">
						<sec_title>RDA</sec_title>
						<section type="none" id="sidelem4x19870">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19870">
									<item>
										<label>•</label>
										<para> (male) 1.7-2 mg; (female) 1.4-1.6 mg</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19877">
							<label>•</label>
							<sec_title>Child 9-13 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19877">
									<item>
										<label>•</label>
										<para> 1 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19884">
							<label>•</label>
							<sec_title>Child 4-8 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19884">
									<item>
										<label>•</label>
										<para> 0.6 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19891">
							<label>•</label>
							<sec_title>Child 1-3 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19891">
									<item>
										<label>•</label>
										<para> 0.5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19898">
							<label>•</label>
							<sec_title>Infant 7-12 mo<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19898">
									<item>
										<label>•</label>
										<para> 0.3 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19903">
						<sec_title>Vit B<emphasis style="inf">6</emphasis> deficiency</sec_title>
						<section type="none" id="sidelem4x19914">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19914">
									<item>
										<label>•</label>
										<para> 5-25 mg/day × 3 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19921">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19921">
									<item>
										<label>•</label>
										<para> 10 mg until desired response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19925">
						<sec_title>Pyridoxine deficiency neuritis/seizure (not drug induced)</sec_title>
						<section type="none" id="sidelem4x19933">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19933">
									<item>
										<label>•</label>
										<para>
											<emphasis style="italic">without neuritis</emphasis> 2.5-10 mg/day after corrected 2-5 mg/day; <emphasis style="italic">with neuritis</emphasis> 100-200 mg/day × 3wk, then 2-5 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19945">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19945">
									<item>
										<label>•</label>
										<para>
											<emphasis style="italic">without neuritis</emphasis> 5-25 mg/day × 3wk, then 1.5-2.5 mg/day in a multivitamin; <emphasis style="italic">with neuritis:</emphasis> 10-50 mg/day × 3wk, then 1-2 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19957">
							<label>•</label>
							<sec_title>Neonate with seizures<route> IM/IV</route></sec_title>
							<para>
								<list id="lidelem4x19957">
									<item>
										<label>•</label>
										<para> 50-100 mg as single dose</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19961">
						<sec_title>Deficiency caused by isoniazid, cycloSERINE, hydrALAZINE, penicillamine</sec_title>
						<section type="none" id="sidelem4x19969">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19969">
									<item>
										<label>•</label>
										<para> 100-300 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19976">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19976">
									<item>
										<label>•</label>
										<para> 10-50 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19980">
						<sec_title>Prevention of deficiency caused by isoniazid, cycloSERINE, hydrALAZINE, penicillamine</sec_title>
						<section type="none" id="sidelem4x19988">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19988">
									<item>
										<label>•</label>
										<para> 25-100 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x19995">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x19995">
									<item>
										<label>•</label>
										<para> 1-2 mg/kg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x19999">
						<sec_title>Palmar-plantar erythrodysesthesia syndrome (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20007">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20007">
									<item>
										<label>•</label>
										<para> 50-150 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20011">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 10, 25, 50, 100 mg; ext rel tabs 100 mg; inj 100 mg/ml; ext rel caps 150 mg</para>
					</section>
					<section type="none" id="sidelem4x20016">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x20019">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x20023">
									<item>
										<label>•</label>
										<para>Do not break, crush, or chew ext rel tabs/caps</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20029">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x20033">
									<item>
										<label>•</label>
										<para>Rotate sites; burning or stinging at site may occur</para>
									</item>
									<item>
										<label>•</label>
										<para>
											<emphasis style="sans-serif">Z</emphasis>-track to minimize pain</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20046">
							<sec_title>IV route</sec_title>
							<para>
								<list id="lidelem4x20050">
									<item>
										<label>•</label>
										<para>Undiluted or added to most IV sol; give ≤50 mg/1 min if undiluted</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Syringe compatibilities:</emphasis> Doxapram</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20060">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20063">
					<section type="none" id="sidelem4x20064">
						<sec_title>CNS:</sec_title>
						<para> Paresthesia, flushing, warmth, lethargy (rare with normal renal function)</para>
					</section>
					<section type="none" id="sidelem4x20069">
						<sec_title>INTEG:</sec_title>
						<para> Pain at inj site</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20074">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x20077">
					<section type="none" id="sidelem4x20078">
						<sec_title>PO/INJ:</sec_title>
						<para> Half-life 2-3 wk, metabolized in liver, excreted in urine</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x20083">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of levodopa</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of pyridoxine—oral contraceptives, isoniazid, cycloSERINE, hydrALAZINE, penicillamine, chloramphenicol, immunosuppressants</para>
			</section>
			<section type="considerations" id="sidelem4x20094">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20097">
					<section type="none" id="sidelem4x20098">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x20106">
							<label>•</label>
							<sec_title>Pyridoxine deficiency</sec_title>
							<para>
								<list id="lidelem4x20106">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Pyridoxine deficiency:</emphasis> seizures, irritability, cheilitis, conjunctivitis, anemia, confusion, red tongue, weakness, fatigue before and during treatment; monitor pyridoxine levels</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x20110">
								<item>
									<label>•</label>
									<para>Nutritional status: yeast, liver, legumes, bananas, green vegetables, whole grains</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20115">
								<item>
									<label>•</label>
									<para>Blood studies: Hct, Hgb</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20120">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20124">
								<item>
									<label>•</label>
									<para>Therapeutic response: absence of nausea, vomiting, anorexia, skin lesions, glossitis, stomatitis, edema, seizures, restlessness, paresthesia</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20130">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x20134">
								<item>
									<label>•</label>
									<para>To avoid vitamin supplements unless directed by prescriber</para>
								</item>
								<item>
									<label>•</label>
									<para>To increase meat, bananas, potatoes, lima beans, whole grain cereals in diet</para>
								</item>
								<item>
									<label>•</label>
									<para>To take as directed; to continue with follow-up exams, blood work</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="59" status="active">
			<mono_name>pyrimethamine (Rx)</mono_name>
			<info>
				<pronunciation>(peer-i-meth′a-meen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x201550">Daraprim</tradename>
				</tradenames>
				<class type="func"> Antimalarial, antiprotozoal</class>
				<class type="chem"> Folic acid antagonist</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x20165">
				<sec_title>Action:</sec_title>
				<para>Inhibits folic acid metabolism in parasite, prevents transmission by stopping growth of fertilized gametes</para>
			</section>
			<section type="uses" id="sidelem4x20170">
				<sec_title>Uses:</sec_title>
				<para>Malaria prophylaxis, <emphasis style="italic">Plasmodium vivax, Pneumocystis jiroveci</emphasis></para>
				<section type="none" id="sidelem4x20178">
					<section type="none" id="sidelem4x20179">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Isosporiasis, pneumocystis pneumonia prophylaxis, toxoplasmic encephalitis prophylaxis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x20184">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, chloroquine-resistant malaria, megaloblastic anemia caused by folate deficiency</para>
				<section type="none" id="sidelem4x20189">
					<section type="none" id="sidelem4x20190">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, geriatric patients, blood dyscrasias, seizure disorder, G6PD disease, renal/hepatic disease</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x20195">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x20198">
					<section type="none" id="sidelem4x20199">
						<sec_title>Prophylaxis of malaria</sec_title>
						<section type="none" id="sidelem4x20208">
							<label>•</label>
							<sec_title>Adult/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20208">
									<item>
										<label>•</label>
										<para> 25 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20215">
							<label>•</label>
							<sec_title>Child 4-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20215">
									<item>
										<label>•</label>
										<para> 12.5 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20222">
							<label>•</label>
							<sec_title>Child &lt;4 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20222">
									<item>
										<label>•</label>
										<para> 6.25 mg/wk</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20226">
						<sec_title>Malaria treatment</sec_title>
						<section type="none" id="sidelem4x20234">
							<label>•</label>
							<sec_title>Adult/adolescent/child &gt;10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20234">
									<item>
										<label>•</label>
										<para> 25 mg daily × 2 days with a sulfonamide</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20241">
							<label>•</label>
							<sec_title>Child 4-10 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20241">
									<item>
										<label>•</label>
										<para> 25 mg/day × 2 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20245">
						<sec_title>Toxoplasmosis</sec_title>
						<section type="none" id="sidelem4x20253">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20253">
									<item>
										<label>•</label>
										<para> 50-75 mg, then reduce by about 50% for 4-5 wk with 1-4 g sulfadoxine × 1-3 wk, then reduce by 50% for 4-5 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x20260">
							<label>•</label>
							<sec_title>Child<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20260">
									<item>
										<label>•</label>
										<para> 1 mg/kg/day in 2 divided doses or 2 mg/kg/day × 3 days, then 1 mg/kg/day or divided twice daily × 4 wk, max 25 mg/day</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20264">
						<sec_title>Toxoplasmosis in AIDS patients</sec_title>
						<section type="none" id="sidelem4x20272">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20272">
									<item>
										<label>•</label>
										<para> 100-200 mg/day × 1-2 days, then 50-100 mg/day × 3-6 wk, then 25-50 mg/day for life (given with clindamycin or sulfADIAZINE)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20276">
						<sec_title>Isosporiasis (unlabeled)</sec_title>
						<section type="none" id="sidelem4x20284">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x20284">
									<item>
										<label>•</label>
										<para> 75 mg/day with leucovorin 10 mg/day × 14 days</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x20288">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25 mg; combo tabs 500 mg sulfadoxine/25 mg pyrimethamine</para>
					</section>
					<section type="none" id="sidelem4x20293">
						<sec_title>Administer:</sec_title>
						<section type="none" id="sidelem4x20296">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x20301">
									<item>
										<label>•</label>
										<para>Leucovorin IM 3-9 mg/day × 3 days if folic acid deficiency occurs</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x20306">
									<item>
										<label>•</label>
										<para>Before or after meals at same time each day to maintain product level, decrease GI symptoms</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x20311">
									<item>
										<label>•</label>
										<para>Store in tight, light-resistant container</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x20319">
								<label>•</label>
								<sec_title>Extemporaneous susp</sec_title>
								<para>
									<list id="lidelem4x20319">
										<item>
											<label>•</label>
											<para>
												<emphasis style="bold">Extemporaneous susp:</emphasis> tabs may be crushed and mixed with 25 ml distilled water, sucrose-containing solution (1 mg/ml); shake well; stable for 5-7 days at room temperature if mixed with sucrose-containing solutions</para>
										</item>
									</list>
								</para>
							</section>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x20323">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x20326">
					<section type="none" id="sidelem4x20327">
						<sec_title>CNS:</sec_title>
						<para> Stimulation, irritability, <emphasis style="bold">seizures,</emphasis> tremors, ataxia, fatigue, fever</para>
					</section>
					<section type="none" id="sidelem4x20335">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Dysrhythmias</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20342">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, vomiting, cramps, anorexia,</emphasis> diarrhea, atrophic glossitis, gastritis</para>
					</section>
					<section type="none" id="sidelem4x20350">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia, leukopenia, pancytopenia, megaloblastic anemia,</emphasis> decreased folic acid, <emphasis style="bold">agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20360">
						<sec_title>INTEG:</sec_title>
						<para> Skin eruptions, photosensitivity, <emphasis style="bold">Stevens-Johnson syndrome</emphasis></para>
					</section>
					<section type="none" id="sidelem4x20367">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="bold">Respiratory failure</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x20374">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x20377">
					<section type="none" id="sidelem4x20378">
						<sec_title>PO:</sec_title>
						<para> Peak 2 hr, half-life 96 hr, half-life accelerated to 23 hr in AIDS patients, metabolized in liver, highly protein bound, excreted in urine (metabolites)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x20383">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x20387">
						<item>
							<label>•</label>
							<para>Synergistic action: folic acid</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: Megaloblastic anemia risk, agranulocytosis, thrombocytopenia—zidovudine</emphasis>
				</para>
				<para>
					<emphasis alert="lifethreat">Increase: bone marrow suppression—bone marrow depressants, folate antagonists, radiation therapy</emphasis>
				</para>
			</section>
			<section type="considerations" id="sidelem4x20399">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x20402">
					<section type="none" id="sidelem4x20403">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x20408">
								<item>
									<label>•</label>
									<para>Folic acid level; megaloblastic anemia occurs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20415">
								<item>
									<para>
										<emphasis alert="nurse">Blood dyscrasias: blood studies, CBC, platelets; 2×/wk if dosage is increased</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x20421">
								<item>
									<para>
										<emphasis alert="nurse">Toxicity: vomiting, anorexia, seizure, blood dyscrasia, glossitis; product should be discontinued immediately</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x20429">
							<label>•</label>
							<sec_title>Serious skin disorders<route> Stevens-Johnson syndrome (swelling of face, lips, throat, fever)</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x20432">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x20436">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased symptoms of malaria, toxoplasmosis</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x20442">
						<sec_title>Teach patient/family:</sec_title>
						<section type="none" id="sidelem4x20450">
							<label>•</label>
							<sec_title>
								<route>To report visual problems, fever, fatigue, bruising, bleeding, sore throat; may indicate blood dyscrasias</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>